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Abstract 
It has been previously shown that the length of complementarity-determining region 3 
(CDR3) loops of a T-cell receptor (TCR) may determine T-cell phenotype, with 
elongated CDR3s being favoured in T helper-type 2 (Th2) cells. Here, in a human 
system of Th2-mediated allergic asthma, TCR CDR3 usage has been studied in T-cell 
lines derived from Human Leukocyte Antigen (HLA)-DR1-positive, cat-allergic 
asthmatic subjects, and generated against peptide 4, a T-cell epitope of the major cat 
allergen Fel d 1. Populations of T-cells expanded that expressed particular TCRs 
carrying elongated CDR3a or p loops. A system was developed to transduce the 
immortalised TCR-negative murine thymoma line BW7 with the human TCR genes 
identified here and also murine Thl and Th2 associated TCR genes identified from 
previous work in our laboratory to allow further study of the influence of TCR structure 
on T-cell phenotype. A TCR/MHC class II transgenic model of allergic asthma has been 
developed by others in our laboratory. As part of the initial characterisation of this 
model, to establish if the TCR was expressed, the impact of the presence of the TCR 
transgenes on thymic selection and the expression of costimulatory molecules was 
studied. A block at the double negative stage in thymocyte development is seen as well 
as differences in expression of the costimulatory molecules CD44, CD62L, ICOS and 
OX40. Allergic inflammatory lung disease was induced in this model using a 
sensitisation and challenge protocol with Fel d 1 and cat dander, and changes usually 
associated with an asthma phenotype studied. Increased airway hyperreactivity, 
eosinophilic lung influx, raised serum IgE, Th2-associated cytokines in BAL and lung, 
mild lung inflammation and increased mucus secretion in the airways were observed, all 
changes that would be expected in a good model of allergic asthma. 
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1. 	Introduction 
1.1 	Clinical and epidemiological aspects of allergic asthma 
1.1.1 Prevalence of allergic asthma 
Allergic asthma is a significant cause of morbidity and mortality in developed countries. 
In the U.K., the incidence of wheeze and diagnosis of asthma in children has increased 
from 1964 to 2004, correlating with an increase in hospital admissions for asthma over 
the same time frame (1). Mortality due to asthma increased sharply during the 1960s 
and to a lesser extent in the 1970s (1). Corresponding trends have also been seen in 
other developed countries such as Australia (2). In more recent years, this trend appears 
to have lessened - a worldwide study of the prevalence of asthma in children suggested 
that the occurrence of asthma in children from developed countries decreased from 
1995-2005 (3, 4) whilst the occurrence of asthma in developing countries increased 
over the same period (3). Overall, therefore, the worldwide prevalence of asthma is still 
increasing. 
1.1.2 The 'hygiene hypothesis' 
An inverse correlation between incidence of allergic rhinitis and increasing family size 
(5) led to the suggestion that development of allergic disease could be prevented by 
exposure to infectious agents at a young age, e.g. through contact with older siblings. 
The concurrent trends of decreasing family size and increasing standards of hygiene and 
health care in developed countries were proposed to have decreased the exposure of 
young children to infection, thus increasing their risk of allergy. A number of studies 
provided epidemiological evidence in support of this hypothesis suggesting that 
children from a rural background, in particular those brought up in a farming 
environment, were protected against the development of allergic sensitisation and hay 
fever (6) as well as allergic asthma. Increased protection was linked both to increased 
exposure to livestock (7) and drinking unpasteurised milk produced on the farm during 
early childhood (8), suggesting that exposure to microbial compounds could protect 
against development of allergic disease. Lipopolysaccharide (LPS), a component of 
some bacterial cell walls (9), and other microbial products such as CpG 
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oligonucleotides (10) were later shown to prevent allergic disease in murine models, 
suggesting that the protective effect of microbial products may be mediated through 
their interaction with innate immune receptors such as Toll-like receptors (TLRs). 
Support came from studies showing that expression of TLR2 messenger RNA (mRNA) 
was increased in the children of farmers (11) and that polymorphisms in the TLR2 gene 
(12) and the CD14 gene, a coreceptor for TLR4 (the LPS receptor) (13), have been 
associated with increased risk of allergy. A more recent study showed lower expression 
of TLR4 on CD4+ T-cells in allergic asthmatics compared with T-cells from normal 
controls (14). Bacterial strains associated with cowsheds reduced allergic disease in 
sensitised mice and promoted the development of human dendritic cells (DC) in vitro 
that promoted a T helper type 1 (Thl) T-cell response (15), which is associated with 
production of the cytokine interferon-y (IFN-y) (16). This suggested that protection was 
due to the promotion of Thl-associated immunity over T helper type 2 (Th2) immunity, 
characterised by production of the cytokine interleukin-4 (IL-4) (16) and which is 
strongly associated with the development of atopy (17) and allergic asthma (18). 
Evidence against a simple Thl/Th2 version of the hygiene hypothesis includes the 
presence of a concurrent increase in Thl-mediated autoimmune diseases such as 
diabetes (19) alongside the increase in Th2-mediated allergic disease, suggesting that a 
more general immune dysregulation may be the basis of the hygiene hypothesis. In 
addition, chronic helminth infection is protective against the development of allergy and 
atopy (20). Helminth infections are associated with 'modified' Th2-mediated immunity 
and not Thl-mediated immunity (21). In mouse models of human autoimmune disease 
(22, 23), helminth infection protects against the development of disease, suggesting that 
the hygiene hypothesis also applies to autoimmune disease. There are conflicting results 
from studies investigating the effect of LPS on allergic disease with some suggesting 
that LPS is protective (9) whilst others showed that it has no effect and can even act to 
potentiate allergic disease (24, 25). Infection with agents that induce a Thl-mediated 
immune response such as certain viruses, e.g. influenza A, do not protect against 
allergic disease but instead exacerbate the associated inflammation (26). These findings 
suggest that the hygiene hypothesis applies to both Th2-mediated allergic disease and 
Thl -mediated autoimmune disease, with reduced exposure to infectious agents during 
early life causing immune dysregulation that leads to development of these diseases. 
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1.1.3 The clinical manifestations of asthma 
Allergic asthma occurs as a result of an inappropriate immune response to an inhaled 
harmless substance such as grass or tree pollen, house dust mite or cat dander (27). A 
distinct subgroup of asthmatic patients present with a form of the disease unrelated to 
atopy or allergy which is associated with neutrophilic airway inflammation rather than 
the eosinophilic inflammation associated with allergic asthma (28). The proportion of 
asthmatic patients with non-eosinophilic asthma is approximately 50% (29) and 
possible causes include exposure to bacterial endotoxin, air pollution, ozone or viral 
infection (30). Asthma is a chronic inflammatory disease of the lower airways 
characterised by bronchial hyperreactivity (BHR), mucus hypersecretion and 
progressive lung damage and remodelling due to persistent inflammation causing 
reversible airway obstruction. This manifests itself as wheeze, cough, shortness of 
breath and in some cases severe bronchoconstriction (an 'asthma attack') (31). The 
disease is mainly treated through use of inhaled anti-inflammatory corticosteroids and 
bronchodilators (132 agonists) which control the symptoms of asthma but do not cure the 
disease (32), and which are less effective in the treatment of neutrophilic asthma (33, 
34). Another treatment for allergic asthma is specific immunotherapy (SIT) - this 
involves exposure to high doses of allergen extract with the aim of inducing tolerance to 
allergen (35). It has been shown to have clinical efficacy (36) but there are safety 
implications due to the potential for the induction of asthmatic episodes and anaphylaxis 
(37). 
A typical asthmatic episode is biphasic - within minutes of exposure to allergen an 
immediate type hypersensitivity reaction (early asthmatic reaction or EAR) occurs, 
causing bronchoconstriction and a decrease in lung function (27). This resolves within a 
short time and is followed 2-6 hours later by the late asthmatic reaction (LAR), 
characterised by more prolonged but less severe bronchoconstriction (38) and which 
usually resolves within 24 hours. 
42 
1.2 	Immune mechanisms of allergic asthma 
1.2.1 Antigen-presenting cells (dendritic cells) in allergic asthma 
Initial exposure to allergen in the airways can lead to sensitisation in pro-asthmatic 
lungs. DC are the most potent antigen-presenting cells (APC) in the lung and are 
thought to play an important role in the development and ongoing pathogenesis of 
allergic asthma - intraepithelial DC isolated from allergic asthmatic patients promoted 
the activation of autologous CD4+ T-cells to produce mediators associated with a Th2 
response, namely interleukin-4 (IL-4) and IL-5 (39). Allergen is taken up by DC which 
form a contiguous network of cells in the respiratory epithelium (shown in 
immunohistochemical analysis of both rat (40) and human (41) airway sections) and 
which are capable of presenting inhaled antigens to T-cells in vivo (reviewed in 42). DC 
and other APC present allergens, like other antigens, in the form of short peptides 
bound to major histocompatibility complex (MHC) molecules which can then be 
recognised by a T-cell bearing a T-cell receptor (TCR) whose structure has specificity 
for the peptide-MHC complex and which can lead to T-cell activation (reviewed in 43, 
and discussed in greater detail in Section 1.4). DC numbers in the bronchial mucosa of 
patients with allergic asthma are greater than those in non-asthmatic controls (44). The 
number of myeloid DC (mDC, surface phenotype human leukocyte antigen (HLA)-D12+ 
CD1le CD lc+) in the peripheral circulation of allergic asthmatic patients rapidly 
decreased from baseline levels upon allergen challenge in the lung, and were still below 
baseline 24 hours post-challenge (45). A previous study (46) investigated the 
recruitment of mDC to the bronchial mucosa in asthmatic patients and showed that 
numbers increased within 4-5 hours of allergen challenge. Taken together, this suggests 
that upon allergen challenge, mDC from the periphery are rapidly recruited to the 
bronchial mucosa where they activate T-cells and mediate asthma pathogenesis. 
Investigation of antigen presentation in rat lung showed that upon uptake of inhaled 
antigen, DC from the airways migrate to the regional lymph nodes within 24 hours of 
allergen exposure and upregulate their antigen-presenting capabilities for up to 7 days 
(47). Antigen-specific T-cells could be isolated from the lymph node after this primary 
sensitisation and a secondary challenge elicited an antigen-specific immune response in 
the airways, characterised primarily by inflammation around blood vessels in the lung. 
This suggests that lung DC are the antigen-presenting cells involved in the development 
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of T-cell-mediated immune responses in the lung, although this has not been 
demonstrated in human lung. 
Both mDC and plasmacytoid DC (pDC, surface phenotype HLA-DR+ CD123+) 
numbers in bronchoalveolar lavage fluid (BALF) increase after allergen challenge, pDC 
to a greater extent than mDC (48), suggesting a role for pDC in asthma pathogenesis. 
The role of pDC in allergic asthma in humans is unclear - in allergic rhinitis, pDC in the 
nasal mucosa activate T-cells in vitro and promote development of a Th2 response from 
both naïve and memory T-cells (49). However, Jansen et al. (46) reported that no pDC 
were present in the bronchial mucosa after allergen challenge and pDC have been 
shown to prevent development of an allergic asthmatic response in mice (50). 
Studies of the function of DC in animal models of allergic lung inflammation have 
shown that the presence of a low dose of LPS, signalling through TLR4, was required at 
the time of sensitisation to induce allergic pulmonary inflammation through induction 
of a Th2-mediated response in the local lymph nodes by LPS-activated DC (51). This 
phenomenon did not occur if sensitisation occurred in the absence of LPS or the 
presence of a high dose of LPS, when a Thl response was induced in the lung instead, 
suggesting that the lung microenvironment at the time of antigen encounter is important 
in determining the nature of the response elicited. The induction of a Th2-type T-cell 
response by exposure to allergen is dependent upon signalling through the CD28-B7 
costimulatory pathway - blocking this pathway using cytotoxic T-lymphocyte antigen-
4-immunoglobulin (CTLA-4-Ig) abolished the induction of Th2-mediated allergic 
inflammation (52). The required costimulatory signal is supplied by DC as mice 
deficient in B7-1/B7-2 (CD80/CD86) on DC only are unable to induce Th2-mediated 
responses to allergen (53). A study (54) using a mouse model of allergic asthma 
demonstrated that mDC were able to induce sensitivity to inhaled allergen. DC isolated 
from bone marrow and pulsed with allergen migrated to regional lymph nodes and 
subsequent challenge with aerosolised allergen induced recruitment of activated T-cells, 
eosinophils and neutrophils to the lung. Recruited CD4+ T-cells predominantly secreted 
IL-4 and IL-5. Analysis of sectioned lung showed eosinophilic infiltrates around 
bronchioles and blood vessels and hyperplasia of mucus-producing goblet cells in the 
airways, all of which is consistent with an allergic asthmatic phenotype. 
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1.2.2 Immunoglobulin E in allergic asthma 
Immunoglobulin E (IgE) is the least abundant of the antibody isotypes with a normal 
concentration in the blood of —150 ng/ml (55). IgE is believed to be involved in the 
immune response against parasites such as helminths and Schistosomonas mansoni (56). 
Parasitic infections induce a Th2-mediated response including production of IL-4 (57) 
which induces isotype switching in antigen-specific B-cells to produce IgE (58). 
Elevated levels of circulating IgE are also associated with allergic asthma (59) as 
asthmatic patients have significantly higher levels of serum IgE than non-asthmatic 
controls. After local allergen challenge, levels of allergen-specific IgE are increased in 
BALF in asthmatic patients (60). High serum levels of IgE in childhood have also been 
associated with development of asthma and/or atopy in later life (61). Levels of IgE 
receptors expressed at the cell surface of relevant cells are up-regulated in asthma; 
expression of the high-affinity receptor for IgE (FcERI), expressed by mast cells, DC, 
macrophages and eosinophils is increased in asthma (62), whilst the low affinity 
receptor for IgE (FcERII) is expressed on B-cells and is also up-regulated in asthma 
(63). 
IL-4 secreted by allergen-specific Th2 cells induces class switching in allergen-specific 
B-cells in the local lymph nodes to produce IgE and migrate to the airways (58). The 
induction of class switching in allergen-specific B-cells has been shown to occur in the 
bronchial mucosa of patients with asthma (64). Class switching to IgE is antagonised by 
IFN-y (65) and can be induced by the Th2-associated cytokine IL-13 through a 
mechanism believed to be analogous to that of IL-4 (66). Secreted IgE binds to its 
receptors and primes cells for activation (in most cases via secretion of pro-
inflammatory mediators) upon further exposure to allergen. IL-4 (67) and IL-13 (68) 
upregulate surface expression of FcERI on tissue-resident mast cells. Levels of FcERI on 
basophils (and mast cells) are believed to correlate with the circulating concentration of 
IgE itself with the interaction between IgE and FcERI causing its up-regulation at the 
cell surface (69). This is further supported by the discovery that treatment of allergic 
patients with anti-IgE (omalizumab) down-regulates expression of FcERI on basophils 
(70). Omalizumab also down-regulates expression of FcERI on DC (71). Antigen 
presentation of allergen captured by IgE bound to FcERI on the surface of DC proceeds 
more efficiently than other methods of antigen processing and could act to increase the 
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frequency of T-cell activation by allergen-primed DC leading to a worsening of disease 
with subsequent allergen exposure (72). 
1.2.3 Mast cells in allergic asthma 
Re-exposure to antigen in a sensitised asthmatic individual causes an immediate 
hypersensitivity response, the EAR, as described previously. Allergen-specific IgE 
molecules bind to FcERI on mast cells and when cross-linked by allergen (i.e. at least 
two IgE molecules bound to FcERI and specific for different epitopes of the same 
allergen bind the allergen simultaneously) trigger signalling cascades via 
immunoreceptor tyrosine activation motif (ITAM) domains in the cytoplasmic portion 
of the receptor (73). The tyrosine kinases Lyn and Syk (74) phosphorylate ITAMs and 
initiate activation of the mast cell via a pathway involving protein kinase C (PKC)-0 
(75). Activation causes degranulation and release of pre-formed pro-inflammatory 
mediators, including histamine, cysteinyl leukotrienes (Cys-LTs), prostaglandins (PG) 
and thromboxanes, which act to induce the immediate bronchoconstriction 
characteristic of the EAR (76). Activation also induces de novo synthesis of further 
CysLTs, PG (especially prostaglandin D2, or PGD2), IL-4, IL-5 and IL-13 (76). These 
newly synthesised molecules may play a number of roles in development of the LAR -
they may directly mediate further bronchoconstriction, they may recruit other 
inflammatory cell types to the lung e.g. IL-5 recruits and activates eosinophils or they 
may recruit and promote activation of antigen-specific Th2 cells. Cys-LTs are potent 
bronchoconstrictors, enhance mucus secretion, vascular permeability and 
vasoconstriction in the lungs and are also a potent chemoattractant for eosinophils, 
acting through their receptors CysLT1 and CysLT2 (77). PGD2, acting through its 
receptors DP1 (PGD2 receptor) and CRTH2 (chemoattractant receptor homologous 
molecule expressed on Th2 cells), mediates recruitment of eosinophils, basophils and 
Th2 cells. Through CRTH2, it promotes the development of Th2 cells in the lung and 
their production of IL-4, IL-5 and IL-13 and the activation and degranulation of 
eosinophils and basophils. Signalling of PGD2 through DP1 may exert anti-
inflammatory effects and antagonise its effects on leukocytes through CRTH2 (78). The 
Th2 cytokines produced by mast cells and Th2 cells induced by the action of PGD2 
have many roles in the pathogenesis of asthma, many of them synonymous with the 
actions of the CysLTs and PGD2 and will be discussed in more detail in Section 1.2.12. 
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The mast cell has recently been postulated to act as the central mediator of airway 
hyperreactivity (AHR) with evidence from a number of studies (79, 80) investigating 
the association between mast cells and the smooth muscle cells of the airways. Subjects 
with allergic asthma and eosinophilic bronchitis (EB), a disease characterised by 
eosinophilic infiltration into the lungs but with no associated BHR, were compared (79). 
The major difference between these two groups was an increase in the number of mast 
cells associated with airway smooth muscle (ASM) bundles in the airways of asthmatic 
subjects compared to both normal subjects and EB subjects where mast cell numbers 
were similar. Further comparison of subjects with allergic asthma and EB showed that 
both diseases were characterised by an increase in ASM mass, basement membrane 
thickening and collagen deposition in the airways (80). The lack of AHR seen in EB 
therefore suggests that airway remodelling is dissociated from AHR development. Mast 
cells in the asthmatic lung associated with ASM secrete IL-4 and IL-13 (81) and human 
lung mast cells up-regulate the IL-13 receptor (IL-13R) in asthma (68). IL-13 can also 
synergise with stem cell factor (SCF) to increase mast cell proliferation, FcERI 
expression and histamine production (68). IL-13 is crucial for the development of AHR 
(82) - its production by mast cells associated with ASM further supports the theory that 
mast cells mediate AHR. 
1.2.4 Eosinophils in allergic asthma 
Allergic asthma is characterised by the presence of large eosinophilic infiltrates in lung 
tissue, BALF and blood (83) of which an increased number are activated in asthmatic 
patients and by an increase in eosinophil progenitors in the bone marrow of allergic 
asthmatic patients (84). Eosinophils migrate to the lungs in response to IL-5 and the 
eotaxins which selectively regulate migration of eosinophils into tissues (85) and which 
bind to the IL-5 receptor (IL-5R) and CC-chemokine receptor-3 (CCR3) respectively 
(86). IL-5, produced by allergen-specific T-cells, is an important signal for the 
expansion and mobilisation of eosinophils from bone marrow and their traffic into the 
lung (87) whilst eotaxin production is induced in lung epithelial cells and ASM cells by 
the actions of the Th2 cytokines IL-9 (88) and IL-13 (89). Eosinophils are activated by 
IL-5 and eotaxin-1 produced after exposure to allergen and secrete pro-inflammatory 
molecules such as major basic protein, eosinophil cationic protein and eosinophil 
peroxidase in pre-formed granules, all of which cause progressive tissue damage and 
inflammation in the lungs (90). Eosinophils can process and present allergen antigens to 
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primed T-cells in the regional lymph nodes and promote their Th2-associated functions 
(91) but they are incapable of mediating activation of naive T-cells (92). A role in lung 
remodelling and repair in response to tissue injury induced by inflammation caused by 
allergen exposure has been suggested for eosinophils. Eosinophils are a major producer 
of transforming growth factor-(3 (TGF-(3) (93) and vascular endothelial growth factor 
(VEGF) (94) which are implicated in tissue remodelling processes (95, 96). A number 
of studies in mice support this theory; tissue remodelling is diminished upon induction 
of disease in mice in which the eosinophil lineage is deleted (97). Induction of allergic 
disease in the IL-5 knockout mouse led to decreased lung eosinophilia, lung fibrosis, 
collagen deposition, ASM thickening and TGF-13 production in the lung (98, 99), whilst 
induction of the same model in a transgenic mouse which overexpressed IL-5 caused 
increased lung fibrosis (99). 
The LAR is associated with increased BALF eosinophilia in allergic asthmatic patients 
(100) but the role of eosinophils in the development of the LAR is uncertain. Use of an 
IL-5 blocking antibody in clinical trials to treat asthma decreased lung eosinophilia but 
had no effect on LAR induction (101). The antibody was only partially effective at 
removing eosinophils from the lung; the remaining eosinophils may be sufficient to 
maintain their role in asthma pathogenesis (102). 
1.2.5 Basophils in allergic asthma 
The role of basophils in the pathogenesis of allergic asthma is not as well-defined as for 
other immune system cells such as mast cells for several reasons. Their relative 
infrequency in the periphery (less than 1% of all leukocytes) and the lack of basophil 
specific antibodies until recently led to difficulty in their isolation from peripheral blood 
and in addition, mouse models of allergic asthma placed a greater emphasis on the 
functionally similar mast cell (103). A model of nematode infection, Nippostrongylus 
brasiliensis, in the rat showed that blood basophilia and associated IL-4 induction led to 
parasite clearance, suggesting a role for basophils in anti-parasite immunity (104), 
although the importance of basophils in protective immunity in humans is less well-
defined. Basophils are implicated in disease pathogenesis of allergic asthma; there are 
increased numbers of basophils in the peripheral circulation (105) and lung (106) of 
asthmatic subjects compared to non-asthmatic controls. Investigation of both sputum 
(107) and bronchial biopsy tissue (108) from asthmatic subjects showed that basophil 
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numbers increase in the lung after allergen challenge and analysis of lung tissue showed 
increased numbers of basophils in fatal asthma (109). 
Basophils are predominantly found in the periphery and are recruited to sites of 
inflammation such as the allergic lung through chemotaxis via, for example, the action 
of PGD2 on CRTH2 (110) or eotaxin on CCR3 (111). IL-3 is important in the rapid 
expansion of basophils in response to infection but is not required for normal 
development as IL-3 knockout mice have normal baseline numbers of basophils (112). 
IL-3, predominantly produced by Th2 cells, can also induce IL-4 production in 
basophils via signalling through FcERI (113). FceRI triggering through cross-linking of 
allergen-specific IgE on basophils leads to degranulation, the release of histamine and 
pre-formed IL-4 (in contrast to mast cells) and the de novo synthesis of IL-13 and IL-4 
(114). This initial burst of IL-4 upon activation could play an important role in the 
development of the Th2-dominated environment seen in allergic asthma, supported by 
the finding that basophils promote the development of Th2 responses when cultured in 
vitro with antigen-stimulated naive T-cells (115). In vitro culture of mast cells or 
basophils with B-cells showed that only basophils could induce class-switching in B-
cells to produce IgE, thought to be at least partially due to the higher levels of IL-4 and 
IL-13 secreted by the basophils in response to activation compared with the mast cells 
(116). These findings raise questions about the relative importance of basophils and 
other innate immune system effector cells such as mast cells in the development of 
allergic asthmatic disease in humans. 
1.2.6 Neutrophils in allergic asthma 
As described previously, there are two distinct types of asthma: the predominantly 
eosinophilic allergic asthma and the predominantly neutrophilic non-allergic asthma, in 
which IL-8 is believed to be a key mediator. However, lung neutrophilia is also 
associated with severe allergic asthma. There are increased neutrophil numbers in 
BALF and bronchial biopsies from severe, corticosteroid-treated, symptomatic 
asthmatics compared with those from mild, corticosteroid-treated, controlled asthmatics 
(117). Neutrophil numbers in induced sputum and bronchial biopsies correlate with a 
measure of chronic asthma severity, forced expiratory volume in 1 second, or FEVI 
(118). Neutrophils are steroid-resistant (119) hence it has been postulated that the lack 
of effect of corticosteroids in the treatment of severe asthma may be due to their failure 
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to control neutrophilic inflammation; conversely, it has been suggested that the presence 
of neutrophils in severe asthma may be caused by corticosteroid treatment as they 
inhibit neutrophil apoptosis (120). 
Epithelial cells in the lung produce IL-8 (CXC chemokine ligand-8 or CXCL8) (121), a 
major chemotactic factor for neutrophils which is also the most potent activator of 
neutrophils (122). The number of IL-8 mRNA+ cells in the bronchial epithelium is 
increased in moderate to severe asthma although IL-8 levels in the submucosa from the 
same subjects were decreased (123). Activated neutrophils produce a number of pro-
inflammatory mediators: some are stored in pre-formed granules, such as the enzymes 
myeloperoxidase, elastase and gelatinase, whilst others are synthesised upon activation, 
such as leukotriene B4 (LTB4), reactive oxygen species, IL-9 (124) and TGF13. IL-9 
promotes mucus production in the lungs (125) and goblet cell hyperplasia (126) and 
also upregulates IL-8 production by polymorphonuclear neutrophils (127). TGF13 
production by neutrophils, which is upregulated in neutrophils from asthmatic subjects 
compared with controls (128), is implicated in lung remodelling; its production by 
neutrophils suggests they may have a potential role in the development of lung 
remodelling. Neutrophils in the lung are the main source of matrix metalloproteinase-9 
(MMP-9) which promotes angiogenesis and is implicated in the development of ASM 
cell hyperplasia (129). 
1.2.7 Invariant natural killer T (iNKT) cells in allergic asthma 
Invariant natural killer T (iNKT) cells recognise and respond to glycolipid antigens 
bound to the non-classical MHC class I molecule CD (130). They express the natural 
killer (NK) cell marker CD161 (131) and an invariant al3 TCR (in humans composed of 
a TCRa chain comprising variable (V) region Va24 and joining (J) region JaQ paired 
with a TCR13 chain including v(311) (132). They are subdivided on the basis of CD4 
and CD8 expression and cytokine secretion upon activation via TCR signalling through 
CD1d. CD is expressed upon epithelial cells (133) and cells of the immune system 
(B-cells, T-cells and monocytes) (134). CD4÷ iNKT cells secrete either IL-4 and IL-13 
upon activation or IFN-y, whilst CD4-CD8- iNKT cells secrete only IFN-y (135). A third 
subset of iNKT cells, CD8+ iNKT cells, secrete IFN-y upon activation (136). iNKT cells 
may bridge the innate and adaptive immune responses - their rapid release of cytokines 
upon activation may drive the development of adaptive immune responses (137). 
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The role of iNKT cells in allergic asthma was suggested from work in iNKT cell 
knockout mice (138). Allergic disease was induced using ovalbumin (OVA) but 
induction of AHR in response to methacholine was abolished and IgE production and 
lung eosinophilia were down-regulated, despite the presence of a normal Th2-mediated 
allergen-specific response. Adoptive transfer of wild-type iNKT cells into the lungs 
restored disease phenotype, suggesting that iNKT cells are essential for the 
development of allergic lung disease. Adoptive transfer of iNKT cells isolated from IL-
4 and IL-13 double-knockout mice did not restore the asthmatic phenotype, implicating 
the IL-4- and IL-13-producing CD4+ iNKT cells in this process. Activation of iNKT 
cells with a-galactosylceramide induces development of AHR without allergen 
sensitisation (139) even in the absence of conventional CD4+ T-cells. 
Whilst the importance of iNKT cells in mouse models of allergic asthma suggested that 
these cells might play a similar role in the human disease, elucidation of the importance 
of iNKT cells in human asthma has not been straightforward. Comparison of iNKT cell 
numbers in BALF and bronchial biopsy samples from asthmatic subjects, patients with 
sarcoidosis (a Thl-mediated lung disease) and normal control subjects found that 
approximately 60% of all CD3÷CD4+ cells also stained with a CD1d tetramer loaded 
with a-galactosylceramide in asthmatic patients, compared with less than 2% of cells in 
patients with sarcoidosis and normal control subjects (140), suggesting that iNKT cells 
play an important role in human disease pathogenesis. The basic finding of this study, 
that iNKT cell numbers are increased in the asthmatic lung, has been confirmed but no 
other study has found such a large proportion of iNKT cells in the lung. Children with 
asthma had a small but significant increase in iNKT cells in BALF (using CD1d 
tetramer staining), from 0% to —0.4%, a much less dramatic increase (141). Another 
study detected an increase in iNKT cell number in induced sputum only in severe 
asthmatic patients, where —14% of cells were iNKT cells, compared with 2-3% in mild 
asthmatics and normal controls (142). iNKT cells were defined in this study as CD3+ 
CD56+. Numbers of CD4+CD56+ cells were much lower (less than 1%) and did not 
differ significantly between the groups. These studies, in conjunction with the murine 
studies, suggest that iNKT cells are involved in asthma pathogenesis. Other studies have 
failed to see increases in iNKT cell number in asthma. Use of the human invariant 
TCRa chain-specific antibody 6B11 with a V(311-specific antibody showed that at most 
2.1% of BALF lymphocytes were iNKT cells (143). Analysis of iNKT cell numbers 
(detected by use of CD tetramers, 6B11 antibody, and Va24- and vp11-specific 
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antibodies) in asthmatic (both mild and severe) patients, patients with chronic 
obstructive pulmonary disease (COPD) and normal controls corroborated these 
findings, as less than 2% of cells obtained from any subject were iNKT cells (144). In 
other studies corroborating these findings (145,146), no difference was seen in iNKT 
cell number between asthmatics and normal controls, and numbers of iNKT cells in 
BALF for both groups were less than 1% of total cells. Currently, there are no studies in 
the literature investigating the actual role or importance of iNKT cells in disease 
mechanisms of human allergic asthma and there is no definitive proof they are required 
for the development of allergic asthma in humans. 
1.2.8 CD8+ T cells (cytotoxic T-cells) in allergic asthma 
CD8+ T cells, or cytotoxic T-cells (CTL) are associated with antiviral and antitumour 
immunity, responding to peptide antigens presented by MHC class I molecules 
expressed at the surface of all cells (147). A role for CD8+ T-cells in asthma was 
suggested through study of occupational asthma caused by exposure to toluene 
diisocyanate (148). This form of asthma shares many features with allergic asthma, 
including the induction of both an EAR and LAR through exposure to the causative 
agent. Analysis of peripheral blood before and at several time points after challenge 
with toluene diisocyanate showed a significant increase in the number of CD8+ T-cells 
up to 48 hours after challenge, corresponding with eosinophilic influx into the blood, in 
contrast to the CD4+ T-cell mediated response seen in allergic asthma. Further studies in 
allergic asthmatic subjects have suggested a role for CD8+ T-cells in allergic asthma, 
but there is conflicting evidence as to their exact role. Two studies investigated TCR 
usage in T-cells isolated from BALF before and after allergen challenge. Analysis of 
TCR usage in CD4+ and CD8+ T-cells by reverse transcriptase polymerase chain 
reaction (RT-PCR) before and after challenge in allergic asthmatic subjects sensitive to 
ragweed pollen showed expanded populations of CD4+ and CD8+ T-cells expressing the 
same TCR Va or VP regions, and in one case showed an expanded population of CD8+ 
T-cells bearing the same TCR (149). Analysis of CD4+ and CD8+ T-cells by flow 
cytometry using antibodies specific for particular TCR Va or vp regions showed 
expansions of certain Va and VP regions in the population of CD8+ T-cells after 
allergen challenge (150). These studies show that CD8+ T-cells can recognise and 
respond to allergen-based antigens presented by MHC class I molecules and may have a 
role in allergic asthma. CD8+ T-cell lines derived from allergic asthmatic subjects 
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secreted increased quantities of IL-5 compared to both atopic and non-atopic non-
asthmatic control subjects (151), indicating that CD8+ T-cells can potentially generate 
Th2-mediated allergic disease in the lung. A study of non-specific stimulation of 
peripheral blood CD8+ T-cells isolated from allergic asthmatic subjects in the presence 
and absence of IL-4 showed that in the presence of IL-4, CD8+ T-cells secreted 
increased levels of IL-5 and IL-13 (152); this suggests that during respiratory system 
viral infections, the IL-4-rich environment in an allergic asthmatic lung could prime 
activated virus-specific CD8+ T-cells to produce IL-5 and IL-13. These mediators can 
then go on to mediate allergic inflammation and AHR and thus underlie the capacity of 
respiratory viral infections to exacerbate asthma. 
CD8+ T-cells may play a role in suppression of allergic asthma (153). Analysis of 
cytotoxic mediator production by peripheral blood CD8+ T-cells in allergic asthmatic 
subjects and non-asthmatic controls showed that numbers of granzyme B- and perforin-
positive CD8+ T-cells, indicative of a more differentiated phenotype, were reduced in 
allergic asthma compared to controls. This reduction also negatively correlated with 
serum levels of IgE, suggesting that these more highly differentiated CD8+ effector T-
cells may suppress and control development of allergic disease. 
Evidence from animal models of allergic asthma supports both viewpoints. A mouse 
model of lung infection (lymphocytic choriomeninigitis virus - LCMV) in the context of 
allergen (OVA) sensitisation was used to analyse responses of virus-specific CD8+ T-
cells in allergic asthma (154). Challenge of wild-type OVA-sensitised mice in vivo with 
intranasally administered LCMV induced significant lung eosinophilia. CD8+ T-cells 
isolated from the lungs of these mice and stimulated non-specifically with anti-CD3 
secreted IL-5 in contrast to cells from non-sensitised mice which secreted IFN-y. A 
similar system in LCMV-peptide-specific TCR transgenic mice showed similar CD8+ 
T-cell responses. This suggests that the lung environment induced by OVA sensitisation 
primes virus-specific T-cells to produce IL-5 upon activation by viral infection. 
Activating CD8+ T-cells isolated from the lungs of LCMV TCR-transgenic mice with 
peptide in the presence of IL-4 led to IL-5 secretion and not IFN-y; this was reversed in 
T-cells stimulated in the absence of IL-4. Induction of allergic disease in the lungs of 
CD8 knockout mice through OVA sensitisation and challenge produced a lesser 
phenotype, characterised by lower AHR, eosinophilia and BALF IL-13 than in 
sensitised wild-type mice (155). The phenotype was restored in the knockout mice by 
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adoptive transfer of wild-type effector CD8+ T-cells, which accumulated in the lung and 
produced IL-13. Sensitisation and challenge of a CD8+ OVA-specific TCR transgenic 
mouse with OVA did not induce the AHR, eosinophilia, increase in Th2 cytokine 
secretion or mucus hypersecretion usually associated with allergic asthma unless mice 
were adoptively transferred with IL-4+ CD4+ T-cells prior to sensitisation, where all the 
features of an allergic asthmatic phenotype were seen and IL-13+ CD8+ T-cells could be 
isolated from the lung (156). IL-4 produced by CD4+ T-cells may be required for the 
induction of IL-13 production by CD8+ T-cells; in the absence of IL-4, allergen-specific 
CD8+ T-cells may suppress development of allergic disease. The previous studies 
support a role for CD8+ T-cells in development of allergic inflammation and AHR in 
the lung, but suggest that IL-4 is required at the time of activation to induce a Th2 
cytokine-producing subset of CD8+ T-cells (sometimes referred to as Tc2 cells) that 
exacerbates disease. 
Other studies support the theory that CD8+ T-cells suppress allergic responses in the 
lung. OVA sensitisation of a low IgE responder' strain of rats caused expansion of 
OVA-specific IFN-y-producing CD8+ T-cells which suppressed the development of Th2 
cells and thus IgE production, inducing 'tolerance' to OVA in the lung (157). Depletion 
of CD8+ T-cells during OVA sensitisation caused a decrease in IFN-y levels and a 
corresponding increase in IL-4 and IgE production, a phenomenon reversed upon 
reconstitution with OVA-specific CD8+ T-cells at a later time point (158). Allergen-
specific CD8+ T-cells were shown to suppress IgE production and development of an 
asthmatic phenotype by production of the Thl -promoting cytokine IL-12 (159), whilst 
IL-18 produced by allergen-specific CD8+ T-cells synergises with IL-12 to promote the 
development of an IFN-y-driven response to allergen over a Th2-mediated allergic 
response (160). 
Evidence from both mouse and human studies suggest that the default function of 
allergen-specific CD8+ T-cells may be to suppress Th2-mediated allergic responses and 
that these cells are defective in allergic asthmatic subjects. However, in the context of 
allergic asthma i.e. an IL-4-rich, Th2-promoting environment, CD8+ T-cells activated 
by viral infection may be skewed towards production of Th2 cytokines, promoting 
exacerbations of the pre-existing allergic disease. 
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1.2.9 The role of T helper type 17 (Th17) cells in allergic asthma 
Th17 cells are a recently described subset of CD4+ T-cells distinct from Thl and Th2 
cells characterised by production of the pro-inflammatory cytokine IL-17 (161, 162). 
Th17 cells (or IL-17) have been implicated in human disease, including autoimmune 
diseases such as multiple sclerosis and tumorigenesis (163). There are several studies 
implicating Th17 cells in allergic asthma pathogenesis. IL-17 levels are increased in 
BALF and induced sputum of asthmatic airways with expression localised to T-cells 
and eosinophils (164). Bronchial fibroblasts isolated from the lungs of asthmatic and 
normal subjects and cultured in vitro with IL-17 produce the pro-fibrotic cytokines IL-6 
and IL-10, suggesting that Th17 cells could be involved in lung remodelling. IL-17 
levels in induced sputum were linked to AHR in both asthma and COPD (165). Another 
study found that IL-17 was produced upon non-specific activation in vitro of peripheral 
blood lymphocytes from both normal and allergic asthmatic subjects, but upon 
activation with specific allergen, IL-17 was only produced by cells from allergic 
asthmatics (166), indicating the presence of allergen-specific Th17 cells in the blood of 
allergic asthmatics. IL-17 has been shown to have an effect on structural cells of the 
lung in vitro: cultures of human ASM cells with IL-17A induced production of eotaxin-
1 (167) and in conjunction with IL-113, IL-17 induced production of IL-8 from the 
smooth muscle cells (168). In conjunction with tumour necrosis factor a (TNFa), IL-17 
stimulates IL-8 and IL-6 secretion from cultured lung epithelial cells (169). 
Neutrophilia is more associated with severe asthma and a study investigating levels of 
IL-17 in bronchial biopsies from allergic asthmatics showed that levels were higher in 
subjects with moderate to severe asthma compared with either mild asthmatic or normal 
control subjects (170). IL-17A and IL-8 levels were increased in the sputum of 
asthmatics and their levels correlated with each other and with the numbers of 
neutrophils in the lung (171). The ability of IL-17 to upregulate IL-8 production in the 
lung and thus induce lung neutrophilia suggest that IL-17 may be involved in the 
development of more severe asthma. IL-17 (partly in conjunction with IL-6) upregulates 
the mucin genes MUC5AC and MUC5B on lung epithelial cells in vitro, suggesting a 
potential role for Th17 cells in mucus hypersecretion (172). 
55 
1.2.10 The role of Thl cells in allergic asthma 
Thl cells produce IFN-y, function in vivo in cellular immunity by promoting responses 
to infection with virus or other intracellular pathogens and have been implicated in 
some autoimmune diseases (173). Thl cells secrete mediators that antagonise 
development of Th2 cells (174), leading to the proposal that Thl cells may protect 
against asthma development through downregulation of Th2-mediated responses. 
Studies investigating this theory have produced conflicting evidence as to whether Thl 
responses protect against or whether they play a role in the development and/or 
exacerbation of allergic asthma. 
Administration of recombinant IFNI to the lungs was investigated as a therapy for mild 
atopic asthma (175). Treatment increased levels of free IFN-y in the BALF of patients 
but had no effect on clinical outcome, nor did it increase lung inflammation despite its 
pro-inflammatory properties. The lack of efficacy of IFN-y in treating asthma suggested 
that Thl cells did not have a particular role in asthma; however, an association between 
levels of IFN-y production from activated peripheral blood mononuclear cells (PBMCs) 
in vitro and asthma severity was seen in a cohort of children (176); decreased 
production correlated with increased disease severity, suggesting that IFN-y production 
may be defective in allergic asthma and the extent of this defect may influence disease 
prognosis. A study of infants investigating the increased incidence of asthma 
development after acute bronchiolitis identified reduced IFN-y production in response 
to IL-2 at the time of bronchiolitis as a risk factor for later development of asthma —
infants producing higher levels of IFN-y were less likely to have developed impaired 
lung function when examined —5 months later (177). Numbers of IFN-y+ CD4+ and 
CD8+ T-cells in peripheral blood were lower in children with atopic asthma and not 
those with non-atopic asthma when compared to healthy controls (178). IFN-y 
production was inversely correlated with the extent of lung eosinophilia and AHR, 
suggesting that IFN-y and thus Thl cells may protect against development of asthmatic 
disease. In vitro culture of PBMCs with IFN-y inhibited allergen-specific proliferative 
responses in PBMCs from allergic asthmatic subjects through upregulation of Fas/Fas 
ligand expression and induction of apoptosis in these cells (179). This could be a 
mechanism by which IFN-y can control development of allergic disease in vivo; the 
defect in IFN-y production seen in allergic asthma prevents effective functioning of this 
pathway, allowing allergen-specific T-cells to persist and mediate disease development. 
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Monocytes from peripheral blood of allergic asthmatic and healthy control subjects 
were differentiated into mature DC in vitro and DC from allergic asthmatic subjects 
expressed higher levels of the costimulatory molecule CD86 and secreted lower levels 
of IL-12 as well as lower levels of the anti-inflammatory cytokine IL-10 (180). Priming 
nave T-cells with allergen using these DC induced secretion of higher levels of IL-4 
from cells primed by DC derived from allergic asthmatic subjects. The differences in 
the DC isolated from asthmatic subjects when compared to healthy controls may 
underlie the promotion of Th2-mediated responses in allergic asthma. 
Data from mouse models of allergic asthma support the theory that Thl cells may be 
protective in allergic asthma. Lung eosinophilia and T-cell capacity to exhibit a Th2 
response was prolonged and induction of allergen-specific IgE was increased in IFN-7 
receptor (IFN-7R) knockout mice, which cannot respond to IFN-y, compared with wild-
type mice after induction of allergic inflammation, suggesting that IFN-y signalling may 
act to resolve lung inflammation caused by allergen (181). Adoptive transfer of 
allergen-specific Th2 cells into the lungs of wild-type mice followed by activation 
through exposure to allergen induced an inflammatory phenotype in the lungs, 
characterised by lung eosinophilia, AHR and mucus hypersecretion (182). Transfer of 
Thl and Th2 cells simultaneously reduced both lung eosinophilia and mucus 
production, suggesting that Thl cells may regulate asthma pathology through an IFN-y 
dependent mechanism, as these protective effects were not seen in IFN-yR knockout 
mice (182). Adoptive transfer of Th2 cells alone in a rat model of allergic asthma 
increased IL-4 expression in the lungs and induced an asthmatic phenotype (AHR and 
eosinophilia); co-transfer of Thl and Th2 cells reversed this phenotype, most likely 
through the effects of IFN-y, as transfer of Thl cells alone increased IFN-y expression 
in the lungs (183). Thl-mediated stimulation of antigen presentation by lung 
macrophages induced a Thl- and IFN-y-mediated response in the lung that inhibited 
development of Th2-mediated allergic inflammation, possibly via a mechanism inherent 
to lung macrophages, a mechanism by which allergic disease may be prevented in 
healthy individuals (184). Expression of T-box expressed in T-cells (T-bet) (a Thl 
lineage-specific transcription factor) is decreased in the airways of allergic asthmatic 
subjects (185) suggesting that the ability of these subjects to induce a protective lung 
Thl response to allergen may be impaired. T-bet knockout mice spontaneously develop 
an allergic asthma-like phenotype in the absence of allergen sensitisation or challenge, 
suggesting that induction of Thl-mediated immune responses in CD4+ T-cells by T-bet 
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may be important in protecting against allergic asthma (185). IFN-y regulates mucous 
cell metaplasia induced by allergen exposure in a mouse model of allergic asthma by 
inducing apoptosis of proliferating bronchial epithelial cells, a phenomenon blocked by 
IL-13 and therefore likely to be impaired in the allergic asthmatic lung (186). IFN-y was 
shown in vitro to inhibit IL-5-mediated traffic of eosinophils (187), which could be 
protective against allergic asthma development in vivo. A study investigating the ability 
of TLR4 ligands such as LPS, which promote Thl -mediated immune responses, to 
modulate allergic disease induction in a mouse model of allergic asthma found that 
TLR4 agonists prevented development of allergic disease if present at the time of 
allergen sensitisation (188). 
There is also evidence, mostly from mouse models of disease, suggesting that Thl cells 
may have a role in asthma pathogenesis and that they may not always protect against 
allergic disease. Adoptive transfer of OVA-specific Th2 cells into both OVA-sensitised 
immunocompromised severe combined immunodeficiency (SCID) mice (which lack the 
ability to mount adaptive immune responses) and into OVA-sensitised wild-type mice 
induced an allergic asthmatic phenotype, characterised by AHR and eosinophilic 
inflammation (189). Transfer of OVA-specific Thl cells into the same mice induced 
lymphocytic lung inflammation; when transferred simultaneously with Th2 cells, they 
did not prevent development of the asthmatic phenotype but instead exacerbated it, 
suggesting Thl-associated mediators were exacerbating the inflammatory response 
rather than abrogating it. A similar phenomenon was seen after OVA challenge when 
transferring OVA-specific Thl, Th2, or mixed Thl/Th2 cells into unsensitised wild-
type mice (190). In this model, adoptive transfer of Th2 cells alone induced minimal 
inflammation; a characteristic asthmatic response was only seen when Thl and Th2 
cells were transferred simultaneously. Respiratory viral infections such as influenza 
exacerbate allergic asthma through promotion of both Thl and Th2-mediated responses 
(26). Pulmonary DC isolated from the lungs of these mice after viral clearance and 
resolution of acute allergic inflammation were transferred into naive mice and conferred 
an increase in allergic disease severity upon sensitisation and challenge with allergen, 
suggesting that viral activation of Thl cells in the lungs positively regulates Th2-
mediated asthmatic responses, at least partly through modulating pulmonary DC. 
Induction of allergic inflammation in IFN-y knockout mice in which IFN-y was 
constitutively expressed in the lungs under control of a lung-specific gene promoter (to 
remove any effects of systemic IFN-y) (191) showed that local IFN-y increased IL-5 
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and IL-13 levels and lung eosinophilia and decreased AHR and specific IgE production 
in comparison to both wild-type and IFN-y knockout mice. A recent study (192) 
investigated the effects of a viral 'danger' signal, double-stranded ribonucleic acid 
(dsRNA) which signals through TLR3 at different doses on sensitisation to inhaled 
allergen. High and low doses of dsRNA induced lung inflammation; low dose dsRNA 
induced increased IL-4 production during sensitisation, whilst high dose dsRNA 
induced increased production of IFN-y. Inflammation was not induced in TLR3 
knockout mice, low dose dsRNA did not induce inflammation in either IL-13 or IL-4 
knockout mice and high dose dsRNA did not induce inflammation in IFN-y knockout 
mice, suggesting that the two doses of dsRNA induced inflammation via different 
pathways, hence exposure to allergen during viral infection could induce an asthmatic 
response through both Thl- and Th2-mediated pathways. 
There is evidence both for and against the hypothesis that Thl cells protect against 
allergic asthma. It may be that in healthy individuals, Thl responses in the lung to 
inhaled allergens protect against asthma and these mechanisms are defective in allergic 
asthmatic subjects, allowing the Th2-mediated disease to develop unhindered. Once 
allergic disease has become established, Thl responses, such as those induced by 
respiratory viral infection, may exacerbate the asthmatic response to inhaled allergen 
through production of pro-inflammatory mediators that synergise with mediators 
produced by allergen-specific Th2 cells, causing a worsening of disease. 
1.2.11 The role of regulatory T cells (Tregs) in allergic asthma 
Tregs are a specific subset of T-cells that control immune responses including 
autoimmune reactions to self antigens and responses to exogenous antigens including 
allergens. There are several types of Treg, such as natural T regulatory cells (nTregs) 
and inducible or adaptive Tregs, including the T regulatory type 1 (Trl) cells and T 
helper type 3 (Th3) cells. Natural Tregs develop in Hassall's corpuscles of the thymus 
as part of the T-cell repertoire (193) although they may also be induced in the periphery 
from memory T-cells (194). They express the surface molecules CD4 and CD25 and the 
Treg lineage-specific transcription factor forkhead box p3 (Foxp3) (195, 196). 
CD8+CD28" Tregs have also been described in humans (197) and mice (198). Natural 
Tregs suppress immune responses via several mechanisms including secretion of anti-
inflammatory cytokines (IL-10 and TGF-(3), and through cell-cell contact via CTLA-4 
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(an inhibitory member of the CD28 superfamily) (199). Adaptive Tregs are induced in 
the periphery from naive T-cells. Tr 1 cells are induced through an IL-10-dependent 
mechanism and produce high levels of IL-10 and TGF-13 (200), whilst Th3 cells are 
induced through oral exposure to antigen and produce high levels of TGF-13 (201). 
Human studies have suggested that Treg function is impaired in allergic asthmatic 
disease. CD4+ CD25+ T-cells were isolated from peripheral blood and stimulated with 
allergen; Tregs from both allergic asthmatic and healthy subjects could suppress 
proliferation and production of Thl and Th2 cytokines from autologous allergen-
specific CD4+ CD25" T-cells (202). However, Tregs from a number of the allergic 
asthmatic subjects could not suppress allergen-specific proliferation or Th2 cytokine 
production whilst retaining the ability to suppress IFN-y production, suggesting a 
potential defect in Treg function in some allergic asthmatic subjects. The balance 
between allergen-specific Th2 cells and induced allergen-specific Trl cells may 
determine the response to allergen exposure, as Tr 1 cells are the dominant allergen-
specific T-cell population in healthy subjects whilst allergen-specific Th2 cells 
dominate in allergic asthmatic subjects (203). CD4+ CD25+ T-cells from healthy atopic 
subjects show decreased ability to suppress the allergen-specific proliferative response 
of autologous CD4+ CD25" T-cells compared to those from healthy non-atopic subjects, 
and this ability decreases even further in CD4÷ CD25+ T-cells from allergic rhinitic 
subjects during the pollen season (204). This supports the theory that an imbalance 
between Th2 and Treg cells may underlie development of allergic asthma and suggests 
that Treg function is impaired in atopic subjects. A study comparing the suppressive 
ability of Tregs from birch pollen allergic subjects in and out of the pollen season 
showed that outside of the pollen season, Tregs from allergic subjects could suppress T-
cell proliferation and production of Thl and Th2 cytokines to a similar degree as Tregs 
from non-atopic subjects (205); however, during the pollen season, the ability of Tregs 
from allergic subjects to suppress the production of IL-13 and IL-5 diminished 
significantly whilst suppression of IFNI production was retained, suggesting an 
impairment in Treg function during the pollen season. Glucocorticoids may treat 
asthma, at least in part, by boosting the ability of Tregs to suppress the Th2-mediated 
mechanisms underlying allergic asthma (206, 207). Specific immunotherapy increases 
the numbers of competent CD4+ CD25+ Treg cells, thus increasing suppression of the 
allergic response and tolerance to allergen (208, 209). TNF-a may inhibit Treg function 
in allergic asthma as it downregulates Foxp3 expression in Tregs in vitro and decreases 
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their suppressive capacity (210). Administration of anti-TNF-a to cultured Tregs from 
allergic asthmatic subjects increased Foxp3 expression and suppressive capacity. TNF-
a is overexpressed in the airways of allergic asthmatic subjects and several of its 
biological functions may exacerbate asthmatic disease (211). The ability of anti-TNF-a 
to not only antagonise these functions but also to increase Treg functional capacity may 
underlie its efficacy in treating asthma. 
1.2.12 The role of Th2 cells in allergic asthma 
It is now widely accepted that allergic asthma is a disease mediated primarily by the 
actions of cytokines produced by Th2 cells, such as IL-4 (16), IL-5 (212), IL-9 (213) 
and IL-13 (214, 66). There is evidence from human studies that CD4+ Th2 cells are the 
central mediators of allergic asthma. Analysis of T-cell activation and cytokine 
production in BALF of allergic asthmatics after allergen challenge showed that CD4+ T-
cell activation occurred in the absence of appreciable CD8+ T-cell activation and there 
was an increase in the number of IL-4 and IL-5 mRNA+ BALF cells, which were 
predominantly T-cells (215). Increase in these cytokines correlated with eosinophil 
number in BALF after challenge, suggesting that cytokines produced by activated Th2 
cells mediate events in the LAR such as eosinophilic influx into the lungs. Spontaneous 
IL-5 production without allergen stimulation is increased in BALF cells and PBMCs 
from both atopic and non-atopic asthmatic groups compared to atopic and non-atopic 
control groups and correlates with lung eosinophilia and airway narrowing (216). Upon 
allergen stimulation, both atopic groups (asthmatic and non-asthmatic) responded to a 
similar extent in terms of T-cell activation, but the increase in IL-5 production was 
greater from both BALF cells and PBMCs in the atopic asthmatic group. Analysis of 
cytokine production from BALF cells taken after specific allergen challenge in allergic 
asthmatic subjects showed increased levels of IL-13 and decreased levels of IFN-y 
compared with baseline (217). T-cell clones derived after diluent challenge produced 
IL-13, IL-4 and IFN-y, whilst those derived after allergen challenge secreted IL-3, IL-4, 
IL-5 and IL-13, suggesting that allergen challenge in allergic asthmatic subjects induces 
a strong Th2-mediated response. Expression levels of T-bet and the Th2 lineage-
specific transcription factors GATA-binding protein 3 (GATA-3) and c-maf increased 
in BALF T-cells after allergen challenge in allergic asthmatic subjects (218). 
Expression of c-maf correlated with the number of IL-4+ CD4+ T-cells in BALF and the 
amount of IL-5 secreted into BALF. IFN-y+ T-cell numbers decreased in response to 
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allergen challenge, suggesting the induction of a dominant Th2-mediated response upon 
allergen exposure in allergic asthmatic subjects. 
There is also evidence suggesting a role for allergen-specific T-cells in induction of the 
LAR. The LAR was previously shown to depend upon allergen-specific IgE (219), but a 
later study demonstrated that the LAR was IgE-independent in asthmatic patients 
sensitive to house dust mite allergen (220). Intradermal challenge of asthmatic patients 
with peptide derivatives of the major cat allergen Fel d 1 showed that an LAR could be 
induced without a preceding EAR (221). A similar result was seen when challenge with 
peptide occurred via inhalation (222). Such peptides cannot cross-link IgE on the 
surface of mast cells due to their short length (less than 20 amino acids) suggesting IgE 
is not necessary for LAR induction. As the response to peptide challenge was dependent 
upon presentation by MHC class II molecules, this suggested that the LAR was 
mediated by allergen-specific T-cells. Allergic asthmatic patients were analysed for T-
cell activity and BHR in response to inhaled Fel d 1-derived peptides (223); in those 
patients who responded to peptide challenge (i.e. a LAR was induced), there was an 
increase in CD4+ T-cell number in BALF and bronchoscopy sections, whilst numbers of 
other inflammatory cell types remained constant. 
Levels of Th2 cytokines are increased in the airways of allergic asthmatic subjects. 
Levels of IL-4 in exhaled breath condensate are significantly higher in children with 
untreated allergic asthma than either normal control subjects or children with steroid-
controlled asthma (224). Levels of IL-5 mRNA in the cells of BALF and bronchial 
biopsy specimens are increased in patients with allergic asthma compared to normal 
controls, with more than 70% of the mRNA signals originating from CD4+ and CD8+ T-
cells, predominantly from in CD4+ cells (18). Levels of IL-9 mRNA are elevated in the 
airways of allergic asthmatic subjects compared with healthy controls even under 
baseline conditions (225). Baseline levels of IL-9 are low in allergic asthmatic and 
normal control subjects but after challenge, IL-9 levels (mRNA and protein) increase in 
the allergic asthmatic group and correlate with the percentage of eosinophils in BALF 
(226). Lymphocytes are the primary source of IL-9 and the correlation with eosinophil 
number suggests that IL-9 may play an important role in the LAR. Numbers of IL-13 
mRNA+ cells are increased in the bronchial mucosa of both atopic and non-atopic 
asthmatics compared with atopic and non-atopic non-asthmatics (227), and levels of IL-
13 mRNA are related to numbers of eosinophils in the bronchial mucosa. 
62 
Evidence from mouse models of allergic asthma supports the role of Th2 cells in 
asthma. Lack of signal transducer and activator of transcription-6 (Stat-6) expression, a 
transcription factor involved in signalling through the IL-4 pathway, prevents the 
differentiation of activated T-cells into Th2 cells and the production of IgE from B-cells 
(228, 229). Stat-6 knockout mice do not develop AHR, mucus hypersecretion or show 
increased IgE production in response to allergic sensitisation, and there is less 
eosinophilia than in wild-type mice (230). Inhibition of Th2 development in these mice 
prevents development of allergic disease, suggesting the development of allergic 
disease in this mouse model is Th2 cell-dependent. CD4+ T-cell-depleting monoclonal 
antibodies inhibit the development of AHR, eosinophilia, IgE production, IL-13 and 
TGF-0 secretion, goblet cell hyperplasia and lung fibrosis in a mouse model of allergic 
asthma (231). Depletion of CD8+ T-cells had no effect on disease. 
Activated allergen-specific Th2 cells in sensitised individuals secrete IL-4, IL-5, IL-9 
and IL-13 and through these cytokines mediate allergic asthma pathogenesis. IL-4 
induces class-switching in allergen-specific B-cells to produce IgE, which primes 
tissue-resident mast cells and basophils recruited from the periphery for activation upon 
subsequent re-exposure to allergen (58). It is also required for the development of a 
Th2-mediated response to antigen (232) and promotes differentiation of newly-activated 
T-cells into Th2 cells (233), thus increasing polarisation of the lung environment 
towards a Th2 phenotype, favouring continuing pathogenesis of the disease. The IL-4 
receptor shares a common subunit with the IL-13 receptor (234) which may explain 
why many of the functions of IL-4 and IL-13 overlap. 
IL-5 induces migration, differentiation and survival of eosinophils in the lung. IL-5 
induces eosinophil differentiation from haematopoietic precursors in culture and 
promotes their survival (235), migration into the airways (236) and activation (237). 
During sensitisation to allergen, IL-5 production causes airway eosinophilia (238), 
priming the lungs with an inflammatory cell which becomes activated upon subsequent 
allergen challenge, as described in section 1.2.4. 
In vitro cultures of human lung mast cells indicate that IL-9 production by Th2 cells 
acts in conjunction with the mast cell growth factor, stem cell factor (SCF), to induce 
proliferation, expansion, survival (239) and differentiation into mature effector cells 
(240). It may induce mucus hypersecretion in the lung during tissue repair (241). IL-9 
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induces differentiation of human bronchial epithelial cells into mucus-secreting goblet 
cells in vitro, both in the context of tissue repair and when cells are not fully 
differentiated. As constant tissue injury and repair processes are a feature of allergic 
asthma, IL-9 may promote mucus hypersecretion. 
IL-13 induces class switching in allergen-specific B-cells to produce IgE and IgG4 
using a mechanism similar to, but not dependent upon, IL-4 (66). It is critical to the 
development of allergic airway inflammation and AHR in mouse models of allergic 
asthma — blocking IL-13 using a soluble IL-13-receptor molecule attenuated the 
allergen-induced asthmatic phenotype, shown as decreased AHR, lung inflammation, 
lung eosinophilia and goblet cell hyperplasia (242). Administration of exogenous IL-13 
causes an asthmatic phenotype independently of T-cell activation, but the IL-4R (shared 
by IL-4 and IL-13) is required for disease induction. Another study used the same 
method of blocking IL-13 but also analysed the effect of IL-13 blockade on levels of 
allergen-specific IgE (243). As IL-13 blockade occurred after allergen sensitisation, its 
lack of effect is possibly due to IgE production having already occurred, supported by 
the finding that administration of exogenous IL-13 to unprimed mice induces an 
increase in IgE production. Human ASM cells express receptors and respond to IL-4 
and IL-13, as shown by phosphorylation of downstream molecules such as Stat-6 and 
the mitogen-activated protein kinase (MAPK) extracellular-signal related kinase (ERK) 
(244). IL-4 and IL-13 caused phosphorylation of these proteins at different times, 
suggesting that they use different mechanisms to signal in ASM cells. IL-13 reduces 
ASM cell responsiveness to the p2-agonist isoproterenol, whilst IL-4 has no effect, 
indicating a potential underlying mechanism for the effects of IL-13 on mediating AHR 
(244). 
1.3 	Mouse models of allergic asthma 
1.3.1 The principles of molecular cloning and their use in animal models of 
disease 
Recombinant DNA technology has revolutionised the study of DNA and the genes 
encoded within it by providing simple techniques through which they can be analysed, 
identified and manipulated. Restriction endonucleases (restriction enzymes) are 
produced by bacteria, each strain producing one or more unique enzymes, as a defence 
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against infection with bacteriophages (245). The enzymes cut DNA at specific 
palindromic sites (creating blunt or overhanging 'sticky' ends) within the sequence, 
destroying the genetic material of invading viruses (the bacterium's own DNA is 
methylated to protect it from degradation). The discovery of DNA polymerase in E.coli 
(246) and the observation that DNA can re-anneal after being denatured into single 
strands by heating (247) provided a way of replicating DNA in vitro, through use of an 
appropriate primer (248). Such primers can be synthesised chemically or through use of 
the polymerase chain reaction (PCR) (249). The finding that viral and bacterial plasmid 
vectors can be used to massively amplify specific sequences of DNA (250), inserted by 
digestion with restriction enzyme and ligation using the bacterial enzyme DNA ligase 
(251), led to the routine use of DNA cloning in the study of genetics. DNA from an 
organism is digested into small fragments using a particular restriction enzyme before 
ligating these fragments into a vector digested using the same enzyme. Vectors are 
transferred into target bacteria either via viral infection or through transformation (use 
of calcium chloride and heat shock to temporarily permeabilise bacterial cell walls to 
DNA) (252). Due to the presence of antibiotic resistance genes in the vectors (253), 
only successfully transformed bacteria will be able to grow on agar containing this 
antibiotic, thus only those bacteria carrying a DNA sequence of interest should form 
colonies (bacteria transformed with empty vectors will also form colonies but can be 
distinguished if inserted DNA sequences disrupt a reporter gene e.g. (3-galactosidase in 
the plasmid — expression of this gene can then be detected through use of a colorimetric 
substrate; colonies containing empty plasmids will appear coloured). This produces 
DNA libraries - similar libraries can be constructed from mRNA products of a cell 
using the viral enzyme reverse transcriptase to convert the mRNA into complementary 
DNA (cDNA) (254). These libraries are used in a variety of ways; for example, use of 
labelled DNA probes can locate genes of interest on chromosomal DNA (or cDNA), 
allowing further characterisation of the gene (255). Probes were initially derived from 
the amino acid sequence of proteins using the genetic code (256) and with the advent of 
robust DNA sequencing methods (257), from DNA sequences themselves. This 
allowed, for example, the identification of genes related to one already known or 
conserved genes in other species (258) and often aided in the study of diseases caused 
by gene mutations, such as cystic fibrosis (259). Cloning techniques have also been 
instrumental in sequencing entire genomes from particular organisms, including humans 
(260). 
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DNA cloning techniques have proved crucial in the field of DNA engineering. These 
techniques allow researchers to manipulate DNA to produce new recombinant 
sequences allowing improved study of genes and products and the regulation of 
transcription and translation. Use of restriction enzymes allows the combination of gene 
segments that would not otherwise exist, allowing use of reporter genes (e.g. green 
fluorescent protein) to monitor gene expression under different conditions and in 
different cell types (261) and to aid in the identification of gene promoter and repressor 
regions (262). Gene sequences can be altered by site-directed mutagenesis, e.g. using 
PCR primers which change the sequence of a gene at one or more base pairs (263), and 
use of expression vectors (264) to express the mutated products (or products of any 
gene) in cells allows investigation into the function of the resulting protein. Expression 
vectors can also be used to produce large quantities of protein encoded by a particular 
gene allowing easier characterisation of protein structure and interaction. 
Another powerful use for DNA cloning techniques is in the generation of transgenic 
organisms (265). Transgenesis can be used to overexpress a particular protein to 
determine its effect in excess (99), to express a mutant form of a protein to determine its 
function (266) or in some cases to 'knock out' expression of a particular gene to assess 
the effect of its absence (98). Such organisms can be particularly useful in the study of 
human disease where transgenic expression of the gene or genes (mutant or otherwise) 
thought to be involved in disease pathogenesis can be used to more accurately model 
the disease in an in vivo setting (98, 99). 
1.3.2 The use of animals in human disease modelling 
To fully characterise and study the aetiology of human diseases, it is necessary to carry 
out studies in an in vivo system or to study organ and tissue systems further in vitro. As 
these studies would be unethical in humans, animal models of disease have been created 
to allow disease to be studied in detail. For animal models to be useful, accurate models 
of human disease, it is preferable that they share the same pathways of initiation and 
pathogenesis. Such models can be generated in many ways dependent upon the disease 
being modelled. For example, models of viral infection involve exposing the animal to 
the same pathogen as causes disease in humans, usually by the same route and 
analysing the disease induced, which, in a successful model, mimics the disease as it 
occurs in humans. A number of these models exist, such as influenza infection models 
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(267) and models of respiratory syncytial virus (RSV) infection (268). Use of such 
models has allowed researchers to identify underlying mechanisms of pathogenesis and 
the immune responses raised against such pathogens (267, 268, 269) as well as the 
effect of co-infection with more than one pathogen, e.g. concurrent influenza and 
bacterial infections (270). Other models of infectious disease include models of malaria 
(271) and Schistosoma mansoni infection (272). 
Other diseases are modelled using chemical or physical means to induce a disease 
phenotype in animals, for those diseases where the underlying cause is not an infectious 
agent, such as epilepsy, where injection of kainic acid into the hippocampus of mice 
induces a disease syndrome similar to temporal lobe epilepsy in humans (273). Such a 
model has allowed testing of anti-epileptic therapies for efficacy (274) as well as 
helping to identify mechanisms leading to disease development (275). Models of 
ischaemic stroke have been developed using direct surgical occlusion of cerebral 
arteries, giving a phenotype which is close to that seen in human stroke (276). Whilst 
not modelling the route of disease induction exactly, these models still give useful 
information as to the underlying disease mechanisms and lead to better understanding of 
the disease and the potential for developing effective therapies. 
Animal models have also been used to extensively study those diseases caused by 
dysregulation of the immune system, such as allergic and autoimmune diseases. The 
most widely used model of allergic asthma is the OVA model which will be described 
in more detail in Sections 1.3.3-1.3.5. An example of an autoimmune disease, where a 
failure of the adaptive immune response to recognise self antigens as self leads to 
destruction of particular tissues, which has been modelled in animals is multiple 
sclerosis (as experimental autoimmune encephalomyelitis, or EAE) (277, 278). These 
original models involved systemic injection of mice with an antigen involved in the 
induction of disease (allergen protein for allergic asthma, the self-antigens myelin basic 
protein or proteolipoprotein for EAE), as these diseases do not occur naturally in mice. 
Such immunisation led to the induction of syndromes similar to the disease in humans, 
despite lacking a similar mode of induction. In the case of EAE, a disease phenotype 
involving progressively severe loss of limb function and paralysis, inflammation of the 
CNS, nerve demyelination and axonal loss, similar to the pathology seen in multiple 
sclerosis, was induced. Such models have been instrumental in identifying the 
mechanisms at work in these diseases, and provide a means of finding targets for 
67 
therapeutic intervention. An example of a naturally-occurring mouse model of 
autoimmune disease is the non-obese diabetic (NOD) mouse, which develops 
spontaneous type I diabetes with many of the features of the human disease, including 
the presence of autoreactive T-cells and B-cells and islet-specific autoantibodies which 
shows similar genetic linkages to those seen in humans (279). This strain has been 
widely used to study the human disease and develop potential therapies. 
As well as the use of wild-type animals in the creation of models of human disease, the 
advent of transgenic technology (265) has allowed further study into mechanisms 
underlying disease pathogenesis in a number of ways. The ability to genetically 
manipulate animals (usually rodent) to induce specific mutations or to overexpress or 
knock out expression of certain genes in a controlled fashion allows the impact of 
various proteins and genes on disease phenotype to be examined and may lead to the 
production of refined models of disease. Examples of the use of such transgenic animals 
in the study of allergic asthma will be discussed in Section 1.3.5, with reference to 
transgenic mice either overexpressing or lacking expression of the Th2 cytokines IL-4, 
IL-5, IL-9 and IL-13. Another example of the use of transgenic mice to produce an 
improved model of disease is the use of humanised TCR transgenic mice in EAE (280, 
281, 282, 283). Such mice express a human TCR isolated through analysis of T-cell 
lines derived from human MS patients and the human MHC class II molecule expressed 
by the patient which is known to present peptide epitopes from the autoantigen 
responsible for causing the disease. These mice provide improved models of disease; in 
some cases, the mice develop EAE spontaneously with a very similar progression of 
disease to the human MS (282, 283). 
As described previously, the study of disease in humans is difficult due to ethical and 
logistical constraints; those investigations that can be carried out are limited in scope. 
Most studies of allergic asthma in humans have been limited to in vitro culture of 
PBMCs or cells taken from bronchial biopsies or BALF, or histochemical analysis of 
sections of human lung tissue. Such studies give information of a limited nature; 
histological analysis gives a view of a single instant in time, whilst in vitro cultures lack 
the complicated interplay of mediators and other cell types found in vivo. Animal 
models of allergic asthma have been widely used to more closely study the interactions 
and disease mechanisms that lead to the development of allergic asthma in humans. 
Whilst models have been developed using animals such as the guinea pig (284) or rat 
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(285), most current models have been developed in the mouse, for several reasons. 
Their small size, ease of housing and the ability to breed large numbers of mice makes 
them ideal for use; the commercial availability of inbred strains with defined 
immunological properties and genetic similarity allow experiments to be well 
controlled. There are also a greater number of reagents, such as monoclonal antibodies 
or soluble cytokine receptors, available for use in mice than for any other species, and 
the technology available for transgenesis and gene knockdown is more advanced in 
mice than other species. 
1.3.3 The use of ovalbumin (OVA) as an allergen in mouse models of allergic 
asthma 
Initial protocols to develop allergic asthmatic-like disease in mice involved two 
intraperitoneal sensitisation injections of OVA adsorbed onto aluminium hydroxide 
(alum) approximately 5 days apart (286, 287). Sensitisation was followed by aerosol 
challenge with nebulised OVA 12 days after the first injection, and Garlisi et al. (249) 
also re-challenged 1, 2 or 3 weeks later. Kung et al. (286) found significant airway and 
BALF eosinophilia in OVA-challenged mice 24 hours post-challenge which persisted 
for up to 10 days. Elevated levels of serum IgE, mucus hypersecretion in the airways, 
epithelial damage and submucosal oedema were also features of this model, all of which 
are consistent with human allergic asthma. Garlisi et al. (287) showed similar findings 
after one challenge with OVA aerosol. They investigated T-cell influx into BALF after 
one challenge, showing an increase in cell numbers, predominantly CD4+ T-cells, 
persisting for up to one week after challenge. Th2-type cytokine mRNA levels (IL-4 
and IL-5) in lung tissue were also increased after one challenge, with no corresponding 
increase in IFN-y. Lung function changes 24 hours after challenge in response to 
acetylcholine showed an increase in BHR in OVA-challenged C57BL/6 X DBA/2 
(B6D2F1) male mice. When mice were re-challenged after 1 week, lung inflammation 
was greater in terms of eosinophil and T-cell influx. A large influx of predominantly 
CD4+ T-cells with an activated memory phenotype (CD44+ CD45RB10"') was seen up to 
3 days after the second challenge after which T-cell numbers declined to the same level 
as that after only one challenge. Higher levels of IL-4 and IL-5 mRNA were also seen, 
and responsiveness to acetylcholine was increased. There were no noticeable changes in 
extent of epithelial damage or mucus hypersecretion. The phenotype induced in the 
mice by the protocols above, of eosinophilic and lymphocytic inflammation in the lung, 
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increased levels of serum IgE and BALF Th2-type cytokines, lung epithelial damage 
and mucus hypersecretion, along with an increase in BHR, is consistent with human 
disease. A different model involved sensitising male Balb/c mice with intraperitoneal 
injections of OVA in saline, and challenging 4 weeks later with aerosolised OVA (288). 
Some features of allergic asthma were seen, such as increases in total and OVA-specific 
serum IgE, an increase in mucosal exudation of macromolecules into BALF and 
increased numbers of degranulated mast cells in the lung. A bronchoconstrictive 
response within 15 minutes of challenge was also seen, similar to the EAR in humans. 
Lung function was measured 12 and 24 hours after challenge and showed an increase in 
responsiveness to methacholine. This model did not elicit any inflammatory cell influx 
into the lungs and BALF, and only small mononuclear cell infiltrates were seen in the 
lungs of some OVA-challenged mice. As such, models using alum as an adjuvant for 
sensitisation have predominated. 
Other models have used different routes and methods of allergen sensitisation to induce 
disease that more faithfully mimics development of disease in humans. One of the main 
criticisms of the original models is use of alum as no such adjuvant is required for 
human sensitisation and because alum may increase non-specific Th2-mediated 
responses to antigen (289), hence could be driving an artificial response in the lungs of 
antigen-alum sensitised mice. Initial experiments without use of alum as an adjuvant 
failed to induce lung inflammation (288), but later studies generated an allergic 
inflammatory response in the lungs of sensitised mice without use of an adjuvant. A 
model in Balb/c mice, requiring intraperitoneal sensitisation with OVA solubilised in 
saline solution and one intranasal challenge with OVA induced an allergic asthmatic-
like disease phenotype characterised by an increase in AHR, serum IgE and IgGl, 
BALF eosinophilia, upregulated production of IL-4, IL-5 and IL-13 in BALF and 
mucus hypersecretion in the airways (230). A novel model used subcutaneous implants 
of heat-coagulated hen's egg white as a source of allergen in Balb/c x A/J mice to 
model persistent allergen exposure (290). Challenge with intratracheal OVA 14 days 
later induced an asthma-like phenotype in the lung, characterised by eosinophilic and 
lymphocytic influx into lung tissue and BALF persisting for up to 3 weeks after 
challenge, mucus hypersecretion and the suggestion of bronchoconstriction in the 
airways from histological analysis. 
Whilst these models have identified a number of pathways and mediators important in 
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asthma, they have been criticised as not being accurate models of human disease. One 
criticism is that the method and route of sensitisation is not the same as for humans, 
where sensitisation occurs via exposure to low doses of allergen in the airways with 
challenge occurring via the same route. Sensitisation using low dose OVA aerosols in 
mice induces unresponsiveness to further allergen challenge (291). Another criticism of 
some models is their lack of a chronic phase; most of the original models induced an 
acute form of disease which lacked the hallmarks of chronic disease seen in humans, in 
particular, lung remodelling. A study addressing these issues investigated the 
importance of mouse strain on development of allergic asthma-like disease. 
Sensitisation and challenge occurred via repeated intranasal administration of OVA to 
mice 3 times a week for 4, 8 or 12 weeks. Disease was induced by this method in one 
strain only, A/J (292). At all time points of analysis in A/J mice, OVA exposure induced 
a massive influx of eosinophils into the lung, an increase in serum IgE, increased 
inflammatory infiltrates into the lung mucosa, goblet cell hyperplasia and increased 
mucus secretion, increased secretion of IL-4, IL-5 and IL-13 into BALF and local 
lymph nodes and increased AHR. This model showed signs of lung remodelling in 
response to chronic challenge with allergen, such as increased collagen deposition in the 
basement membrane, thickening of airway walls and ASM layer and an increase in 
BALF TGF-I3 levels. This model demonstrates allergen sensitisation and challenge 
through a similar route to that believed to occur in humans and induction of chronic 
disease by repeated allergen exposure leading to lung remodelling. It also demonstrates 
that the strain of mouse used can have a significant impact on the extent of disease 
induction; no disease was induced using this protocol in Balb/c or C57BL/6 mice. 
A model of chronic disease induction has been developed in Balb/c mice, involving 
sensitisation through intraperitoneal injection of OVA adsorbed onto alum, followed by 
challenge with aerosolised OVA for 3 days/week for up to 8 weeks (293). Increasing 
duration of exposure to OVA challenge increased the extent of disease, characterised by 
increasing serum levels of total and OVA-specific IgE, increasing tracheal and airway 
eosinophilic and lymphocytic inflammation, increased AHR in response to 
methacholine, increasing goblet cell hyperplasia, subepithelial fibrosis in the airways 
and epithelial thickening in the trachea accompanied by increased collagen deposition 
beneath the epithelium. The latter features are characteristic of lung remodelling. 
Another protocol of chronic allergic airway disease induction was developed in Balb/c 
mice, involving sensitisation through two intraperitoneal injections with OVA 
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solubilised in saline, followed by challenge on two consecutive days with aerosolised 
OVA one week later (294). Mice were allowed to recover from the induced acute 
disease and then re-challenged with aerosolised OVA at time points from 3-18 months 
after initial sensitisation, allowing both acute and chronic disease induction to be 
modelled and analysed. Analysis of disease induction after the acute phase of the 
protocol showed a typical disease phenotype i.e. infiltration of eosinophils and 
lymphocytes into BALF and peribronchial and perivascular spaces, goblet cell 
hyperplasia and mucus hypersecretion, increased serum IgE and increased AHR. These 
responses were greater in magnitude upon re-challenge at all time points analysed 
except for AHR, which remained increased to the same extent at all time points, and 
mucus production, which peaked when re-challenge occurred 3 months after initial 
sensitisation. When re-challenge with OVA occurred nearly 18 months after original 
induction of acute allergic airway disease, in vitro stimulation of splenocytes and 
mediastinal lymph node cells with OVA induced production of high levels of IL-4 and 
IL-5, suggesting the presence of a pool of long-lived antigen-specific memory T-cells in 
this model. T-cells isolated from the lung nearly two years after OVA sensitisation had 
a memory phenotype (CD44+ CD45RBI0w CD62LI' CD251'), suggesting that T-cell 
memory persists in the lungs of mice that have recovered from acute allergic airway 
disease. Whilst this model induced a chronic form of allergic airway disease, there was 
no analysis of the effects on phenomena associated with chronic disease, such as lung 
remodelling. 
1.3.4 Adoptive transfer of OVA-pulsed APCs or OVA-specific T-cells as a means 
of inducing allergic airway disease in mice 
A number of studies have investigated the ability of DC pulsed with OVA in vitro to act 
as APC and induce disease pathology in the lung when transferred into naïve mice. 
Intratracheal administration of OVA-pulsed DC followed two weeks later by challenge 
on seven consecutive days with aerosolised OVA induced significant eosinophilic and 
lymphocytic (predominantly CD4+ T-cells) infiltration into BALF, peribronchial and 
perivascular eosinophil-rich inflammatory infiltrates, goblet cell hyperplasia and mucus 
hypersecretion (54). Levels of IL-4 and IL-5 were increased in BALF and mediastinal 
lymph nodes, predominantly localised to CD4+ T-cells. 
Others have investigated the ability of adoptively transferred OVA-specific CD4+ T- 
72 
cells to induce disease in naive recipients upon challenge with OVA. Splenocytes were 
isolated from unsensitised mice and cultured for 3 days in the presence of OVA before 
transfer into naïve recipients. (295). After a single challenge with aerosolised OVA 3 
days later, a disease phenotype indicative of allergic airway disease was induced, 
comprising eosinophilic and lymphocytic influx into BALF, an increase in IL-5 
secretion into BALF and an increase in serum IgE. The effect of transferred cells on 
lung eosinophilia was dose-dependent and mediated by CD4+ T-cells with an activated 
memory phenotype (CD4high CD62L1' CD25+); depletion of cells with this phenotype 
before transfer abolished eosinophilia and IL-5 production. A similar protocol 
adoptively transferred purified cultures of OVA-specific T-cells differentiated in vitro 
into Thl or Th2-type cells (296). T-cells were originally isolated from a strain of mice, 
D011.10, that transgenically express a TCR specific for a particular epitope of the 
ovalbumin protein, OVA323-339  (297). CD4+ T-cells isolated from the spleens of 
D011.10 mice and cultured in the presence of OVA323-339 and either Thl- or Th2-
polarising cytokines produced Thl and Th2 OVA-specific T-cell cultures which were 
transferred into recipient naive wild type Balb/c mice, followed by challenge on 
consecutive days for 7-10 days starting 1 day after transfer. Transfer of OVA-specific 
Th2 cells induced moderate lung inflammation, primarily eosinophilic with some 
lymphocyte infiltration and increased mucus production upon challenge, consistent with 
an allergic asthma-like phenotype. Transfer of OVA-specific Thl cells induced 
moderate, predominantly neutrophilic, lung inflammation and no mucus production 
upon challenge. T-cells of both types trafficked to the lungs and the draining lymph 
node. 
1.3.5 Use of the OVA model in investigating disease pathogenesis in allergic 
asthma 
The various models of allergic asthma using ovalbumin as a model allergen have 
allowed investigation into the mechanisms and mediators governing the development 
and exacerbation of allergic asthma. Work in human studies and mouse models has 
identified certain molecules and cell types which are implicated in causing or worsening 
of the disease. The OVA model allows further studies into the mode of action of these 
mediators, either through the ability to study or modulate their function in an in vivo 
system, or, often more informatively, through the ability to genetically manipulate mice 
to either overexpress or delete expression of a gene. It is possible to control the 
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expression of certain molecules so that they are only expressed in certain parts of the 
body or only at certain times, for example when the animals are treated with a substance 
that switches on or off expression of a gene. Entire cell lineages can be deleted through 
deletion of a specific gene crucial to their differentiation or development. The effect of 
the overexpression or absence of each mediator on the disease phenotype (e.g. it may 
worsen, abolish or cause no change to the phenotype) can give further insight into the 
processes mediated by the cell or molecule. Many such experiments have been carried 
out using the OVA model, investigating the causes behind many of the characteristic 
hallmarks of asthma, such as AHR, lung inflammation and airway remodelling. 
Examples of these experiments are described below as an illustration of the use of 
animal models of human disease to elucidate disease mechanisms and identify 
therapeutic targets. 
The OVA models have been extremely informative in elucidating the role of Th2 
cytokines in allergic asthma; many of the findings described in Section 1.2.12 were 
discovered using these models. Additional experiments in cytokine gene knockout and 
transgenic mice have added to this knowledge. The lack of disease induction by OVA 
sensitisation seen in IL-4-/- (298) and IL-54" (299) mice highlights the importance of 
these cytokines in allergic lung disease; disease phenotype was restored in IL-5-/- mice 
by adoptive transfer of wild-type OVA-specific Th2 cells (238) or viral expression of 
IL-5 (299). Blocking both IL-4 and IL-5 in the OVA model in Balb/c mice was required 
to abolish all features of allergic asthma (300). Induction of allergic airway disease 
using OVA in IL-94" mice was relatively unaffected by the lack of IL-9 (301), despite 
the efficacy of an IL-9 blocking antibody during sensitisation in decreasing the 
development of allergic airway disease (302). Differences in methodology or strains 
(C57BL/6 x DBA/2 (302), Balb/c (301)) may explain this discrepancy. IL-13-/- mice fail 
to develop AHR in response to OVA sensitisation and challenge, but other 
characteristics of allergic airway disease such as lung eosinophilia, elevated serum IgE 
and increased production of IL-4 and IL-5 in the lung remain (82). Administration of 
recombinant IL-13 early in the sensitisation phase could reconstitute the AHR response. 
Blocking IL-13 function using a soluble IL-13R molecule attenuated induction of 
disease by OVA sensitisation (242, 243). The effects on disease induction by OVA of 
gene depletion of IL-13 was compared with gene depletion of four major Th2-
associated cytokines (IL-4/5/9/134-) (303). Whilst AHR, ASM hyperplasia and increase 
in serum OVA-specific IgE were abolished in both strains, goblet cell hyperplasia and 
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lung eosinophilia were completely abolished in the quadruple knockout mice but only 
partially attenuated in IL-13-/- mice, suggesting that some allergic disease features are 
dependent upon IL-13, whilst others also require action of at least one other Th2-related 
cytokine. Transgenic overexpression of lung-specific IL-5 (304), IL-9 (305, 306) and 
IL-13 (307) induces a phenotype similar to allergic disease (AHR, lung eosinophilia, 
goblet cell hyperplasia, increased serum IgE and Th2 cytokine expression in the lung, 
and some features of lung remodelling) without any requirement for allergen 
sensitisation, indicating that it is the actions of these cytokines that induce many 
features of allergic lung disease in these models. 
The OVA model has been used to track changes ocurring during a LAR (308). Mice 
were intraperitoneally sensitised with OVA and challenged with OVA aerosol, before 
being allowed to recover for 10 days. Mice were then provoked by nebulisation with 
high dose OVA and changes in lung function were monitored over the next several 
hours. A decrease in lung function was observed beginning about 90 minutes after 
provocation and persisting for up to 6 hours, peaking at approximately 4 hours, similar 
to the LAR seen in humans. Changes in the lung corresponding to the decrease in lung 
function were investigated; a significant influx of lymphocytes and eosinophils into 
BALF was seen, increasing up to 24 hours after provocation, followed by a sharp 
decrease in cell number at 48 hours. Significant mucus secretion was seen in lung 
sections taken 6 hours after provocation at the end of the observed late phase response. 
Cytokine levels in BALF and serum were analysed at various time points — a general 
increase in concentration of the Th2-type cytokines was seen up to 6 hours in BALF 
before a gradual decline to 48 hours, with no change in IFN-y; IL-13 levels in serum 
increased gradually up to 24 hours and then declined whilst a sharper increase was seen 
in IL-5 levels up to 6 hours, after which levels declined more gradually. Levels of 
serum IL-4 and IFN-y were not significantly changed by provocation. Expression of 
Th2 cytokines in lung tissue was significantly increased 6 hours post-provocation. The 
role of T-cells in the induction of the late phase response was investigated by treating 
OVA-sensitised and challenged recovered mice with CD4 or CD8 depleting antibodies. 
Depletion of CD4+ T-cells abolished the late-phase response indicating that CD4+ T-
cells are responsible for induction and mediation of the late phase response in this 
model of allergic asthma. 
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The advent of chronic disease induction protocols using OVA has allowed investigation 
into the underlying mechanisms and mediators involved in airway remodelling, thought 
to be induced in humans by chronic exposure to allergen. The role of the pro-fibrotic 
cytokine TGF-f3 has been investigated in chronic models of disease to ascertain its role 
in the development of allergic airway disease. Administration of an anti-TGF-P 
monoclonal antibody to mice in which allergic airway disease had already been induced 
by OVA sensitisation and challenge at the same time as further challenges with allergen 
prevented deposition of extracellular matrix material in the peribronchiolar regions, 
ASM cell proliferation and mucus production from goblet cells, but had no effect on 
airway inflammation or Th2-type cytokine production established during the acute 
phase of the protocol (309). This implicated TGF-p in the development of lung 
remodelling in chronic allergic airway disease. Thickening of lung epithelium, ASM 
hyperplasia and pulmonary fibrosis can make airway walls stiffer and more prone to 
hyperreactivity, suggesting a role for TGF-p in mediating AHR. Levels of the TGF-(31 
isoform increased in BALF after OVA sensitisation and challenge, peaking 
approximately 7 days after the initial challenge, and being primarily produced by 
airway epithelial cells (310). Administration of anti-TGF-01 had no effect on 
eosinophilic lung inflammation in OVA-sensitised and challenged mice; production of 
IL-4 and IL-13 was enhanced in the absence of TGF-P 1 . Blocking TGF-131 function 
decreased deposition of subepithelial collagen and lessened airway remodelling, but 
increased AHR. This suggests that whilst TGF-f31 is involved in development of lung 
remodelling in allergic airway disease, it may also suppress development of AHR 
induced by allergen exposure, ameliorating the clinical signs of allergic asthma and 
therefore antagonising TGF-p signalling as a means of asthma therapy may not be 
advisable as it could lead to worsening lung function. 
1.3.6 The use of house dust mite allergens in a mouse model of allergic asthma 
A criticism of using ovalbumin as a model allergen in mice is that humans do not 
become sensitised to it, hence it is irrelevant to the development of allergic asthma in 
humans. Models using an allergen known to cause allergic asthma in humans have been 
developed, many making use of house dust mite (HDM) allergens, particularly the 
major allergen from Dermatophagoides pteronyssinus, Der p 1. 
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A number of protocols are used to induce allergic airway disease in mice using HDM 
extract or Der p 1 protein. Protocols were developed along the same lines as the original 
OVA protocols, using intraperitoneal sensitisation with HDM extract followed by 
airway challenge with HDM extract. Sensitisation in one of these protocols occurred 
with HDM extract in complete Freund's adjuvant (CFA), a stimulator of cell-mediated 
immunity, and also involved intraperitoneal injection of pertussis toxin to stimulate an 
enhanced IgE response to allergen (311). This was followed by challenge once a week 
for seven weeks with intranasally-administered HDM extract and induced a phenotype 
consistent with human allergic asthma, namely induction of an inflammatory response 
in the lungs, primarily eosinophilic and lymphocytic and an increase in serum HDM-
specific IgE. An increase in HDM-specific proliferation was seen in T-cells isolated 
from draining lymph nodes 10 days after the last sensitisation injection. Another 
protocol administered Der p 1 adsorbed onto alum intraperitoneally at high, medium or 
low dose protein, followed 2 weeks later by intranasal challenge with high, medium or 
low dose Der p 1 protein, after which disease induction was analysed (312). Disease 
induction was evident using even low doses of Der p 1; induction was most efficient 
with either high or low dose Der p 1 and was characterised by the presence of 
predominantly eosinophilic alveolar and peribronchial cell infiltrates, and increased Der 
p 1-specific IgE levels. Mucus production was marked, often totally obstructing some 
airways. These features are characteristic of allergic asthma. 
Adoptive transfer of PBMCs from HDM-allergic patients into SCID mice, followed by 
challenge with aerosolised HDM extract led to development of significant AHR and 
markedly increased serum levels of total and HDM-specific human IgE in response to 
challenge compared with mice receiving cells from non-allergic subjects (313). 
Immunohistochemical analysis of lung sections identified human CD45+ cells in the 
perivascular and peribronchial areas in the 'allergic' SCID mice; these cells were not 
seen in the lungs of 'non-allergic' mice. Although no obvious lung eosinophilia was 
seen in either group, levels of IL-5 in BALF of the 'allergic' mice was greatly increased 
compared with 'non-allergic' mice. Therefore, adoptive transfer of PBMCs from human 
HDM-allergic subjects into SCID mice sensitises these mice to HDM, and an allergic 
airway disease phenotype can be induced by airway challenge with HDM allergen. 
Intranasal sensitisation and challenge protocols have been developed in mice using 
HDM allergens to induce allergic airway disease. Unlike in OVA models, use of 
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intranasally-administered HDM extract for sensitisation is effective in priming mice to 
develop allergic airway disease in response to further airway exposure to allergen. An 
acute protocol for the induction of allergic airway disease using HDM allergen involved 
exposing Balb/c mice to intranasally-administered HDM extract for 10 consecutive 
days. Mice were allowed to recover fully, before a recall response was induced by 
challenging for 3 days with further intranasal HDM extract (314). Mice in which the 
recall response was not induced showed induction of allergic airway disease -
eosinophilic and lymphocytic infiltrate into the lungs, increased serum levels of IgE and 
IgG1 and development of AHR in response to methacholine. There was an 
approximately 20-fold increase in the number of activated (CD69±) CD8+ T-cells in the 
lung compared with naïve mice as well as an approximately 50-fold increase in the 
number of activated (CD69+) CD4+ T-cells, of which a majority also expressed the 
putative Th2 marker T1/ST2. Cultures of splenocytes from sensitised mice with HDM 
extract secreted increased levels of IL-4, IL-5 and IL-13; mRNA levels for these 
cytokines were increased in the lung. Responses after recall challenge were generally 
greater, particularly in the numbers of cells infiltrating the lung. Induction of chronic 
disease by intranasal sensitisation and challenge has also been demonstrated (315). 
Chronic allergic airway disease was induced in mice exposed to intranasally-
administered HDM extract for five consecutive days a week followed by two rest days 
for up to seven weeks, characterised by influx of predominantly eosinophilic and 
lymphocytic cells into the lungs after three weeks. Cell numbers stayed constant until 
the end of allergen administration. Expression of markers of activated Th2 cells such as 
inducible costimulator (ICOS) and T 1/ST2 were increased on T-cells isolated from the 
lungs of challenged mice. T-cells cultured in vitro with HDM extract proliferated and 
secreted increased levels of IL-5 and IL-13 from one week of allergen exposure. Total 
IgE levels increased from three weeks of exposure and total IgG1 levels were 
significantly increased at five weeks. AHR was significantly increased from baseline 
after five weeks of allergen exposure. Analysis of lung sections indicated the presence 
of severe eosinophilic perivascular and peribronchial inflammation after five weeks of 
allergen exposure accompanied by development of features of remodelling, including 
mucus hypersecretion, increased subepithelial collagen deposition and increased ASM 
actin levels. After seven weeks of allergen exposure, mice were left to recover and 
analysed for signs of persistent inflammation or remodelling. Inflammation resolved 
within two weeks of cessation of allergen exposure, but remodelling was present nine 
weeks later, suggesting that the induced changes were permanent. Increased AHR in 
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response to methacholine also persisted after allergen exposure stopped, as did the 
capacity of lung T-cells to secrete increased levels of Th2 cytokines after in vitro 
challenge with HDM extract. Nine weeks after the last exposure to allergen, rechallenge 
with HDM induced eosinophilic lung inflammation and increased further the capacity 
of lung T-cells to secrete Th2 cytokines upon HDM allergen stimulation, suggesting 
that a chronic persistent disease phenotype had been induced. 
1.3.7 Uses of the HDM mouse model of allergic asthma to investigate lung 
remodelling processes 
The HDM model of allergic asthma described previously demonstrated that chronic and 
persistent changes could be elicited in the airways of mice challenged repeatedly with 
intranasally-administered HDM allergen. This is in contrast to the models developed 
using ovalbumin, where a more acute and transitory phenotype is usually induced. The 
HDM model, utilising an allergen that is clinically relevant in humans, therefore 
induces a disease phenotype in mice that is more similar to the disease occurring in 
humans. The HDM model has been used to investigate mechanisms underlying chronic 
features of the disease, such as vascular remodelling. A study investigated the 
relationship between development of AHR and other features of allergic airway disease 
using a chronic model of HDM challenge (316). Early development of AHR was 
associated with inflammatory cell infiltration into the lungs, whereas more sustained 
and persistent increases in reactivity and maximum respiratory system resistance were 
seen after clearance of lung inflammation and were associated with increased collagen 
deposition in the lung, features which persisted for at least four weeks after the last 
exposure to allergen. The AHR seen in allergic asthma may have more than one 
underlying cause and be linked to both acute lung inflammation and aspects of chronic 
remodelling. Another study used a chronic disease protocol, challenging Balb/c mice 
intranasally with HDM extract five days a week for either seven or twenty weeks, and 
investigated the extent of vascular remodelling induced (317). Both protocols induced 
persistent airway inflammation; inflammation was predominantly eosinophilic after 
seven weeks of challenge, with a greater proportion of neutrophils seen after twenty 
weeks. Proliferation of endothelial cells and vascular smooth muscle cells was increased 
after both seven and twenty weeks of HDM administration, with a higher level of 
proliferation of endothelial cells in bronchial-associated vessels seen after twenty weeks 
of challenge. A significant increase in total smooth muscle area was also seen after 
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twenty weeks. Myofibroblast numbers around bronchial-associated vessels were 
increased after both seven and twenty week protocols. Perivascular collagen was 
significantly increased after seven weeks of challenge with HDM extract; after twenty 
weeks total collagen levels in bronchial areas were also significantly increased. All 
aspects of collagen deposition were more pronounced after twenty weeks of challenge. 
The study also analysed these features four weeks after the last exposure to HDM 
extract to investigate the persistence of these changes in the absence of allergen 
challenge. With the exception of collagen levels, all features had significantly decreased 
or returned to baseline levels within four weeks of cessation of allergen exposure. 
Collagen levels showed little or no change four weeks after challenge. This model 
therefore induces a vascular remodelling phenotype similar to that seen in human 
disease, but in contrast to airway remodelling (thickening of the basement membrane, 
increased ASM mass) which appears to be permanent in the lungs, some aspects of 
vascular remodelling may be reversible in the absence of allergen. 
Blocking TGF-P in the HDM model using both continuous and intermittent exposure 
protocols was analysed (318). In the continuous protocol, mice were exposed 
intranasally to HDM extract five days a week for five weeks, whilst in the intermittent 
exposure protocol, mice were exposed intranasally to HDM extract for ten days, 
allowed to rest for thirty days, after which cycles of HDM exposure for three days 
followed by twelve days of rest were administered up to six times. Both protocols 
induced Th2-mediated allergic airway disease; partial resolution was seen during each 
rest period in the intermittent protocol. Numbers of cells infiltrating the lungs in the 
continuous protocol increased with increasing duration of exposure, as did TGF-P levels 
and activity. Administration of anti-TGF-f3 antibody on alternate days during the HDM 
exposure protocol from day 14 of the protocol decreased TGF-13 activity in BALF, but 
had no effect on airway remodelling as it did not prevent or reverse collagen deposition, 
production of smooth muscle actin, goblet cell hyperplasia or mucus hypersecretion. 
Similar results were seen when anti-TGF-13 was administered earlier in the protocol (day 
4), and when anti-TGF-I3 was administered during re-challenge in the intermittent 
protocol. Anti-TGF-f3 treatment exacerbated Th2-mediated lung inflammatory events, in 
particular causing an increase in lung eosinophilia, serum IgE levels and AHR, as well 
as the production of Th2 cytokines, suggesting that TGF-I3 may be involved in the 
regulation of inflammatory events in allergic airway disease but not in the regulation of 
airway remodelling events. 
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1.3.8 Other uses of the HDM mouse model of allergic asthma 
A number of studies have investigated antigen-specific T-cell responses in the HDM 
model of allergic asthma. Splenocytes isolated from HDM sensitised and challenged 
mice and cultured in vitro with Der p 1 proliferated to a greater extent than splenocytes 
isolated from nave mice i.e. proliferation was allergen-specific (312). Splenocytes 
isolated from sensitised but unchallenged mice proliferated to an even greater extent 
than those from sensitised and challenged mice, perhaps an indication of allergen-
specific T-cells having trafficked to the lung from the spleen in the challenged mice. T-
cells isolated from the draining (inguinal, popliteal and periaortic) lymph nodes of mice 
immunised with intraperitoneal HDM extract and challenged intranasally proliferated in 
response to HDM extract stimulation in vitro (311). Allergen-specific T-cell hybridoma 
clones generated from these cultures were analysed in terms of TCR usage and a 
restricted repertoire was demonstrated. T-cell clones predominantly expressed TCRa 
chains comprising Va8 Ja32, and TCR chains comprising VI36 J132.3, suggesting the 
presence of a dominant expansion of T-cells bearing a particular HDM-specific TCR. 
The HDM model of allergic asthma has been used in a number of studies to investigate 
the efficacy and mechanism of action of potential therapeutic agents, such as 
corticosteroids e.g. prednisolone and dexamethasone in treating allergic asthma (319). 
They were effective in preventing and reversing the influx of inflammatory cells into 
the lung and at high dose could downregulate IL-13 production in the lung. 
Administration of anti-TNF-a in this model decreased AHR in response to 
methacholine, decreased numbers of inflammatory cells infiltrating the lung and 
reduced mucus secretion in the lung, supporting the use of anti-TNF-a therapy in 
allergic asthma (320), despite it also appearing to lead to up-regulation of Th2-type 
cytokines. It also downregulated eotaxin levels in the lung, providing a potential 
mechanism through which it could mediate its anti-inflammatory effects. 
1.3.9 Other mouse models of allergic asthma 
Mouse models of allergic asthma have been developed using other allergens, although 
none are as widely used as the OVA or HDM models. Examples include a model of 
cow's milk allergy using p-lactoglobulin (321). Mice were sensitised through 
intraperitoneal injection of p-lactoglobulin adsorbed onto alum, and challenged 
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intratracheally 24 days later. This elicited a response characterised by an EAR, where 
BALF levels of histamine increased within minutes of challenge and a LAR 24 hours 
after challenge, characterised by AHR, lung eosinophilia, increased levels of BALF IL-
4 and IL-5, plasma exudation and increased mucus secretion, providing a model of 
allergic asthma using a clinically relevant allergen. Another clinically relevant mouse 
model of allergic asthma has been developed using cockroach allergens, a significant 
cause of allergic asthma in children living in inner city areas (322). Intraperitoneal 
sensitisation with house dust extract followed by airway challenge with either house 
dust extract or the major cockroach allergen, Bla g 2, induced a phenotype characteristic 
of allergic asthma, comprising eosinophilic and lymphocytic infiltrate into the lungs and 
BALF, increased levels of eotaxin expression in the lung and significantly increased 
AHR. The ability of purified Bla g 2 to induce this phenotype after sensitisation with 
house dust extract suggests that the response induced is due to sensitisation to 
cockroach allergens present in the extract. Intranasal administration of ragweed extract 
to mice induced Th2-mediated sensitisation to ragweed in these mice (323). The 
phenotype induced was relatively mild - minor inflammation was seen in the lung and 
modest clinical symptoms such as laboured breathing after administration and sneezing 
was seen; stimulation of splenocytes from exposed animals with ragweed extract 
induced moderate levels of Th2 cytokine production. This may be a useful model of 
mild allergic asthma. A mouse model of latex allergy has also been developed - 
intraperitoneal sensitisation with the main allergen of latex extract, Hey b 1, followed 
by intratracheal challenge starting from day 24, provoked a Th2-mediated pulmonary 
response typified by lung eosinophilia, increased secretion of IL-5 into BALF, mucus 
hypersecretion by airway epithelial cells and an increase in serum levels of allergen-
specific IgE, of a similar magnitude to that induced by administration of OVA by the 
same protocol (324). 
1.3.10 TCR transgenic models of allergic asthma 
Using OVA as a model allergen in all but one strain of wild-type mice requires systemic 
sensitisation before challenge via the airways. Using HDM as a model allergen, it is 
possible to induce allergic airway disease in wild-type mice when all allergen exposure 
occurs via the airways. The protocols involved in disease induction via this method 
require repeated frequent exposure to allergen over a prolonged period of time to induce 
disease. The use of a TCR transgenic mouse model, in which a significant proportion of 
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T-cells bear an allergen-specific receptor, may make disease induction more 
straightforward and similar to the way in which allergic asthmatic disease is induced in 
humans. 
An ovalbumin-specific murine TCR transgenic mouse line, D011.10 (297) has been 
generated and investigated for its use as a model of allergic asthma. The transgenically-
expressed TCR is specific for the epitope OVA323-339  bound to MHC class II H-2d (325). 
Studies investigating disease induction in D011.10 mice used protocols based on 
inhalational challenge with whole OVA aerosol. Challenge of nave D011.10 mice with 
repeated OVA aerosol led to transcription of IL-4 mRNA in lung tissue, and an 
apparent progressive decrease in IFN-y transcription (326). When lung T-cells or 
peripheral lymph node cells from challenged mice were cultured with OVA protein, 
transcription of IL-4, IFN-y and TNFa was seen. An increase in eosinophil numbers 
was also seen in BALF and lung tissue after OVA challenge; cell numbers increased 
with number of challenges. The numbers of transgenic TCR-expressing T-cells showed 
only a small increase when challenged and when cultured in vitro with OVA, increasing 
challenges were shown to have a greater inhibitory effect on T-cell proliferation and IL-
2 production. This inhibitory effect was not seen in spleen or lymph node T-cells. A 
response with some features of allergic disease is induced in D011.10 mice through 
challenge via the airways without systemic immunisation with OVA protein. The 
effects of OVA aerosol exposure on naive D011.10 mice compared with OVA-
sensitised wild-type mice of a similar strain (327) showed that a single OVA aerosol 
exposure caused a large increase in BALF neutrophils 6 hours post-challenge which 
returned to baseline a week later. A small increase in BALF eosinophils was also seen 
24 hours after exposure which persisted a week later. Lymphocytes in BALF also 
increased by 6 hours, and increased up to 96 hours after challenge; levels were still high 
one week after challenge. This contrasted with wild-type mice, where pronounced 
BALF eosinophilia was seen, accompanied by a much lesser neutrophilia. A single 
OVA challenge induced increased mucus secretion in both sensitised wild-type and 
naive D011.10 mice. Levels of IL-4 and IL-13 decreased upon aerosol exposure in 
D011.10 mice whilst levels of IFN-y increased markedly, directly opposite to the 
effects seen in wild-type sensitised mice. Total serum IgE in D011.10 mice was 
unchanged after OVA challenge, again in contrast to wild-type sensitised mice, where 
IgE levels markedly increased both with and without challenge. Treatment of D011.10 
mice before OVA challenge with anti-IFN-y caused significant lung eosinophilia, 
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suggesting that IFN-y was inhibiting development of a Th2 response to allergen; 
blocking of CD4+ T-cell function with an anti-CD4 antibody inhibited the effects seen 
in D011.10 mice upon OVA challenge. Whilst multiple airway challenges with OVA 
induced significant AHR in sensitised wild type mice, no such effect was seen in 
D011.10 mice. The response to OVA aerosol challenge in D011.10 mice has features 
of both Thl and Th2 mediated responses, some of which are reminiscent of allergic 
asthma. In contrast to this finding, another study exposing naive D011.10 mice to OVA 
aerosol challenge showed an increase in AHR in response to three challenges but no 
accompanying eosinophil influx into the lungs or increase in serum IgE (328). Lung 
inflammation was seen, but was composed primarily of T-cells with an activated 
phenotype (CD69±). Cultured OVA-specific lung T-cells isolated from OVA-challenged 
mice secreted increased levels of IL-4, IL-5 and IL-13 upon stimulation with OVA. 
As discussed in Section 1.3.4, OVA-specific T-cells have also been used in adoptive 
transfer experiments into naive mice. D011.10 OVA-specific Th2 cells (differentiated 
in vitro) were transferred into naive wild-type mice and these mice were then 
challenged with OVA (296). The phenotype induced was moderate, comprising lung 
eosinophilia and increased mucus secretion, but reminiscent of allergic asthma. 
Induction of the allergic-type phenotype by transferred Th2 cells was dependent upon 
their IL-4 production, as transfer of Th2-polarised OVA-specific T-cells from IL-4-/-
mice did not induce this phenotype. Analysis of lung tissue and BALF from these mice 
demonstrated that IL-44" T-cells were not recruited into the lung, and thus were unable 
to mediate development of an allergic disease phenotype. TNF-a administration 
overcame this deficit, and IL-44" OVA-specific Th2-type T-cells recruited to the lung 
through TNF-a mediated lung eosinophilia and mucus hypersecretion as normal. 
Another study used a similar adoptive transfer protocol of Thl- and Th2-polarised 
D011.10 T-cells into naive mice followed by repeated aerosol challenge (326). OVA 
challenge increased numbers of D011.10 T-cells in the lung compared with mice which 
had received D011.10 cells but were not challenged with OVA. Lung T-cells isolated 
from mice adoptively transferred with either Thl -type or Th2-type T-cells showed 
markedly reduced proliferative responses and IL-2 production after aerosol challenge, 
unlike spleen and lymph node-isolated T-cells, where no effect was seen. IL-4 
production by lung T-cells from mice transferred with Th2 cells was unaffected. 
Inhibition of proliferation was caused by interstitial macrophages in the lung - removal 
of these cells from total lung mononuclear cell populations before culture restored 
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OVA-specific proliferation. This suggests that allergen-specific T-cells do not 
proliferate in the lungs in response to allergen challenge but are instead recruited to the 
lung. A recent study used adoptive transfer protocols to investigate the effects of 
allergen-specific Th17-type T-cells in the development of allergic airway disease (329). 
Th2- and Th17-type D011.10 T-cells were generated in vitro and adoptively transferred 
into naive Balb/c SCID mice. OVA challenge of mice receiving Th2 cells induced a 
typical allergic asthma-like phenotype and AHR which could be attenuated by 
administration of dexamethasone. OVA challenge of mice receiving Th17 cells induced 
IL-17-dependent lung neutrophilia, increased IL-17 and keratinocyte chemoattractant 
(KC) (murine homologue of human IL-8) production and AHR, all of which were 
unaffected by dexamethasone. These findings support the hypothesis that Th17 cells 
may be involved in development of non-eosinophilic asthma and severe, steroid-
resistant asthma. 
A murine TCR transgenic mouse line expressing a receptor specific for an 
immunodominant epitope of the house dust mite allergen, Der p 1, has also been 
generated and evaluated for its use as a model of allergic asthma (330). The TCR was 
identified from a murine T-cell hybridoma, 1 AD2, that responds to Der p 1110-131, an 
epitope shown to be immunodominant in human allergic asthmatics (331), as well as in 
mice of the H-26 haplotype, such as the C57BL/6 strain, onto which transgenic founders 
were backcrossed. The relevant TCRa and TCRp genes were cloned from cDNA from 
the 1 AD2 hybridoma line, inserted into a construct containing the entire human CD2 
promoter (a T-cell specific promoter) region and injected into oocytes for the generation 
of TCR transgenic mice. Transgenic TCR genes were identified in founders using PCR 
to amplify the transgenic gene products. Expression of the transgenic TCRP gene was 
assessed through flow cytometry — 2% to 12% of T-cells were found to express the 
transgenic TCR. TCR transgenic mice, backcrossed onto C57BL/6J mice for five 
generations, and non-transgenic C57BL/6 control mice, were challenged twice five days 
apart by intratracheal administration of Der p 1 protein or saline. Splenocytes and 
draining lymph node cells were cultured with either Der p 1 protein or Der p 1110-131 
peptide and proliferative responses were assayed. Splenocytes from TCR transgenic 
mice responded to protein and peptide irrespective of whether they had been challenged 
with Der p 1, and IL-4 production increased in these cells upon in vitro stimulation with 
allergen or peptide. Control mice did not respond under any conditions tested. Cells 
isolated from draining lymph nodes of TCR transgenic mice responded to a much lesser 
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extent in response to protein and peptide than splenocytes, and only when mice had 
been challenged with Der p 1. Again, no response was elicited in control mice. The 
difference in responses between spleen and lymph node cells was suggested to be due to 
the tolerogenic environment present in the lung that inhibits T-cell activation unless 
overcome by a high dose challenge with antigen. Such a tolerogenic environment is not 
present in the spleen hence splenocytes responded to stimulation as normal. Analysis of 
lung histology in TCR transgenic mice after Der p 1 challenge showed induced 
inflammation in the lung, mostly limited to perivascular and peribronchial areas, 
predominantly composed of lymphocytes and granulocytes, a response not seen in Der 
p 1 challenged control mice. Differential counts of BALF cells and measurement of 
eosinophil peroxidase activity in lung tissue suggested that eosinophil and lymphocyte 
numbers were increased in the lungs of Der p 1-challenged, TCR transgenic mice. 
Immunohistochemical analysis indicated that 40% of infiltrating mononuclear cells in 
the lung were CD3+ T-cells, and there was also an increase in infiltrating B-cells. Mucus 
production was increased in TCR transgenic mice after Der p 1 challenge compared 
with saline. This model may have some use as a model of allergic asthma involving 
induction of a disease-like phenotype in response to airway challenge with allergen 
without prior systemic sensitisation. It provides a physiologically relevant model of 
human disease induction and can be used to investigate immunological mechanisms 
underlying disease pathogenesis and regulation, and may be useful for testing potential 
immunotherapeutic strategies. 
As allergic asthma is a disease mediated by allergen-specific T-cells, there would be 
much value in the development of a humanised mouse model, comprising the entire 
human MHC class II molecule-allergen epitope-TCR interaction, to allow study of the 
disease and testing of potential therapies in a relevant human context. To make such a 
mouse, a well-defined interaction known to be active in human disease is required. 
Studies have been carried out investigating T-cell responses to particular allergens as a 
means of developing T-cell-directed immunotherapy strategies. One example of such a 
system which has been characterised is the response to the major allergen in cat dander, 
Fel d 1. 
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1.3.11 Human T-cell responses in allergic asthma caused by the major allergen in 
cat dander, Fel d 1 
Specific responses to Fel d 1, a member of the secretoglobin family found in cat dander 
extracts, account for approximately 90% of all allergic reactions to cats (332). Fel d 1 is 
a 35 kD tetrameric protein, formed of two heterodimers composed of chain 1 and chain 
2 (333). Most T-cell recognition of Fel d 1 is limited to chain 1 of the protein (334). 
Intradermal administration of three short (16-17 amino acid), overlapping peptides 
derived from chain 1 to cat-allergic asthmatic subjects induced LARs in 9/40 patients 
(221). EARs were not induced in any patient due to the peptides' lack of secondary 
structure preventing recognition by allergen-specific IgE. Pre-challenge PBMCs from 
patients were cultured with each of the peptides and each patient mounted a response to 
at least one peptide but no patient responded to all three. Of the nine patients who 
developed a LAR after challenge, four expressed HLA-DRB1*13, suggesting that 
DR13 is capable of presenting one or more of the peptides tested. FC1P 3 
(KALPVVLENARILKCNV) and HLA-DR1 induced a proliferative response and IL-5 
secretion from DR13+ and DR1÷ T-cells, whilst FC1P 2 (EQVAQYKALPVVLENA) 
presented by human fibroblast lines transfected with human HLA-DR4 induced these 
responses from DR4+ T-cells. The MHC restriction of certain peptides in inducing T-
cell responses in vitro suggests that induction of the LAR is T-cell mediated. MHC 
class II restriction of T-cell responses to allergen-derived peptides has been reported for 
the birch pollen allergen Bet v 1 (335), the grass pollen allergen Phl p 1 (336), and the 
bee venom allergen Api m 1 (337). Repeated intradermal challenge with the same 
peptides within 2-6 weeks in patients in whom a LAR was induced did not induce a 
LAR, suggesting induction of tolerance. When challenge was repeated after 12 months, 
a LAR of the same magnitude as that initially induced was seen, suggesting that 
hyporesponsiveness was transient. A mixture of short, overlapping peptides spanning 
the whole of both chains 1 and 2 of Fel d 1 (to increase the likelihood of exposing 
patients to a peptide presented by the MHC class II molecules they express) was 
injected intradermally into cat-sensitive allergic asthmatic patients, and those who 
developed a LAR were re-challenged 3 days-68 weeks later (338). Hyporesponsiveness 
increased gradually up to 2 weeks after initial exposure, with no LAR being induced 
between 2-8 weeks after initial challenge. After 8 weeks, re-challenge was associated 
with a gradual return of responsiveness, which was of original magnitude after 40 
weeks. A single injection of peptides decreased in vitro T-cell proliferation and IL-4, 
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IL-13 and IFN-y secretion in response to stimulation with both peptides and whole cat 
dander extract, suggesting that bronchial hyporesponsiveness was due to inhibition of 
allergic T-cell responses. Inhalation of allergen-derived peptides induces tolerance to 
whole allergen in mice (339) hence the ability of inhaled Fel d 1-derived peptides to 
induce tolerance to cat allergen was investigated (340). Initial exposure to peptides by 
inhalation induced a LAR without a preceding EAR, associated with sputum 
eosinophilia and increased sputum concentration of CysLTs. Repeated challenge 
induced a LAR of a similar magnitude indicating that inhalational exposure to peptides 
in humans does not induce tolerance. LARs induced by inhalation of Fel d 1-derived 
peptides were associated with an increase in activated CD3+CD4+ T-cell numbers in 
lung tissue (223). 
A double-blinded clinical trial of Fel d 1 peptides as an immunotherapeutic agent 
involved intradermal injection of peptides into cat-sensitive allergic asthmatic patients 
over a course of 2 weeks, with an increasing dose of peptide given at each injection 
(341). If an injection induced a LAR, the next injections used the same dose of peptide 
until no LAR was induced. Patients were challenged intradermally with whole cat 
dander extract and Fel d 1 at two later time points, the first 2-8 weeks after 
administration of peptides, and the second between 3 and 9 months after administration 
of peptides; early and late phase cutaneous reactions were monitored. Late phase 
responses to Fel d 1 were significantly reduced at both challenges, but the early 
response was only significantly reduced at the second challenge. A significant decrease 
in the size of the late phase response to whole cat dander extract was also seen at both 
time points. Proliferation of T-cells in vitro was significantly decreased after the first 
challenge compared with pre-trial T-cell responses and secretion of IL-4, IFN-y and IL-
13 significantly decreased at both time points. IL-10 secretion was significantly 
increased from pre-trial levels at both time points, being highest after the first challenge. 
This suggested that Fel d 1-derived peptides corresponding to T-cell epitopes of the 
allergen could induce tolerance to allergen, possibly through induction of an IL-10-
mediated anti-inflammatory response. A regime of intradermal Fel d 1-derived peptide 
immunotherapy given at 2-weekly intervals for 12 weeks significantly decreased the 
magnitude of the induced LAR to whole cat dander extract (342), indicating a change in 
a clinically relevant parameter, supporting their potential use in the treatment of allergy. 
Comparison of in vitro T-cell responses to cat allergen before and after peptide 
immunotherapy showed down-regulation of proliferative responses and IL-13 secretion 
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but these changes were not related to an increase in suppression by CD4+ CD25+ Tregs, 
suggesting that induction of conventional Tregs did not underlie tolerance induction 
(343). Comparison of the cutaneous response to whole cat allergen challenge before and 
after intradermal peptide immunotherapy showed a significant increase in the number of 
CD4+ CD25+ IFN-y+ T-cells in biopsies taken after immunotherapy, corresponding with 
the lack of cutaneous late phase response seen after whole cat allergen challenge (344). 
This suggested that tolerance induction through peptide immunotherapy might be 
caused by recruitment of IFN-i-producing Thl cells and not Tregs to the site of 
challenge. Intradermal peptide immunotherapy was shown to down-regulate IL-5 
production and proliferation of allergen-specific T-cells in vitro and to possibly increase 
IL-10 production (345). CD4+ T-cells isolated from PBMCs taken after peptide 
immunotherapy suppressed allergen-specific proliferation of non-CD4+ PBMCs, 
suggesting that peptide immunotherapy induces a Treg population that mediates 
allergen hyporesponsiveness. 
Difficulty in determining mechanisms underlying tolerance induction highlights the 
usefulness of humanised mouse models of allergic asthma. More information about 
tolerance may be gained from in vivo studies than is possible from in vitro studies in 
humans. Elucidation of mechanisms underlying allergic asthma in general may also be 
obtained from a mouse model engineered to express a human disease-associated 
interaction, and such a model would be useful in testing potential therapies for safety 
and efficacy before their use in humans. The discovery of specific T-cell epitopes in Fel 
d 1 as well as the MHC class II restrictions of these epitopes led to the development of a 
human TCR transgenic model of allergic asthma by postdoctoral research associates in 
the Boyton laboratory (Dr. Carol Pridgeon, Dr. Alexander Annenkov, Dr. Catherine 
Reynolds and Dr. Xiaoming Cheng), funded by Asthma UK. At the time of writing, this 
model has not been reported in the literature. HLA-DRB1*01-restricted T-cell lines 
were derived from DR1+ cat-sensitive allergic asthmatic patients, and grown in response 
to a peptide epitope of Fel d 1 known to be presented by DR1 (peptide 4, FCP1 3 in 
221). After several restimulations with peptide to expand allergen-specific T-cells, TCR 
sequence clonotypic analysis of the lines was carried out. One particular TCR was 
predominantly expressed. The TCRa and TCR13 chains (TRAY 36-DV7 TRAJ 32 
TRAC and TRBV 9 TRBJ 2-7 TRBC 2 as identified by the IMGT database) were 
cloned into the T-cell specific pTacass and pTf3cass expression vectors (346) and used 
to create humanised TCR transgenic mice. Two lines, line 4 and line 16, were generated 
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and crossed onto an HLA-DR1 transgenic background to create humanised transgenic 
lines containing both a peptide 4-specific human TCR and the MHC class II molecule to 
which its response is restricted. 
1.4 	T-cell receptor structure 
1.4.1 Identification of the T-cell antigen receptor (TCR) 
The two major T-cell subsets, helper T-cells and cytotoxic T-cells (described originally 
in 347) respond to molecules expressed on the surface of other cells encoded by the 
major histocompatibility complex; cytotoxic T-cells respond to antigen and those MHC 
molecules expressed on all cells, encoded in mice in the H2-K and H2-B regions (348) 
and in humans in the HLA-A and HLA-B regions (349) of the MHC (class I), whilst 
helper T-cells respond to antigen and MHC molecules expressed only on certain cells of 
the immune system (APC such as macrophages) encoded in mice by the H2-A region 
and in humans by the HLA-DP, -DQ and —DR regions of the MHC (class II) (349, 350). 
The receptors on T-cells were initially defined biochemically with antibodies, using a 
monoclonal antibody specific for an antigen of a murine T-cell lymphoma (351). This 
antigen was specific to the lymphoma and not found in cells isolated from normal 
mouse spleen or thymus and was identified as a glycoprotein composed of two 
disulphide-bonded subunits (39 kilodalton (kD) and 41 kD molecular weight). Further 
analysis of such proteins isolated by specific monoclonal antibodies through tryptic 
fingerprint analysis showed that these proteins contained regions that were both 
constant and variable between receptors (352). The key conceptual breakthrough came 
when a gene encoding the receptor protein was isolated from the polysomal mRNA 
fraction of a T-cell hybridoma through hybridisation with a B-cell cDNA library (353). 
The remaining mRNA species showed T-cell specific expression and one particular 
species was shown to be somatically rearranged in T-cells but not B-cells, suggesting 
that this was the T-cell receptor gene. Chromosomal mapping studies identified the 
gene loci for the human TCRa genes as chromosome 14 (354) and the human TCRI3 
genes as chromosome 7 (355). Similar studies placed the murine TCRa genes on 
chromosome 14 (356) and the TCRf3 genes on chromosome 6 (357). The al3 TCR is 
expressed at the cell surface in association with the CD3 complex (CD37s, SE and c 
subunits) which is required for the correct assembly of the TCR and signalling upon 
antigen recognition (358). MHC class II-restricted helper T-cells are associated with 
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another cell surface molecule, CD4 (OKT4 in 359), involved in stabilising the 
interaction between TCR and MHC molecule in T helper cells (CD4 is referred to as 
L3T4 in 360). A similar phenomenon has been observed for CD8 and cytotoxic T-cells 
(T8 in 361, CD8 in 362). The presence of T helper cells is required for optimal cytolytic 
effector function of cytotoxic T-cells (363) and antibody production from B-cells (359). 
1.4.2 The interaction between TCR, peptide and MHC molecule 
APC such as macrophages and DC present antigen in the form of a short peptide 
determinant bound to cell-surface MHC class I or class II molecules (364, 365). In 
humans, the MHC (known as HLA) is located on chromosome 6 and is approximately 
7.6 megabases (Mb) in size (366). The HLA-A, -B, -DP, -DQ and -DR loci are highly 
polymorphic — according to the IMGT (Immunogenetics)/HLA database, there are 
currently 2,215 class I alleles and 986 class II alleles known to be expressed in humans 
(367). Class I molecules are composed of a larger 'heavy' polymorphic a chain 
(al/a2/a3 domains) complexed with a smaller 'light' invariant 132-microglobulin chain 
(368), whilst class II molecules comprise a dimer of polymorphic a (al/a2) and f3 
031/(32) chains (369, 370). Despite their dissimilar subunit composition, crystal 
structures of MHC class I molecule HLA-A2 (371) and MHC class II molecule HLA-
DR1 (372) show that they have a similar structure; domains al and a2 of HLA-DR1 
correspond to domain al and the 132 microglobulin domain of HLA-A2, whilst domains 
in and f32 of HLA-DR1 correspond to domains a2 and a3 of HLA-A2. The peptide-
binding site is located at the most membrane distal portion of the protein in both class I 
and class II molecules, formed of al/a2 domains for class I and a 1 431 domains for class 
II molecules. The peptide-binding site has a 'floor' composed of an eight-stranded 
antiparallel 13-sheet, with a-helical 'sides' surrounding a cleft into which the peptide 
epitope binds (373 - HLA-A2, 374 - HLA-DR1). The residues of the MHC molecules in 
this domain which potentially contact the peptide are the most polymorphic residues of 
the molecule, thus increasing within a population the number of peptide antigens that 
can be presented to T-cell scanning (375). Crystal structures of TCR-peptide-MHC 
molecule complexes have been determined for both MHC class I e.g. HLA-A2/Tax 
viral peptide/TCR A6 (373), and class II molecules e.g. HLA-DR1/HA influenza 
peptide/TCR HA1.7 (376), suggesting a similar diagonal mode of docking of the TCR 
onto the peptide-MHC complex. Contact occurs through flexible loops on the TCR 
known as complementarity-determining regions, and the whole of the peptide and a 
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significant proportion of the MHC surface are hidden by the interaction. Whether this 
mode of docking is universal to all TCR-peptide-MHC complexes is unknown; other 
crystal structures have suggested that the angle of rotation of the TCR upon the peptide-
MHC complex may range from 32° to 87° (377). 
1.4.3 T-cell receptor structure 
According to the IMGT database (378), the human TCRa gene locus on chromosome 
14 spans 1000 kilobases (kb) and contains 54 TRAY (Va) gene segments, 61 TRAJ (Ja) 
segments and 1 unique TRAC (Ca) region. The human TCR gene locus on 
chromosome 7 spans 620 kb, and contains 64-67 TRBV (V(3) segments, 2 TRBD or 
diversity (DP) segments, 14 TRBJ (J(3) segments and 2 TRBC (C(3) segments. The 
segments are separated by intronic sequence that is removed during recombination 
events in the thymus during T-cell development, leading to the production of a 
functional and unique TCR, as discussed further in Section 1.5. A functional af3 TCR 
comprises successfully rearranged TCRa and TCRP chains. Each TCRa chain is made 
up of a variable region composed of a Va segment spliced to a Ja segment, which in 
turn is spliced to a constant region (Ca segment). Each TCRP chain comprises a 
variable region made up of spliced VP, Dp and Jp segments which are then spliced to a 
constant region (CP segment). The peptide-MHC molecule contacts in the TCR are 
residues found in the variable portion of the protein in the most variable regions, the 
complementarity-determining regions (CDR) 1, 2 and 3. CDR1 and CDR2 are 
germline-encoded and are primarily thought to mediate contact with the MHC molecule 
(379), whilst CDR3 is found at the junction between V and J segments (V, D and J in 
TCR(3 chains) and is thought to primarily contact the bound peptide antigen (380), 
although all three CDRs can contact either peptide or MHC molecule. The CDR3 is the 
most hypervariable part of the TCR — the joining of V segment to J segment is not 
always exact, and base pairs can be inserted or deleted from this junction through non-
homologous end joining (NHEJ) during recombination (see section 1.4.4). 
1.4.4 V(D)J recombination and T-cell receptor diversity 
V(D)J recombination is a process unique to lymphocytes, occurring in both T-cells and 
B-cells producing populations that carry within them a wide range of specificities for 
antigen (381). Joining of different V, D and J gene segments in multiple combinations, 
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each giving rise to a unique receptor, causes variation within the TCR repertoire of an 
individual known as combinatorial diversity. This process generates the TCR in T-cells 
(and the antibody in B-cells). Recombination in these cells follows a similar pattern and 
is confined to the TCR and immunoglobulin (Ig) genes of the two lineages —
rearrangement of TCR genes only occurs in T-cells and rearrangement of Ig genes only 
occurs in B-cells (382). Rearrangement has a strictly regulated order, with the 
rearrangement of TCR13 genes (heavy chain Ig genes in B-cells) occurring before 
rearrangement of TCRa (Ig light chain) genes (383, 384). Allelic exclusion is seen —
rearrangement of TCR(3/Ig heavy chain genes occurs on both alleles but correct 
rearrangement of the segments on one allele leads to its expression at the cell surface in 
conjunction with a surrogate TCRa chain/light chain and prevents further rearrangement 
at the other allele. This avoids development of lymphocytes with specificity for more 
than one antigen, where there is a likelihood of one receptor being self-reactive and 
leading to autoimmunity (385). Expression of a rearranged TCRI3/Ig heavy chain at the 
surface provides signals for the further development of the T/B-cell progenitor and 
ultimately to rearrangement at the TCRa/Ig light chain loci. Recombination at both 
TCRa and TCRIEI loci involves the same recombination machinery, the recombination-
activating gene (RAG) complex, composed of RAG-1 (386) and RAG-2 (387) which 
has a similar mode of action to transposases and viral integrases (388). 
Each gene segment is flanked on either side by a recombination signal sequence (RSS), 
consisting of a conserved palindromic heptamer and an AT-rich nonamer separated by a 
non-conserved spacer region of either 12 (12-RSS) or 23 base pairs (23-RSS) (389). 
The 12/23 rule states that gene segments flanked by 12-RSSs may only combine with 
those flanked by 23-RSSs and vice versa (390, 391). In the TCR locus, V regions are 
flanked by 23-RSSs, J regions by 12-RSSs, whilst the D regions are flanked by 5'-12-
RSSs and 3'-23-RSSs, allowing only V-to-D or D-to-J rearrangements — although direct 
V-to-J recombination is theoretically possible, it is not seen, a phenomenon known as 
the beyond 12/23 rule (392). Rearrangement of D-to-J and V-to-D segments occurs 
sequentially with V to D combination occurring only upon successful D to J 
rearrangement (393). 
The RAG complex induces single-strand breaks between the gene segment and RSS 3' 
of the upstream segment and 5' of the downstream segment (394). Conversion to 
double-strand breaks occurs through attack on the 5' non-coding strand by the 3' 
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hydroxyl group on the coding strand, forming a closed hairpin loop adjacent to the gene 
segment and blunt 5' phosphorylated ends on the RSS segment (395). The RAG 
complex holds the strands in position (396), so that joining of the segments can be 
mediated by proteins involved in DNA repair; in this context they are referred to as 
NHEJ proteins. RSS ends are joined precisely resulting in an excised loop. Joining of 
gene segments is less precise; nucleotides can be added or removed before joining 
occurs (397). NHEJ proteins recruited to the RAG complex after the formation of 
double-strand breaks include components of the DNA-dependent protein kinase (DNA-
PK) — the Ku complex, Ku70 (398) and Ku80 (399), and the DNA-PK catalytic subunit 
(DNA-PKcs). The Ku complex is necessary for joining coding regions and RSS ends to 
form a signal loop that is excised from the chromosome whilst DNA-PKcs is required 
only for joining of coding regions (400). Another protein required for gene segment 
joining is Artemis, the mutation of which in humans causes severe combined 
immunodeficiency — Artemis may mediate opening of the hairpin loop (401). In vitro 
studies suggest that Artemis may form a complex with DNA-PKcs. Phosphorylation of 
Artemis by DNA-PKcs induces endonuclease activity which opens the hairpin loop 
(401). Loop opening can occur at the apex of the loop or to one side or the other, 
forming overhanging ends which if filled in and not removed form palindromic (or P) 
regions (397). Additional nucleotides can be added to the ends by terminal 
deoxynucleotidyl transferase (TdT) forming an N region unique to the receptor which is 
not germline-encoded (402, 403). Nucleotides can also be removed from the opened 
ends further increasing diversity of sequence at this point. This junction between V, (D) 
and J segments encodes the CDR3 described previously as the region of the receptor 
which determines antigen specificity. The ability to induce further diversity here 
(known as junctional diversity) increases the capacity of the TCR repertoire to 
recognise and respond to the vast array of antigens it may encounter (404). 
Other NHEJ proteins involved in the joining reaction include X-ray repair 
complementing defective repair in Chinese hamster cells 4 (XRCC4) (405) and DNA 
ligase IV (406). An XRCC4-DNA ligase IV complex mediates joining of gene segment 
and RSS ends although the enzymatic mechanisms underlying this process remain 
unknown (407). XRCC4 is involved in DNA repair and may recruit polynucleotide 
kinase to the end joining complex (408), facilitating end processing for correct joining 
by DNA ligase IV (409). Correct joining forms a functional TCR chain if the modified 
V-J/V-D-J junction allows in-frame readthrough (397). Production of successfully 
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rearranged TCRO and TCRa chains and their expression at the cell surface as a 
complete receptor signals to the cell to proceed to the next phase of development in the 
thymus. 
1.5 	T-cell development in the thymus 
The TCR repertoire of an individual is selected in the thymus to recognise and respond 
to a wide variety of foreign antigens whilst lacking self-reactivity. The lower limit of 
the naïve peripheral ap TCR repertoire in humans is approximately 2.5 x 107 different 
specificities (410); the corresponding figure for the mouse is approximately 2 x 106 
(411). The estimated number of potential TCR molecules capable of being produced by 
V(D)J recombination is thought to be 1012-1015, but most combinations will produce a 
TCR unable to recognise self-MHC molecules or a TCR too strongly specific for self 
peptide-MHC complexes. During transit through the thymus, developing T-cells 
rearrange their TCR genes. If rearrangement is successful, the surface-expressed TCR is 
assayed for its potential to recognise foreign antigen in the context of self-MHC 
molecules whilst lacking significant self-reactivity. Cells bearing receptors that do not 
fulfil these requirements are deleted before they reach the periphery, allowing only 
those cells bearing receptors of the required specificity (a small proportion of the total 
cells) to mature and emigrate from the thymus. 
1.5.1 Precursor entry into the thymus and the earliest stages of T-cell 
development 
The earliest T-cell progenitors migrate into the thymus at the cortico-medullary junction 
(412) and are derived from haematopoietic stem cells (413). They express high levels of 
CD44, which is thought to home them to the thymus (Pgp-1 in 414). Cells entering the 
thymus can develop into other cell types e.g. yo T-cells (which express a TCR 
composed of y and 6 chains) (415) or iNKT cells. 
Thymocytes are defined by their expression of the TCR-associated coreceptors, CD4 
and CD8. At their earliest developmental stage, they express neither coreceptor and are 
known as double negative (DN, CD4-CD8") cells. They are divided into further 
subpopulations DN1 to DN4, based on expression of the cell surface molecules CD44 
and CD25 (416): DN1, the earliest subset developmentally, phenotype CD44+CD25-, 
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DN2 (CD44+CD25+), DN3 (CD44-CD25+) and DN4 (CD44-CD25"). As the cells 
progress from DN1 to DN4, their ability to repopulate a thymocyte-depleted thymus 
decreases, indicating their commitment to development along the T-cell lineage 
pathway. 
The first stage of V(D)J recombination, rearrangement of TCRI3 chains, occurs at the 
DN3 stage (383). Thymocytes in mice deficient in RAG gene expression fail to develop 
beyond the DN phase (417, 418) as they cannot initiate recombination. This suggests 
the existence of a checkpoint requiring a fully rearranged TCRJ3 chain to be expressed at 
the cell surface before progression to the next phase of development. Transgenic 
expression of a rearranged TCR chain in RAG-deficient thymocytes allows them to 
pass this checkpoint (419). RAG depletion arrests thymocyte development specifically 
at the DN3 stage, as does disruption of the TCR gene locus. Deletion or disruption of 
the TCRa locus has no effect on DN thymocyte development, consistent with the 
observation that TCRa gene rearrangement occurs in the the next stage of development 
where thymocytes express both CD4 and CD8 and are termed double positive (DP) 
cells (420). 
The correctly rearranged TCR13 chain is expressed at the cell surface of DN3 
thymocytes in complex with the invariant pre-TCRa (pTa) chain, forming the pre-TCR 
(421). There is little homology between the pre-TCRa and any TCRa gene (422). A 
significant block in thymocyte development at the DN stage is seen in pTa /" mice 
suggesting that the pre-TCR is required to progress to the DP stage (423). The pTa 
chain is not merely a surrogate for the TCRa chain — transgenic expression of a 
correctly rearranged TCRa chain at the time of 13-selection interferes with normal 
progression through the checkpoint (424), suggesting that the pre-TCR transmits a 
unique signal allowing progression past the checkpoint. The induction of a noticeable 
block in thymocyte development at this stage has been documented in a number of a13 
TCR transgenic mice and indicates that transgenic TCR expression is occurring (425). 
Mutation of the cytoplasmic tail of the pTa chain abolished the ability of the pre-TCR 
to mediate progression of DN thymocytes into the DP stage (426), suggesting that pre-
TCR signalling is required for a13 T-cell development. Cells in which gene 
rearrangement fails to produce a correctly-rearranged TCR13 gene (or a correctly 
rearranged y8 TCR) undergo apoptosis (427) as they cannot pass the 13-selection 
checkpoint. 
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1.5.2 TCRa gene rearrangement 
Thymocytes which have passed the 0-selection checkpoint undergo several rounds of 
proliferation and upregulate expression of CD4 and CD8, becoming DP (CD4+ CD8+) 
thymocytes (428). Most thymocytes (approximately 80-85%) are DP thymocytes. Of 
these, approximately 20% are rapidly-dividing blast cells undergoing TCRa gene 
rearrangement. The remaining 80% are small, non-proliferating thymocytes expressing 
TCR undergoing positive and negative selection (429). Signalling through the pre-TCR 
initiates rearrangement at the TCRa gene locus (384). Upon productive rearrangement 
of a TCRa chain, it is expressed at the surface in complex with the rearranged TCRI3 
chain, displacing the pTa chain (430). 
TCRa rearrangement is not subject to allelic exclusion (420). Both TCR" and TCR DP 
thymocytes express RAG-1 and are therefore undergoing recombination. In cultured 
TCR transgenic DP thymocytes, subsequent analysis of TCR chain expression showed 
that approximately 25% of cells did not express the transgenic TCRa chain, suggesting 
that rearrangement at the TCRa locus continues after initial expression of a functional 
a0 TCR, and that newly-rearranged TCRa chains can replace the transgenic TCRa 
chain. The lack of allelic exclusion at the TCRa locus maximises the potential of a 
developing thymocyte to express a self-tolerant TCR which can recognise self-MHC 
and is likely to recognise foreign antigen. T-cells expressing two TCRa chains in 
conjunction with one TCR0 chain have been observed in the periphery (431). New 
productively-rearranged TCRa chains are expressed in conjunction with TCRI3 until 
cells are selected (positively or negatively), all gene segments have been used in 
unproductive rearrangements or the cell has received signals to undergo apoptosis 
known as 'death by neglect'. 
1.5.3 Positive and negative selection 
DP thymocytes expressing a correctly-rearranged a(3TCR undergo positive and 
negative selection (432). Positive selection identifies those thymocytes with a low 
affinity for self peptide-MHC complexes (and therefore potentially high affinity for 
foreign peptide-MHC complexes) and signals for their survival and maturation. 
Negative selection identifies those thymocytes that are autoreactive and signals for their 
deletion by apoptosis (433). Most DP thymocytes are deleted, either through negative 
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selection (5-10% of thymocytes) or, for the majority of cells, because they fail to 
produce a functional TCR or produce one with no affinity for peptide-MHC and so do 
not receive the necessary signals for survival. Only 1-5% of DP thymocytes are 
positively selected and mature into peripheral T-cells (432). 
DP thymocytes progress from the cortex into the medulla, interacting with thymic 
stromal cells as they do so. Positive selection is mediated by cortical epithelial cells 
(434), whilst negative selection occurs in both the cortex and as the cells progress into 
the medulla, suggesting that the two processes occur independently (435, 436). In TCR 
transgenic mice on the appropriate MIIC class I background, injection with specific 
peptide causes deletion of TCR transgenic thymocytes (437). In the absence of peptide, 
TCR transgenic thymocytes were positively selected and developed as normal, 
indicating that interaction between TCR and peptide-MHC is required for correct 
negative selection. Mice homozygous for a mutation which disrupts functional cell 
surface expression of MHC class I molecules lack mature CD8+ T-cells whilst other T-
cell subsets develop normally, suggesting that positive selection of CD8+ T-cell 
precursors from DP thymocytes depends upon interaction with peptide-MHC class I 
complexes (438), thus the same interaction between the TCR of a developing thymocyte 
and a self-peptide/MHC complex expressed on thymic stromal cells mediates both 
positive and negative selection. Expression of a transcription factor, autoimmune 
regulator (Aire), in medullary thymic epithelial cells (mTECs), suggests that an 
important component of negative selection occurs in the medulla (439). Aire promotes 
expression of proteins in mTECs from other tissues of the body, which are processed 
and presented as peptides in complex with MHC molecules; developing thymocytes are 
tested against self antigens that they would not otherwise encounter in the thymus and 
those that are self-reactive are deleted before they reach the periphery (440). The ability 
of the same TCR-peptide-MHC interaction to mediate both positive and negative 
selection may be based on differential avidity of the interactions. Interactions above a 
certain threshold lead to negative selection due to their intrinsic self-reactivity, whilst 
interactions with avidity below this threshold would lead to positive selection (441). 
Avidity is related to intrinsic affinity of TCR for a particular peptide-MHC complex and 
the number of TCR-peptide-MHC interactions at the thymocyte surface; the greater the 
number of engaged TCRs, the higher the avidity. Lower avidity interactions that initiate 
positive selection recognise the basic structure of a self-peptide-MHC complex without 
being overly specific and thus are likely to lack overt self-reactivity. 
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1.5.4 The CD4 vs. CD8 lineage decision 
Positively-selected thymocytes receive signals to survive and proliferate and proceed to 
the single positive (SP) stage of development (442). Here, thymocytes downregulate 
expression of either CD4 or CD8 and develop along the helper (CD4 associated) or 
cytotoxic (CD8 associated) lineage, depending upon the MHC-restriction of the TCR 
they express. This ensures that the complete TCR (a(3TCR, CD3 and co-receptor)-
peptide-MHC interaction will be at its most stable, as CD4 and CD8 contact MHC class 
II and I molecules respectively and stabilise the overall complex. It is therefore 
important that thymocytes retain expression of the correct co-receptor. Thymocytes are 
thought to be directed into the correct lineage through a 'strength of signal' model 
where the strength and/or duration of the signal through the TCR determines lineage 
fate (443). All positively-selected thymocytes initially down-regulate expression of 
CD8, forming a CD4high CD8I0W subpopulation (444). A decrease in or cessation of 
signalling at this point then signals for development into a CD8+ T-cell, whilst 
continuation of signalling signals for development into a CD4+ T-cell. Thymocytes 
which have down-regulated expression of the correct co-receptor in accordance with the 
specificity of their TCR mature into peripheral T-cell precursors in the medulla before 
emigrating from the thymus into the periphery as naive T-cells (445). 
1.6 	T-cell signalling, activation and differentiation 
1.6.1 Proposed mechanisms of TCR triggering 
The mechanism by which interaction with foreign peptide-MHC complex triggers 
signalling within the T-cell is still largely unknown. Several mechanisms have been 
proposed to explain how the signal is transduced across the plasma membrane. 
Conformational change models suggest that TCR binding to foreign peptide-MHC 
induces a conformational change within the TCR-CD3 complex, transducing a signal 
across the plasma membrane which is then propagated inside the T-cell. This can 
account for the ability of very low levels of foreign peptide-MHC to trigger signalling, 
as one complex could theoretically trigger one TCR to activate the T-cell (446). The 
TCR-CD3 complex can undergo conformational change in the absence of 
phosphorylation events i.e prior to TCR signalling, such as binding of adaptor protein 
Nck to CD3E upon TCR-peptide-MHC binding (447). CD3t subunits can undergo 
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conformational change rendering them more susceptible to phosphorylation (448). 
However, in a TCR repertoire with huge structural diversity and many different modes 
of peptide-MHC binding, induction of the same conformational change in each TCR-
peptide-MHC interaction seems unlikely (377). Bearing in mind the constraints placed 
upon the interaction by TCR variability, there are possible changes that could occur, 
such as a change in orientation of one TCR-CD3 complex with respect to another - this 
would require TCRs to exist as dimers in the membrane (446), and there is evidence of 
multimeric organisation (449), but the basic TCR-CD3 unit appears to be monovalent. 
Alternative conformational changes include change in orientation of TCRaf3 to CD3 
within one complex, or change in orientation of the TCR-CD3 complex with respect to 
the membrane - peptide-MHC binding could exert pulling, pushing or twisting forces on 
the TCR, changing the orientation of the TCR to CD3 or TCR-CD3 to the membrane 
(446); there is little evidence supporting or disproving these possibilities. 
The TCR oligomerisation model is based on the observation that TCR-specific 
antibodies and peptide-MHC oligomers cause aggregation of TCR molecules and can 
initiate signalling. Bringing TCRs into close proximity may allow signalling to proceed 
as their aggregation causes aggregation of TCR-associated signalling molecules (446). 
However, foreign peptide-MHC complexes are present at very low density on APC cell 
surfaces, and might be unable to mediate such large-scale aggregation. Also, a single 
foreign peptide-MHC complex can induce triggering of TCR signalling, an observation 
incompatible with this mechanism (450). Another aggregation-based model requires the 
TCR to associate with its coreceptor for correct triggering (the coreceptor heterodimer 
model). CD4 and CD8 are associated with the protein tyrosine kinase Lck (451), which 
is important for signal propagation, and this heterodimerisation would bring Lck into 
close contact with its target (ITAMs in the TCR-CD3 complex), facilitating triggering, 
but TCR triggering can occur in the absence of either coreceptor (452). The 
pseudodimer model suggests that self and foreign peptide-MHC complexes bind TCR in 
concert, forming a pseudodimer that triggers signalling, based on the observation that 
covalently-linked self peptide-MHC/foreign peptide-MHC heterodimers trigger 
signalling (453). TCR binds a foreign peptide-MHC complex for which it is specific, 
before a second TCR, associated with coreceptor, dimerises with the first and binds 
self-peptide MHC. Self peptide-MHC complexes are present at the APC surface in high 
concentration, so dimerisation would be efficient and provides an explanation as to how 
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a single foreign peptide-MHC can trigger signalling. There is currently no evidence that 
peptide-MHC complexes form such dimers at the APC surface. 
The kinetic segregation model suggests that TCR-peptide-MHC binding forms regions 
of close membrane contact (-15 nm apart) excluding proteins with large extracellular 
domains (454), such as the protein phosphatase CD45 which can down-regulate 
signalling mediated by phosphorylation e.g. TCR signalling. These regions would trap 
the TCR-CD3 complex in close contact with molecules such as Lck, prolonging 
signalling through the TCR in the absence of phosphatase activity. CD45 is excluded 
from regions of TCR signalling (455) and removal of its large extracellular domains 
inhibits TCR triggering (456). Engineered elongation of the peptide-MHC complex, 
increasing the distance between the two membranes, prevents efficient exclusion of 
CD45 from the TCR signalling region and interferes with correct TCR signalling (457). 
However, there is no evidence that segregation is actually required for triggering. 
Both clustering and conformational change within the CD3 subunits have been 
suggested to be required for TCR triggering (458). Multimeric forms of peptide-MHC 
complexes triggered efficient T-cell signalling by bringing TCR-CD3 complexes into 
close association and forcing a particular geometry upon the interaction that induced 
conformational change in the CD3 subunits and propagated downstream signalling 
events. This model requires peptide-MHC complexes to form dimers at cell surfaces; 
evidence of this has not been found. 
1.6.2 T-cell signalling through the TCR 
The interaction between a TCR, its associated coreceptor and peptide-MHC causes their 
aggregation into higher order structures known as supramolecular activation clusters 
(SMACs) (459). This brings the Lck associated with CD4 and CD8 intracellular regions 
(451) into close proximity with the TCR-CD3 complex. All CD3 subunits contain at 
least one ITAM (consensus sequence YXX(L/I)X6_8YX.X(L/I), Y indicates tyrosine, L is 
leucine, I is isoleucine and X is any amino acid) and TCR subunits contain three (460). 
Lck phosphorylates tyrosine residues in these motifs providing binding sites for 
activated protein of 70 kDA (ZAP-70) through its Src homology 2 (SH2) domain (461). 
Recruited ZAP-70 is phosphorylated by Lck, activating its protein kinase function 
(462). ZAP-70 and Lck phosphorylate tyrosine residues within the membrane- 
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associated scaffold (adaptor) protein, linker of activated T-cells (LAT) (463) which 
allows the assembly of a large signalling complex comprised of both scaffold and 
signalling proteins, as outlined in Figure 1.1. Growth factor receptor-bound protein 2 
(Grb2) binds to LAT (464) and initiates signalling through MAPK cascades (465), 
ultimately leading to nuclear translocation of the transcription factor activator protein 1 
(Ap-1) (466). Grb2-related adaptor downstream of Shc (GADS) (464) facilitates 
binding between LAT and the cytoplasmic adaptor protein SH2-domain-containing 
leukocyte protein of 76 kDa (SLP-76) (467). GADS promotes interaction between SLP-
76 and adhesion and degranulating promoting adaptor protein (ADAP) (468) which 
initiates signalling promoting cell adhesion (469). SLP-76 binds Vav 1 (470), a guanine 
nucleotide exchange factor, which is involved in the control of cytoskeleton 
rearrangement in response to peptide-MHC engagement by the TCR (471) as well as 
being involved in the activation of calcium signalling pathways, MAPK cascades (472) 
and phospholipase Cy (PLCy1) signalling (473). PLCy1 binds LAT and SLP-76 (464), 
which targets it to the plasma membrane and its substrate, the lipid phosphatidylinositol 
4,5-bisphosphate, where is catalyses its degradation into diacylglycerol (DAG) and 
inositol 1,4,5-trisphosphate (InsP3) (474). Phosphorylation of IL-2-inducible T-cell 
kinase (Itk) enhances PLCy1 activation (475). DAG activates PKC-0 which mediates 
phosphorylation of the transcription factor NF-icB allowing its translocation into the 
nucleus (476). InsP3 induces release of Ca2+ ions from the endoplasmic reticulum into 
the cytoplasm (477), increasing intracellular Ca2+ concentration and activating the 
calcium-dependent phosphatase calcineurin, which phosphorylates nuclear factor of 
activated T-cells (NFAT) and allows its nuclear translocation (478, 479). Along with 
Ap-1 and NF-KB, NFAT initiates transcription of genes involved in T-cell activation, 
proliferation and differentiation. The exact composition of the T-cell signalling complex 
is unknown - differing recruitment of proteins and thus differential signalling may be 
important in determining cell phenotype upon activation. 
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Figure 1.1 	Downstream T-cell signalling pathways that are activated upon TCR 
binding to peptide-MHC. See section 1.6.2 for a detailed discussion of these 
pathways. A shows the initial recruitment of kinase and adaptor molecules to the 
engaged TCR. B shows the initiation of downstream signalling by these molecules. 
Adapted from refs. 469, 480 and 481. 
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T-cell signalling is also negatively regulated. Lck is controlled through phosphorylation 
by C-terminal Src kinase (Csk) which deactivates its kinase function (482). Csk is the 
main negatively-regulating kinase and is tethered to the membrane through association 
with the membrane scaffold protein PAG (phosphoprotein associated with GEMs 
(glycosphingolipid-enriched microdomains)) which is constitutively phosphorylated in 
resting T-cells (483). TCR triggering causes CD45 to dephosphorylate PAG, 
dissociating Csk from the membrane (483) allowing CD45 to dephosphorylate and 
activate Lck (484). CD45 may also negatively regulate Lck activity, controlling its 
activity in resting T-cells or down-regulating its activation after T-cell signalling (485). 
1.6.3 The immunological synapse 
The immunological synapse is formed at the interface between APC and T-cell where 
reorganisation of membrane molecules and the cytoskeleton is seen, as defined by 
Blanchard and Hivroz (486) although similar synapses are also formed between CD4+ 
T-cells and B-cells, CTLs and their target cells and by other cells in the immune system 
such as NK cells (487). The immunological synapse was originally visualised using 
fluorescence imaging as having a 'bull's eye'-like organisation (459), with a smaller 
central supramolecular cluster (cSMAC) containing TCR and associated signalling 
molecules such as CD3 and PKC-0 surrounded by a peripheral supramolecular cluster 
(pSMAC) containing the integrin lymphocyte function-associated antigen-1 (LFA-1) 
and talin. This structure has been seen in both in vitro (459) and in vivo (488) systems. 
Further studies have localised other TCR signalling associated molecules such as Lck 
(489), ZAP70 and LAT (490) and CD28 (491) within the cSMAC. It has been shown 
that phosphatases such as CD45 and CD43 and other molecules with large extracellular 
domains are excluded from the synapse (492, 493). This 'bull's eye' structure forms 
within 30 minutes of initial engagement of TCR with pMHC (459) and can persist for 
many hours. 
The formation of the immunological synapse was originally thought to be necessary for 
the co-ordination of T-cell signalling, (494) but there is evidence suggesting that TCR 
signalling is initiated before the synapse forms (495) and that signalling may be largely 
terminated by the time the synapse forms; it may be involved in the down-regulation of 
signalling through internalisation of TCRs in this region (496). That formation of the 
immunological synapse is not necessary for TCR signalling to occur is also suggested 
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by the observations that signalling occurs in the absence of this structure in human 
CD4+ T-cell lines (486) and during the interaction between thymocytes and the thymic 
stroma during T-cell development, where small clusters of signalling TCR-CD3 
complexes are formed all over the thymocyte/APC contact (497). 
Formation of the immunological synapse is initiated by the development of small 
clusters of signalling TCR-pMHC complexes, and the cSMAC structure develops 
within 5-10 minutes of this interaction when the pMHC contains antigenic peptide for 
which the TCR is specific (498). The cSMAC initially forms as clusters of LFA-1 
molecules surrounded by a peripheral ring of TCR-pMHC; this arrangement inverts to 
form the typical `bull's-eye' within 5 minutes (494). TCR signalling is initiated in 
small microclusters outside the cSMAC (499) which are continuously transported to the 
cSMAC, where signalling is then terminated. Without this continuous movement of 
TCR microclusters into the cSMAC region signalling through the TCR is not sustained 
(500, 501). 
The function of the immunological synapse is unclear, particularly in view of the 
observation that TCR signalling and T-cell activation can occur in the absence of its 
formation (495). It may mediate downregulation of signalling through internalisation of 
the TCR signalling complexes (496) to prevent unrestrained signalling. The function of 
the synapse may be determined by the strength of the signal through the TCR — CTLA-
4 is recruited to the synapse in proportion to the strength of signalling through the TCR 
where it acts to inhibit signalling events i.e. a stronger signal recruits more CTLA-4 
than a weaker signal (502). Thus, through CTLA-4, the immunological synapse may 
modulate TCR signalling by preventing excessive signalling from a stronger TCR-
pMHC interaction whilst not affecting signalling from a weaker interaction. CTLA-4 
may also counteract the activating signals through CD28, which is also recruited to the 
synapse (491), suggesting that the overall function of the immunological synapse is to 
modulate signalling depending on the strength of the TCR-pMHC interaction. An 
alternative suggestion for the function of the synapse is to act as a directed route for the 
delivery of various chemical modulators, such as release of cytolytic granules from 
CTLs to their target cell (503) or the directed secretion of cytokines from T-cells e.g. 
secretion of IL-4 or IFN-y from CD4+ T-cells to B-cells to induce their differentiation 
into mature antibody-secreting B-cells (504). 
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1.6.4 The signalling pathways involved in differentiation of naive T helper cells 
into effector T helper lineages 
Upon activation through peptide-MHC engagement of the TCR and subsequent 
signalling, naive T helper cells proliferate and differentiate into one of several effector 
subsets. The subset a given cell will differentiate into depends upon a number of factors 
present at the time of its activation, and these factors will be discussed in more detail 
later. Each cell lineage has a distinct pathway of development involving interaction of 
specific cytokines, receptors, signalling cascades and transcription factors which co-
operate to induce the appropriate phenotype. 
Thl cells: As described in Section 1.2.10, Thl cells are characterised by production of 
IFN-y (16) and are mediators of cellular immunity. Development of a TCR-peptide-
MHC stimulated naive CD4+ T-cell into a Thl cell is mediated primarily through action 
of the transcription factor T-bet (505). T-bet expression is induced by IFN-y (506); 
binding of IFN-y to its receptor on the cell surface induces signalling through the 
receptor-associated tyrosine kinases Janus kinase (JAK) 1 and JAK2 and their 
downstream effector Statl (507). Upon activation, Statl initiates transcription of T-bet 
(508) which in turn induces expression of the Ifng gene locus (505) and the inducible 
chain of the IL-12 receptor, IL-1210, making the T-cells responsive to IL-12 (509). IL-
12 has a twofold function in the differentiation of naive Th cells into Thl cells: it is 
produced by activated macrophages (510) and DC (511) upon their exposure to viral 
antigen and induces IFN-y production from other cells of the innate immune system, 
such as NK cells (512). It is this IFN-y which is believed to initiate signalling in the 
naive T-cell. Up-regulation of the IL-12 receptor through IFN-y signalling makes T-
cells responsive to IL-12. The IL-12 receptor signals through JAK2 and tyrosine kinase 
(Tyk) 2 (513) and Stat3/Stat4 (514) to potentiate production of IFN-y (515) and up-
regulate IL-18Ra chain expression (516). IL-18 synergises with IL-12 to induce IFN-y 
production in dedicated Thl cells (517). Both IL-27 and type I interferons such as IFN-
a can induce IFN-y production in T-cells (518). 
Th2 cells: As described in Section 1.2.12, Th2 cells are characterised by production of 
cytokines such as IL-4 (16), IL-5 (212) and IL-13 (214). They direct humoral adaptive 
immune responses and are implicated in the development of allergic disease. 
Differentiation of a naive T-cell into a Th2 cell is primarily controlled by the 
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transcription factor GATA-3 (519). Binding of IL-4 to its receptor on the cell surface 
activates JAK1/JAK3 and they transduce the signal into the nucleus through 
phosphorylation of Stat6 (520, 521). Stat6 binds to the GATA-3 gene, up-regulating its 
expression (228). GATA-3 directs IL-4 synthesis (522) and is crucial for production of 
other Th2-type cytokines (522) as well as autoactivating its own transcription, thus 
reinforcing differentiation along the Th2 pathway through positive feedback (523). The 
source of exogenous IL-4 that initiates Th2 differentiation is currently unknown. Mast 
cells (76), human eosinophils (524) and NKT cells (135) can produce IL-4 and may be 
the source of IL-4 required. IL-4 transcription is also induced by c-Maf (525) but c-Maf 
does not regulate expression of other Th2 cytokine genes (526). IL-2 signalling via 
Stat5 (527) is important in Th2 differentiation (528); lack of IL-2 causes a significant 
decrease in levels of IL-4 secreted by developing Th2 cells. This pathway is 
independent of signalling via the IL-4/Stat6 pathway, as IL-4 production is induced by 
IL-2 in Stat6-/- and IL-4WD- mice (527). GATA-3 and Stat5 bind the IL-4 gene locus at 
different sites and have a synergistic effect on IL-4 production (527, 528, 529). The 
apparent lack of requirement for exogenous IL-4 in IL-2/Stat5 signalling and its 
importance in the early production of IL-4 in developing Th2 cells suggests that this 
pathway may also be independent of GATA-3. However, lack of IL-4 production and 
Th2 differentiation in conditional GATA-3-/- mice suggest GATA-3 is crucial for the 
early production of IL-4 (522). It is expressed at basal levels in all naive T-cells, and 
this basal level is enough to facilitate the effects of IL-2 and Stat5 on IL-4 production 
(522). 
Th17 cells: As described in Section 1.2.9, Th17 cells are distinct from both Thl and 
Th2 cells and characterised by production of IL-17 (161, 162). They are thought to play 
a role in local tissue inflammation and have been implicated in autoimmunity (163). 
Less is known about their development than their Thl/Th2 counterparts but their 
differentiation is thought to be primarily controlled by the transcription factor RORyt 
(530). In mice, IL-6 and TGF-I3 are required to initiate Th17 cell development (531). In 
the absence of IL-6, TGF-I3 directs development along the Treg developmental pathway 
(532). TNF-a and IL-113 are capable of augmenting the differentiation process (531); in 
humans, it is IL-113 that is necessary for Th17 differentiation with no absolute 
requirement for IL-6 or TGF-I3 (533). IL-6 may initiate Th17 differentiation by 
signalling through interaction of its receptor, gp130, with Stat3 (534). Signalling 
through this pathway is required for RORyt expression and subsequent Th17 
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differentiation. IL-23, a member of the IL-12 gene family, stimulates memory Th17 
cells and may support stabilisation of the Th17 phenotype in a similar manner to the 
reinforcement of the Thl phenotype by IL-12 (535). 
1.6.5 Factors affecting the differentiation of naive T-cells into effector 
phenotypes upon antigen stimulation 
Several factors may influence which effector phenotype an antigen-stimulated naive T-
cell differentiates into, including cytokine environment at the time of activation, type of 
APC, antigen dose, co-stimulation during stimulation and strength and duration of 
signalling through the TCR, which is influenced by TCR affinity for its cognate 
peptide-MHC. 
Cytokine environment: Differentiation of a naive T-cell into an effector cell can be 
determined by cytokines present in the environment of the cell when it is activated. 
These cytokines promote differentiation of one particular phenotype but also actively 
suppress development of other phenotypes. IFN-y and IL-12 signal to naive T-cells to 
develop along the Thl pathway and inhibit IL-4 and IL-17 production and therefore 
Th2 (536, 537) and Th17 differentiation (161, 162). The master regulator of Thl 
differentiation, T-bet, induces expression of Thl-specific genes (505) and interferes 
with binding of GATA-3 to the IL-4 gene cluster (538). IL-4 has a similar effect on the 
Thl pathway, inhibiting its function (539) and also that of the Th17 pathway (161, 162). 
GATA-3 blocks transcription from Thl-specific genes: ectopic expression of GATA-3 
in developing Thl cells reprogrammes them into Th2 cells by increasing IL-4 and IL-5 
production and blocking production of IFN--y and T-bet (540). How IL-4 and IFN-1 and 
their associated transcription factors interfere with Th17 cell differentiation is less clear, 
but Th17 differentiation in vitro only occurs in the absence of both cytokines (161, 
162). 
The immunological synapse may underlie the ability of Thl and Th2 polarising 
cytokines to govern the differentiation of naive T helper cells into Thl or Th2 cells 
(541). Analysis of the IS in the minutes immediately following engagement of peptide-
MHC by TCR under neutral (i.e. no polarising cytokines) conditions showed co-
localization of the IFN-yR with TCR into the IS and subsequent development of these 
cells into Thl cells. This pathway was more active in T-cells from the `Thl -like' 
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C57BL/6 strain of mice and less active in T-cells from the `Th2-like' Balb/c strain, 
where less co-localisation of the IFN-yR was seen upon TCR engagement. IL-4 
prevented this co-localisation through a Stat6-dependent mechanism and instead 
directed cells along the Th2 developmental pathway. A later study showed that Thl 
development was mediated by Statl signalling through the IFN-yR, and that IL-4R 
signalling (i.e. when IL-4 was present) antagonised the recruitment of Statl to the IFN-
yR (542). In addition, in T-cells where Thl development was deficient or Th2 
development was constitutive the IL-4R was recruited into the synapse instead of the 
IFN-yR. This suggests that the recruitment of IFN-yR to the synapse upon TCR 
engagement under normal conditions may be a default occurrence and therefore Thl 
differentiation may be the default pathway of development for naive T helper cells in 
the absence of the overriding Th2-promoting cytokine IL-4. 
Cytokine environment is probably the most important factor in determining T-cell 
phenotype upon activation by antigen but development of Thl and Th2 responses have 
been observed in the absence of their polarising cytokines (515, 543, 544). This 
suggests that other cytokines may also drive Thl/Th2 differentiation e.g. IL-13 for Th2 
cells (545) or that other factors can also drive differentiation in the absence of a 
definitive cytokine signal. 
Role of the antigen presenting cell:• The APC e.g. DC that interacts with a naïve T 
helper cell provides three signals required for correct activation and differentiation. 
Signal 1 is provided by the peptide-MHC complex that interacts with the TCR, whilst 
signal 2 is provided through interaction of the constitutively-expressed T-cell 
costimulatory molecule CD28 with its ligand, CD80 or CD86, on the DC surface (546). 
Signal 3, either in the form of a soluble mediator e.g. IL-12, or membrane protein e.g. 
OX4OL, may then provide an additional signal indicating which differentiation pathway 
to follow (547). 
DC reside in tissues and mucosal areas where they constantly sample their surroundings 
for pathogens, becoming activated in response to 'danger' signals such as specific 
pathogen-associated molecular patterns (PAMPs) (547). PAMPS include dsRNA, a sign 
of viral infection and components of bacterial/fungal cell walls, such as LPS or 
zymosan. They interact with TLRs on the DC surface and activate them (548). The 
nature of the 'danger' signal induces maturation of the DC - signalling through TLR3 
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(dsRNA) (549) or TLR4 (E.coli LPS) (550) induces differentiation into a DC1-type cell 
which produces IL-12 and promotes Thl differentiation. Signalling through TLR2 
(zymosan (551)) initiates differentiation into a DC2-type cell, which does not produce 
IL-12 and hence promotes Th2 responses. DC1 maturation is induced by IFN-y (552) 
whilst DC2 maturation is linked to PGE2 (553). Site of antigen exposure may determine 
the response - gut mucosal DC preferentially induce Th2 responses to antigen which are 
overridden by high levels of IFN-y (554), whilst even in a strain of mice which typically 
favours Thl responses (C57BL/6), antigen exposure in the lung induces predominantly 
Th2-type responses (555), suggesting that DC environment may condition them to 
induce one type of immunity over another. 
Co-stimulation at the time of activation: Interaction of the costimulatory molecule 
CD28 with its ligands, CD80 and CD86, on APC is crucial for the development of Th 
effector cells in the absence of IL-2 (546); if IL-2 is present, costimulation through 
CD28 may only be required for the induction of Th2 responses (556). T-cell responses 
in a CD28-/- TCR transgenic mouse suggest that costimulation via CD28 is required for 
development of Th2-mediated primary responses (557). CD86 may direct development 
of Th2 cells from naive precursors (558, 559); other studies suggest that CD80 and 
CD86 costimulation may both result in Thl or Th2 responses (560) and Th2 responses 
can be elicited in the absence of either molecule (561). CD86 costimulation may 
mediate Th17 responses in antigen-induced arthritis whilst CD80 costimulation in this 
model may downregulate development of Th2 responses (562). 
OX40 is up-regulated on T-cells within 48 hours of activation and interaction with its 
ligand OX4OL on APC may promote IL-4 production and Th2 differentiation (563). 
The CD28 family member ICOS, which functions similarly to CD28 but is up-regulated 
only upon T-cell activation may favour Th2 cell development (564). Absence of CD4 
signalling may be detrimental to Th2 cell development (565) whilst signalling through 
CD4 may inhibit development of Thl responses (566). Interaction of lymphocyte 
function-associated antigen-1 (LFA-1) with its ligand CD54 on APC inhibits Th2 cell 
development and may be important for development of Thl responses (567). The 
influence of these molecules on Thl/Th2 differentiation may be linked to antigen dose. 
The ability of CD4 and LFA-1 to affect development of Th2 responses is dose-
dependent whilst OX40 and CD28 can promote Thl as well as Th2 responses 
depending on the dose of antigen (568). 
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Effect of antigen dose/concentration: In vivo priming of mice with a particular peptide 
antigen showed that immunisation with an increased dose of antigen which induces Th2 
differentiation at a lower dose switches the phenotype of primed T-cells to Thl (569). A 
peptide derived from keyhole limpet haemocyanin induced a Th2 phenotype at a low 
dose (2[ig) but the phenotype switched to Thl at a higher dose (50ps) (570). T-cells 
from the peripheral blood of allergic subjects grown in culture in the presence of 
antigen differentiated into Th2-type cells if the dose was less than 0.01 i.tg/m1 but 
differentiated into Thl -type cells if the dose increased to between 10-30 µg/ml (571). 
Naive T-cells from a TCR transgenic mouse specific for a moth cytochrome c peptide 
could differentiate into Thl or Th2 cells upon stimulation with this peptide, dependent 
on the dose of peptide administered; at doses between 0.05 µg/ml and 50 µg/ml, a Thl-
type phenotype dominated, whereas at doses below 0.005 1.1g/ml, a Th2-type response 
dominated (572). A conflicting result was achieved using a different TCR transgenic 
system (573), where naive OVA-specific TCR transgenic T-cells grown in response to 
specific peptide showed Thl responses at intermediate doses (0.3 [iM to —10 µM) whilst 
above 10 µM and below 0.03 1.1M, Th2 responses were induced. The study using 
cytochrome c-specific T-cells may not have assessed doses high enough to see Th2 cell 
development and the intermediate dose range that induced Thl differentiation in OVA-
specific T-cells may correlate with the 'high' dose assayed using moth cytochrome c. 
Strength and duration of TCR signalling: The ability of differing doses of antigen to 
promote differentiation along different pathways led to the suggestion that the strength 
of signal received by the cell could influence development. Low doses of antigen would 
restrict availability of peptide-MHC complexes resulting in a lower intensity signal than 
when peptide-MHC complexes are plentiful, which would occur with high doses of 
peptide (574). Use of peptide variants known as altered peptide ligands (APLs) which 
differ from known immunogenic peptides by one amino acid involved in TCR contact 
(575) may alter the affinity of the TCR-peptide-MHC interaction. When naive TCR 
transgenic T-cells were stimulated with specific peptide or an APL of —300-fold lower 
affinity for the TCR, the wild type peptide induced development of a Thl response at 
the dose assayed (556). The lower affinity APL at the same dose favoured development 
of Th2 responses but could induce Thl responses, suggesting that lower affinity TCR-
peptide-MHC interactions promote Th2 cell development whilst higher affinity 
interactions promote development of Thl cells. The pattern of TCRC chain 
phosphorylation and ZAP-70 recruitment to the signalling complex was different when 
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activation was induced using wild-type peptide compared with APL (575). Distinct 
patterns of Ca2+ mobilisation within the cell were induced; wild-type peptide induced a 
strong, sustained calcium mobilisation, whilst the APL induced a smaller, more 
transient change. Interactions of differing affinities may induce qualitatively different 
signalling pathways which may signal for differentiation along different pathways. 
Further investigation of the different signalling pathways identified NFAT signalling, 
specifically the ratio between NFATc and NFATp (two forms of NFAT), as being 
important in determining the phenotype of an activated T-cell (576). The lower affinity 
interaction and transient calcium flux induced by APL favoured nuclear translocation of 
NFATc and the increased ratio promoted Th2 development. 
Duration of signalling may also be important. Naive T-cells require prolonged antigenic 
stimulation (at least 20 hours) under optimal conditions (optimal antigen dose, co-
stimulation through CD28, antigen presentation by 'professional' APCs) (577). The 
long time required for activation and development of effector functions may be due to 
the need to synthesise components of the signalling pathways and/or for chromatin 
remodelling of genes involved in T-cell differentiation. The effect of duration of 
signalling on differentiation of naive CD4÷ T-cells was analysed showing that a short 
burst of signalling (approximately 24 hours) in the presence of IL-12 was sufficient for 
differentiation of Thl cells without any Th2 cell differentiation (578). Th2 cell 
differentiation was only seen after prolonged antigenic stimulation and absolutely 
required the presence of IL-4 during stimulation. Low levels of IL-4 can suppress Thl 
cell development overriding the effects of IL-12 on developing cells. In the absence of 
added cytokines, 24 hours of stimulation induced proliferation in naive T-cells but 
significant development of effector phenotypes was only seen after 72 hours (Thl) or 
96 hours (Th2), suggesting that duration of signalling through the TCR strongly 
influences differentiation of naive T-cells. 
1.6.6 The serial triggering model 
Whilst naive T-cells require prolonged antigenic stimulation for correct activation and 
differentiation into effector T-cells, the interaction between a TCR and peptide-MHC 
complex lasts only seconds (579, 580) due to its intrinsic low affinity (PM) and fast 
dissociation rate (off-rate). The TCRs of a T-cell undergoing activation must therefore 
interact with large numbers of peptide-MHC complexes. A single peptide-MHC 
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complex can activate a T-cell (450); these findings appear to contradict each other. The 
serial triggering model (581, 582) was proposed to explain how sustained signalling is 
achieved when the TCR-peptide-MHC interaction persists for only a few seconds. It 
suggests that a few peptide-MHC complexes on the APC surface serially engage many 
TCRs; the continued engagement of TCRs sustains signalling for as long as is required 
to activate the T-cell and direct its differentiation. The low affinity, fast dissociation rate 
and short half-life of TCR-peptide-MHC interactions facilitates serial triggering by 
limiting the duration of engagement, allowing one peptide-MHC complex to trigger 
many TCRs (581). The kinetic proofreading model (583) suggests that a basic 
`triggered' TCR-CD3 complex, where ITAMs on CD3/TCR are phosphorylated and 
ZAP-70 is recruited must be formed before the TCR-peptide-MHC interaction 
dissociates for further signalling events to occur. If the duration of this interaction is too 
short, triggering will be incomplete leading to partial or no activation of the T-cell. If 
the interaction persists beyond the time required for triggering, failure to dissociate and 
allow engagement with other TCRs interferes with serial triggering, preventing 
sustained signalling and/or resulting in a qualitatively different signal. Comparison of 
the capacity of APLs to trigger signalling with wild-type peptide in a TCR transgenic 
system specific for an epitope of vesicular stomatitis virus (VSV) found that an 
alteration in peptide sequence changed the half-life of the TCR-peptide-MHC 
interaction (584). Different APLs had different effects; a decrease in affinity caused a 
decrease in half-life by increasing the dissociation rate and preventing full T-cell 
activation, whilst an increase in affinity either increased half-life leading to decreased 
T-cell activation or increased the rate of association between TCR and peptide-MHC, 
making T-cell activation more efficient. This suggests that there is an optimal range of 
half-life for the TCR-peptide-MHC interaction where T-cell activation is most efficient. 
Alternatively, this may form the basis for differential signalling leading to differential 
development; incomplete signalling, where ZAP-70 is not recruited to the signalling 
complex, may lead to development of Th2 cells (575). 
1.6.7 The role of TCR structure in determining the affinity of the interaction 
with peptide-MHC 
The affinity of binding between TCR and cognate peptide-MHC determines at least in 
part the fate of a T-cell when it is stimulated by antigen. The affinity of this interaction 
can be altered by changing residues within the peptide antigen, presumably due to loss 
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or gain of contacts with either TCR or MHC molecule which enhances or diminishes 
the stability of the interaction. As discussed in section 1.6.5, change in peptide structure 
through use of APLs can directly alter developmental fate of a naive T-cell upon 
antigen stimulation. It is possible that a change in TCR structure may influence the 
binding affinity and kinetics of the interaction with peptide-MHC and thus T-cell fate. 
Crystal structures of the interaction between TCR and peptide-MHC complex show that 
areas of TCR contact with the peptide-MHC complex (the antigen-binding site) are in 
the variable region, most specifically the CDRs (373, 376, 377). Comparison of crystal 
structures of TCR alone with the structure when complexed with peptide-MHC suggest 
that conformational change within the TCR occurs primarily at the antigen-binding site, 
with the CDR3s forming loops capable of undergoing significant conformational 
change to accommodate binding (585). 
Moss and Bell (586) analysed CDR3 amino acid sequences of human al3 TCRs from 
peripheral blood, defining the CDR3a as being the amino acids between and not 
including the conserved alanine (A) residue in the Y-(L/F)-C-A motif found in most 
TCR Va regions, and the phenylalanine (F) in the F-G-X-G-T motif found in most TCR 
Ja regions. The IMGT database now defines the CDR3a as containing the conserved A 
residue (378). The CDR3I3 was defined as being the amino acids between and not 
including the second conserved serine (S) residue in the Y-(L/F)-C-A-S-S motif found 
in most TCR VI3 regions, and the same phenylalanine residue as that used for the 
CDR3a. The IMGT database now defines the CDR3f3 as containing the conserved A 
and two S residues or their counterparts (378). Analysis of CDR3 lengths using a 
consensus definition of the CDR3 so that a and 13 lengths were comparable (by counting 
from the second serine residue in the CDR313 chain) suggested that in an unpolarised T-
cell population, CDR3 lengths are normally distributed, CDR3a loops having a mean 
length of 9.7 (approximately 12 by IMGT definitions), and CDR313 loops having a mean 
length of 10.3 (approximately 12 by IMGT definitions). No significant difference in 
mean length was seen between adult and foetal blood T-cells, or between CD4+ and 
CD8+ T-cells. The amino acid composition of the CDR3 loops was also analysed; 
CDR3a loops contained a higher proportion of polar or charged residues at positions 
likely to contact the peptide (positions 2 and 3 from the conserved alanine described 
above). A less obvious distribution of amino acids was observed in the CDR3I3 loop; 
polar and charged residues were present throughout the loop with no preference for 
position and a higher proportion of glycine was seen. 
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Mutagenesis studies investigated the importance of the CDRs in antigen recognition and 
binding. Using APLs where the TCR contact residues were modified to hold opposite 
charge or polarity changed the gene segment usage of the TCRs that responded 
specifically, and in particular, changes were induced in the CDR3 regions of these 
TCRs to maintain peptide contact i.e. the residue thought to contact the peptide in the 
CDR3 of the responding TCR now carried the opposing charge (587). Alanine-scanning 
studies (where residues in the TCR thought to be crucial for antigen-binding are 
mutated to alanine) in murine and human TCRs have identified that most residues in the 
CDR1, CDR2 and CDR3 loops contact the peptide or the MHC molecule; the general 
consensus is that most of the peptide specificity is present in the CDR3 loops (588, 
589). TCRs with higher affinity for their cognate ligands than their wild-type 
counterparts have been developed by mutation of CDR3 residues indicating that peptide 
specificity of TCR is seated in this region of the protein as alteration in this region 
changes TCR affinity for its ligand, but also suggesting that the low affinity of 
naturally-occurring TCRs is a function of their thymic selection rather than a physical 
limitation intrinsic to their framework (590, 591, 592). 
1.6.8 Clonotypic expansion of T-cells in response to antigen stimulation and 
functional maturation of the T-cell response 
A T-cell-mediated immune response to antigen is characterised by the clonotypic 
expansion of antigen-specific T-cells, where T-cells bearing antigen-specific receptors 
preferentially proliferate in response to antigen and dominate the T-cell population at 
the site of infection and nearby draining lymph nodes. Such antigen-specific expansions 
have been documented in CD8+ T-cell responses to herpes simplex virus in mice (593), 
and in human CD4+ T-cell responses to myelin basic protein in multiple sclerosis (594). 
In humans, limited expansions of particular TCR vp regions in BALF of both atopic 
and non-atopic asthmatic subjects has been observed (595, 149, 596). 
Expansions of antigen-specific T-cells have been tracked in both CD4+ (597) and CD8+ 
(598) primary and recall immune responses in terms of TCR amino acid sequence 
particularly at the antigen-binding site. Activated CD8÷ T-cells isolated from peripheral 
blood of mice immunised through injection of HLA-Cw3-transfected cells were 
analysed by single-cell PCR (598). As this response shows a preference for TCRs 
containing a TCR V1310401.2 chain, primers specific for this combination were used to 
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amplify the TCRI3 chain of all such activated T-cells. Analysis of the CDR3 loops from 
these TCRs showed significant conservation of CDR3 amino acid sequence; in all but 
one sequence, a uniform length of 6 amino acids (as defined in 586) was seen and all 
but one sequence preserved a germline-encoded negatively-charged glutamate residue. 
There was also a high incidence of a glycine residue within the non-germline-encoded 
region suggesting that these residues were potentially important for enhancing contact 
with the peptide and for TCR specificity and those T-cells bearing receptors with these 
characteristics were therefore selected for expansion. Analysis of T-cells involved in 
recall responses showed that the TCR repertoire raised against this antigen remained 
very similar, suggesting that the responding repertoire is largely selected and defined 
during the primary response to antigen. 
Another study followed the expansion of antigen-specific CD4+ T-cells after primary 
and secondary immunisation of mice with pigeon cytochrome c (PCC) (597). Activated 
CD4+ T-cells were isolated from draining lymph nodes on different days after 
immunisation and cDNA products were analysed by PCR. Antigen-specific T-cells 
increased in frequency as the response progressed, peaking at approximately day 7 of 
the primary response (250-fold increase compared with day 0) and day 3 (i.e. an 
accelerated response) after secondary immunisation. PCR analysis of the CDR3a and 13 
loops after immunisation identified eight features that were partially conserved in the 
responding T-cells. One of these features (a glutamate residue in the CDR3a loop) was 
conserved amongst most TCR Val 1 chains, regardless of whether TCRs were PCC-
specific or not; the remaining seven features only became apparent as the response 
proceeded. T-cells bearing receptors with such CDR3 features (conserved CDR3 
lengths, conserved J region usage, particular conserved residues) became more 
dominant as the response progressed. In resting cells, such features were present in less 
than 30% of all Val 1 V133 TCRs; by day 7, over 80% of isolated T-cells carried 
receptors containing six or more of these features and the TCR repertoire for this 
response was considered to be restricted. Analysis of TCR sequence after secondary 
immunisation showed that by day 3 of the recall response, 96% of all responding T-
cells carried TCRs with six or more of these features, suggesting that the memory 
response was even more restricted than the primary response. This study suggested that 
as an immune response progresses, selective expansion of T-cells on the basis of their 
TCR structure occurs, favouring expansion of those TCRs particularly well-suited to 
respond to the antigen from the original pool of antigen-specific TCRs i.e. antigen- 
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driven selection of the T-cell repertoire. This leads to functional maturation of the T-cell 
response by favouring those TCRs with CDR3 loops containing particularly high 
capacity to bind and recognise antigen, giving a faster, more specific and higher affinity 
response upon subsequent challenge. 
T-cell immune responses involve selection of particular T-cells for expansion based on 
the affinity of their TCR for antigen and this selection is based on the capacity of the 
TCR structure to bind antigen with higher affinity than other available TCRs. TCR 
structure itself may therefore play a role in determining T-cell phenotype upon antigen 
stimulation as small differences in the structure that increase antigen specificity or 
affinity can lead to their preferential expansion. At the time of activation, other factors 
present e.g. cytokines could lead to the preferential selection of T-cells bearing 
receptors favouring development of one T helper phenotype over another from the 
available pool of antigen-responsive T-cells. As Th2 development is associated with the 
transmission of a weaker signal through the TCR than Thl development, expansion of 
TCRs that naturally transmit a weaker signal in response to antigen may be selected for 
when external conditions favour the development of a Th2 response and vice versa. In 
other words, the structure of the TCR itself could be an important factor in determining 
the fate of a naive CD4+ T-cell upon its activation under certain circumstances. 
1.6.9 Can TCR structure influence the fate of a naive T helper cell upon 
stimulation with antigen? 
A number of studies have provided evidence that TCR structure may play a role in 
determining differentiation of a naive T helper cell into a Thl or Th2 effector cell. A 
single point mutation in the CDR2 of a chicken conalbumin-specific TCR, mutating 
leucine to serine, altered the phenotype of cells from Thl to Th2 (599). The mutated 
residue contacted a particular residue of the relevant peptide; mutation of this peptide 
from arginine to glycine restored the Thl response in the cells carrying the mutated 
TCR. As TCR structure itself, particularly the CDR loops, determines peptide-MHC 
specificity and therefore affinity of the interaction with peptide-MHC, structure at the 
antigen-binding site may influence the fate of the cell upon its activation and a 
difference, even at one residue of the antigen-binding site, could have a dramatic effect 
on T-cell fate. Another study compared the response in Thl and Th2 clones raised 
against a peptide epitope involved in EAE induction in mice, proteolipoprotein 139-151 
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(PLP139_151) (600). Whilst not all Thl clones expressed TCRs composed of the same 
gene segments, each clone absolutely required the presence of a tryptophan residue at 
position 144 of the peptide. If this residue was mutated to alanine, Thl clones failed to 
mount a response. In contrast, Th2 clones raised against the same peptide epitope could 
respond to the peptide altered at position 144 but showed a requirement for the residues 
at positions 141 (leucine) and 142 (glycine) as they failed to respond when challenged 
with peptides mutated at these positions, suggesting that TCRs favoured by the Thl 
clones mediated their response through recognition of a different peptide residue than 
TCRs favoured by the Th2 clones. It is likely that the TCR structures favoured by each 
type of clone will be those best able to recognise the relevant residue. 
A further study based in our laboratory investigated TCR usage in Thl- or Th2-
polarised T-cell lines and clones raised against the same peptide-MHC complex (PLP56_ 
70 bound to MHC class II I-Ag7) (601). Lines and clones were Thl if they produced 
IFN-y in the absence of IL-4, -5 or -10, and Th2 if they produced IL-4 and -5, but not 
IFN-y. TCRa and 13 chains used in the long-term differentiated clones were analysed by 
PCR and gene segment selection and CDR3 features were compared. Selection of 
TCRI3 chains showed no obvious differences between Thl and Th2 clones in terms of 
CDR3 length. The main difference seen between Thl and Th2 clones in terms of TCRa 
chains was in length and composition of the CDR3 loop — Thl clones predominantly 
expressed TCRs with a CDR3a length of 10 amino acids, whilst CDR3a loops from 
Th2 clones were longer at 13 amino acids. A similar TCR sequence analysis was carried 
out on short-term Thl- or Th2-polarised T-cell lines that had been re-stimulated with 
peptide-MHC three times. Selection of dominant clonotypes was seen in these lines. 
The Thl and Th2 lines selected different TCRs for expansion from the original bulk 
population from which they were both derived. The Thl line favoured expansion of a 
TCR bearing a CDR3a loop of 12 amino acids, whilst the Th2 line favoured a TCR 
bearing a 14 amino acid CDR3a. The mean CDR3a lengths of all TCRs present in each 
line were significantly different with the Th2 line in general expressing TCRs with 
longer CDR3a loops. The Thl-dominant TCR was present in a small proportion of Th2 
line cells, but the Th2-dominant TCR was not found in the Thl line, suggesting that 
whilst cells may favour elongated CDR3a loops when developing along the Th2 
pathway, they can also use TCRs with shorter loops. In contrast, the use of an elongated 
CDR3a does not seem to occur in Thl-developing cells, marking a difference between 
Thl and Th2 cells in terms of TCR usage. Molecular modelling of TCRs isolated from 
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two clones, A10(2) (a Thl clone) and D3(3) (a Th2 clone), which differed in CDR3a 
length by three amino acids suggested that the elongated loop in the Th2 TCR which 
was composed of amino acids with bulkier side-chains protruded into the TCR-peptide-
MHC binding interface and provided steric hindrance. This would most likely lead to a 
lower affinity interaction with peptide-MHC, which is linked with the development of 
Th2 cells. This study suggested that the conditions under which a T-cell is activated can 
promote selection of particular TCRs that best fit the developmental fate being 
followed. Under Th2-polarising conditions, the expansion of T-cells bearing receptors 
with a lower affinity for the peptide-MHC complex may be favoured. The derivation of 
the T-cell clones A10(2) and D3(3) is shown in Figure 1.2. 
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Figure 1.2 Characterisation of the TCRs expressed by PLP 56-70-specific T-cell 
clones A10(2) and D3(3) (see reference 601). The above scheme shows a summary of 
previous work carried out in the Boyton laboratory that led to the identification of TCRs 
from two independent T-cell clones derived from long-term T-cell lines raised against 
PLP56-7o and restricted to the same MHC class II molecule, H2-Ag7. The lines were 
polarised in vitro towards a Thl (A10(2)) or Th2 (D3(3)) phenotype, and transferred 
into the pQC series of retroviral vectors. 
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1.7 	Aims of this thesis 
Previous work from our laboratory suggested that TCR structure may be important in 
determining T-cell phenotype upon activation through interaction with its cognate 
peptide-MHC complex, with elongated CDR3s being favoured by developing Th2 cells. 
This led to the hypothesis that in the human Th2-mediated disease allergic asthma, 
TCRs will expand in response to allergen challenge that carry elongated CDR3 loops. In 
order to test this hypothesis, Chapter 3 shows the analysis of TCR CDR3 usage in 
human T-cell lines derived from HLA-DR1+ cat-allergic asthmatic subjects and 
generated against the important T-cell epitope of Fel d 1, peptide 4. Expanded T-cell 
populations expressing particular TCRs were identified in these lines that carried 
elongated CDR3a and 13 loops. Attempts to transduce the TCR-negative line BW7 (602) 
with TCR genes identified from this work and from the initial study (601) in order to 
further study the impact of these elongated CDR3 loops on T-cell function were not 
successful and I did not take this work forward. 
A humanised TCR/MHC class II transgenic mouse model of allergic asthma has been 
developed in our laboratory by postdoctoral research associates funded by Asthma UK. 
It expresses a TCR identified through clonotypic analysis of HLA-DR1-restricted 
peptide 4-specific T-cell lines derived from HLA-DR1÷ cat allergic subjects, as well as 
transgenically expressed HLA-DR1, on a murine MHC class II knockout background. 
This model was developed in order to test the hypothesis that a humanised TCR/MHC 
class II transgenic model of allergic asthma would be an improved mouse model of 
allergic asthma, and the early experimental characterisation of this model that I carried 
out with Dr. Catherine Reynolds and Dr. Xiaoming Cheng is shown in Chapter 4. In 
addition, basic characterisation of the TCR transgenic mice in terms of expression of 
costimulatory molecules in the spleen and thymus in comparison to non-TCR transgenic 
mice was carried out to test the hypothesis that expression of a transgenic TCR alters 
the expression of other T-cell signalling associated molecules in both the thymus and 
the periphery. Differences in the expression of some costimulatory molecules, namely 
CD44, CD62L, ICOS and OX40, were seen in the thymus but not the spleen, and the 
possible implications of these findings are discussed. 
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2. 	Materials and Methods 
All stock solutions and buffers are shown in appendix 1. 
2.1 	Molecular biology techniques 
2.1.1 Human TCR CDR3 analysis 
2.1.1.1 RNA isolation from human T-cell lines 
HLA-DR1-restricted, peptide 4-specific human T cell lines at successive restimulations 
with peptide 4 (KALPVVLENARILKCNV) (these lines were generated from HLA-
DR1+ cat allergic individuals in Professor Mark Larches laboratory, National Heart and 
Lung Institute, Imperial College, London) were supplied either frozen at -80°C in 
RNAlater (Ambion, 7020) or fresh on the day of restimulation. RNA from frozen cells 
was extracted using RNAzo1 B (Biogenesis, CS-105B) via the single-step guanidinium 
disruption/acid phenol extraction method. The product was solubilised in 20 µ1 RNase-
free dH2O (Sigma, W4502) with 0.5 pl (20U) RNase OUT ribonuclease inhibitor 
(Invitrogen, 10777-019) added. RNA from fresh cells was extracted on the same day by 
guanidine thiocyanate lysis followed by binding to a silica-based matrix and DNase 
treatment using the Absolutely RNA Nanoprep Kit (Stratagene, 400573) and eluted into 
20 µI Elution Buffer (from the kit). RNA was stored at -20°C. 
2.1.1.2 cDNA preparation from human T-cell RNA 
First-strand cDNA synthesis was carried out using Cloned AMV Reverse Transcriptase 
with oligo(dT)20 primers (Invitrogen, 12328-032). cDNA was synthesised from 5 µg of 
RNA. RNA was first mixed with 1 µ1 of 50 µM oligo(dT)20 primers and 2 µ1 10 mM 
dNTP mix and made up to 12 µI with RNase-free dH2O. This mix was denatured at 
65°C for 5 minutes before being placed on ice. cDNA was then synthesised in a final 
reaction volume of 20 µI comprising the 12 µ1 reaction mix described previously in lx 
reaction buffer (50 mM Tris-acetate (pH 8.4), 75 mM potassium acetate, 8 mM 
magnesium acetate, 4 µg/m1 BSA) and 5 mM dithiothreitol (DTT) with 40 U RNase 
OUT RNase inhibitor and 15 U cloned AMV reverse transcriptase added. The reaction 
was incubated at 25°C for 10 minutes, 50°C for 50 minutes and stopped by heating to 
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85°C for 5 minutes. The cDNA product was precipitated three times using a final 
concentration of 2M ammonium acetate (Sigma, A7262) in at least three volumes of 
100% ethanol. The pellet was resuspended in 20 µI RNase-free dH2O after the first two 
precipitations and in 11 µ1 RNase-free dH2O after the third. This cDNA was polyG-
tailed using recombinant terminal transferase (Roche, 3 333 566) in a reaction volume 
of 20 µ1, comprising 11 µl cDNA, lx enzyme buffer (200 mM potassium cacodylate, 25 
mM Tris-HC1, 0.25 mg/ml BSA (bovine serum albumin), p16.6), 0.75 mM cobalt 
chloride, 5 mM dGTP (Bioline, B10-39037) and 400U terminal transferase. The 
reaction was incubated at 37°C for 15 minutes and stopped by heating to 75°C for 10 
minutes. Enzyme was removed by addition of acid-equilibrated phenol:chloroform (5:1) 
(Sigma, P1944) and tailed cDNA was extracted in the aqueous phase. A final 
ammonium acetate/ethanol precipitation was carried out and the cDNA pellet was 
resuspended in 200 µ1 dH2O. cDNA was stored at -20°C. 
2.1.1.3 Polymerase chain reaction (PCR) 
PCRs (see appendix 2 for primer sequences and reaction conditions) were carried out 
using the BIOTAQ PCR kit (Bioline, B10-21071). Reactions occurred in a volume of 
25 µ1 comprising lx NH4-based buffer (16 mM (NH4)2SO4, 67 mM Tris-HC1, 0.01% 
Tween-20, pH 8.8), 1.5 mM MgC12, 200 µM dATP, dCTP, dGTP and dTTP (Bioline, 
B10-39025), 50-100 ng template DNA, 0.5 µM forward and reverse primers (Sigma-
Genosys) and 0.6U Taq polymerase. Each completed reaction was run in a separate lane 
on a 1% agarose TAE gel (appendix 1) with 3-10 µ1 (depending on gel size) of 10 
mg/ml ethidium bromide (Sigma, E1510) added, alongside Promega 1 kb DNA ladder 
(G5711), and visualised under UV light. Loading buffer (appendix 1) was added to a lx 
concentration to allow visualisation of how far the gel had run. 
2.1.2 Cloning of TCR a and 3  chains into MFG and pTcass expression vectors 
To transduce the murine thymoma line BW7 (602) with genes coding for TCRs 
identified from the CDR3 analysis of the human T-cell lines from cat allergic subjects 
and the TCRs identified from murine Thl and Th2 clones A10(2) and D3(3) (from 
601), I designed and carried out strategies to clone these genes into relevant expression 
vectors. In the first instance, a retroviral transduction system was used, requiring the 
transfer of TCR genes into a vector designed for use in such a system. Retroviral 
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transduction systems, such as the Phoenix system used here (603), comprise packaging 
lines which have been stably transduced with all the genes required for production of 
retroviral particles except for the packaging signal, y. This is supplied as a component 
of a retroviral expression vector which also includes the gene which is to be expressed 
in the target cell line. The retroviral expression vector chosen for use here was MFG 
(604, 605), shown in Figure 2.1, which was created using Moloney murine leukaemia 
virus (MoMuLV) long terminal repeat sequences to generate both full length viral RNA 
molecules (allowing packaging into functional viral particles) and a shorter subgenomic 
viral RNA molecule (analogous to the envelope gene in unmodified MoMuLV viral 
genome). It is this latter feature that allows the expression of inserted sequences in 
target cells. The vector also contains sequences in the viral gag region that have been 
shown to improve packaging and thus increase virus titre, as well as the splice donor 
and acceptor sites needed to generate the env mRNA and allow for the expression of the 
inserted genes. Whilst MFG lacks a selectable marker (such as an antibiotic resistance 
gene) found in many other retroviral expression vectors, an advantage of it is that unlike 
most other retroviral expression vectors, it also lacks a specific deletion in the 5'- long 
terminal repeat region of the genome. This deletion is deliberately incorporated into the 
sequence if it is present as a safety factor — virus harvested from packaging cells 
transfected with such a vector are replication-incompetent and are incapable of 
producing infectious virus in the target cells, as the packaging signal can no longer be 
expressed. It was found to be necessary here to use a serial system of two packaging 
lines (as will be discussed further in Chapter 3 of this thesis) and the lack of this 
deletion in MFG meant that it could be used in such a system. I was unsuccessful in 
transducing cells using a retroviral expression system so I also used a system based on 
electroporation, the Amaxa Nucleofector system (discussed in more detail in Chapter 3) 
to transduce the target cell line with TCR genes. This required transfer of the genes into 
a different expression vector, one which could initiate gene expression in cells of the T-
cell lineage such as BW7. The pTcass vectors (346) were designed for use in the 
production of TCR transgenic mice, using T-cell-specific promoter and enhancer 
sequences to ensure that the transgene is only expressed in the T-cells of the mouse. 
These constructs have also been used in an electroporation system to successfully 
transduce the BW7 line with TCR genes (606) and so the human and murine TCRs of 
interest were moved into these vectors for use with the Amaxa system. 
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Figure 2.1 MFG(eGFP) (604, 605) This vector diagram shows the retroviral 
components of the vector MFG, derived from the Moloney murine leukaemia virus 
(MoMuLV) genome, and the target gene eGFP. The gene of interest (here, eGFP) is 
inserted between NcoI and BamHI restriction sites — the NcoI site contains an ATG 
motif that coincides with the start codon of the viral env gene. There is no selectable 
marker present in the vector. 
splice acceptor 
splice donor 
to+ 
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The strategies devised to move the TCR genes into these vectors are described in detail 
in Chapter 3 of this thesis. 
2.1.2.1 RNA isolation from murine T-cells 
RNA was extracted from a single cell suspension of freshly-isolated mouse splenocytes 
using Trizol reagent (Invitrogen, 15596-018) via the single-step guanidinium 
disruption/acid phenol extraction method as for RNAzo1B above. The product was 
solubilised in 20 R1 RNase-free dH2O with 0.5 R1 (20U) RNase OUT ribonuclease 
inhibitor added. 
2.1.2.2 cDNA preparation from murine T-cell RNA 
RNA was first treated with RQ1 RNase-free DNase (Promega, M6101) to remove any 
contaminating genomic DNA. The reaction was carried out in a final volume of 20 RI 
comprising RNA (5 iug), RQ1 RNase-free DNase (1 U per 1 Rg RNA) and 1x reaction 
buffer (40 mM Tris-HC1 (pH 8.0), 10 mM magnesium sulphate and 1 mM calcium 
chloride) and was incubated at 37°C for 30 minutes. Enzyme was removed by addition 
of acid-equilibrated phenol:chloroform (5:1). The aqueous phase was extracted and all 
traces of phenol were removed through treatment with chloroform:isoamyl alcohol 
(24:1). The aqueous phase was again extracted and washed in at least 2.5 volumes of 
100% ethanol. The final RNA pellet was resuspended in 20 1A1 RNase-free dH20 with 
20 U RNase OUT. First-strand cDNA synthesis was carried out using Superscript III 
Reverse Transcriptase with random hexamer primers (Invitrogen, 18080-093). RNA (2 
R1) was first mixed with 1 pd of 50 ng/R1 random hexamer primers and 1 R1 10 mM 
dNTP mix, made up to 13 R1 with RNase-free dH2O. This was denatured at 65°C for 5 
minutes before being placed on ice for at least 1 minute before proceeding. cDNA was 
then synthesised in a final reaction volume of 20 11,1 comprising the 14,t1 mix described 
previously in lx reaction buffer (50 mM Tris-HC1 (pH 8.3), 75 mM potassium chloride, 
0.75 mM magnesium chloride) and 5 mM DTT with 40 U RNase OUT RNase inhibitor 
and 200 U Superscript III reverse transcriptase added. The reaction was incubated at 
25°C for 5 minutes, 50°C for 60 minutes and stopped by heating to 70°C for 15 
minutes. cDNA was stored at -20°C. 
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2.1.2.3 PCR using high-fidelity DNA polymerase 
PCRs to amplify DNA sequences to be used in cloning steps (see appendices 3 and 4 for 
primer sequences and reaction conditions) were carried out using the high-fidelity DNA 
Taq polymerase BIO-X-ACT SHORT (Bioline, BIO-21065). For the steps involving 
site-directed mutagenesis of one or more base pairs (or the addition of a base pair into 
the sequence), primers were designed accordingly. For the strategies designed to 
transfer TCR genes into the MFG vector, 22 primers were used in total of which I 
designed 15 and 7 of which were designed by other researchers in the Boyton laboratory 
(as indicated in Appendix 3). I redesigned one primer as the initial primer did not 
produce a PCR product — an extra restriction site added for ease of cloning was 
removed from the primer sequence (see Appendix 3). For the strategies designed to 
transfer TCR genes into the pTcass vectors, 26 primers were used in total of which I 
designed 23 and 3 of which were designed by other researchers in the Boyton laboratory 
(as indicated in Appendix 4). No primers were redesigned for these strategies. 
Reactions occurred in a volume of 25 1,11 comprising I x Optibuffer, MgC12 (see 
appendices 3 and 4 for concentration used for each reaction), 200 uM dATP, dCTP, 
dGTP and dTTP mix, 50-100 ng template DNA, 0.5 [tM forward and reverse primers 
and 2U BIO-X-ACT SHORT. Each completed reaction was run in a separate lane on a 
1% agarose TAE gel (or 2% gel for PCR products less than 100 bp in size) containing 
ethidium bromide alongside either Promega 1 kb DNA ladder (as before) or Invitrogen I 
kb DNA ladder (15615) and visualised under UV light. Loading buffer was added as 
described previously. All other PCR reactions (i.e. to check orientation of final inserts 
in MFG) were carried out using BIOTAQ polymerase as described above in 2.1.1.3 
(primers and reaction conditions are shown in Appendices 3 and 4). 
2.1.3 General DNA cloning techniques 
2.1.3.1 Preparation of competent cells 
Two strains of competent cells were used — XL-GOLD and K12 ER2925 (New England 
Biolabs, E4109S). K12 ER2925 was used for any step involving restriction digest with 
Clal (Promega, R6551); for all other transformations, XL-GOLD cells were used. To 
prepare competent cells, cells from a previous stock of XL-GOLD or glycerol stock of 
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ER2925 were streaked onto an Luria-Bertani (LB) agar plate containing 50 µg/m1 
tetracycline (Sigma, T3258) (appendix 1) (XL-GOLD) or 25 µg/m1 chloramphenicol 
(Sigma, C0378) (appendix 1) (ER2925) and grown overnight at 37°C. A single colony 
was expanded overnight at 37°C with shaking in 5 ml LB broth containing the same 
antibiotic at the same concentration. This culture was used to inoculate 200 ml 
autoclaved LB broth containing 3 ml 1M MgC12 (Sigma, M8266) and grown at 37°C 
with shaking until the OD600 was 0.6. The culture was then placed on ice for 10 
minutes. Solutions A (60 ml) and B (12 ml) (appendix 1) were prepared previously and 
cooled on ice. The culture was centrifuged in pre-chilled centrifuge tubes at 1500 x g 
for 10 minutes at 4°C; pellets were resuspended in 30 ml solution A and chilled on ice 
for 20 minutes. The tubes were then centrifuged at 1500 x g for 10 minutes at 4°C and 
pellets were resuspended in 6 ml ice cold solution B. 250 IA aliquots were transferred to 
sterile eppendorfs on dry ice and tubes were stored at -80°C. 
2.1.3.2 Restriction digests 
Restriction digests for all cloning steps in the MFG and pTcass cloning strategies were 
carried out in 40 µI volume containing lx restriction enzyme buffer (appendix 5), 2U 
restriction enzyme and 1-4 lag of plasmid DNA. The reaction was incubated at the 
specified temperature (appendix 5) for 1 hour followed by inactivation by heating to 
65°C for 15 minutes. If a single restriction enzyme digest had been carried out, the 
vector was dephosphorylated using Calf Intestinal Alkaline Phosphatase (Promega, 
M1821) to prevent re-ligation without an insert. Two aliquots of 0.01U alkaline 
phosphatase per pmol DNA ends were required, where 1 lig of 1,000 bp DNA = 3.03 
pmol ends. Each reaction was incubated for 1 hour at 37°C with the second aliquot of 
enzyme being added after 30 minutes. Completed digests were run down a 1% agarose 
TAE gel alongside a DNA ladder, correct bands (vector and insert) were excised from 
the gel and purified as described previously. 1 µ1 of the purified eluate was run down a 
1% agarose TAE gel with Hyperladder I (Bioline, BIO-33025) to quantify the amount 
of DNA purified. 
Restriction digests were also used to check for the presence of an insert in the human 
TCR CDR3 analysis or to check for the presence of a correctly-oriented and correctly-
sized insert at each step in the MFG and pTcass cloning strategies. Reactions were 
carried out in a final reaction volume of 20 µ1 containing lx restriction enzyme buffer 
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(appendix 5), 1U restriction enzyme and 1 p,g of plasmid DNA. Reactions were 
incubated at the specified temperature (appendix 5) for 1 hour before being run down a 
1% agarose TAE gel alongside a DNA ladder and analysed for correct insertion, size 
and/or orientation. 
2.1.3.3 Oligonucleotide preparation 
Oligonucleotides (single strands, Sigma-Genosys), reconstituted at 500 12g/m1 in sterile 
dH2O, were diluted to a concentration of 50 ng/µ1 in a volume of 20 µ1, heated to 70°C 
for 5 minutes and allowed to anneal by slowly cooling to room temperature (annealed 
linkers were placed in a beaker of water at 65°C and left to cool). Annealed 
oligonucleotides were incubated in a volume of 50 pl with 20U polynucleotide kinase 
(Promega, M4101), 1 x reaction buffer (70 mM Tris-HC1 (pH 7.6), 10 mM MgSO4, 5 
mM DTT) and 1 mM ATP (Sigma, A6559) at 37°C for 1 hour before incubation for 1 
hour at -20°C in 200 µ1 isopropanol. The final pellet was resuspended in 20 1.11 dH2O 
and the annealed, phosphorylated linker was ligated into the vector. 
2.1.3.4 Nuclease treatment 
To destroy the NcoI restriction enzyme site in MFG, vector DNA (1-4 µg) was digested 
with restriction enzyme NcoI (appendix 6), treated with 0.5-4U Si nuclease (Promega, 
M5761) in 1 x reaction buffer (50 mM sodium acetate (pH 4.5), 280 mM sodium 
chloride, 4.5 mM ZnSO4) and incubated at 37°C for 30 minutes. The reaction was 
stopped by heating to 70°C for 5 minutes and the digested vector was re-ligated without 
insert. Destruction of the restriction site had occurred if there was no cutting upon 
digestion of the re-ligated plasmid with NcoI. The re-ligated plasmid was also cut with 
NotI (appendix 6) to ensure that the nuclease digestion had not destroyed that site. 
2.1.3.5 Cloning ligations 
Ligations were carried out at varying vector:insert ratios. To determine the amount of 
insert DNA required for the correct ratio, the following formula was used: 
ng insert = ng vector x kb size of insert x molar ratio  insert 
kb size of vector 	 vector 
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Ratios of 1:1, 1:3, 1:6 and 1:12 were used with approximately 100 ng vector used per 
reaction. Controls were carried out at a 1:0 vector:insert ratio either with or without 
ligase to determine the efficiency of enzyme restriction and frequency of vector re-
ligation. All ligations were carried out in a volume of 10 Ill containing insert and vector 
DNA, 1 x ligase buffer (described previously) and 2.5U T4 DNA ligase (Invitrogen, 
15224-041) and incubated at 16°C overnight. 
2.1.3.6 TA cloning ligations 
DNA bands of the correct size for each reaction were excised from the gel and purified 
using a silica matrix protocol (QBiogene, 1101-200) to preserve the A overhangs 
incorporated by Taq polymerase. Products were cloned into pCR®2.1 (TA cloning kit, 
Invitrogen, R2000-01), supplied pre-linearised. 10-20 ng of PCR product were ligated 
into 25 ng of pCR®2.1 using 3U T4 DNA ligase (Invitrogen 15224-041) in lx reaction 
buffer (50 mM Tris-HC1 (pH 7.6), 10 mM MgC12, 1 mM ATP, 1 mM DTT and 5% 
(w/v) PEG-8000) in a reaction volume of 10µ1 and incubated at 16°C overnight. 
2.1.3.7 E.coli transformation 
XL-GOLD competent cells were used to transform TA cloning ligations and other 
cloning ligations. 2 ill of ligation mixture was added to 50 Ill cells and incubated on ice 
for 30 minutes. Heat shock was carried out at 42°C for 30 seconds followed by addition 
of 250 Ill of LB broth (Sigma, L3022) at room temperature. Cells were incubated with 
shaking for 1 hour at 37°C then spread onto LB agar (Sigma, L2897) plates containing 
50 µg/ml ampicillin (Sigma, A9518) (appendix 1), previously spread with 40 1.11 of a 40 
mg/ml solution of X-Gal (5-bromo-4-chloro-3-indoly1 b-D-galactopyranoside) (Bioline, 
B10-37035) and 8 ul of a 100 mM solution of IPTG (isopropyl beta-D-1-
thiogalactopyranoside) (Sigma, 16758) to allow for blue/white screening of colonies 
(only TA cloning transformations). 
Any plasmid involved in a cloning step requiring digestion with the enzyme ClaI was 
transformed into the dam" (Dam methylase deficient) strain K12 ER2925 to allow ClaI 
digestion to occur correctly. Transformation occurred as for XL-GOLD (without X-gal 
or IPTG). 
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2.1.3.8 Plasmid DNA preparation 
Successfully transformed colonies (white or mostly white colonies) were expanded in 
liquid culture (8 ml LB broth containing 50 µg/m1 ampicillin) overnight at 37°C with 
shaking. Bacteria were pelleted by centrifugation at 1500 x g for 4 minutes followed by 
extraction and purification of plasmid DNA by alkaline lysis (Sigma, NA0160). 
Plasmids were screened for insertion of the PCR product by restriction digest as shown 
in Appendices 2 and 6. Diagnostic digests were carried out in a 20 !Al volume containing 
2 µg plasmid DNA, 1U restriction enzyme and 2 µI 10x restriction enzyme buffer. 
Reactions were incubated at the optimum temperature specified for 1 hour. Digests 
were run on a 1% agarose TAE gel with DNA ladder. 
For the final MFG and pTcass constructs, once correct insertion and sequence had been 
ascertained, a larger-scale plasmid preparation was carried out using 500 ml bacterial 
culture. 5m1 cultures were inoculated into 500 ml LB broth containing 50 µg/ml 
ampicillin and grown overnight at 37°C with shaking. Bacteria were pelleted by 
centrifugation at 1500 x g for 30 minutes at 4°C and plasmid DNA was extracted and 
purified by alkaline lysis (Invitrogen, K2100-07). Plasmids were screened by restriction 
digest as before. 
2.1.3.9 Sequence analysis 
For the human TCR clonotypic analysis and for the MFG and pTcass cloning strategies 
where the step involved a PCR amplification step and transformation into pCR82.1, all 
plasmids yielding a correctly-sized fragment after digestion with EcoRl were sequenced 
at the Natural History Museum DNA Sequencing Facility (London, UK) using the M13 
forward sequencing primer (appendix 2) and in the case of the MFG and pTcass 
sequences, with the M13 reverse primer also (appendices 3 and 4). For the final 
constructs of the MFG and pTcass cloning strategies, all plasmids yielding a correctly-
sized fragment after diagnostic restriction enzyme digest and in the case of the MFG 
constructs, shown to be correctly oriented by PCR, were also sequenced at the Natural 
History Museum DNA Sequencing Facility using sequencing primers described in 
Appendices 3 and 4. Intermediate cloning steps that did not involve PCR were not 
sequenced but were confirmed using diagnostic restriction digests and/or PCRs where 
appropriate and as stated in Chapter 3. Sequence data was manipulated using 
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GeneJockeyll software, raw sequence data being read by EditView software (Perkin 
Elmer). Sequences were aligned against the International Immunogenetics (IMGT) 
information system database (http://imgt.cines.fr) and classified according to their 
definitions. 
2.2 	Genotyping of P4 TCR/DR1/ABO transgenic mice 
2.2.1 Genomic DNA extraction from tail tips 
Genomic DNA for use in genotyping of transgenic mice and for the amplification of J-
region-intronic sequences in the pTcass cloning strategies was extracted from tail tips 
after digestion with proteinase K (Sigma, P2308). Tail tips were incubated overnight at 
56°C in a final volume of 400 ul of tail digestion buffer (appendix 1) with 10 1A.1 of 20 
mg/ml proteinase K added and mixed by vortexing before incubation. Genomic DNA 
was isolated by high concentration salt extraction by adding 200 µl 6M saturated 
sodium chloride (Sigma, 57653) solution and mixing by shaking for 30 seconds to 
precipitate all protein in the sample. Samples were centrifuged at 16100 x g using a 
microcentrifuge to pellet the protein and the supernatant was extracted and treated with 
an equal volume of isopropanol to precipitate the DNA. Samples were centrifuged at 
16100 x g and the DNA pellet was washed with 70% ethanol to remove any excess salt. 
The final pellet was left to air dry and resuspended in 50 Ill sterile dH20 (Sigma, 
W4502). DNA samples were diluted by 1 in 50 using sterile dH2O before use in PCR. 
2.2.2 Genotyping by PCR 
Genotyping PCRs (see appendix 6 for primers and reaction conditions) were carried out 
as described above in 2.1.1.3. 
2.2.3 Collection, preparation and staining of tailbleed samples for phenotyping 
by flow cytometry 
Tailbleed samples were collected in 50u1 heparin (Leo Laboratories) at 0.5U/121, diluted 
in sterile PBS (pH 7.4, Invitrogen, 10010-015), with 6-8 drops of blood being collected 
from the tail vein of each mouse. The tail vein was nicked using a fresh sterile scalpel 
for each mouse which had previously been kept for at least 10 minutes in a heat- 
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controlled box at 37°C to enlarge the vein. Blood samples were mixed thoroughly with 
the heparin to prevent clotting. Red blood cells were lysed by the addition of 1 ml dH2O 
and repeated passage through a 23G hypodermic needle for no more than 30 seconds 
before being added to 11 ml complete RPMI-1640 medium (appendix 1). After 
centrifugation at 300 x g the cell pellet was washed twice in 10 ml FACS buffer 
(appendix 1). Cells were then stained using liul anti-CD45R-FITC and 0.5[1,1 anti-I-A/I-
E-PE antibodies (all antibodies are shown in appendix 6), made up to a total volume of 
20121 with FACS buffer. Control samples were stained with either 0.5µ1 anti-CD3e-
FITC, 0.5R1 anti-CD4-PE, both, or left unstained. Antibodies were selected on the 
advice of Prof. Danny Altmann and matched the antibodies used in his laboratory for 
phenotyping of DR1/ABO mice by this method. Samples were incubated at 4°C in the 
dark for 30 minutes and then washed twice in ample FACS buffer before being 
resuspended in a small volume of FACSFlow (BD Biosciences). Samples were run on a 
FACSCalibur (BD Biosciences) flow cytometer and data was analysed using CellQuest 
Pro software (BD Biosciences). 
2.2.4 Genotyping by Southern analysis 
2.2.4.1 Southern (DNA) blotting 
101.i.g of genomic DNA was digested overnight with restriction enzyme at the specified 
temperature (appendix 6) in a reaction volume of 500 comprising DNA, 5R1 restriction 
enzyme, lx restriction enzyme buffer, 0.1 mg/ml BSA (Promega, R396), 0.1 mg/ml 
RNase A (Sigma, R4875) and 1 mM spermidine (Sigma, S2501). Digests were run 
overnight on a 1% agarose TAE gel (300 ml) without ethidium bromide at 45V. The gel 
was then cut to size to remove unnecessary gel and incubated in depurination solution 
(appendix 1), so that the gel was completely covered, at room temperature for 10 
minutes with shaking. The gel was washed briefly in dH2O before incubation in 
denaturation solution (appendix 1) at room temperature with shaking for 40 minutes. 
Again, the gel was washed briefly in dH2O and incubated in neutralisation buffer 
(appendix 1) at room temperature with shaking for at least 40 minutes. The DNA from 
the gel was then blotted overnight onto Hybond-N4- nylon membrane (GE Healthcare, 
RPN203B) by upward neutral transfer using 20x SSC (appendix 1). After blotting, 
DNA was fixed to the membrane by UV cross-linking and air dried before being stored 
at 4°C until use. 
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2.2.4.2 Probe production 
A probe of approximately 800 bp was produced by PCR amplification (appendix 6) 
using template containing the gene of interest. PCR products were run down a 1% 
agarose TAE gel, cut out and purified as described previously. 160 of PCR product was 
boiled for 10 minutes before immediately being placed on ice to prevent reannealing. 
41a1 of DIG-High Prime (from Roche kit, 11 585 614 910) containing the optimal 
concentrations of random primers, nucleotides, DIG-dUTP, Klenow enzyme and buffer 
components at a 5x concentration was added to the DNA and the reaction was incubated 
for 20 hours at 37°C. The DIG-labelled DNA was purified from the reaction mix using 
a silica-based spin column (Bioline) and eluted into 20ti1 elution buffer (supplied with 
the kit). The extent of labelling was determined by use of a dilution series of the 
labelled probe compared against a dilution series of control DIG-labelled DNA (Roche, 
11 585 738 910) of known labelling intensity. Probe and control DNA was diluted in 
DNA dilution buffer (appendix 1). Each dilution of probe and control DNA was spotted 
(1 Ill) onto Hybond-N+ nylon membrane, air dried and fixed by UV cross-linking. To 
determine the concentration of DIG-labelled DNA in the probe, the dot blot was first 
washed for 2 minutes in maleic acid buffer (appendix 1) at room temperature before 
detection of DIG-labelled DNA was carried out as described below. 
2.2.4.3 Hybridisation of DIG-labelled probe to the DNA blot 
The DNA blot was pre-hybridised for at least 30 minutes at 42°C in 10 ml DIG 
EasyHyb solution (Roche, 11 796 895 001) with rolling to ensure the blot did not dry. 
The pre-hybridisation solution was then replaced with 8 ml fresh DIG EasyHyb solution 
containing 17-25 ng/ml DIG-labelled probe and incubated overnight at 42°C with 
rolling. Excess unbound probe was then removed by stringency washing. The blot was 
removed from the hybridization solution and washed twice in 2x SSC, 0.1% SDS for 5 
minutes at room temperature with shaking and then washed twice in 0.5x SSC, 0.1% 
SDS for 15 minutes at 65°C with shaking. The blot was then washed for 5 minutes in 
maleic acid washing buffer (appendix 1) before detection of bound probe DNA. 
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2.2.4.4 Detection of probe binding to membrane 
The DNA blot was incubated for at least 30 minutes at room temperature with shaking 
in ample lx blocking solution (Roche, 11 585 614 910, diluted to lx concentration with 
maleic acid buffer) to allow complete coverage of the membrane. Antibody solution 
was prepared by the addition of anti-digoxigenin-alkaline phosphatase conjugate 
(Roche, 11 585 614 910) to lx blocking solution to give a 1:10000 dilution of antibody. 
The antibody was centrifuged at 9300 x g in a microcentrifuge for 5 minutes 
immediately prior to its use. As small as volume as possible (25 ml for a DNA blot, 
10m1 for a dot blot) was used to allow complete coverage of the membrane whilst 
conserving antibody. The blocking solution was removed and replaced with the freshly-
prepared antibody solution and the blot was incubated at room temperature with shaking 
for 30 minutes, after which the blot was washed twice in ample maleic acid washing 
buffer at room temperature with shaking for 15-20 minutes. The blot was then 
equilibrated to the required pH (pH 9.4) to allow correct function of the alkaline 
phosphatase in the chemiluminescent reaction with CSPD (disodium 3-chloro-3-
(methoxyspiro {1,2-dioxetane-3,2' -(5 ' -chloro) tricyclo [3.3.1.1] decan} -4-y1) phenyl 
phosphate) by incubating for 2-5 minutes in DIG-detection buffer (appendix 1) at room 
temperature with shaking. The blot was removed from the detection buffer and placed 
on a development folder and 1 ml of CSPD ready-to-use (Roche, 11 585 614 910) (or 
0.3 ml for a dot blot) was added dropwise to completely cover the blot with substrate. 
The blot was then immediately covered by the second sheet of the development folder 
and all air bubbles between the folder and the membrane were removed before 
incubation at room temperature for 5 minutes. Excess liquid was squeezed out from the 
folder and the edges sealed before exposure of the blot to photographic film (Kodak 
BioMax Light Film, Light-1, Sigma, Z378516) for 2 hours (25 minutes for a dot blot). 
The film was then developed and analysed. Further exposures could be taken if required 
up to 48 hours after addition of the CSPD substrate. 
2.3 	Tissue culture and transduction techniques 
2.3.1 Culture of adherent cell lines EcoPhoenix, PT67 and NIH3T3 
Cell lines were cultured from frozen stocks stored in liquid nitrogen. Vials were thawed 
quickly at 37°C and the cells were added to 25 ml of pre-warmed complete Dulbecco's 
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Modified Eagle's Medium (DMEM) medium (Appendix 1). Cells were spun at 300 x g 
for 3 minutes and supernatant decanted thoroughly. Cells were then resuspended in 
complete DMEM medium and cultured in either 25 cm2 (8 ml) or 80 cm2 (30 ml) 
culture flasks with filter caps (Nunclon, 136196/178905) in a humidified incubator at 
37°C with 5% CO2. 
EcoPhoenix (Orbigen, RVK-10001), PT67 (BD Biosciences Clontech, 631510) and 
NIH3T3 (Sigma, 93061524) adherent cell line cultures were split by up to 1 in 5 when 
at 70-80% confluency by addition of 1 ml (25 cm2) or 3 ml (80 cm2) lx trypsin-EDTA 
(Invitrogen, 15400-054, diluted in PBS, pH 7.4, Invitrogen, 10010-056) to cells that had 
been washed twice with PBS and incubation for 1 minute at 37°C. Cells were dislodged 
by gentle agitation. An equivalent volume of medium was added to quench 
trypsinisation, cells were spun at 300 x g for 3 minutes and resuspended in 1 ml 
medium. The correct volume of cells for the split was added to a new flask containing 8 
ml or 30 ml of fresh medium as appropriate. 
2.3.2 Reselection of PT67 cells 
PT67 cells were reselected using hypoxanthine, aminopterin and thymidine (HAT) 
medium. Cells undergoing reselection were grown for 5 days in complete DMEM with 
100 nM aminopterin (Sigma, A3411) added. The cells were then grown for 5 days in 
complete DMEM-HAT medium (appendix 1). Finally, cells were grown for 1 week in 
complete DMEM-HT medium (appendix 1) before being returned to normal culture 
conditions. Cells were split as described above as required. 
2.3.3 Culture of non-adherent cell lines BW7 and CTLL-2 
Cell lines were cultured from frozen stocks stored in liquid nitrogen. Vials were thawed 
quickly at 37°C and the cells were added to 25 ml of pre-warmed complete RPMI-1640 
medium. Cells were spun at 300 x g for 3 minutes and supernatant decanted thoroughly. 
Cells were then resuspended in 40-50 ml complete RPMI-1640 in 80 cm2 culture flasks 
with filter caps and cultured in a humidified incubator at 37°C with 5% CO2. CTLL-2 
cells required the addition of 20 U/ml recombinant IL-2 (R&D Systems, 402-ML-100) 
to the culture medium for survival. BW7 (569) and CTLL-2 cells were split every 2-3 
days before becoming overgrown by spinning at 300 x g for 3 minutes and resuspending 
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the pellet in 1 ml medium and transferring the appropriate volume of cells to a new 
flask containing fresh medium. 
2.3.4 Retroviral transduction 
2.3.4.1 Retroviral transfection of packaging cell line EcoPhoenix 
EcoPhoenix cells were plated in 25 cm2 tissue culture flasks at the required density 24 
hours prior to transfection. On the day of transfection cells were incubated at 37°C, 5% 
CO2 in 3 ml of fresh medium with 25 [AM chloroquine (Sigma, C6628, appendix 1) 
added if required for at least 30 minutes before transfection. A transfection cocktail 
(0.6m1/flask) was prepared containing 10 ps retroviral expression vector DNA 
containing a gene of interest, 125 mM CaC12 (Sigma, C3881, appendix 1) and lx 
HEPES-buffered saline (HBS) (appendix 1) (or in later transfections, using the reagents 
provided in a calcium phosphate transfection kit from Invitrogen, K2780-01). HBS was 
added to the DNA/CaC12 with bubbling and was either added dropwise immediately to 
the cells or incubated at room temperature for 30 minutes before dropwise addition to 
the cells (Invitrogen kit). Cells were incubated at 37°C15% CO2 for 8 hours. After this 
time the medium was replaced with 5 ml fresh (trial and original protocols) or 2.5 ml 
(modified protocol). For the trial and original protocols the medium was again replaced 
with 3 ml fresh medium 12 hours later for supernatant collection 48 hours after initial 
transfection. For the modified protocol supernatant was harvested 36 hours after initial 
transfection and 2.5 ml fresh medium was added to the cells for a second collection of 
supernatant 24 hours later. Supernatant was collected and filtered to remove any cells 
(0.45 gm syringe filter - Nalgene, 190-2545) before being used to infect target cells. 
Supernatant was diluted as required in fresh medium and polybrene (hexadimethrine 
bromide, Sigma, 52495, appendix 1) was added to a final concentration of 4 µg/ml 
before infection. 
2.3.4.2 Infection of secondary packaging line PT67 with retroviral supernatant 
PT67 cells were plated at a density of 100,000 cells per 25 cm2 flask 18 hours before 
infection. Retroviral supernatant, prepared as described previously, was then used to 
replace the medium on the cells. Cells were incubated at 37°C and 5% CO2 for 3 hours 
before an extra 2 ml of fresh medium was added. Medium was changed after 24 hours 
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to remove retroviral supernatant. 48 hours after initial infection, medium was replaced 
with 3 ml fresh for retroviral supernatant collection. Supernatant was collected at 72 
hours after infection (for the final modified protocol supernatant was replaced with 3 ml 
fresh medium for a second collection of supernatant at 96 hours after infection). 
Supernatant was filtered (0.45 [tm syringe filter) and diluted if required before being 
used to infect target cells. Polybrene was added to a final concentration of 4 µg/ml 
before infection. 
2.3.4.3 Infection of adherent target cell line NIH3T3 with retroviral supernatant 
NIH3T3 cells were plated at a density of 50,000 cells per well of a 6-well tissue culture 
plate (Nunclon, 140675) 24 hours before infection. Retroviral supernatant, prepared as 
described previously, was then used to replace the medium on the cells. Cells were 
incubated at 37°C and 5% CO2 for 3 hours before an extra 2 ml of fresh medium was 
added. Medium was changed after 24 hours to remove retroviral supernatant. Cells were 
harvested at different time points after infection (usually some or all of 24, 48, 72 and 
96 hours) and analysed for eGFP expression by flow cytometry (no antibody staining 
required). Data analysis was carried out using CellQuest software (BD Biosciences). 
2.3.4.4 Infection of non-adherent target cell line BW7 with retroviral supernatant 
BW7 cells (1 x 105) were added to 2 ml retroviral supernatant, prepared as described 
previously, and centrifuged at 1000 x g for 90 minutes at 32°C for the trial and original 
protocols. For the final modified protocol BW7 cells (1 x 105) were added to 2 nil 
retroviral supernatant, prepared as described previously, and centrifuged at 680 x g for 
30 minutes at room temperature. Cells were then resuspended in the same medium in 
wells of a 12-well tissue culture plate (Nunclon, 150628). Cells were incubated at 
37°C/5% CO2 for at least 3 hours after which 1 ml (BW7) of fresh medium was added. 
Medium was changed after 24 hours to remove retroviral supernatant. Cells were 
harvested at different time points after infection (usually some or all of 24, 48, 72 and 
96 hours) and analysed for eGFP expression or TCR/TCRI3 chain expression (see 
Appendix 7 for antibodies used and section 2.2.3 for protocol) by flow cytometry. 
Antibodies for the analysis of TCR expression were selected predominantly on the basis 
of availability, as in most cases, there is only one commercially available antibody for 
each TCRI3 chain (and frequently no antibody available for a particular TCRa chain). 
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Where isotype controls were used, they were purchased from the same company as 
supplied the original antibody to match them as far as possible to each other in terms of 
concentration and intensity. Data analysis was carried out using CellQuest software. 
2.3.4.5 Principles of flow cytometry 
Flow cytometry involves the analysis of cells in terms of their size and granularity and 
when bound to fluorophore-labelled antibodies, analysis of cell surface molecule 
expression (and in some cases intracellular molecule expression) using light from a 
laser. Flow cytometry involves single cell analysis, as each individual cell is directed 
through the laser beam separately and is hence analysed individually. Light scattering 
properties (forward and side scatter) identify cells in terms of size and granularity, 
whilst cells can be incubated with fluorophore (eg. FITC/PE)-labelled antibodies before 
analysis. A number of fluorophores can be monitored simultaneously depending on the 
flow cytometer. Excitation of the fluorophore by the laser leads to emission of light 
which is intercepted by detectors set to receive light at ranges of wavelengths 
corresponding to the emission spectra of the fluorophores (one detector for each 
fluorophore). If the cell has bound such an antibody due to its expression of the 
molecule being assayed, the laser will excite the fluorophore, light will be emitted and 
detected and the cell will appear as positive. Detectors amplify the signal (linearly or 
logarithmically) and convert it into electronic data which is then collected and analysed 
on a computer. 
Compensation of signals is required as the emission spectra from many fluorophores 
overlap (spectral overlap) and hence there is overlapping of the signals detected. This 
can lead to the appearance of a higher level of expression of a molecule than is actually 
there. Compensation reduces this overlap by removing the part of the signal that is due 
to fluorescence from other fluorophores by manipulating voltage levels of the various 
detectors. Gating allows the definition of a population of cells on the basis of their light 
scattering characteristics so as to isolate a particular population of cells within a mixed 
culture e.g. lymphocytes in a sample of PBMCs, or separation of live cells from dead 
cells. Gating is also used in analysis of the data to differentiate between cells that do or 
do not express a specific molecule and can be used to calculate the proportion of cells 
that express a number of molecules simultaneously. 
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2.3.5 Transfection of non-adherent target cell line BW7 with TCR expression 
vectors using the Amaxa NucleofectorTM electroporation system 
3 x 106 BW7 cells were used in each transfection. Prior to transfection, NucleofectorTM  
solution V (component of Cell Line NucleofectorTM Kit V, Amaxa, VCA-1003) was 
warmed to room temperature and a 12-well culture plate was prepared containing 1 
ml/well of complete RPMI-1640 without added penicillin/streptomycin for each 
transfection to be carried out and pre-warmed to 37°C. Cells were centrifuged at 300 x g 
for 5 minutes and all supernatant was carefully removed. Cells were then resuspended 
in 100 IA NucleofectorTM solution V (suggested for this cell line by the Amaxa Cell 
Line Database (www.amaxa.com)). Plasmid DNA (1 lug of the control plasmid 
pmaxGFP (component of Amaxa, VCA-1003) or up to 5 lig each of TCRa and TCR(3 
expression vectors containing the TCR chains of interest) was added to the cells and 
mixed. Cells were then transferred carefully into an Amaxa-certified cuvette 
(component of Amaxa, VCA-1003), ensuring that the suspension covered the bottom of 
the cuvette and that there were no air bubbles, and closed using the provided cap. The 
required programme (T-016 or T-001 as suggested for this cell line on the Amaxa Cell 
Line Database) was entered into the Amaxa Nucleofector-ITM (Amaxa, AAD-1001) and 
the cuvette was inserted into the cuvette holder. The button marked "X" on the 
NucleofectorTM was pressed to start the programme. Once the programme had finished, 
the cuvette was removed and the cells were immediately transferred into the previously 
prepared tissue culture plates using one of the provided Pasteur pipettes (component of 
Amaxa, VCA-1003). Cells were then incubated at 37°C and 5% CO2 and analysed for 
expression of either GFP or TCR13 chain (see Appendix 7 for antibodies used and 
section 2.2.3 for staining protocol) by flow cytometry at different time points - 24 
hours, 48 hours, 72 hours, 96 hours and 9 days after transfection. Data analysis was 
carried out using CellQuest software. 
2.3.6 Analysis of cell death by flow cytometry using propidium iodide 
Cells (either previously stained with fluorescently-conjugated antibody or unstained) 
were washed in 2 ml FACS buffer (appendix 1), centrifuged at 300 x g for 5 minutes, 
supernatant was decanted thoroughly and cells were resuspended in 100111 FACS buffer 
(appendix 1). Cells were stained with 5 !al propidium iodide solution (PI, from 
Immunotech kit, PN IM3546), reconstituted at a concentration of 250 µg/ml in lx 
140 
binding buffer (supplied at 10x concentration with the kit and diluted in dH2O) and 
incubated on ice in the dark for 10 minutes. After this time, 400 µ1 of lx binding buffer 
was added to the cells. Samples were run on a FACSCalibur (BD Biosciences) flow 
cytometer and data was analysed using CellQuest Pro software (BD Biosciences). 
2.3.7 Measurement of IL-2 production in transduced BW7 cells using the CTLL-
2 assay 
5 x 104 BW7 cells (both transduced and untransduced) in HL-1 medium (appendix 1) 
were incubated with 25 or 50 µg/m1 specific peptide (PLP56-70 diluted in PBS and 5 x 
105 irradiated (30 Gy) NOD.E splenocytes (also in HL-1 medium) in triplicate in a 96-
well tissue culture plate (Nunclon, 163320) for 48 hours at 37°C and 5% CO2. Negative 
(medium alone) and positive (5µg/m1 concanavalin A (ConA), Sigma, L7647) controls 
were also included in the assay for both transduced and untransduced BW7. After 48 
hours, 100 IA of supernatant from each well was transferred to a new plate and frozen at 
-20°C to lyse any remaining cells. After thawing of the supernatants, 100 µ1 of HL-1 
medium containing 3 x 103 cells from the IL-2 dependent CTLL-2 cell line that had 
been starved of IL-2 for 24 hours prior to their use were added to each well. The cells 
were then incubated for 36 hours at 37°C and 5% CO2. Negative (HL-1 medium alone) 
and positive (HL-1 medium containing 20U/ml recombinant IL-2) controls were also 
included in the assay, After 24 hours of culture, 5 µCi of [3H]-thymidine (MP-2405905) 
was added to each well. After 36 hours, plates were stored at -20°C until processed. 
Plates were thawed completely before processing and were harvested (MACH III M 
Harvester 96) before liquid scintillation counting (Wallac 1450 microbeta TRILUX). 
2.4 	Induction of allergic asthma in a murine model using Fel d 1 
These experiments were carried out with Dr. Catherine Reynolds and Dr. Xiaoming 
Cheng, postdoctoral research associates in the Lung Immunology Group, National Heart 
and Lung Institute, Imperial College, London. 
2.4.1 Sensitisation with Fel d 1 
This was carried out with Dr. Catherine Reynolds. To induce allergic inflammation in 
the lung, a suspension of recombinant Fel d 1 (made by Rebecca Beavil, MRC and 
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Asthma UK Centre in Allergic Mechanisms of Asthma Protein Production Facility) in 
alum (Alu-Gel-S suspension, Serva Electrophoresis, 12261) was prepared under sterile 
conditions by the addition of recombinant Fel d 1 solution to alum to a final 
concentration of 50 µg/m1 Fel d 1. An equivalent volume of PBS was added to alum for 
treatment of control mice. The suspensions were then rolled for at least 1 hour to allow 
the Fel d 1 antigen to be adsorbed onto the alum before injection. Mice were injected 
intraperitoneally with 200 µl of Fel d 1/alum (treated groups) or PBS/alum (controls). 
Sensitisation occurred on days 0 and 11 of the protocol. 
2.4.2 Challenge with cat dander extract 
This was carried out with Dr. Catherine Reynolds. Mice were challenged with cat 
dander extract (obtained from Laboratorios Leti, SA Madrid, Spain) on days 21, 22 and 
23 of the protocol by intranasal administration under general anaesthetic (isoflurane and 
oxygen) of 25 µI of cat dander extract at 10 mg/ml concentration (diluted in sterile PBS) 
for the experiment in P4 TCR/DR1/ABO line 4 mice and at 20 mg/ml concentration for 
the experiment in P4 TCR/DR1/ABO line 16 mice. Control mice received a 
corresponding intranasal administration of 25 µI sterile PBS. 
2.4.3 Measurement of lung function - Penh 
This was carried out with Dr. Catherine Reynolds. The Whole Body Plethysmography 
System (EMMS) was used to measure Penh in unanaesthetised, unrestrained mice. Mice 
were placed into plethysmograph chambers (PLY 310, EMMS) connected to a nebuliser 
aerosol delivery system (AEX 142, EMMS) and a bias flow unit (AEX 142, EMMS) to 
regulate levels of CO2, heat and humidity in the chambers. Measurements were 
collected using EDacq software (EMMS) via transducers (TPF 100, EMMS) connected 
to the chambers. Baseline measurements of air flow in the chambers containing the 
mice were taken for 5 minutes using nebulised sterile PBS (200 [xl) before challenge 
with methacholine (acetyl-13-methylcholine chloride, Sigma, A2251). Measurement of 
methacholine-induced airway hyperreactivity was carried out by nebulising 200 tkl of 
solutions containing increasing concentrations of methacholine (3/10/30/100 mg/ml in 
sterile PBS) into the system and measuring airflow parameters for 5 minutes for each 
concentration. 
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2.4.4 Measurement of lung function - resistance and compliance 
This was performed by Dr. Kate Choy. Resistance and Compliance Plethysmographs 
(EMMS) were used by Dr. Choy to measure pulmonary resistance (RL) and dynamic 
compliance (Cdyn) in response to methacholine challenge in anaesthetized, 
tracheostomised, mechanically ventilated mice. Mice were anaesthetized by 
subcutaneous injection of 100 [11 of a 1:0.55:0.42 mix of PBS, medetomidine 
hydrochloride (Domitor®, Pfizer) and ketamine (Ketaset®, Fort Dodge Animal Health 
Ltd.); an additional 150 [11 was administered by intramuscular injection once the mice 
were immobilised. Once fully anaesthetized, an intratracheal cannula (EMMS) was 
inserted. Mice were placed into plethysmograph chambers connected to a nebuliser 
aerosol delivery system and the cannula was connected to a ventilator and a transducer 
to measure air flow parameters using EDacq software. Baseline measurements were 
taken using 50 	nebulised sterile PBS and measuring for 5 minutes. Response to 
nebulised methacholine (50 [Al) at increasing concentrations (3/10/30/100 mg/ml in 
sterile PBS) was then measured for 5 minutes after each nebulisation. 
2.4.5 Collection of BAL fluid and cytospin preparation 
This was carried out with Dr. Catherine Reynolds. Three 0.4 ml aliquots of PBS (1.2 ml 
total volume) were instilled into the lungs of anaesthetised mice through a cannulated 
trachea using a 1 ml syringe and collected. Samples were then centrifuged at 250 x g for 
8 minutes. Supernatant was collected without disturbing the cell pellet for analysis of 
cytokine production by ELISA and stored at -20°C. Cells were resuspended in 100 ill 
PBS and counted on a haemocytometer. 5 x 104 cells were spun onto a polysine 
microscope slide (VWR, 631-0107) at 400 rpm using a Cytospin 4 (Thermo Shandon), 
air dried and fixed in methanol for 5 minutes. Slides were then stored at room 
temperature until stained for analysis. 
2.4.6 Collection of serum for measurement of total serum [IgE] 
This was carried out with Dr. Catherine Reynolds. Blood was collected from 
anaesthetised mice after BAL fluid collection by cardiac puncture. Blood was incubated 
overnight at room temperature to allow clotting to occur. Samples were centrifuged at 
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full speed in a microcentifuge for 10 minutes after which the supernatant (serum) was 
collected for measurement of total IgE production. Serum samples were stored at -20°C. 
2.4.7 Lung inflation for histological analysis 
This was carried out with Dr. Catherine Reynolds. After collection of BAL fluid and 
blood, the lungs and heart were excised from the mouse. The left lobe of the lung was 
clamped and all but one of the right lobes were tied off to prevent them being inflated. 
The remaining lobe of the lung was inflated using a 1:1 mixture of sterile PBS and 
O.C.T. compound (VWR, 361603E) and placed in a mould filled with O.C.T. 
compound, in the same orientation for each mouse. The tissue was held in place with a 
cork disk before being snap frozen in ultra-cold cyclopentane on dry ice. The frozen 
tissue was then stored at -80°C. 
2.4.8 Disaggregation of cells from lung tissue and cytospin preparation 
The left lobe of the excised lung was used for disaggregation. The lung was chopped 
into small pieces using a mechanised tissue mincer and stored on ice in 2 ml RPMI-
1640 until processed. 25 R1 aliquots of stock solutions of collagenase D (Roche, 11 088 
858 001) and DNase I (Roche, 11 284 932 001) (Appendix 1) were added to 3 ml 
RPMI-1640 for each sample and added to the tissue. The tissue was incubated at 37°C 
with gentle agitation for 1 hour and strained through a 70 1.tm cell strainer (BD Falcon, 
352350) with cells being washed through gently with extra RPMI-1640. Cells were 
centrifuged at 300 x g for 5 minutes and washed twice more in RPMI-1640. The final 
pellet was resuspended in 1 ml RPMI-1640 and cells were counted on a 
haemocytometer. 5 x 104 cells were spun onto a polysine microscope slide at 400 rpm 
using a Cytospin 4, air dried and fixed in methanol for 5 minutes. Slides were then 
stored at room temperature until stained for analysis. 
2.4.9 Staining of cytospins for differential cell count analysis 
Cytospin slides were stained for analysis using modified Wright-Giemsa stain (Sigma, 
WG16). Slides were immersed in Wright-Giemsa stain to cover the cells for 1 minute 
without agitation before the slides were immersed in deionised water without agitation 
for 6 minutes to allow blueing to occur. The slides were then briefly dipped into running 
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deionised water 2-3 times to rinse them and left to air dry. Once the slides were 
thoroughly dried, a coverslip was applied using DPX mountant (BDH, 360294H) and 
slides were left to dry flat overnight before analysis. 
2.4.10 Differential cell counting 
300 cells per cytospin were analysed and identified on the basis of cell morphology as 
shown in Appendix 8. The proportions of neutrophils, eosinophils, macrophages and 
lymphocytes were then calculated, first as percentages of the total cell count, before this 
was used in conjunction with the total cell count to calculate the total number of each 
cell type in each sample. Slides were randomized and coded before counting was 
carried out by three blinded investigators (myself, Dr. Catherine Reynolds and either 
Dr. Xiaoming Cheng or Eleanor Raynsford). 
2.4.11 Lung tissue homogenisation 
At the time of harvesting, one lobe of the lung was placed in a cryovial and snap frozen 
in liquid nitrogen for subsequent processing. Samples were weighed and 1 ml lx 
Hanks' Buffered Saline Solution (HBSS) (without calcium or magnesium) (Invitrogen, 
14175-137) containing lx complete mini protease inhibitor cocktail with EDTA 
(Roche, 11 836 153 001) per 100 mg tissue was added and machine homogenised. 
Homogenised samples were centrifuged at full speed in an ultracentrifuge for 10 
minutes. Supernatant was collected for measurement of cytokine production by ELISA 
and stored at -20°C. 
2.4.12 Measurement of total [IgE] in serum by ELISA 
Immunosorbent plates (Nunc-Immuno Maxisorp 96-well plate, Nunc, 456537) were 
coated with 100111 anti-IgE capture antibody (appendix 9) diluted to a concentration of 2 
µg/m1 in PBS (appendix 1), sealed and incubated overnight at 4°C. Antibody was 
removed and plates were washed three times with 400 µl/well wash buffer (appendix 1). 
After the last wash, excess buffer was removed by tapping the plates on paper towels. 
200 111 blocking/diluent buffer (appendix 1) was then added to each well, plates were 
covered and incubated at room temperature for at least 1 hour. Plates were then washed 
three times as before. Samples were diluted 1 in 2 and 1 in 10 in blocking/diluent buffer 
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before addition to the plate. A standard curve was prepared in duplicate by diluting an 
IgE standard (appendix 9) in a series of seven 1 in 2 dilutions from a starting 
concentration of 500 ng/ml. 500 of sample or standard was added to each well, with an 
additional two wells containing 100 0 blocking/diluent buffer only as a measure of 
background. Plates were covered and incubated at room temperature for 1 hour before 
being washed three times as before. 1000 biotinylated detection antibody (anti-IgE, 
appendix 9) at a concentration of 2 µg/ml was added to each well, plates were covered 
and incubated at room temperature for 1 hour. Plates were washed six times as before. 
Streptavidin-horseradish peroxidase conjugate (R&D Systems, DY998) was diluted in 
blocking/dilution buffer as directed on the vial and 1000 was added to each well before 
plates were covered and incubated at room temperature for 30 minutes, after which 
plates were washed six times as before. Substrate solution - a 1:1 mix of Color Reagent 
A (stabilised hydrogen peroxide) and Color Reagent B (stabilised tetramethylbenzidine) 
(Substrate Reagent Pack, R&D Systems, DY999) was prepared immediately prior to 
use and 100 0 was added to each well. Plates were then incubated in the dark at room 
temperature for approximately 30 minutes to allow colour to develop. The reaction was 
stopped by the addition of 50 0 stop solution (appendix 1). Plates were read on a 
Sunrise plate-reader (Tecan) with a measurement absorbance of 405 nm and a reference 
absorbance of 570 nm using Magellan (Tecan) software. Readings were corrected by 
subtracting the background measurement, a standard curve was plotted and total [IgE] 
in each sample was calculated from the equation of the standard curve. 
2.4.13 Measurement of cytokine concentrations in BAL fluid and lung homogenate 
by ELISA 
Immunosorbent plates were coated with 1000 anti-cytokine capture antibody diluted to 
the specified working concentration in PBS (appendix 9), sealed and incubated 
overnight at room temperature. Antibody was removed and plates were washed three 
times with 400 0/well wash buffer. After the last wash, excess buffer was removed by 
tapping the plates on paper towels. 300 0 blocking buffer (appendix 1) was then added 
to each well, the plates were covered and incubated at room temperature for at least 1 
hour. Plates were then washed three times as before. Samples were diluted 1 in 2 in 
diluent buffer (appendix 1) before addition to the plate. A standard curve was prepared 
in duplicate by diluting cytokine standards (appendix 9) in a series of eight 1 in 2 
dilutions from a starting concentration of 4000 pg/ml. 500 of sample or standard was 
146 
added to each well with an additional two wells containing 100 IA diluent buffer only as 
a measure of background. Plates were covered and incubated at room temperature for 2 
hours before being washed three times as before. 100111 biotinylated anti-cytokine 
detection antibody at the specified working concentration (appendix 9) was added to 
each well, plates were covered and incubated at room temperature for 2 hours. Plates 
were washed three times as before. Streptavidin-horseradish peroxidase conjugate was 
diluted in diluent buffer as directed and 100v1 was added to each well before plates 
were covered and incubated at room temperature for 20 minutes, after which plates 
were washed three times as before. Substrate solution - a 1:1 mix of Color Reagent A 
and Color Reagent B was prepared immediately prior to use and 100 IA was added to 
each well. Plates were then incubated in the dark at room temperature for approximately 
20 minutes to allow colour to develop. The reaction was stopped by the addition of 50 
ml stop solution (appendix 1). Plates were read on a Sunrise plate-reader with a 
measurement absorbance of 540 nm and a reference absorbance of 570 nm using 
Magellan software. Readings were corrected by substracting the background 
measurement, a standard curve was plotted and cytokine concentration in each sample 
was calculated from the equation of the standard curve. 
2.4.14 Preparation of lung sections and staining with haematoxylin and eosin for 
histological analysis 
Frozen lung sections were cut to a thickness of 5 !Lim using a cryostat (Bright 
Instruments, OTF model) and mounted on polysine microscope slides by Dr. Catherine 
Reynolds. Slides were left to air dry completely before staining - no fixative was 
required. Slides were immersed in mercury-free Harris' haematoxylin (VWR, 351945S) 
for 15 seconds before blueing in running tap water. Slides were then immersed in 1% 
eosin solution (appendix 1) for 5 seconds and rinsed briefly in running tap water. Slides 
were dehydrated by immersion with gentle agitation in 70% industrial methylated spirit 
(IMS) (15 seconds), 90% IMS (15 seconds), 100% IMS (30 seconds) and 100% IMS 
(30 seconds). Slides were then given 3 x 5 minute changes of Histoclear (National 
Diagnostics, HS-200) before the slides were drained and a coverslip was applied using 
DPX mountant. Slides were air dried lying flat overnight before analysis. 
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2.4.15 Inflammation scoring system (for haematoxylin and eosin stained slides) 
The system used for scoring lung sections for inflammation was based on the system 
outlined in reference 607. Each airway and blood vessel in a section was scored 
separately for the degree of inflammatory infiltrate surrounding it and assigned a score 
between 0 and 3. Scores were assigned according to the following criteria: 0 - no 
inflammatory cells surrounding the airway or vessel, 1 - a few inflammatory cells 
cuffing an airway or vessel, 2 - a thin layer (1-5 cells thick) of inflammatory cells 
surrounding the airway or vessel, 3 - a thick layer (more than 5 cells thick) of 
inflammatory cells surrounding the airway or vessel. Two scores were then calculated 
for airway or vessel inflammation - an absolute score, where the modal value for 
airways and for vessels gave the score for each section and an average score, where the 
scores for all airways or vessels were summed and divided by the total number of 
airways or vessels. These scores were then averaged to give a final score for each group 
being assessed. Slides were randomized and coded before scoring was carried out by 2 
blinded investigators (myself and Dr. Catherine Reynolds). 
2.4.16 Preparation of lung sections and staining with periodic acid-Schiff's reagent 
(PAS reagent) for histological analysis 
Frozen lung sections were cut to a thickness of 5µm using a cryostat (Bright 
Instruments, OTF model) and mounted on polysine microscope slides by Dr. Catherine 
Reynolds. Slides were balanced to 0°C and fixed in ice-cold acetone for 15 minutes 
before being air-dried. Slides were oxidised in ice-cold 1% periodic acid (appendix 1) 
and rinsed in deionised water. Slides were then immersed in Schiff's reagent (Fisher 
Scientific, J/7300/PB08) in a fume cupboard for 10 minutes and rinsed in deionised 
water. Slides were then rinsed in running tap water for approximately 5 minutes. Nuclei 
were counterstained by immersion of the slides in mercury-free Harris' haematoxylin 
for 15 seconds before blueing in running tap water. Slides were dehydrated by 
immersion with gentle agitation in 70% industrial methylated spirit (IMS) (15 seconds), 
90% IMS (15 seconds), 100% IMS (30 seconds) and 100% IMS (30 seconds). Slides 
were then given 3 x 5 minute changes of Histoclear before the slides were drained and a 
coverslip was applied using DPX mountant. Slides were air dried lying flat overnight 
before analysis. 
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2.4.17 Scoring of mucus-producing cells (for PAS reagent stained slides) 
The system used for scoring lung sections for mucus-producing goblet cells was based 
on the system outlined in reference 608. Each airway in a section was scored separately 
for the extent of PAS-stained goblet cells in the airway and assigned a score between 0 
and 4. Scores were assigned according to the following criteria: 0 - <5% goblet cells in 
the airway, 1 - 5-25% goblet cells in the airway, 2 - 25-50% goblet cells in the airway, 
3 - 50-75% goblet cells in the airway, 4 - >75% goblet cells in the airway. Two scores 
were then calculated - an absolute score where the modal value gave the score for each 
section and an average score where the scores for all airways were summed and divided 
by the total number of airways. These scores were then averaged to give a final score 
for each group being assessed. Slides were randomized and coded before scoring was 
carried out by 2 blinded investigators (myself and Dr. Catherine Reynolds). 
2.5 Analysis of costimulatory molecule expression in P4 TCR/DR1/ABO 
transgenic mice 
2.5.1 Isolation of splenocytes for flow cytometric analysis or RNA isolation 
Mice were sacrificed by cervical dislocation and the spleen was removed by dissection, 
placed in 15 ml complete RPMI-1640 medium and kept on ice. Each spleen was then 
transferred into a Petri dish along with the medium it was stored in and the medium was 
used to flush the splenocytes from the spleen using a 5 ml syringe equipped with a 23G 
hypodermic needle. The medium containing the splenocytes was collected and 
centrifuged at 300 x g for 5 minutes. Supernatant was discarded and cells were 
haemolysed in dH2O. Haemolysed cells were collected in 11 ml fresh complete RPMI-
1640 and stored on ice until needed. 
2.5.2 Isolation of thymocytes for flow cytometric analysis 
Mice were sacrificed by cervical dislocation and the thymus was removed by dissection, 
placed in 10 ml complete RPMI-1640 medium and stored on ice. Each thymus was then 
mashed through a 70 vm cell strainer using the plunger of a 5 ml syringe, and cells were 
washed through with fresh complete RPMI-1640 medium and collected in a fresh 
centrifuge tube and stored on ice until needed. 
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2.5.3 Staining of cells with fluorescently-conjugated antibodies for flow 
cytometric analysis 
Splenocytes and thymocytes kept on ice in complete RPMI-1640 medium were 
centrifuged for 5 minutes at 300 x g and supernatant was discarded. Cells were washed 
twice in 10 ml FACS buffer (appendix 1) and resuspended in FACS buffer (400 tal -
splenocytes, 800 !Al - thymocytes). Antibody mixes (20 iul per sample comprising 
antibodies required and made up to volume with FACS buffer) were prepared during 
the washing steps and kept on ice in the dark before use - splenocytes were stained with 
two antibodies, either anti-CD4 or anti-CD8 and one of the following antibodies: anti-
CD3, anti-CD25, anti-CD44, anti-CD54, anti-CD62L, anti-CD69, anti-0X40, anti-
OX4OL or anti-ICOS. Thymocytes were stained with three antibodies - anti-CD4, anti-
CD8 and one of the following antibodies: anti-CD3, anti-CD25, anti-CD44, anti-CD54, 
anti-CD62L, anti-CD69, anti-0X40, anti-OX4OL or anti-ICOS. All antibodies used, 
including the source and clone used as well as the required working concentration of 
each, are shown in Appendix 10. Single stain controls for each antibody were also 
prepared to allow for correct gating and compensation of the flow cytometer. Antibody 
mixes were transferred into wells of a 96-well plate and 20 ill of splenocyte or 
thymocyte suspensions were added as required and mixed. Plates were wrapped in 
aluminium foil and incubated at 4°C for 30 minutes to allow staining to occur. After 
staining, plates were centrifuged at 250 x g for 3 minutes, supernatant was flicked off 
and cells were washed twice in 200 t1 of FACS buffer. Cells were then resuspended in 
100 1,11 FACS buffer and transferred into tubes for analysis on the flow cytometer. 
Samples were run on a FACScalibur flow cytometer, with 50,000 events counted for 
each sample, and analysed using CellQuest Pro software. 
2.6 	Statistical analysis 
For both analysis of allergic disease induction in the P4 TCR/DR1/ABO mice and 
analysis of costimulatory molecule expression in P4 TCR/DR1/ABO mice the same 
statistical analysis was carried out using Prism software. First, all samples were tested 
for normal distribution using the Kolmogorov-Smirnov goodness-of-fit test unless 
sample number was too small. If both samples being compared for a particular test were 
normally distributed according to this test, an F test to compare variances of the samples 
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was carried out. Where variances were the same or similar by this test a two-tailed 
unpaired Student's t test was used to calculate statistical significance; if the variances 
were different, Welch's correction to the Student's unpaired two-tailed t test was used 
(and is stated where appropriate). Two-tailed tests were used for statistical significance 
as a means of identifying whether the mean values of the two samples being compared 
were significantly different from each other regardless of the direction in which the 
change occurred. Where sample size was too small to test for normality, the 
nonparametric two-tailed Mann-Whitney U test, which does not assume that data is 
distributed normally, was used to test for statistical significance. Where the Mann-
Whitney U test could not be applied (if group numbers were too small or sample sizes 
too different), a two-tailed unpaired Student's t test was used as above. P values of less 
than 0.05 were considered significant. 
It should be borne in mind when carrying out multiple tests on a set of data that the 
greater the number of tests carried out when comparing one group to another (e.g. Fel d 
1-sensitised against non-sensitised or TCR transgenic against non-TCR transgenic as 
here), the more likely it is that an apparent difference between the two groups will 
appear by chance. Using a p value of less than 0.05 as significant indicates that in every 
20 tests carried out, one will appear to give a difference by chance. One means of 
addressing this problem would be to use Bonferroni's correction, which uses a level of 
statistical significance that is 1/n (where n is the number of tests being carried out on the 
data) i.e. here, 0.05 x 1/n. This provides a more stringent means of testing for statistical 
significance (a result is statistically significant when the probability of a difference 
between two populations being due to chance alone is less than a particular value set by 
the researcher assuming that the original hypothesis is correct). However, due to the 
small group numbers used here, this correction was not applied to the data shown in this 
thesis. 
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3. 	TCR CDR3 analysis of cat allergic asthmatic patients and a 
transduction system to express TCRs of interest in the TCR-
negative murine thymoma line BW7 
3.1 	TCR CDR3 analysis in cat allergic asthmatic individuals 
3.1.1 Overview 
Three T-cell lines generated in the laboratory of Professor Mark Larch& Imperial 
College, London, from peripheral blood of HLA-DR1+ cat-allergic patients were grown 
in vitro against the major allergen in cat dander, Fel d 1 and a peptide derived from Fel 
d 1 known as peptide 4. Peptide 4 is an important epitope of Fel d 1 in cat-allergic 
individuals expressing the MHC class II molecule HLA-DR1 (221). Analysis of TCR 
usage in these lines was carried out to identify if there is a peptide-specific expansion of 
T-cells with particular TCR Va/V13, Ja/Jp and CDR3a/13 regions to test the hypothesis 
that in the human Th2-mediated disease allergic asthma, TCRs carrying elongated 
CDR3 loops expand in response to allergen challenge. 
Of the three T-cell lines CIR014 had been re-stimulated twice, initially with whole Fel d 
1 protein and then with peptide 4. Lines B1 and CIR010 had each been re-stimulated 
four times, initially with whole Fel d 1 protein and subsequently with peptide 4. 
RNA was extracted from cells from each line at these time points and converted to 
cDNA for analysis of TCR usage. TCR usage was studied using a strategy designed by 
Henwood et al. (609), which is outlined in Figure 3.1. The cDNA products of each line 
are modified by addition of a poly(dG) tail and used in an anchor PCR. PCR products 
corresponding to rearranged TCR V-J regions for both a and 13 TCR chains, as shown in 
Figure 3.2, were cloned and sequenced. TCR sequences were analysed in terms of V 
and J region usage (according to IMGT definitions) and also the length and sequence of 
the CDR3 for both TCR a and 13 chains. The CDR3 was defined (according to the 
IMGT database definition) as being those amino acids forming the junction between the 
V and J regions, between but not including the conserved cysteine residue at the end of 
the V region and the conserved FGXG motif at the beginning of the J region (610). 
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Figure 3.1 	Outline of the strategy used to investigate TCR usage in HLA-DR-1 
restricted T-cell lines against peptide 4. RNA was extracted from HLA-DR-1-
restricted, peptide 4-specific T cells and first strand cDNA synthesis was carried out. 
Addition of poly(dG) tails to the cDNA products occurred using terminal nucleotide 
transferase and dGTP. Such 'tailing' allowed PCR amplification of TCR V-J regions 
expressed by the cells through use of a poly(dC) anchor forward primer and a specific 
TCR a or 13 constant region reverse primer. PCR products between 300 and 700 base 
pairs in size were ligated into pCR2.1 (shown in Appendix 11) and transformed into 
XL-GOLD competent cells. Successfully transformed colonies were expanded in liquid 
culture, and plasmid DNA was extracted from the cultures by alkaline lysis 
(`miniprep'). EcoRI digests were carried out on each sample, and plasmids containing 
inserts of the correct size were sequenced with the M13 forward primer. Resulting 
sequence data were aligned against the IMGT database. All PCR primer sequences and 
reaction conditions, and restriction enzyme digest conditions are shown in Appendix 2. 
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Figure 3.2 	Agarose gel pictures at different stages of the human TCR analysis. 
(a) A typical RNA preparation from the HLA-DR-1-restricted, peptide-4 specific cell 
lines. RNA from each preparation of 1 x 106 cells (1 [11) was run on an agarose gel and 
showed a characteristic pattern of RNA: two distinct bands with an indistinct smear 
between them, which comprises mRNA; the larger band is 18S rRNA, the smaller band 
is composed of small RNA species. (b) and (c) Typical products obtained from the a (b) 
and 13 (c) human TCR PCRs carried out on tailed cDNA derived from the isolated RNA. 
Products of interest were between 300 and 700 bp and appeared as a 'smear' of DNA 
around a more defined central band — this band was excised and purified for TA 
cloning. (d) Typical EcoRI digest of the final plasmid pCR2.1 containing the TCR V-J 
inserts. Plasmids with an insert of the correct size (300-700 bp) were sequenced. The 
proportion of plasmids containing an insert of the correct size that were subsequently 
sequenced ranged from 54% (for the TCR CDR3p analysis of line CIR010) to 84% (for 
the TCR CDR3(3 analysis of line B1). 
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3.1.2 TCRa chain and CDR3 usage in human peptide 4-specific, DR1-restricted 
T-cell lines 
Analysis of TCRa chain V region and J region usage as well as the CDR3 sequence and 
length was carried out in the lines CIR014, B1 and CIR010. Tables of the results of this 
analysis are shown in Table 3.1 (CIR014 TCRa usage), Table 3.2 (B1 TCRa usage) 
and Table 3.3 (CIR010 TCRa usage). In all cases, a population of cells and in the case 
of line B1 two populations of cells expressing a particular TCR were seen to have 
expanded. In line CIR014, the population of expanded cells (which represented 33% of 
all cDNA clones analysed from this line that corresponded to a TCRa chain, 30 in total) 
expressed a TCRa chain comprising TRAY 26-2 TRAJ 48. There were two populations 
of expanded cells in line B1 - the TCRa chains expressed by these populations were 
TRAV 13-1 TRAJ 52 and TRAV 21 TRAJ 28. Both represented about 40% of all 
cDNA clones corresponding to a TCRa chain that were analysed for this line (23 in 
total). In line CIR010, the expanded TCRa represented 70% of all cDNA clones 
corresponding to a TCRa chain analysed in the line (of which there were 43) and 
comprised TRAY 8-4 TRAJ 32. The expanded TCRa chains in each line were different 
and there appeared to be no common or similar V or J region usage from this analysis. It 
was also noted that in lines B1 and CIR010 which had been restimulated three times 
with peptide 4 there was more restriction of the TCRa repertoire, with only five 
different TCRa chains in total being identified in line B1 and eight in line CIR010. In 
the line which had only been restimulated once with peptide 4, CIR014, there was less 
restriction in the repertoire with 18 different V-J combinations being identified. This 
might be expected as the lines which had been restimulated a greater number of times 
would be more peptide-specific. 
The PCR used in this TCR CDR3 analysis used a C region-specific reverse primer to 
bind to all TCR sequences in the cDNA sample and a polyC anchor forward primer to 
bind to the poly(dG) tail previously added to the cDNA. As the cDNA samples used 
comprised a heterogeneous mixture of mRNA products, the proportion of these 
products corresponding to TCR chains was likely to be low and there was also likely to 
be more than one TCR chain within each sample. Therefore, even if a clonal expansion 
of one chain had occurred, the overall frequency of this chain would be very low. The 
apparent clonal expansions seen could therefore be an artefact caused by the preferential 
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TRAV CDR3 a TRAJ CDR3 % of total 
length  sequences 
2 AVFHGSSNTGKLI 37 13 3.3 
8-4 AVSDRYSGGGADGLT 45 15 6.7 
8-6 AVRSTAGSYQLT 28 12 3.3 
9-2 AAERNTDKLI 34 10 3.3 
12-3 AMSAGTGRRALT 5 12 3.3 
13-1 AASESGGGADGLT 45 13 3.3 
AASKDNDMR 43 9 3.3 
20 AVHAGNNRKLI 38 11 3.3 
AVQAVPASGTYKYI 40 14 3.3 
AVQSPNAGGTSYGKLT 52 16 3.3 
23/DV 
6 
AAGPNSGYALN 41 11 3.3 
24 AFRANQAGTALI 15 12 3.3 
26-2 ILRESYNDYKLS 20 12 3.3 
ILRDPTSGTYKYI 40 13 3.3 
ILLFGNEKLT 48 10 3.3 
Total: 
33.3 
ILRFGNEKLT 10 6.7 
IL IFGNEKLT 10 3.3 
ILRDNFGNEKLT 12 6.7 
ILRDVSNFGNEKLT 14 3.3 
ILRGGNEKLT 10 6.7 
ILRDDYEKLT 10 3.3 
27 AGAINNAGNMLT 12 3.3 
38-2/ 
DV8 
AYRSAGSGGGADGLT 39 15 6.7 
ALRGGGGADGLT 45 12 6.7 
Mean 	12.1 ± 0.4 
length 
Table 3.1 	TCRa sequences obtained from TCR CDR3 analysis of HLA-DR1- 
restricted, peptide 4-specific T-cell line CIR014 at its l't restimulation with peptide 
4 TRAV and TRAJ selection is shown for each receptor identified, along with the 
amino acid sequence at the CDR3 junction and the length of the CDR3. Also shown is 
the percentage of total TCR sequences obtained for this line that each TCR comprised. 
The major expansion identified is shown in bold type. Mean length is shown as mean ± 
standard error of the mean. 66% of the total plasmid sequences obtained for this line 
corresponded to a correctly-rearranged TCRa chain. 
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TRAV CDR3 a TRAJ CDR3 % of total 
length sequences_ 
1-1 AVRDKGQKLL 16 10 13.0 
13-1 AATVPWAGGTSYGKLT 52 16 39.1 
21 AVSGGAGSYQLT 28 12 39.1 
AVRPRLM 31 7 4.3 
26-1 IVRVEDTGKL I 37 11 4.3 
Mean 13.0 ± 0.6 
length 
Table 3.2 	TCRa sequences obtained from TCR CDR3 analysis of HLA-DR1- 
restricted, peptide 4-specific T-cell line B1 at its 3rd restimulation with peptide 4 
TRAV and TRAJ selection is shown for each receptor identified, along with the amino 
acid sequence at the CDR3 junction and the length of the CDR3. Also shown is the 
percentage of total TCR sequences obtained for this line that each TCR comprised. The 
two equally dominant expansions are shown in bold type. Mean length is shown as 
mean ± standard error of the mean. 33% of the total plasmid sequences obtained for this 
line corresponded to a correctly-rearranged TCRa chain. In the analysis of this line, it 
was notable that 26% of the total plasmid sequences represented TCR sequences 
containing a frameshift in the CDR3, and they are not included in this analysis. 
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TRAV CDR3 a TRAJ CDR3 % of total 
length sequences 
8.3 AVGARGDSNYQLI 33 13 11.6 
AVGAIGNEKLT 48 11 
11 
9.3 
67.4 8-4 AVWSGATNKLI 32 
8-6 AVSDQSGGYQKVT 13 13 2.3 
12-2 AVITGRRALT 5 10 2.3 
14/DV4 AIVGRGSTLGRLY 18 13 2.3 
20 AVQEAGFQKLV 8 11 2.3 
21 AVKDPAGGGTSGSRLT 58 16 2.3 
Mean 11.4 ± 0.2 
length 
Table 3.3 	TCRa sequences obtained from TCR CDR3 analysis of an HLA- 
DR1-restricted, peptide 4-specific T-cell line, CIR010, at the 3rd restimulation 
with peptide 4 TRAY and TRAJ selection is shown for each receptor identified, along 
with the amino acid sequence at the CDR3 junction and the length of the CDR3. Also 
shown is the percentage of total TCR sequences obtained for this line that each TCR 
comprised. The expanded population identified is shown in bold type. Mean length is 
shown as mean ± standard error of the mean. 79% of the total plasmid sequences 
obtained for this line corresponded to a correctly-rearranged TCRa chain. 
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amplification of one particular TCR chain over the others which is unrelated to its 
actual frequency within the sample and gives the false impression that it is a clonally 
expanded TCR chain. For each line analysed here, this PCR was carried out multiple 
times and in all cases the frequency of the identified chains remained approximately 
constant for each reaction, suggesting that the expansions seen were not artefacts but 
were accurate representations of the TCR chain frequencies within the samples. Single 
cell RT-PCR or cloning the original T-cell line by limiting dilution and analysing each 
clone separately could be used to confirm this, where each T-cell in the original sample 
would be analysed in a separate reaction. This would identify the TCR chain expressed 
by each individual T-cell and the frequency of T-cells expressing a particular chain 
would determine whether it was clonally expanded. 
Analysis of CDR3a sequences and length in each line was also carried out. For the 
expanded TCRa chains in lines B1 (TRAV 13-1 TRAJ 52 and TRAY 21 TRAJ 28) and 
CIR010 (TRAV 8-4 TRAJ 32), each example of the combination that was analysed 
expressed the same CDR3 amino acid sequence. For line Bl, the two CDR3s were the 
16 amino acid AATVPWAGGTSYGKLT (TRAV 13-1 TRAJ 52) and the 12 amino 
acid AVSGGAGSYQLT (TRAV 21 TRAJ 28). For line CIR010, the expanded CDR3 
was 11 amino acids long and comprised the sequence AVWSGATNKLI. In the case of 
the line at a lesser restimulation, line CIR014, however, this was not true. For the 
expanded TCRa VJ region TRAJ 26-2 TRAJ 48 there were seven different CDR3 
loops, as shown in Table 3.1. Most of the loops were 10 amino acids long but CDR3 
loops of 12 and 14 amino acids were also identified and no particular sequence 
dominated the response. There was a high degree of similarity in amino acid usage at 
the beginning and end of the sequences and there were most differences (including 
insertion of the extra amino acids for the longer CDR3s) in the centre of the sequence. 
The amino acids which are the same in each case (the first two and last four) are likely 
to be those encoded in the germline sequence of the V and J regions, whilst the differing 
amino acids are more likely to be coded for by non-germline DNA that is inserted 
through the action of TdT during recombination events in the developing T-cell (402, 
403). In comparison to the mean length of the human CDR3a loop as defined by Moss 
and Bell (586) which when interpreted using the IMGT definition (610) is 
approximately 12, one of the TCRa chains from line B 1 , TRAV 13-1 TRAJ 52, 
expresses a CDR3a loop which is notably long in comparison as it is 16 amino acids 
long. The CDR3a loops expressed by the expanded TCRa chains in line CIR010 and 
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CIR014 as well as the other chain in line B1 express CDR3a loops which are more 
comparable in length to the mean value defined by Moss and Bell (586). 
The mean length of all CDR3 loops identified from the analysis in line CIR014 was 
12.1 ± 0.4 (range - 9 to 16) which is similar to the mean length of 12 for human TCR 
CDR3a loops (586). In line B1 the mean length was 13.0 ± 0.6 (range 7 to 16) which is 
slightly increased in comparison to the mean length of 12 (586), due to the expansion of 
a T-cell population expressing a 16 amino acid CDR3a. In line CIR010 the mean length 
of CDR3a loops was 11.4 ± 0.2 (range 10 to 16), perhaps a slight decrease in 
comparison to the mean published length of 12 amino acids due to the expansion of a T-
cell population expressing an 11 amino acid CDR3a loop. The mean lengths of 
expanded CDR3a loops in these lines are similar and close to the mean length of 
CDR3a loops in unstimulated human T-cells; in line Bl, expansion of T-cells bearing a 
receptor with a CDR3a loop that is 4 amino acids longer than this mean value gave the 
line a mean length which was slightly longer. 
In summary, expansions of T-cells bearing specific TCRa chains was seen in each line 
analysed, occurring to a greater extent in the two lines which had been restimulated 
more often with peptide 4. One line, Bl, showed expansion of two populations of T-
cells bearing different receptors, one of which also expressed a CDR3a loop of 16 
amino acids which is notably longer than the published mean length of CDR3a loops of 
unstimulated human T-cells (12 amino acids, 586). 
3.1.3 TCR(3 chain and CDR3 usage in human peptide 4-specific, DR1-restricted 
T-cell lines 
As for the TCRa chains, TCR13 chain composition in terms of V and J region usage as 
well as CDR3 amino acid sequence and length was analysed in the lines CIR014 
(shown in Table 3.4), B1 (shown in Table 3.5) and CIR010 (shown in Table 3.6). 
Expansions of T-cells bearing specific receptors were seen in each line, as for the TCRa 
chain analysis. The extent of the expansion seen in line CIR014 was small with the 
expanded TCR(3 chain, TRBV 20-1 TRBJ 2-2, only comprising 14.3% of all TCR 
sequences obtained for this line (42 clones in total). This was in contrast to the 
expansions seen in lines B1 and CIR010 which were represented by a much larger 
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TRBV CDR3 S TRBJ CDR3 % of total 
length  sequences 
2 ASRGGGEPQH 1-5 10 2.4 
ASRGGRKQY 2-3 9 7.1 
3-1 ASSGGTGPYEQY 2-7 12 2.4 
4-2 ASSFQGGGQPQH 1-5 12 4.8 
5-1 ASSWGDRVAMNTEAF 1-1 15 4.8 
ASSLLSGVETQY 2-5 12 2.4 
ASSFGETQY 9 4.8 
ASSYRTSSSYEQY 2-7 13 2.4 
ASSRLPGQGAYEQY 14 2.4 
5-5 ASSLRVAMTYEQY 2-7 13 2.4 
7-8 ASSPTGGEQY 2-7 10 2.4 
12-3 ASSPGPYYGYT 1-2 11 2.4 
ASSLTSRNQPQH 1-5 12 2.4 
ASS TRSVRETQY 2-5 12 2.4 
13 ASSRGTRNTEAF 1-1 12 2.4 
19 ASRNRRDRGMRGAF 1-1 14 2.4 
ASSPDRASLQPQH 1-5 13 2.4 
ASS ILRQSYNEQF 2-1 13 4.8 
ASSKPSGPSTDTQY 2-3 14 2.4 
20-1 SARKRTTNEKLF 1-4 12 2.4 
SARDLARSTQPQH 1-5 13 2.4 
SALSGIYNEQL 2-1 11 2.4 
SARSAGRSGELF 2-2 12 14.3 
SARQGARGETQY 2-5 12 4.8 
28 ASSLRSGGFNYGYT 1-2 14 2.4 
29-1 SVSRTGFFTEAF 1-1 12 4.8 
30 AWAIGAANEGF 2-1 11 4.8 
AWSVHRAATQY 2-5 11 2.4 
Mean 11.9 ± 0.2 
length 
Table 3.4 	TCRI3 sequences obtained from TCR CDR3 analysis of HLA-DR1- 
restricted, peptide 4-specific T-cell line CIR014 at its 1st restimulation with peptide 
4 TRBV and TRBJ selection is shown for each receptor identified, along with the amino 
acid sequence at the CDR3 junction and the length of the CDR3. Also shown is the 
percentage of total TCR sequences obtained for this line that each TCR comprised. The 
modest expansion identified is shown in bold type. Mean length is shown as mean ± 
standard error of the mean. 71% of the total plasmid sequences obtained for this line 
corresponded to a correctly-rearranged TCRI3 chain. 
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TRBV CDR3 13 TRBJ CDR3 % of total 
lm 0,11 sequences 
4-1 ASSQVQNEQF 2-1 10 4.1 
ASSQGVNGNIQY 2-4 12 2.0 
6-5 ASS TRDRWSGGLT 2-6 13 36.7 
7-8 ASSLGPPLAVYNEQF 2-1 15 2.0 
11-1 ASSQNPNEQF 2-1 10 40.8 
20-1 SARGFGHDEYNEQF 2-1 14 2.0 
27 ASSLLGSTGELF 2-2 12 12.2 
Mean 11.6 ± 0.2 
length 
Table 3.5 	TCRI3 CDR3 sequences obtained from an HLA-DR1-restricted, 
peptide 4-specific T-cell line, Bl, at its 3rd restimulation with peptide 4 TRBV and 
TRBJ selection is shown for each receptor identified, along with the amino acid 
sequence at the CDR3 junction and the length of the CDR3. Also shown is the 
percentage of total TCR sequences obtained for this line that each TCR comprised. The 
expanded populations are identified in bold type. Mean length is shown as mean ± 
standard error of the mean. 76% of the total plasmid sequences obtained for this line 
corresponded to a correctly-rearranged TCRP chain. 
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TRBV CDR3 ii TRBJ CDR3 % of total 
length sequences  
3-1 ASSQGGGPYEQY 2-7 12 2.8 
5-1 ASSFLTATNEKLF 1-4 13 2.8 
ASSLATGGVDTQY 2-3 13 2.8 
ASSLEWTRNQETQY 2-5 14 2.8 
6-1 ASSEAGWGASGTEAF 1-1 15 36.1 
6-2 ASGGVAETQY 2-5 10 5.6 
7-2 ASSLDRQIGQPQH 1-5 13 13.9 
AS SLDSSAGNTGELF 2-2 15 2.8 
9 ASSVAGTGQETQY 2-5 13 2.8 
ASSVAPSGGHLEQY 2-7 14 2.8 
11-1 ASSQNPNEQF 2-1 10 2.8 
20-1 SARDPDGYGYT 1-2 11 19.4 
SAAAGTSGAYPLTQY 2-5 15 2.8 
Mean 13.2 ± 0.3 
length 
Table 3.6 	TCR13 sequences obtained from TCR CDR3 analysis of the HLA- 
DR1-restricted, peptide 4-specific T-cell line, CIR010, at its 3rd restimulation with 
peptide 4 TRBV and TRBJ selection is shown for each receptor identified, along with 
the amino acid sequence at the CDR3 junction and the length of the CDR3. Also shown 
is the percentage of total TCR sequences obtained for this line that each TCR 
comprised. The dominant expansion identified is shown in bold type. Mean length is 
shown as mean 1 standard error of the mean. 60% of the total plasmid sequences 
obtained for this line corresponded to a correctly-rearranged TCRf3 chain. 
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proportion of the analysed TCR sequences. This would perhaps be expected as these 
lines have been restimulated more often with peptide 4 and are therefore more peptide-
specific and the peptide-specific T-cells would have expanded to a greater degree. In 
line Bl, as for the TCRa chain analysis in this line, the expansion of two populations of 
T-cells expressing different receptors was seen; one expressed the receptor TRBV 6-5 
TRBJ 2-6 and the other expressed the receptor TRBV 11-1 TRBJ 2-1. These receptors 
comprised 36.7% (TRBV 6-5 TRBJ 2-6) and 40.8% (TRBV 11-1 TRBJ 2-1) of all TCR 
sequences analysed (49 in total). This compares with the extent to which the two TCRa 
chains from line B1 were expanded in the line and it is likely that each of the expanded 
TCRa chains pairs with one of the TCRI3 chains from this analysis. It is not possible to 
tell which chain would pair with which from this analysis - this would requiring cloning 
of the line and analysis of TCR usage within the clones. In line CIR010 there was more 
than one population of T-cells which expanded in response to peptide 4 stimulation and 
none of these matched the expansion seen in the TCRa analysis from this line in terms 
of extent. The largest expansion, represented by 36.1% of all TCR sequences analysed 
from this line (49 in total), was TRBV 6-1 TRBJ 1-1 and the two smaller expansions 
were TRBV 11-1 TRBJ 1-2 (19.4%) and TRBV 7-2 TRBJ 1-5 (13.9%). It is most likely 
that the dominant TCRa chain from this line, TRAY 8-4 TRAJ 32, pairs with the most 
frequent TCRI3 chain, TRBV 6-1 TRBJ 1-1, although there is also the possibility that it 
could be pairing with one of the other expanded chains instead of or alongside the most 
frequent chain. Again, as for the TCRa chains, there was no similarity in V and J region 
usage between the three lines in the expanded TC143 chains. 
CDR313 analysis of the expanded TCR13 chains in each line indicated that for the 
expanded TCR chain (or chains) expressed, the same CDR3p amino acid sequence was 
also expressed. In line CIR014, the CDR3p loop expressed by the expanded TCR, 
TRBV 20-1 TRBJ 2-2, was 12 amino acids in length, SARSAGRSGELF. This was in 
contrast to the expanded TCRa chain in this line in which the expanded VJ combination 
expressed a number of different CDR3a sequences. In line Bl, the two expanded TCRI3 
chains expressed the CDR3s ASSTRDRWSGGLT (13 amino acids, TRBV 6-5 TRBJ 2-
6) and ASSQNPNEQF (10 amino acids, TRBV 11-1 TRBJ 2-1). In line CIR010 the 
TCR13 chain which had expanded to the greatest degree, TRBV 6-1 TRBJ 1-1, 
expressed the 15 amino acid CDR3I3 ASSEAGWGASGTEAF. The mean length of the 
CDR3I3 loop in human unstimulated T-cells as defined by Moss and Bell (586) is 
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approximately 12 when interpreted using the IMGT definition (610). In comparison to 
this length, only the expanded TCR(3 chain in line CIR010 is noticeably longer at 15 
amino acids. The lengths of the expanded receptors in line CIR014, 12 amino acids, and 
in line B 1, 13 and 10 amino acids, are comparable with the mean defined length in 
unstimulated T-cells. 
In line CIR014 the mean length of all CDR3(3 loops expressed in the cDNA clones 
analysed was 11.9 ± 0.2 (range - 9 to 15) which is similar to the mean length of 12 for 
human TCR CDR3I3 loops (586) and is very similar to the mean length of CDR3a loops 
from the same line. The mean length of CDR3 I3 loops in line B1 was 11.6 ± 0.2 (range 
10 to 15); this is similar when compared with the published mean length of 12 (586) and 
is shorter than the corresponding mean length for the CDR3a loops from this line which 
is not surprising as the expanded CDR3 loops in the TCRP analysis had lengths of 10 
and 13, compared with 12 and 16. In line CIR010 the mean length of CDR3(3 loops was 
13.2 ± 0.3 (range 10 to 15). This is the longest mean length seen in any of the lines for 
either CDR3a or CDR3P and is probably due to the expansion of a T-cell population 
bearing a receptor with a 15 amino acid CDR3 p. With the exception of line CIR010 
where the mean CDR30 length appears to be longer, the mean CDR3I3 lengths in these 
lines are comparable to the published CDR3(3 length in unstimulated human T-cells 
(586). 
To summarise, in each line analysed there was at least one expansion of T-cells bearing 
specific receptors and these expansions occurred with more frequency in lines B1 and 
CIR010 which had been restimulated more often with peptide 4 than line CIR014. Line 
B1 expanded two populations of T-cells bearing different receptors, as was also seen for 
this line in the TCRa analysis. Line CIR010 expanded a population of T-cells 
expressing a TCRI3 chain with a CDR3 (3 loop of 15 amino acids which is noticeably 
longer than the published mean length of CDR3 (3 loops in unstimulated human T-cells 
(12 amino acids, 586). The lengths of the expanded CDR3P loops from the other lines 
were similar to this mean length and the mean lengths of CDR313 loops analysed in each 
line were also comparable to this value; only in line CIR010 did the mean length appear 
to be increased. 
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3.1.4 Summary 
The expansions seen in each line of both TCRa and TCRI3 chains are shown as pie 
charts in Figure 3.3 (line CIR014), Figure 3.4 (line B1) and Figure 3.5 (line CIR010). 
The pie charts highlight how the size of the expansion in response to peptide 4 
stimulation tends to increase with increasing numbers of restimulation, being smaller in 
line CIR014 (restimulated once with peptide 4) and larger in lines B1 and CIR010 (each 
restimulated three time with peptide 4). 
For each T-cell line analysed individual expansions were seen of certain TCRa and 
TCR(3 V-J combinations and CDR3s and these are summarised in Table 3.7. 
Between the lines there was no obvious correlation in terms of V or J region selection or 
CDR3 amino acid sequence. In lines B1 (CDR3a) and CIR010 (CDR3(3), one of the 
expanded chains was long in comparison to the published mean length for the CDR3 
loops in unstimulated human T-cells, 12 amino acids (586), whilst all other expanded 
CDR3 loop lengths were similar to this length. The mean lengths of all CDR3a or 
CDR3 (3 loops analysed in each line were also broadly comparable to this mean length 
with the exception of CDR3cc length in line B1 and CDR3(3 length in CIR010, where 
the mean lengths were both at least 1 amino acid longer than the published mean length, 
suggesting that expressed TCRs carried longer CDR3 loops lengths in these instances. 
There was no obvious sequence homology between the dominant CDR3 loops in each 
line at the amino acid level. 
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A. 	 B. 
TRAY 	 TRBV 
Key: 
Black = TRAV 26-2 TRAJ 48 
White = other expressed 
TCRs identified through the 
analysis 
Key: 
Black = TRBV 20-1 TRBJ 2-2 
White = other expressed TCRs 
identified through the analysis 
Figure 3.3 Expansion of T-cells with specific TCRa (A) and TCR 13 (B) CDR3 
regions in an HLA-DR1-restricted T-cell line, CIR014, after one restimulation with 
peptide 4 Each segment of each pie chart corresponds to a particular V region-J region 
combination identified through TCR analysis of the mRNA products from the line. The 
dominant expansion (i.e. the V-J combination found at the highest frequency) is shown 
in black with its extent shown as a percentage of all chains analysed for the line. For the 
a chain the dominant expansion was TRAY 26-2 TRAJ 48, comprising 33% of all 
TCRa chain PCR products sequenced. For the p chain the dominant expansion was 
TRBV 20-1 TRBJ 2-2, and comprising 14% of all TCRP chain PCR products 
sequenced. 
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A. 	 B. 
TRAV 
	
TRBV 
Key: 
Black = TRAV 13-1 TRAJ 52 
Stippled = TRAV 21 TRAJ 28 
White = other expressed TCRs 
identified through the analysis  
Key: 
Black = TRBV 6-5 TRBJ 2-6 
Stippled = TRBV 11-1 TRBJ 2-1 
White = other expressed TCRs 
identified through the analysis 
Figure 3.4 Expansion of T-cells with specific TCRa (A) and TCRI3 (B) CDR3 
regions in an HLA-DR1-restricted T-cell line, Bl, at its 3rd restimulation with 
peptide 4 Each segment of the pie chart corresponds to a particular V region-J region 
combination identified through TCR CDR3 analysis of the mRNA products from the 
line. The dominant expansions (i.e. the V-J combinations found at the highest 
frequency) are shown in black or stippled with the percentage of all chains analysed for 
the line; there were two equally dominant expansions in both a and p chains in this line 
— the a chain expansions were TRAY 13-2 TRAJ 52 and TRAY 21 TRAJ 28, 
comprising 39% each of all TCRa chain PCR products sequenced. For the 3 chain the 
dominant expansions were TRBV 6-5 TRBJ 2-6 (37% of all TCR chain PCR products 
sequenced), and TRBV 11-1 TRBJ 2-1 (41% of all TCR(3 chain PCR products 
sequenced). 
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A. 	 B. 
TRAV 
	
TRBV 
Key: 
Black = TRAV 8-4 TRAJ 32 
White = other expressed TCRs 
identified through the analysis 
Key: 
Black = TRBV 6-1 TRBJ 1-1 
Stippled = TRBV 20-1 TRBJ 1-2 
Striped = TRBV 7-2 TRBJ 1-5 
White = other expressed TCRs 
identified through the analysis 
Figure 3.5 Expansion of TCRa (A) and TCR13 (B) chains in the HLA-DR1-
restricted T-cell line CIR010 at its 3rd restimulation with peptide 4 Each segment of 
the pie charts corresponds to a particular V region-J region combination identified 
through TCR analysis of the mRNA products from the line. Expansions (i.e. V-J 
combinations found at the highest frequencies) are shown in black only for the TCRa 
analysis, and in black, stippled and striped for the TCRI3 analysis. The extent of each 
expansion is shown as a percentage of all chains analysed for the line. For the a chain 
the dominant expansion was TRAY 8-4 TRAJ 32, comprising 67% of all TCRa chain 
PCR products sequenced. For the (3 chain the largest expansion was TRBV 6-1 TRBJ 1-
1, comprising 36% of all TCR13 chain PCR products sequenced, but there were two 
lesser expansions. 
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Line/re- 	TRAV/ 
stimulation TRBV 
with peptide 4 
CDR3a  TRAJ/ CDR3  
TRBJ length  
  
      
CIR014, ft TRAV 
26-2 
I L L F G N E K L T 
ILRFGNEKLT 
ILIFGNEKLT 
ILRDNFGNEKLT 
ILRDVSNFGNEKLT 
ILRGGNEKLT 
ILRDDYEKLT 
TRAJ 
48 
10 
10 
10 
12 
14 
10 
10 
TRBV SARSAGRSGELF TRBJ 12 
20-1 2-1 
Bl, 311 TRAV AATVPWAGGTSYGKLT TRAJ 16 
13-1 52 
TRAV AVSGGAGSYQLT TRAJ 12 
21 28 
TRBV ASSTRDRWSGGLT TRBJ 13 
6-5 2-6 
TRBV ASSQNPNEQF TRBJ 10 
11-1 	j 2-1 
CIR010, 3rd TRAV A V W S G A T N K L I TRAJ 11 
8-4 32 
TRBV A S S E A G W G A S G T E A F TRBJ 15 
6-1 1-1 
Table 3.7 	a and (3 expansions of the three lines CIR014, B1 and CIR010 with 
their related CDR3 amino acid sequences For lines CIR014 and CIR010, there is only 
one expansion seen for both a and p chains; for line Bl, there are two a and two 13 
chains, suggesting that there are two dominant T-cell populations in this line capable of 
responding to the I-ILA-DR-J./peptide 4 complex. 
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3.2 	Preparation of TCR expression constructs for the transduction of the cell 
line BW7 
One of the aims of the TCR CDR3 analysis of the T-cell lines derived from HLA-DR1+ 
cat allergic asthmatic subjects was to identify peptide 4-specific dominant TCRs that 
could be used to address the question as to what extent TCR structure/sequence, 
particularly at the CDR3 loops, can impact upon T-cell phenotype. Previous work in the 
Boyton laboratory (601) has showed that T-cell clones raised against the same antigen, 
PLP56-7o complexed with the murine MHC class II molecule I-Ag7, and polarised 
through the addition of exogenous cytokines to develop into a Thl or Th2 phenotype 
expressed different TCRs, most notably differing in terms of the length and amino acid 
sequence of the CDR3a loops. Short-term Thl and Th2 polarised T-cell lines raised 
against the same antigen were then analysed for expression of both TCRs. The Thl line 
did not express the TCR with an elongated CDR3a loop from the Th2 clone. In contrast, 
the TCR from the Thl clone was expressed in the Th2-polarised line, although the Th2 
TCR was more predominant. This work suggested that TCR structure, specifically the 
structure of the CDR3 loops, can impact on effector T-cell phenotype. Molecular 
modelling of the two TCRs suggested that the longer CDR3a loop of the Th2 TCR, 
which contained a higher proportion of amino acids with large, bulky sidechains that 
protrude into the TCR-peptide-MHC interface would hinder this interaction, thus 
predicting that a reduced affinity/avidity interaction is associated with the development 
of a Th2 response. 
Cytokine polarisation may, therefore, favour T-cells expressing TCRs with structural 
characteristics that promote development into effector cells with a particular phenotype. 
To further explore this relationship between TCR sequence/structure and the prevailing 
cytokine milieu at the time of initial peptide-MHC encounter and the subsequent 
activation of particular antigen-specific T-cells, it was considered useful to develop a 
system whereby TCRs of interest could be expressed in a TCR-negative immortalised 
cell line of T-cell lineage, known as BW7 (602). TCRs intended for expression using 
this system include those identified here in human allergic asthma; those TCRs 
identified in the TCR CDR3 analysis that expanded in response to repeated activation 
by antigen in vitro, and those TCRs associated with specific T-cell phenotypes (Thl and 
Th2) identified in the previous study using polarised T-cell clones raised against PLP56-
74-Ag7 (601). 
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The cell line BW7 was chosen for use in this system for several reasons. It is a 
transformed murine thymoma line, modified to lack expression of TCR (602), but still 
retaining the signalling systems and other machinery that are required for T-cell 
function. The transduction of this line with constructs allowing the expression of a 
particular TCR has a number of advantages over using T-cell clones. The line is 
transformed, so it is more robust than a T-cell clone, and does not require re-stimulation 
or addition of exogenous cytokines to survive and proliferate, and as it grows quickly 
regardless of the presence of TCR or not, it can be rapidly expanded to yield a large 
number of cells for use in experiments. As BW7 is a transformed line, it is not as 
physiologically relevant as using a T-cell clone, but the line retains enough of its T-cell 
nature that results obtained using TCR-transduced BW7 lines will have relevance. 
Such transduced lines would be useful reagents to investigate the extent to which TCR 
structure itself can influence T-cell function upon stimulation with its cognate peptide-
MHC complex. TCR-transduced BW7 lines provide large numbers of cells expressing 
the same TCR allowing the impact of TCR structure on downstream events to be 
studied. Avenues of investigation could include basic studies on T-cell phenotype, 
TCR-peptide-MHC interaction kinetics, or the effect of TCR structure on the 
downstream signalling pathways following TCR engagement. 
A retroviral transduction system was selected to transduce BW7 cells with the TCRs of 
interest. The retroviral transduction of a gene of interest leads, in many cases, to the 
stable expression of the transduced gene in the target cell line (611). Genes encoding 
the human TCR from line CIR010 and the two murine TCRs expanded from T-cell lines 
polarised towards either a Thl or Th2-type phenotype in response to PLP56-70/1-Ag7  (as 
described in reference 568 and shown in Figure 1.2) were cloned into the retroviral 
expression vector MFG (604) for use in the Phoenix retroviral transduction system 
(603). 
I was not able to transduce BW7 cells using the retroviral transduction system outlined 
above, and so tried using an alternative system, using pTacass and pTi3cass TCR 
expression constructs (346) containing genes for the same TCRs and nucleofection 
using Amaxa technology (www.amaxa.com/technology). This system is based on 
electroporation as a means of transferring construct DNA into the target cells, but has 
the disadvantage that it does not lead to stable expression of the gene or genes of 
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interest in the target cell. I was unable to transduce BW7 cells using the nucleofection 
system and was not able to take this line of investigation any further. 
3.2.1 Preparation of TCR expression constructs for use in a retroviral 
transduction system 
A retroviral transduction system allows the stable expression of a gene of interest in a 
cell type where it is not endogenously found. Retroviral transduction systems utilise 
packaging cell lines which have been previously stably transduced with the genes 
necessary for production of retroviral particles except for one, the packaging signal iv. 
This is supplied to the packaging cells as part of a retroviral expression vector which 
can also contain a gene of interest to be expressed in the target cell line. The retroviral 
vector MFG (604) (shown in Figure 2.1 with the target gene eGFP inserted and 
described in more detail in Section 2.1.2) was selected for use in the TCR transduction 
system due to its lack of a mutation in the long terminal repeat sequence of the viral 
genome encoded in the plasmid. Such a mutation is often included in retroviral vectors 
and renders the virus produced from use of these constructs replication-incompetent 
after one round of viral production, and is used as a safety factor to prevent any chance 
of there being further virus production in the target cell line. It also prevents these 
vectors from being used in a serial infection system where more than one viral 
packaging cell line is used before infection of the target line, and this was found to be 
required for successful transduction of the BW7 line. MFG was therefore used in 
preference to the other retroviral vectors available in the laboratory, the pQC (Clontech, 
631516) series of vectors (Figure 3.6, with the target gene eGFP inserted), in spite of 
the advantage they have of containing antibiotic resistance genes allowing for selection 
of successfully transfected cells, as these vectors contain such a self-inactivating 
mutation. 
The genes for the two murine PLPso-n-specific TCRs had previously been cloned into 
the pQC vectors by Dr. Alexander Annenkov, a postdoctoral scientist in the laboratory, 
and these vectors were the source of the genes that were transferred into MFG. For the 
peptide 4-specific human TCR from the line CIR010, the same cDNA as that used for 
the TCR CDR3 analysis was used as the source of the TCR chains. 
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b-lactamase (ampR) 
Col El or' 
5' LTR (CMV/MSV) 
packaging signal 
pQCXIP(eGFP) CMV early promoter 
7952 bp 
Notl 2240 
	BstXI 2245 
'\EcoRV 2255 
EcoRI 2267 
eGFP 
SV40 on 6000 
SV40 promoter 
3' MoMuLV LTR 
containing deletion EcoR 13090 
BstXl 3098 
pel 3119 
amHl 3125 
coRl 3132 
IRES 
duromycin resistance 
Figure 3.6 	pQCXIP(eGFP) (Clontech, 631516) The vector diagram shows the 
retroviral components of the vector pQC and the target gene eGFP. It also shows the 
positioning of two genes that confer antibiotic resistance to any cell transformed or 
transduced with this plasmid, ampicillin and puromycin resistance (other variants of this 
plasmid carry neomycin or hygromycin resistance genes in place of puromycin 
resistance). Ampicillin resistance allows the plasmid to be cloned and amplified in 
bacteria, whilst puromycin resistance gives a means of selecting successfully infected 
target cells at the end of the transduction process. The deletion in the 3'-LTR renders 
the vector self-inactivating after one round of transfection/transcription, as it destroys 
the MoMuLV promoter required for transcription of the packaging signal. 
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3.2.1.1 Transfer of genes encoding TCR a and 13 chains from the PLP56-7o-specific 
murine T-cell clones A10(2) and D3(3) into the retroviral expression vector 
MFG 
3.2.1.1.1 Vector modifications 
MFG was originally supplied with restriction sites for NcoI and NotI allowing the target 
gene to be cloned into the vector (see Figure 2.1). As part of the NcoI restriction site 
(CCATGG), there is an ATG motif that is intended to be used as the start codon for 
expression of the target gene. However, in order to clone genes into the vector using 
this site, there is a requirement for the second codon of the gene to begin with G, which 
was not the case for a number of the TCR genes being transferred here. To overcome 
this obstacle, the vector MFG was modified to destroy the NcoI restriction site through 
nuclease digestion of NcoI-cut plasmid, and to henceforth use NotI as the sole site for 
inserting genes into the vector. The strategy followed to achieve this is shown in steps 
(a)-(d) of Figure 3.7. Briefly, a linker containing an additional NotI site was inserted 
into MFG(eGFP) using NcoI. The eGFP gene was then removed using NotI. The vector 
was then cut with NcoI and treated with Si nuclease to degrade the sticky ends formed 
by the digest, before the now blunt-ended vector was re-ligated. This led to the 
formation of a vector where the NcoI site had been destroyed whilst the NotI site 
remained intact for use in the insertion of target genes. The steps of the strategy are 
shown as gel images in Figure 3.8. 
For insertion of the TCR chains into MFG, there was now a requirement for the genes 
to be flanked on either side with a NotI site, which was not the case for the A10(2) and 
D3(3) TCR chains in pQC. A strategy was designed to transfer the TCR chains into 
MFG through pBluescriptII (vector diagram is shown in Appendix 12) which had also 
been modified, through insertion of a linker, to carry two NotI sites in its multiple 
cloning site, as shown in steps (e)-(f) of Figure 3.7 (gel images of this step are shown in 
Figure 3.8). These sites were placed in such a way as to allow the TCR chains from 
pQC to be transferred into pBluescriptII so that they were flanked by NotI sites, which 
would then allow their transfer into MFG. 
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e. pBluescriptII 	 g. pQC(TCRa A10(2) or 
D3(3)) 
XhoI 	EcoRI 	 EcoRI 	EcoRI 
NotI 
a. MFG(eGFP) 
NcoI 
	 NotI 
eGFP 
111, 
NcoI--NotI--NcoI 	Nco I 	 XhoI/ClaI Notl--ClaI XhoI— 
b. MFG(linker-eGFP) 	 f. pBluescriptll(linker) 
NcoI 	NcoI 	 Not! 	 XhoI 	Clal 	Not! 
Notl 	eGFP 	 Notl 	EcoRI 
linker: 
ClaI 
linker: 
NotI EcoRI 
  
TCR alpha chain 
(A10 or D3) 
EcoRI 
c. MFG(modified) 
Neal 
V 
Notl 
	 h. pBluescriptll(TCRa A10(2) or D3(3)) 
NotI 	Si nuclease 	 EcoRI 
	
EcoRI 
d. MFG(NcoI destroyed) 
Not! 
NotI 	TCR alpha chain 	NotI 
(A10 or D3) 
Not! 
Notl 
i. MFG(TCRa A10(2) or D3(3)) 
Noll Noti 
TCR alpha chain (A10 or D3) 
Figure 3.7 The cloning strategy designed to move TCRa chains for clones 
A10(2) (chains 5-D4 and 7-D3) and D3(3) from the vector pQC into MFG. TCRa 
chains of A10(2) and D3(3) had been previously inserted into pQC (g). MFG was 
available as MFG(eGFP) (a) and required modification before the TCR chains could be 
inserted. A linker was inserted containing a NotI site (b) allowing the removal of eGFP 
from the vector using NotI (c). The NcoI site was then destroyed (to remove the start 
codon in the restriction site) by digestion of the NcoI-cut vector with Si nuclease (d), 
producing a vector into which the TCR chain genes could be inserted using NotI. The 
TCR chains were subcloned into pBluescriptll (e), previously modified by insertion of a 
linker containing an additional NotI site (f), using EcoRI (h). They were then 
transferred into MFG using NotI (i). A PCR was carried out on each inserted chain to 
ascertain its orientation, as described in the text. Vectors with correctly oriented genes 
were sequenced. All PCR primers, reaction conditions, oligonucleotide linkers and 
sequencing primers are shown in Appendix 3. All restriction enzymes and digests are 
shown in Appendix 5. 
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10000 
4— MFG 	3000 -4. 
44—cut MFG - 
4-1 6950 bp 
I— uncut MFG 
11— linker-eGFP -
789 by 
bp 
1000-0-
750 H''' 
zi 0 
,__, 
o'.., Z 
,,, Z 
Y.) ,I., 
-t 5' t 1:7 	 b. co a. 
C. 
bp 
10000-0- 
1000-0- 
4—pBSII 
11-----uncut plasmid 
4--linker - 48 bp 
Figure 3.8 	Gel images showing stages of the cloning strategy followed to modify 
the vectors MFG and pBluescriptll to allow cloning of the TCR chains from 
murine T cell clones A10(2) and D3(3) and the dominant TCR from the human T 
cell line CIR010 into MFG from pQC The images above show the steps involved in 
the modification of the cloning vector pBluescriptII and the retroviral vector MFG to 
allow the TCR chains from the murine T cell clones A10(2) and D3(3) and the 
dominant TCR from the human T cell line 010 to be cloned into MFG using NotI (as 
outlined in the strategy for the TCR a chains from A10(2) and D3(3) shown in Figure 
3.8). (a) shows a NotI digest of MFG(eGFP) (a in Figure 3.8) after insertion of a 50 bp 
oligonucleotide linker containing an additional NotI site into the plasmid, upstream of 
the gene sequence (b in Figure 3.8). This allowed the eGFP insert (789 bp) to be excised 
from MFG using NotI, c in Figure 3.8. (b) shows restriction digests of Si nuclease-
treated MFG (d in Figure 3.8). The Si nuclease removed overhanging single-stranded 
ends of DNA caused by digestion with NcoI, destroying the site. The plasmid was then 
rejoined by blunt-end ligation. Uncut plasmid was run as a comparison, alongside a 
NcoI digest (which did not cut, as the band appears to be the same size as the uncut 
plasmid) and a NotI digest (which did cut, as the band is of a different size (6950 bp) to 
the uncut plasmid, which has an apparent smaller band size due to uncut plasmid being 
supercoiled and therefore migrating atypically on a gel). This indicated that the NcoI 
site had been successfully destroyed without destruction of the NotI site just 
downstream. (c) shows a XhoI/ClaI digest of pBluescriptII after insertion of an 
oligonucleotide linker (48 bp) containing a NotI site (f in Figure 3.8). The gel was only 
run a very short distance to allow visualisation of the 48 bp linker, and 1 µI of uncut 
plasmid was run alongside as a comparison. 
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3.2.1.1.2 Transfer of TCRa chains from T-cell clones A10(2) and D3(3) into the 
vector MFG 
The genes for each TCRa chain were transferred into MFG in the same way, shown in 
steps (g)-(i) of Figure 3.7. Each gene was transferred into the modified pBluescriptll 
vector using EcoRI, and subsequently transferred into the modified MFG vector using 
NotI. As only one restriction enzyme was used to clone the chains into MFG, a PCR 
was carried out on each inserted chain to ascertain its orientation in MFG, using MFG-
specific forward and reverse primers situated on either side of the NotI insertion sites, 
and a TCR-specific V region forward primer. Vectors with correctly oriented genes 
(giving a band of 962 bp (A10 5-D4), 957 bp (A10 7-D3) or 965 bp (D3) with the TCR-
specific forward and MFG-specific reverse primers) were sequenced to check for any 
mutations incorporated during the cloning process, after which the constructs were 
ready for use in the retroviral expression system. Gel images of the predicted PCR 
products for both correctly and incorrectly aligned TCRa chains are shown in Figure 
3.9. 
Gel images for the production of MFG (Al 0(2)a 5-D4) are shown in Figure 3.10, and a 
diagram of the final construct is shown in Figure 3.11. Sequence data for the TCR chain 
is shown in Appendix 13. For the construct MFG (A10(2)a 7-D3), gel images of its 
production are shown in Figure 3.12, with a vector diagram being shown in Figure 3.13, 
and sequence data for the TCR chain in Appendix 14. Gel images of MFG (D3(3)a) 
production are shown in Figure 3.14. A vector diagram of the final construct is shown 
in Figure 3.15, and sequence data for the TCR chain is shown in Appendix 15. 
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Figure 3.9 Orientation of TCR chains in MFG using PCR The images above 
show representative examples of the PCRs used to orient the TCR chains in MFG once 
they had been inserted. The gels above were obtained from orientation PCRs on 
MFG(CIRO1 OamCa) and MFG(CIR01013mq3), using the PCR primers as described in 
the text. Constructs with a TCR insert were assayed using both sets of primers. Those 
clones giving a product of 910 bp (TCR a) or 974 bp (TCR po with the V region-
specific primer and the MFG reverse primer were oriented correctly and sequenced. (a) 
and (b) above show the two PCRs for the a construct, (a) shows the PCR using the V 
region-specific primer and the MFG reverse primer (i.e. correct orientation) (NB 1 and 
2 indicate two clones that are the same in both reactions), and (b) shows the PCR using 
the V region-specific primer and the MFG forward primer (i.e. incorrect orientation). (c) 
and (d) show the same PCRs for the (3 construct — (c) shows correct orientation and (d) 
shows incorrect orientation. NB. As the PCRs were carried out on plasmid DNA, non-
specific bands of the same size as the expected band may be seen. In such cases, whilst 
it was likely that the higher intensity band indicated the orientation of the insert, 
sequencing these clones was used as further confirmation of the correct orientation 
having been achieved. Primers used to orient each TCR chain are shown in Appendix 3. 
Forward primers were those used to originally clone the TCR chains into pQC vectors 
by Dr. Alexander Annenkov. 
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pBSII 
41— TCR a A10(2) 
5-D4 - 902 bp 
1000-* 
750 
a. 
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b. 
bp 
1000-* 
750-* 
4- MFG 
1-TCR a A10(2) 
5-D4 - 902 bp 
Figure 3.10 Gel images of the stages involved in moving the TCRa chain 5-
D4 of murine clone A10(2) into MFG The TCR chain (902 bp) was supplied 
already cloned into vector pQC, another retroviral vector. The TCR chain was 
moved from the pQC vector into cloning vector pBluescriptII using EcoRI (a 
above, h in figure 3.7). pBluescriptII had previously been modified by insertion of 
an oligonucleotide linker to contain an extra NotI site, in addition to one already 
present (see Figure 3.7). The linker was inserted such that the NotI sites flanked 
the EcoRI insertion site, allowing the TCR chain to be moved from pBluescriptII 
into MFG using NotI. A clone of pBluescriptII showing insertion of a correctly 
sized insert upon EcoRI digestion was subsequently digested with NotI and 
inserted into MFG (b above, i in Figure 3.7). Correct insertion was ascertained by 
NotI digest, and orientation of the TCR chain in MFG was determined by PCR 
(see Figure 3.9). Correctly oriented clones were sequenced. 
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5' LTR (MoMuLV) 
packaging signal 
MFG(A10(2) 5-D4 alpha) 
6902 bp 	splice donor 
plice acceptor 
I~IIIIIIII 
	iffill111111 3' MoMuLV LTR 
Notl 1 
TRAV 5D-4 
TRAJ 13 
TRAC 1 
Notl 902 
Figure 3.11 Final construct map of TCRa chain 5-D4 from the murine Thl T-
cell clone A10(2) in the retroviral expression vector MFG The diagram shows the 
composition of the vector in terms of the genes required for its function in a retroviral 
packaging gene transduction system and the position of the inserted TCR gene along 
with the restriction sites used in cloning the sequence into MFG. 
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1— TCR a A10(2) 1000 —0. 
7-D3 - 897 bp 	750 TCR a A10(2) 
7-D3 - 897 by 
Figure 3.12 Gel images of the stages involved in moving the TCR a chain 7-D3 of 
murine clone A10(2) into MFG The 897 bp TCR chain had previously been cloned 
into vector pQC by Dr Alexander Annenkov. The TCR chain was transferred into 
modified pBluescriptII using EcoRI (a above, h in figure 3.7). pBluescriptII had 
previously been modified, as shown in Figure 3.7, to contain an extra NotI site in 
addition to the one already present, such that the NotI sites flanked the EcoRI insertion 
site, thus allowing the TCR chain to be moved into MFG using NotI. A clone of 
pBluescriptII that showed insertion of a correctly sized insert upon diagnostic EcoRI 
digestion was digested with NotI and the TCR chain was inserted into MFG (b above, i 
in Figure 3.7). A diagnostic Not I digest identified correct insertion of the TCR chain 
before its orientation MFG was determined by PCR (see Figure 3.9). Correctly oriented 
clones were sequenced. 
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packaging signal 
‘11+ 
MFG(A10(2) 7-D3 alpha) 
6897 bp 	splice donor 
plice acceptor 
illI111
1111 
1111111111111111111111111111111111111111 	TRAC 1 
Notl 1 
TRAV 7D-3 
3' MoMuLV LTR 
TRAJ 15 
otl 902 
5' LTR (MoMuLV) 
Figure 3.13 Final construct map of TCRa chain 7-D3 from the murine Thl T-
cell clone A10(2) in the retroviral vector MFG The composition of the vector in 
terms of the genes required for correct functioning in a retroviral packaging system is 
shown in addition to the position of the inserted TCR chain gene and the restriction sites 
used in cloning the sequence into MFG. 
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Figure 3.14 Gel images of the stages involved in moving the TCR a chain of 
murine clone D3(3) into MFG The TCR chain (905 bp) was supplied already 
cloned into vector pQC. The TCR chain was moved from pQC into modified 
pBluescriptll using EcoRI (a above, h in figure 3.7). pBluescriptll had been 
modified to contain an extra NotI site in addition to the one already present (as 
shown in Figure 3.7). The two NotI sites flanked the EcoRI insertion site, and 
allowed the TCR chain to be moved from pBluescriptll into MFG using NotI. A 
clone of pBluescriptII containing a correctly sized insert upon EcoRI digestion 
was then digested with NotI and inserted into MFG (b above, i in Figure 3.7). 
Correct insertion of the TCR chain was ascertained by NotI digest and its 
orientation in MFG was then determined by PCR (as shown in Figure 3.9). 
Correctly oriented clones were sequenced. 
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5' LTR (MoMuLV) 
packaging signal 
MFG(D3(3)alpha) 
6904 bp splice donor 
plice acceptor 
Notl 1 
TRAV 7-4 
TRAJ 26-like (95% identical by 
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Figure 3.15 Final construct map of the TCRa chain from the murine Th2 T-cell 
clone D3(3) in the retroviral vector MFG The diagram shows the vector composition 
in terms of genes required for function in a retroviral packaging system, as well as the 
position of the inserted TCR gene sequence and the restriction sites used in cloning it 
into MFG. 
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3.2.1.1.3 Transfer of TCRI3 chains from T-cell clones A10(2) and D3(3) into the 
vector MFG 
Each TCRP chain was transferred into the modified MFG vector via modified 
pBluescriptll, according to the strategy outlined in Figure 3.16. However, upon 
sequencing of the final constructs, the same mutation was discovered in the TCR C 
region of both constructs, a deletion of one base pair at the 3' end of the sequence. 
When the TCR chains were previously cloned into the pQC vector, the same mutated C 
region was used to construct both TCRp chains. As such, new strategies were developed 
to correct the mutation in both constructs by PCR site-directed mutagenesis. These 
strategies made use of unique restriction sites in the sequence of the TCRP genes, Clal 
for the A10(2) TCRp chain and BstXI for the D3(3) TCR chain, allowing the corrected 
PCR product to replace the mutated version of the gene, producing a final gene product 
with the missing base pair inserted. 
The strategy to correct the mutated version of the A10(2) TCRP gene is shown in Figure 
3.17. Briefly, a PCR using high-fidelity DNA polymerase was carried out on the gene in 
pBluescriptII, using a reverse primer containing the missing base pair and an additional 
EcoRI site for ease of cloning, and a forward primer just upstream of the unique Clal 
restriction site in the TCR V-J region. This product was ligated into the TA cloning 
vector pCR2.1 and transferred into unmodified pBluescriptII. The mutated version of 
the TCR chain was then replaced with the corrected version through use of ClaI, and the 
complete corrected TCR chain was moved into MFG. Gel images of this strategy are 
shown in Figure 3.18, and the full corrected sequence of this TCR chain with the 
inserted base highlighted is shown in Figure 3.19. Figure 3.20 shows the final construct 
as a vector diagram. 
The strategy to correct the mutated version of the D3(3) TCRp gene is shown in Figure 
3.21. The same basic PCR mutagenesis strategy as used for the A10(2) TCR chain was 
followed to correct the D3(3) TCR chain, making use of a unique BstXI restriction site 
to replace the mutated version with the corrected version, before the complete corrected 
TCR chain was moved into MFG. Figure 3.22 shows gel images of the steps in this 
strategy, and the full corrected sequence with the inserted base highlighted is shown in 
Figure 3.23. The final construct is shown as a vector diagram in Figure 3.24. 
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TCR beta chain (A10(2) or D3(3)) 
Figure 3.16 A schematic diagram showing the cloning strategy designed to move 
TCR 13 chains for clones A10(2) and D3(3) from the vector pQC into MFG. The 
TCR chains for A10(2) and D3(3) had previously been inserted into pQC by Dr. 
Alexander Annenkov in our laboratory (a). pBluescriptll (b) had previously been 
modified by insertion of a linker containing an additional NotI site as shown in Figure 
3.8. The TCR chains were transferred into the modified pBluescriptll using EcoRI (c). 
MFG (d) had previously been modified to destroy the NcoI site in its multiple cloning 
site (as shown in Figure 3.8). TCR13 chains were transferred to MFG from pBluescriptII 
using NotI (e). A PCR was carried out on each inserted chain to ascertain its orientation, 
as described in the text. Vectors with correctly oriented genes were sequenced. All PCR 
primers, reaction conditions, oligonucleotide linkers and sequencing primers are shown 
in Appendix 3. All restriction enzymes and digests are shown in Appendix 5. 
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g. MFG(3A10(2) TCR) 	 
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Figure 3.17 Cloning strategy designed to mutate the C13 region of TCR chain 
3 A10(2) The incorrect 13 chain was already inserted into pBluescriptll from the strategy 
in Figure 3.16 (a). A PCR using a primer incorporating the missing base pair and a 
primer just upstream of a unique restriction site, ClaI, within the TCR sequence was 
used to insert the missing base pair. The PCR product was ligated into pCR2.1 (b). The 
insert was sequenced to check for successful mutagenesis and a correct clone was 
moved into linker-modified pBluescriptll (c) using EcoRl (d). Using ClaI, the corrected 
fragment was used to replace the incorrect fragment of the chain inserted into 
pBluescriptll (e). Inserts were checked for their correct orientation by diagnostic digest 
with EcoRI. A correctly oriented clone was moved into MFG (f) using NotI (g). Clones 
were oriented and sequenced as described previously. All PCR primers, reaction 
conditions, and sequencing primers are shown in Appendix 3. All restriction enzymes 
used and digest conditions are shown in Appendix 5. 
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Figure 3.18 Gel images of the stages involved in moving the TCR 3  chain from 
the murine T cell clone A10(2) into MFG including correcting a mutation in the 
cp region The images above show the steps involved in the strategy as outlined in 
Figure 3.17. (a) shows the PCR product for the co region in which the mutation has 
been corrected (700 bp), using a primer incorporating the missing base pair. Template 
DNA was the TCR chain in the cloning vector pBluescriptll, a in Figure 3.17. The PCR 
product was ligated into pCR2.1 by TA cloning, and moved into pBluescriptll 
subsequently, as shown in (b) above, d in Figure 3.17. This was then combined with the 
original TCR chain in pBluescriptll to replace the mutated sequence by restriction 
digest, as shown in (c) above, and e in Figure 3.17. The corrected TCR13 chain (1012 
bp) was then moved into MFG using NotI as shown in (d) above, corresponding to g in 
Figure 3.17, (e) above. Orientation of the insert was determined by PCR, as shown in 
Figure 3.17, and clones with a correctly oriented TCR chain were sequenced. 
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ATG GGC ACC AGG CTT CTT GGC TGG GCA GTG TTC TGT CTC CTT GAC ACA GTA CTG TCT GAA GCT 
MG T R L L G W A V F CL L D T V L SE A 
64 
GGA GTC ACC CAG TCT CCC AGA TAT GCA GTC CTA CAG GAA GGG CAA GCT GTT TCC TTT TGG TGT 
G V T QS P R Y A V L Q E G Q A V SF WC 
127 
GAC CCT ATT TCT GGA CAT GAT ACC CTT TAC TGG TAT CAG CAG CCC AGA GAC CAG GGG CCC CAG 
D PISGHD TLYWYQQPRDQGPQ 
190 
CTT CTA GTT TAC TTT CGG GAT GAG GCT GTT ATA GAT AAT TCA CAG TTG CCC TCG GAT CGA TTT 
L L V Y F RDE A V I DNS Q L PS D R F 
253 
TCT GCT GTG AGG CCT AAA GGA ACT AAC TCC ACT CTC AAG ATC CAG TCT GCA AAG CAG GGC GAC 
S A V R P KG TNS T L K I Q S A K Q G D 
316 
ACA GCC ACC TAT CTC TGT GCC AGC AGC CCC CTC GAC TGG GGG GAT GAA CAG TAC TTC GGT CCC 
T ATY LC AS S P L DWG D E Q Y F GP 
379 
GGC ACC AGG CTC ACG GTT TTA GAG GAT CTG AGA AAT GTG ACT CCA CCC AAG GTC TCC TTG TTT 
G T R L T V L EDL R N V T P P K VSLF 
442 
GAG CCA TCA AAA GCC GAG CTG GCA AAC AAA CAA AAG GCT ACC CTC GTG TGC TTG GCC AGG GGC 
E PS K A E L A N K Q K AT LV CL A R G 
505 
TTC TTC CCT GAC CAC GTG GAG CTG AGC TGG TGG GTG AAT GGC AAG GAG GTC CAC AGT GGG GTC 
F F PD H V ELS WWV N G K E V HS G V 
568 
AGC ACG GAC CCT CAG GCC TAC AAG GAG AGC AAT TAT AGC TAC TGC CTG AGC AGC CGC CTG AGG 
S T D P Q A Y K E SN Y S Y C L S S R L R 
631 
GTC TCT GCT ACC TTC TGG CAC AAT CCT CGA AAC CAC TTC CGC TGC CAA GTG CAG TTC CAT GGG 
✓ S A T F W H N PR N HE R C Q V Q F HG 
694 
CTT TCA GAG GAG GAC AAG TGG CCA GAG GGC TCA CCC AAA CCT GTC ACA CAG AAC ATC AGT GCA 
L S E E D K W P E GSPKP VT Q N I S A 
757 
GAG GCC TGG GGC CGA GCA GAC TGT GGA ATC ACT TCA GCA TCC TAT CAT CAG GGG GTT CTG TCT 
E A W G R A DC G I T S A S Y HQ G V L S 
820 
GCA ACC ATC CTC TAT GAG ATC CTA CTG GGG AAG GCC ACC CTA TAT GCT GTG CTG GTC AGT GGC 
A TILYE IL LGIC A T L Y AVL VS G 
883 	 921 
CTG GTG CTG ATG GCC ATG GTC AAG AAA AAA AAT TCC TGA 
L V L MAMVK K KNSSTOP 
Figure 3.19 Amino acid sequence of the TCR 13 chain (TRBV 14 TRBJ 2-7 TRBC 1) 
from the murine T cell clone A10(2) cloned into retroviral vector MFG TRBV 14 is 
highlighted in green, TRBJ 2-7 in purple and TRBC 1 in turquoise. The CDR3 is 
highlighted in blue with the coding DNA sequence underlined. The letter underlined in red 
indicates the base pair that was inserted by site-directed mutagenesis in order to convert 
the incorrect sequence to the original DNA sequence, thus allowing for correct read-
through of the amino acid sequence and correct positioning of the stop codon. 
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Figure 3.20 Final construct map of the TCR § chain from the murine Thl T-cell 
clone A10(2) in the retroviral vector MFG The position of the genes required for 
correct function in a retroviral packaging system as well as the position of the inserted 
TCR gene and the restriction sites used in cloning the sequence into MFG are shown. 
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Figure 3.21 Cloning strategy designed to mutate the C13 region of TCR chain 
13D3(3) The incorrect 13 chain (a) had already been inserted into pBluescriptll from the 
strategy in Figure 3.16. A mutagenesis PCR using a primer incorporating the missing 
base pair (the same primer as that used in the strategy to correct the mutation in the 
A10(2) TC143 chain with a primer just upstream of a unique restriction site, BstXI, 
within the TCR sequence, was used to correct the mutation. The resulting PCR product 
was cloned into pCR2.1 (b). The insert was sequenced to check for successful 
correction of the mutation before a correct clone was moved into linker-modified 
pBluescriptll using EcoRI (c to d). The incorrect fragment was then replaced in 
pBluescriptll by the corrected fragment using BstXI in order to produce a correct TCR 
gene sequence (e). Diagnostic digest of clones using EcoRI determined the correct 
orientation of the insert and a correctly oriented clone was moved into MFG (f) using 
NotI (g). Clones were oriented and sequenced as described previously. All PCR 
primers, reaction conditions, and sequencing primers are shown in Appendix 3. All 
restriction enzymes used and digest conditions are shown in Appendix 5. 
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Figure 3.22 Gel images of the stages involved in moving the TCR fi chain from 
the murine T cell clone D3(3) into MFG including correcting a mutation in the C13 
region The images above show the steps involved in the strategy as outlined in Figure 
3.21. The PCR product for the Cp region in which the mutation has been corrected (577 
bp) using a primer incorporating the missing base pair is shown in (a). Template DNA 
used was the TCR chain in the cloning vector pBluescriptll, a in Figure 3.22. The PCR 
product was ligated into pCR2.1, sequenced, and moved into pBluescriptll as shown in 
(b), d in Figure 3.21. The corrected fragment was then combined with the original TCR 
chain in pBluescriptll using BstXI to replace the mutated sequence, and diagnostic 
digest with Not! was carried out to confirm correct insertion, as shown in (c), and e in 
Figure 3.22. The corrected TCRP chain (999 bp) was moved into MFG using NotI as 
shown in (d), corresponding to g in Figure 3.21. Orientation of the insert was 
determined by PCR, as shown in Figure 3.9. Clones with a correctly oriented TCR chain 
were sequenced. 
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ATG GGC TCC ATT TTC CTC AGT TGC CTG GCC GTT TGT CTC CTG GTG GCA GGT CCA GTC GAC CCG 
M GS I F LS CL AVCL LVA G PV DP 
64 
AAA ATT ATC CAG AAA CCA AAA TAT CTG GTG GCA GTC ACA GGG AGC GAA AAA ATC CTG ATA TGC 
K I I Q K PKYLV AV TG SEK IL IC 
127 
GAA CAG TAT CTA GGC CAC AAT GCT ATG TAT TGG TAT AGA CAA AGT GCT AAG AAG CCT CTA GAG 
E Q Y L G H N A M Y WY R Q S AK K PL E 
190 
TTC ATG TTT TCC TAC AGC TAT CAA AAA CTT ATG GAC AAT CAG ACT GCC TCA AGT CGC TTC CAA 
F M F S Y S Y Q K LMDN Q T A S S R F Q 
253 
CCT CAA AGT TCA AAG AAA AAC CAT TTA GAC CTT CAG ATC ACA GCT CTA AAG CCT GAT GAC TCG 
P Q S SK K N H L D L Q I T AL K PDDS 
316 
GCC ACA TAC TTC TGT GCC AGC AGC CAA GCC GGG ACT GGA GAA GAC ACC CAG TAC TTT GGG CCA 
AT Y F C A S S Q AGT GE DT Q Y F G P 
379 
GGC ACT CGG CTC CTC GTG TTA GAG GAT CTG AGA AAT GTG ACT CCA CCC AAG GTC TCC TTG TTT 
G T R LLVL E DL RNV T PP K VS L F 
442 
GAG CCA TCA AAA GCC GAG CTG GCA AAC AAA CAA AAG GCT ACC CTC GTG TGC TTG GCC AGG GGC 
E PSK A E L A N K Q K A TLV CL ARG 
505 
TTC TTC CCT GAC CAC GTG GAG CTG AGC TGG TGG GTG AAT GGC AAG GAG GTC CAC AGT GGG GTC 
F F PDH V E L S W W V N G K E V H S G V 
568 
AGC ACG GAC CCT CAG GCC TAC AAG GAG AGC AAT TAT AGC TAC TGC CTG AGC AGC CGC CTG AGG 
S T D P Q A Y K E SNYSYCL S S R L R 
631 
GTC TCT GCT ACC TTC TGG CAC AAT CCT CGA AAC CAC TTC CGC TGC CAA GTG CAG TTC CAT GGG 
✓ S A T F W H N P RNH FR C Q V Q F HG 
694 
CTT TCA GAG GAG GAC AAG TGG CCA GAG GGC TCA CCC AAA CCT GTC ACA CAG AAC ATC AGT GCA 
L S E E D K W P E G S P K PV T Q N I S A 
757 
GAG GCC TGG GGC CGA GCA GAC TGT GGA ATC ACT TCA GCA TCC TAT CAT CAG GGG GTT CTG TCT 
E A W G R A DCG I T S A S Y HQ G V L S 
820 
GCA ACC ATC CTC TAT GAG ATC CTA CTG GGG AAG GCC ACC CTA TAT GCT GTG CTG GTC AGT GGC 
A TILYE IL L G K AT LYAVLVSG 
883 	 921 
CTG GTG CTG ATG GCC ATG GTC AAG AAA AAA AAT TCC TGA 
L V L M A M V K K K N SSTOP 
Figure 3.23 Amino acid sequence of the TCR 3  chain (TRBV 2 TRBJ 2-5 TRBC 1) 
from the murine T cell clone D3(3) cloned into retroviral vector MFG TRBV 2 is 
highlighted in green, TRBJ 2-5 in purple and TRBC 1 in turquoise. The CDR3 is 
highlighted in blue with the coding sequence underlined. The letter underlined in red 
indicates the base pair inserted by site-directed mutagenesis to convert the incorrect 
sequence to the original DNA sequence, allowing for correct read-through of the amino 
acid sequence and correct positioning of the stop codon. 
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Figure 3.24 Final construct map of the TCR [3 chain from the murine Th2 T-cell 
clone D3(3) in the retroviral vector MFG The diagram shows the position of the 
genes required for correct function of the vector in a retroviral packaging gene 
transduction system and also the position of the inserted TCR gene and the restriction 
sites used in cloning the sequence into MFG. 
195 
3.2.1.2 Transfer of genes encoding dominant TCR a and /3 chains from the peptide 
4-specific human T-cell line CIR010 into retroviral expression vector MFG 
3.2.1.2.1 Transfer of the dominant TCRa chain from human T-cell line CIR010 
into MFG 
A strategy was designed to transfer the gene encoding the dominant TCRa chain from 
the line CIR010 into MFG, which is shown in Figure 3.25. Briefly, a PCR was carried 
out using high-fidelity DNA polymerase to amplify the full TCRa chain from cDNA 
obtained from the line at its 3"I re-stimulation with peptide 4. The primers used 
incorporated NotI sites into the PCR product at either end, allowing the TCR chain to be 
moved directly into MFG from the TA cloning vector into which the PCR product was 
originally ligated. The final construct was then sequenced. Gel images of the process 
are shown in Figure 3.26, and the final construct is shown as a vector diagram in Figure 
3.27. The full sequence data for this TCR chain is shown in Appendix 18. 
3.2.1.2.2 Combination of the dominant recombined TCRa V-J segment from the 
human T-cell line CIR010 with a murine TCRa C region and transfer 
into MFG 
It was realised that in order to allow the expression of a human TCR in the murine line 
BW7, it would be necessary to combine the human V-J region with a mouse C region; it 
has been shown previously that there is a defect in signalling through the TCR in the 
periphery of human TCR13 transgenic mice when the full human VJC structure is used 
(612). Peripheral T-cell function in human TCR transgenic mice generated using the 
pTcass constructs (346), however, which contain an endogenous murine C region in the 
vector to which the inserted rearranged VJ region is spliced, is as expected (283). In 
order to achieve this, a new strategy was designed based on PCR, shown in Figure 3.28. 
Briefly, two PCRs were carried out, the first to amplify the human TCRa V-J region 
from cDNA isolated from the line CIR010 at its fourth re-stimulation with peptide 4. 
The second PCR was carried out on murine T-cell cDNA to amplify the mouse Ca 
region TRAC. The primers for these PCRs incorporated a base change from C-->A in 
the sequences of both products, to introduce a PstI site into the sequence at the J region-
C region junction without changing the underlying amino acid sequence of the 
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a. cDNA from human T cell line CIR010, 3"1 
restimulation with peptide 4 c. MFG 
NotI 
TRAV8-4Notl 
T Dominant TCR a chain - 	RAC 1 noNotI  
TRAV 8-4 TRAJ 32 TRAC 1 
i PCR using high-fidelity Taq polymerase and V-region and C-region specific primers containing additional NotI sites 
b. pCR2.1(CIR010 
TCR a chain) 
TA clone PCR product 
into pCR2.1 
 
Notl 
 
EcoRI 
1  
Dominant TCR a chain 
EcoRI 	 NotI 
NotI 
'----------__ 	,---'---- 
d. 	MFG(CIR010 TCR a chain) 
NotI 
Dominant TCR a chain 	Notl 
Figure 3.25 Cloning strategy designed to transfer the dominant TCRa chain 
from the human T cell line CIR010 into the retroviral vector MFG The a chain for 
the dominant TCR from line CIR010 was amplified from cDNA extracted from the line 
at its 3rd restimulation with peptide 4 of Fel d 1 (a) using PCR and the product was 
ligated into pCR2.1 (b). The insert was then sequenced to check that no mutations had 
been incorporated by the PCR before the TCRa chain was moved into MFG (previously 
modified to destroy its endogenous NcoI site as shown in Figure 3.7) (c) using NotI (d). 
Clones were checked for correct orientation of the insert by PCR, as described 
previously and shown in Figure 3.9. Correctly-oriented clones were sequenced. All PCR 
primers, reaction conditions, and sequencing primers are shown in Appendix 3. All 
restriction enzymes used and digest conditions are shown in Appendix 5. 
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Figure 3.26 Gel images of the stages involved in moving the dominant TCR a 
chain of human T cell line CIR010 into the retroviral vector MFG The images 
above show the steps involved in the strategy as outlined in Figure 3.25. (a) shows the 
PCR product (of 878 bp) obtained from cDNA from the human T cell line CIR010 (a in 
Figure 3.25). The band was excised from the gel, purified and ligated into the TA 
cloning vector pCR2.1. (b) shows a NotI digest of the PCR product ligated into pCR2.1 
(b in Figure 3.25). Uncut plasmid (10) was run as a comparison. Clones containing a 
correctly-sized insert were used to move the TCR chain into MFG. The final product, 
MFG(CIR010a TRAV 8-4 TRAJ 32 TRAC 1) (d in Figure 3.25) is shown in (c), as a 
NotI digest. Uncut plasmid (1 1A1) was run as a comparison. Clones with a correctly-
sized insert were checked for correct orientation of the sequence by PCR (see figure 
3.9), and correctly oriented clones were sequenced. 
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TRAJ 32 
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Figure 3.27 Final construct map of the dominant TCR a chain from the human 
T cell line CIR010 in the retroviral vector MFG The diagram shows the composition 
of the vector; the position of the genes required for its function in a retroviral packaging 
as well as the position of the inserted TCR gene and restriction sites used in cloning the 
sequence into MFG are shown. 
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Figure 3.28 Cloning strategy designed to combine the VJ region from the 
dominant TCRa chain from the human T cell line CIR010 with a murine TCR Ca 
region in the retroviral vector MFG A murine TCR Ca region was amplified from 
murine T cell cDNA (a) using high-fidelity PCR. The forward primer incorporated a 
base change to the sequence to introduce a unique restriction site, PstI, into the nucleic 
acid sequence (without altering the amino acid sequence) to allow later combination 
with the human VJ sequence using this enzyme. The reverse primer incorporated a NotI 
site to allow ease of cloning into MFG at a later stage of the strategy. The PCR product 
was TA cloned into vector pCR2.1 using T4 ligase (c). The VJ regions of the a chain 
for the dominant TCR from line CIR010 was amplified from cDNA extracted from the 
line at its 3rd restimulation with peptide 4 of Fel d 1 (b) using high-fidelity PCR. The 
forward primer incorporated a NotI site to allow ease of cloning into MFG at a later 
step, and the reverse primer incorporated a base change into the TCR sequence to 
incorporate a PstI site, allowing direct overlap between the human variable region and 
murine constant region at this point without change to the overall amino acid sequence. 
The PCR product was TA cloned into vector pCR2.1 using T4 ligase (d). Clones 
containing an insert for both PCRs were then sequenced to check that no unintended 
mutations had been incorporated during the reaction. The murine C region from a 
correct clone was then moved into pBluescriptII (e) using PstI and EcoRI, and correct 
insertion was determined by restriction digest (f). The human VJa sequence from 
pCR2.1 was then inserted into a correct clone using PstI and BamHI, and correct 
insertion was checked by restriction digest (g). A correctly combined and oriented 
sequence was moved into MFG (previously modified to destroy its endogenous NcoI 
site) (h) using NotI, and checked for insertion by restriction digest (i). Clones were 
checked for correct orientation of the insert by PCR as described previously. Correctly-
oriented clones were sequenced, after which the constructs were ready for use in the 
retroviral expression system. All PCR primers, reaction conditions and sequencing 
primers are shown in Appendix 3. All restriction enzymes used and digest conditions 
are shown in Appendix 5. 
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expressed protein. This allowed the combination of the two products in pBluescriptll to 
produce a gene consisting of the CIR010 dominant V-J region combined to a mouse Ca 
region in such a way as to produce a full-length TCRa chain gene, which could then be 
transferred into MFG. Gel images of this process are shown in Figure 3.29, with the 
final construct being shown as a vector diagram in Figure 3.30. The full-length 
sequence of the human V-J region-mouse C region TCRa chain, including the 
incorporated base change, is shown in Appendix 19. 
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Figure 3.29 Gel images of the stages involved in moving the variable region (VJ) 
of the dominant TCRa chain of human T cell line CIR010 combined with a 
murine constant region (C) into MFG The images above show the steps involved in 
the strategy as outlined in Figure 3.28. (a) shows the PCR products for the murine Ca 
region (left-hand side of ladder, 422 bp) and the human VJa region (right hand side of 
ladder, 439 bp). The murine Ca region was obtained from mouse T cell cDNA, and the 
human VJa region was obtained from cDNA from the human T cell line CIR010 (a and 
b in Figure 3.28). EcoRI digests of the PCR products ligated into pCR2.1 are shown in 
(b) - pCR2.1(CIR010 VJa), d in Figure 3.29, and (c) - pCR2.1(murine Ca), c in Figure 
3.29. (d) shows a PstI/EcoRI digest of pBluescriptll(murine Ca) (f in Figure 3.28) 
showing a correctly-sized insert corresponding to the murine Ca region. (e) shows a 
PstI/BamHI digest of pBluescripth (CIR010 VJa murine Ca) (g in Figure 3.28), with 
an insert corresponding to the correctly combined TCR chain. The final product, 
MFG(CIR010a TRAV 8-4 TRAJ 32 TRAC 1) (i in Figure 3.28) is shown in (f), as a 
NotI digest. Clones with a correctly-sized insert were checked for correct orientation of 
the sequence by PCR (see figure 3.9). Correctly oriented clones were sequenced. 
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Figure 3.30 Final construct map of the dominant TCR a chain (combined with a 
murine Ca region) from the human T cell line CIR010 in the retroviral vector 
MFG The diagram shows the composition of the vector in terms of the genes required 
for its function in a retroviral packaging gene transduction system as well as the 
position of the inserted TCR gene, and restriction sites used in the cloning of the 
sequence into MFG. 
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3.2.1.2.3 Combination of the dominant recombined TC1113 V-J segment from the 
human T-cell line CIR010 with a murine TCRI3 C region and transfer 
into MFG 
A similar strategy was designed to allow the combination of the dominant TCRP V-J 
region from the human T-cell line CIR010 with a murine Cp region. The strategy is 
shown in Figure 3.31. Briefly, two PCRs were carried out, the first to amplify the 
human TCRP V-J region from cDNA isolated from the line CIR010 at its fourth re-
stimulation with peptide 4. The second PCR was carried out on murine T-cell cDNA to 
amplify the mouse CP region TRBC 1. In addition, a short linker corresponding to the J 
region-C region junction was inserted into pBluescriptII to allow correct joining of the 
V-J region to the C region. The linker was required as there was no part of the sequence 
that could be easily mutated in both products to form a restriction site to allow 
combination of the two PCR products. Instead, an endogenous HindIII site in the human 
V-J region was used to combine it to the linker in pBluescriptII. The forward primer for 
the murine CP region incorporated a base change from 	to introduce a PpuMI site 
into the sequence at the 5'-end of the C region without changing the amino acid 
sequence of the expressed protein. This allowed the combination of the C region with 
the linker (designed to include this base change from the underlying sequence) in 
pBluescriptII. The two PCR products were thus combined through the linker to produce 
a full length TCRP gene consisting of the CIR010 dominant V-JP region combined to a 
murine cp region, which was then transferred into MFG. Gel images of this process are 
shown in Figure 3.32. The final construct is shown as a vector diagram in Figure 3.33, 
and the full-length sequence of the human V-J region-mouse C region TCRf3 chain, 
including the base change incorporated into the sequence, is shown in Appendix 20. 
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Figure 3.31 Cloning strategy designed to combine the VJ region from the 
dominant TCR(3 chain from the human T cell line CIR010 with a murine TCR cp 
region in the retroviral vector MFG High-fidelity PCR was used to amplify a murine 
TCR C(3 region from murine T cell cDNA (a). The forward primer incorporated a base 
change to introduce a unique restriction site, PpuMI, into the nucleic acid sequence 
(without altering the underlying amino acid sequence) to allow later combination with 
the human VJ sequence using this enzyme. The reverse primer incorporated a NotI site 
to allow easier cloning into MFG at a later stage of the strategy. The PCR product was 
then TA cloned into vector pCR2.1 using T4 ligase (b). The VJ regions of the (3 chain 
for the dominant TCR from line CIR010 was amplified from cDNA extracted from the 
line at its 3rd restimulation with peptide 4 of Fel d 1 (c) using high-fidelity PCR. The 
forward primer incorporated a NotI site to allow easier cloning into MFG at a later step, 
and the reverse primer included an endogenous HindIII site in the TCR sequence, 
allowing combination with the mouse C region. The resulting PCR product was TA 
cloned into vector pCR2.1 using T4 ligase (d). Inserts from both PCRs were sequenced 
to check that no unintended mutations had been incorporated. Simultaneously, a linker 
was inserted into the subcloning vector pBluescriptll (e) corresponding to the sequence 
at the junction between the J and C regions to allow the joining of the murine C region 
with the human VJ region. The linker contained a base change from the original C 
region sequence to incorporate a PpuMI site and contained the HindIII site from the 
human VJ region, as well as a XhoI site to allow insertion into pBluescriptll using XhoI 
and HindIII (f). Correct insertion was determined by restriction digest. The murine C 
region was then moved into pBluescriptll(linker) using PpuMI and Apal, and correct 
insertion was determined by restriction digest (g). The human VJ(3 sequence was 
inserted into pBluescriptll(linker-murine C(3) using HindIII (h), and checked for correct 
insertion and orientation by restriction digest. A correctly combined sequence was 
moved into modified MFG (its endogenous NcoI site destroyed) (i) using NotI, and 
checked by restriction digest (j). Inserts were checked for correct orientation by PCR as 
described previously. Correctly-oriented clones were sequenced, after which the 
constructs were ready for use in the retroviral expression system. All PCR primers, 
reaction conditions, oligonucleotide linkers and sequencing primers are shown in 
Appendix 3. All restriction enzymes used and digest conditions are shown in Appendix 
5. 
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Figure 3.32 Gel images of the stages involved in moving the variable region (VJ) 
of the dominant TCR 13 chain of the human T cell line CIR010 combined with a 
murine constant region (C) into MFG The images above show the steps involved in 
the strategy as outlined in Figure 3.31. (a) shows the PCR product for the murine Cp 
region, (b) shows the PCR product for the human VJ(3 region and (c) shows a 
HindIII/XhoI digest of a 40 bp VJC-linking oligonucleotide inserted into pBluescriptII 
(f in Figure 3.31). The murine CP region was obtained from mouse T cell cDNA, and 
the human VJP region was obtained from cDNA from the human T cell line CIR010 (a 
and b in Figure 3.31). PCR products were ligated into pCR2.1, and then combined in 
pBluescriptII(VJC-linker) via two restriction digests to form pBluescript (CIRO1OVJ(3-
linker-mC(3), shown as a NotI digest in (d) above and corresponding to h in Figure 3.31. 
This insert was transferred into MFG using NotI, as shown in (e) above, corresponding 
to j in Figure 3.31. Orientation of the insert was determined by PCR, as shown in Figure 
3.9, and clones with the TCR chain correctly oriented in MFG were sequenced. 
208 
packaging signal 
41+ 
MFG(CIROlObeta VJ/murine Cbeta) 
5' LTR (MoMuLV) 
	splice donor 
6944 bp 
TRBV 6-1 
plice acceptor 
'Islotl 1 
HindlIl 381 
1 11111iii,  
TRBJ 1-1 
111111111111111111111111111111111111111110107:11r
Hillnijelli TRBC 1 
otl 944 
3' MoMuLV LTR 
puMI 411 
Figure 3.33 Final construct map of the dominant TCR p chain (combined with a 
murine Ci3 region) from the human T cell line CIR010 in the retroviral vector 
MFG The diagram shows the position of the genes required for its function in a 
retroviral packaging gene transduction system and of the inserted TCR gene, along with 
the restriction sites used in the cloning of the sequence into MFG. 
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3.2.2 Preparation of TCR expression constructs for use in the Amaxa 
transduction system 
3.2.2.1 Overview of the Amaxa Nucleofector system and TCR expression vectors 
The Amaxa Nucleofector system (www.amaxa.com) is a proprietary technology: a non-
viral method of transducing cell lines with a target gene that is based on electroporation. 
An expression vector containing a gene of interest is transfected into a target cell line 
using one of the many programmes provided by the Nucleofector device. Any type of 
expression vector can be used in this system. It can be used as a means of transfecting 
retroviral packaging lines with a retroviral vector, but can also be used as a means of 
transducing a target cell line directly, if the correct expression vector is used. 
As the Amaxa system involves transduction of the target line directly, it was necessary 
to transfer the TCR genes from the murine PLP56_70-specific T-cell clones A10(2) and 
D3(3) and the dominant TCR genes from the peptide 4-specific human T-cell line 
CIR010 into vectors designed specifically to allow the expression of TCRs in a T-cell-
restricted manner. The TCR expression cassette vectors, pTacass and pT(3cass, 
designed by Mathis and Benoist (346) for use in the production of TCR-transgenic 
mice, have been previously used to express the Ob 1 Al2 TCR in T-cell hybridomas 
based on the BW7 line (602) using electroporation. As such, it was decided to transfer 
the TCRs of interest into the pTacass and pT(3cass vectors for use in the Amaxa system 
to transduce the BW7 line with these TCR genes. 
The pTacass and pT(3cass vectors have been specifically designed and constructed to 
direct the expression of TCR exclusively in cells of the T-cell lineage. They are large 
vectors (approximately 20 kb in size) as they contain extensive segments of the TCRa 
and (3 promoter regions as well as the intronic sequence between the rearranged V-J 
region and the C region, in order to ensure that all necessary promoter and enhancer 
elements required for successful TCR expression in cells of the T-cell lineage are 
included. The murine C region is included within the vector, hence only the rearranged 
V-J region of the TCR is inserted into the vector to make the final construct. The V-J 
region can be obtained from T-cell genomic DNA or cDNA; however, if the sequence is 
obtained from cDNA, it is necessary to include approximately 50 bp of intronic 
sequence immediately downstream of the J region to allow for correct splicing of the 
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gene. Rearranged TCRa chains are inserted into the pTacass vector at a specific point 
using XmaI and SacII; in the pl.  Pcass vector, rearranged TCRI3 chains are inserted 
using XhoI and SacII. 
The rearranged V-J segments for the two murine PLP56-7o-specific TCRs were obtained 
from the relevant MFG constructs and the intronic sequence was obtained from murine 
genomic DNA. The rearranged V-J segments for the peptide 4-specific human TCR 
from line CIR010 were obtained from the same cDNA as that used for the TCR CDR3 
analysis. The required intronic sequence was obtained from the IMGT database and 
synthesised as an oligonucleotide linker. 
3.2.2.2 Transfer of genes encoding TCR a and 13 chains from the PLP56-7o-specific 
murine T-cell clone A10(2) into the pTcass TCR expression vectors 
3.2.2.2.1 Transfer of TCRa chain 5-D4 from the T-cell clone A10(2) into the 
vector pTacass 
A strategy to allow the rearranged TCRa 5-D4 V-J segment (TRAV 5-D4 TRAJ 13) 
from the murine T-cell clone A10(2) to be transferred into the TCR expression vector 
pTacass is shown in Figure 3.34. As the source of the rearranged V-J segment was the 
complete TCRa chain from the MFG construct, MFG(TCR A10(2)a 5-D4), it was 
necessary to combine this with intronic sequence immediately downstream of the J 
region. To achieve this, PCR primers were designed to make use of an endogenous 
BstXI site in the J region to join the two products. The first product was the rearranged 
V-J segment as far as the BstXI site, amplified from the MFG construct, and the second 
product was the J region-intron segment, comprising the J region from its BstXI site to a 
point approximately 55 base pairs into the downstream intron. The products were 
combined in the subcloning vector pUC19 (shown in Appendix 21) before being 
transferred into pTacass using XmaI and SacII. Gel images of the process are shown in 
Figure 3.35, and the final construct is shown in Figure 3.36. The full sequence of the 
insert in pTacass is shown in Appendix 22. 
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Figure 3.34 Cloning strategy designed to move the TCRa chain (VJ region plus 
intronic sequence) from the mouse Thl-type T cell clone A10(2) 5-D4 into the TCR 
expression vector pTacass As pTacass contains as part of its structure a murine TCR 
Ca region, only the VJ region of the A10(2) 5-D4 TCR a chain was moved into the 
vector. This was combined with a short length of intronic sequence downstream of the J 
region to allow for correct splicing of the sequence to the endogenous C region, as the 
VJ region was amplified from a fully rearranged sequence and not from genomic DNA. 
The VJ region was amplified from MFG(TCR a A10(2) 5-D4) which contained the full 
version of the TCR chain gene (a) using high-fidelity PCR. The forward primer 
incorporated an XmaI site at its 3' end to allow for eventual cloning of the TCR 
sequence into pTacass. The reverse primer incorporated an endogenous BstXI site in 
the J region to allow the VJ region and the J-intron region to be combined in a later 
cloning step. The PCR product was inserted into pCR2.1 (b). The J region-intron was 
amplified from mouse genomic DNA (c), the forward primer incorporating the BstXI 
site from the J region and the reverse primer incorporating a SacII site at its 5' end to 
allow for cloning of the combined product into pTacass. The PCR product was inserted 
into pCR2.1 (d). Clones containing an insert of the correct size upon EcoRI digestion 
were sequenced to check that no unintended mutations had been incorporated during the 
reactions. As the vector pCR2.1 contains two BstXI sites in its MCS, this prevented the 
use of BstXI as a means of combining the two segments directly from this plasmid, and 
so it was necessary to move the VJ region into pBluescriptII (e) using EcoRI. Correct 
insertion and orientation of the sequence was determined by restriction digest (g). 
Simultaneously, the J region-intron segment was moved into the subcloning vector, 
pUC19 (f), using PstI and HindIII, and correct insertion was determined by restriction 
digest (h). The VJ region from pBluescriptII was then moved into pUC19 containing the 
J region-intron segment using BstXI and XbaI, and correct combination was determined 
by restriction digest (i). The combined sequence was moved into pTacass (supplied 
already containing an irrelevant TCR a chain as a circular plasmid) (j) using Xmal and 
SacII, and correct insertion was determined by restriction digest (k). Correct clones 
were sequenced, after which the constructs were ready for use in the Amaxa 
transfection system. All PCR primers, reaction conditions and sequencing primers are 
shown in Appendix 4. All restriction enzymes used and digest conditions are shown in 
Appendix 5. 
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Figure 3.35 Gel images of the stages involved in moving the rearranged VJ 
region from the TCR a chain from murine T cell clone A10(2) 5-D4 combined 
with intronic sequence immediately downstream of the J region terminus into the 
TCR expression vector pTacass The images above show the steps involved in the 
strategy as outlined in Figure 3.34. (a) and (b) show the PCR products corresponding to 
the J region-intron of the TCRa chain (a) obtained from murine NOD.E T cell genomic 
DNA (c in Figure 3.34) and the rearranged VJ region (b) obtained from MFG(Al 0(2) 5-
D4) (a in Figure 3.34). PCR products were ligated into pCR2.1 and sequenced to check 
that no unintended mutations had occurred. (c) shows a SacII/XmaI digest of the 
combined VJ-intron sequence inserted into pUC19 (h in Figure 3.34). The correctly 
combined TCRa VJ-intron segment was moved into pTacass. The final product of the 
strategy, pTacass(Al 0(2)a TRAV 5D-4 TRAJ 13 intron) (k in Figure 3.34) is shown in 
(d) as a SacII/XmaI digest to show correct insertion of the insert and (e) as a BamHI 
digest, to check that the integrity of the plasmid remained intact. Band sizes shown are 
those expected for the plasmid; there is an extra band compared to other pTacass 
constructs as there is a BamHI site in the inserted sequence. Clones with a correctly-
sized insert were sequenced. 
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Figure 3.36 Final construct map showing the insertion of the TCRa chain 5-D4 
from the Thl murine T-cell clone A10(2) into the TCR expression vector pTacass 
Only the rearranged VJ region (TRAV 5-D4 TRAJ 13) from the sequence was inserted 
as the vector contains a murine Ca region already, designed to be spliced to the VJ 
region during mRNA processing to produce a full-length TCR chain gene. As the VJ 
region was amplified from cDNA, it was necessary to include the beginning of the 
intronic sequence immediately downstream of the J region, to allow correct splicing to 
occur. Restriction sites that were used to create the VJ-intron sequence and to clone the 
sequence into pTacass are shown, along with the position of the bacterial sequence 
required for the propagation of the construct in bacterial culture. 
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3.2.2.2.2 Transfer of TCRa chain 7-D3 from the T-cell clone A10(2) into the 
vector pTacass 
Figure 3.37 shows the strategy used to transfer the rearranged TCRa 7-D3 V-J segment 
(TRAV 7-D3 TRAJ 15) from the murine T-cell clone A10(2) into the TCR expression 
vector pTacass. As for the 5-D4 TCRa chain, the rearranged V-J segment, amplified 
from the complete TCRa chain in the MFG construct, MFG(TCR A10(2)a 7-D3), was 
combined with intronic sequence immediately downstream of the J region. An 
endogenous Sad site in the J region was used to join the two sequences, and PCR 
primers were designed to allow this. The first PCR product was the rearranged V-J 
segment as far as the Sad site, amplified from the MFG construct. The second product 
was the J region-intron segment, consisting of the J region from its Sad site to a point 
approximately 50 base pairs into the downstream intron. The products were combined 
in pBluescriptll before being transferred into pTacass using XmaI and SacII. Gel 
images of the steps of the strategy are shown in Figure 3.38, with a vector diagram of 
the final construct being shown in Figure 3.39. The full sequence of the insert in 
pTacass is shown in Appendix 23. 
3.2.2.2.3 	Transfer of the TCRI3 chain from the T-cell clone A10(2) into the 
vector pTfl cass 
A similar strategy was used to transfer the rearranged TCRI3 V-J segment (TRBV 14 
TRAJ 2-7) from the murine T-cell clone A10(2) into the TCR expression vector 
pT13cass, which is shown in Figure 3.40. Primers were designed to incorporate an XmaI 
site into the J region by changing one base pair from C-->G without changing the 
underlying amino acid sequence, which could then be used to join the two segments of 
the sequence. The first PCR product was the rearranged V-J segment as far as the 
introduced XmaI site, which was amplified from the MFG construct. The second 
product was the J region-intron segment, starting in the J region at the introduced XmaI 
site and extending to a point 56 base pairs into the downstream intron. The products 
were combined in pBluescriptll before transfer into pTI3cass using XhoI and SacII. 
Figure 3.41 shows gel images of the steps involved, and the final construct is shown in 
Figure 3.42. The full sequence of the insert in pTpcass including the base pair change to 
incorporate the XmaI site is shown in Appendix 24. 
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Figure 3.37 Cloning strategy designed to move the TCRa chain (VJ region plus 
intronic sequence) from the mouse Thl-type T cell clone A10(2) 7-D3 into the TCR 
expression vector pTacass pTacass contains a murine TCR Ca region within its 
structure, and thus only the VJ region of the A10(2) 7-D3 TCR a chain was moved into 
the vector, combined with a short stretch of intronic sequence immediately downstream 
of the J region to allow correct splicing of the VJ sequence to the endogenous C region, 
as the VJ region was amplified from a fully rearranged TCR sequence and not from 
genomic DNA. High-fidelity PCR was used to amplify the VJ region from MFG(TCR 
a A10(2) 7-D3) containing the full version of the TCR chain gene (a). The forward 
primer incorporated an XmaI site at its 3' end to allow for cloning of the TCR sequence 
into pTacass. The reverse primer incorporated an endogenous Sad site in the J region 
to allow the VJ region to be combined with the J-intron region in a later cloning step. 
This PCR product was ligated into pCR2.1 (b). The J region-intron was amplified from 
mouse genomic DNA (c), with the forward primer incorporating the Sad site from the J 
region and the reverse primer including a SacII site at its 5' end to allow cloning of the 
combined product into pTacass. The PCR product was ligated into pCR2.1 (d). Clones 
containing an insert of the correct size upon EcoRI digestion were sequenced to check 
that no unintended mutations had been incorporated. The J region-intron segment was 
moved into pBluescriptll (e) using Sad and Spel. Correct insertion was determined by 
restriction digest (f). The VJ region segment was moved into this construct using Sad 
and correct insertion and orientation was determined by restriction digest (g). A 
correctly combined sequence was moved into pTacass (supplied already containing an 
irrelevant TCR a chain as a circular plasmid) (h) using XmaI and SacII, and its correct 
insertion was determined by restriction digest (i). Correct clones were sequenced, after 
which the constructs were ready for use in the Amaxa transfection system. All PCR 
primers, reaction conditions, and sequencing primers are shown in Appendix 4. All 
restriction enzymes used and digest conditions are shown in Appendix 5. 
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Figure 3.38 Gel images of the stages involved in moving the rearranged VJ 
region from the TCR a chain of murine T cell clone A10(2) 7-D3 combined with 
intronic sequence immediately downstream of the J region terminus into the TCR 
expression vector pTacass The images show the steps involved in the strategy 
outlined in Figure 3.37. The PCR product in (a) is the J region-intron of the TCRa chain 
obtained from murine NOD.E T-cell genomic DNA (c in Figure 3.37) and the product 
in (b) is the rearranged V-J region obtained from MFG(A10(2) 7-D3) (a in Figure 3.37). 
Both products were ligated into pCR2.1 and sequenced to check that no mutations had 
been introduced during the PCRs. (c) shows a SacII/XmaI digest of the combined VJ-
intron sequence inserted into pBluescriptII (g in Figure 3.37). This was then moved into 
pTacass. The final product, pTacass(TRAV 7D-3 TRAJ 15 intron) (i in Figure 3.37) is 
shown in (d) as a SacII/XmaI digest to show insertion of the sequence into the vector 
and in (e) as a BamHI digest, to demonstrate the maintenance of plasmid integrity. Band 
sizes shown are those expected. Clones with a correctly-sized insert were sequenced. 
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Figure 3.39 Final construct map showing the insertion of the TCRa chain 7-D3 
from the Thl murine T-cell clone A10(2) into the TCR expression vector pTacass 
Only the rearranged VJ region (TRAY 7-D3 TRAJ 15) from the sequence was inserted 
into the vector, as there is an endogenous a murine Ca region already present, which is 
designed to be spliced to the VJ region during mRNA processing to produce a full-
length TCR chain gene. As the VJ region inserted here was amplified from cDNA, it 
was necessary to include the first —50bp of the intronic sequence downstream of the J 
region, to allow correct splicing to occur. Restriction sites that were used to create the 
VJ-intron sequence and to clone the sequence into pTacass are shown, along with the 
position of the bacterial sequence required for the propagation of the construct in 
bacterial culture. 
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Figure 3.40 Cloning strategy designed to move the TCRI3 chain (VJ region plus 
intronic sequence) from the mouse Thl-type T cell clone A10(2) into the TCR 
expression vector pTf3cass pT(3cass contains as part of its structure a murine TCR C(3 
region, hence only the VJ region of the A10(2) TCR 13 chain was moved into the vector 
along with some intronic sequence (to allow for correct splicing of the sequence to the 
endogenous C region, as the VJ region was amplified from a fully rearranged sequence 
and not from genomic DNA). The VJ region was amplified from the MFG(TCR (3 
A10(2)) construct which contained the full version of the TCR chain gene (a) using 
high-fidelity PCR. The forward primer included an XhoI site at its 3' end to allow for 
cloning of the TCR sequence into pT(3cass. The reverse primer included a base change 
to incorporate an XmaI site into the J region, without changing the amino acid 
sequence, to allow the VJ region and the J-intron region to be combined. The PCR 
product was ligated into pCR2.1 (b). The J region-intron was amplified from mouse 
genomic DNA (c), the forward primer including a base change to incorporate the 
necessary XmaI site into the J region and the reverse primer including a SacII site at its 
5' end to allow for cloning into pT(3cass. The PCR product was ligated into pCR2.1 (d). 
Clones containing an insert of the correct size upon digestion with EcoRI were 
sequenced to check that no unintended mutations had been incorporated. The J region-
intron segment was moved into pBluescriptII (e) using KpnI and XmaI., and correct 
insertion was determined by restriction digest (f). The VJ region segment was moved 
into this construct using XbaI and XmaI. Correct insertion was determined by 
restriction digest (g). A correctly combined sequence was moved into pT(3cass (supplied 
containing an irrelevant TCR (3 chain as a circular plasmid) (h) using XhoI and SacII, 
and correct insertion was determined by restriction digest (i). Correct clones were 
sequenced, after which the constructs were ready for use in the Amaxa transfection 
system. All PCR primers, reaction conditions, and sequencing primers are shown in 
Appendix 4. All restriction enzymes used and digest conditions are shown in Appendix 
5. 
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Figure 3.41 Gel images of the stages involved in moving the rearranged VJ 
region from the TCR f3 chain of murine T cell clone A10(2) combined with 
intronic sequence immediately downstream of the J region terminus into the TCR 
expression vector pTpcass The images show the steps involved in the strategy as 
outlined in Figure 3.40. PCR products corresponding to the J region-intron of the TCR(3 
chain (a) obtained from murine NOD.E T-cell genomic DNA (b in Figure 3.40) and to 
the rearranged V-J region (b) obtained from MFG(A10(2)(3) (a in Figure 3.40) are 
shown. The bands were ligated into pCR2.1 and sequenced to check for any unintended 
mutations. (c) shows a SacII/XhoI digest of the combined VJ-intron sequence (469 bp) 
inserted into pBluescriptII (g in Figure 3.40). The correctly combined TCR13 VJ-intron 
segment was then moved into pTficass, and the final product of the strategy, 
pT(3cass(TRBV 14 TRBJ 2-7 intron) (i in Figure 3.40) is shown in (d) as a SacII/XhoI 
digest to show correct insertion and in (e) as an EcoRI digest, to show that the integrity 
of the plasmid remained intact. Band sizes shown are those expected. Clones with a 
correctly-sized insert were sequenced. 
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Figure 3.42 Final construct map showing the insertion of the TCR 13 chain from 
the Thl T-cell clone A10(2) into the TCR expression vector pTr3cass Only the 
rearranged VJ region (TRBV 14, TRBJ 2-7) from the sequence was inserted into the 
vector as it already contains a murine Cp region which is designed to be spliced to the 
VJ region during mRNA processing to produce a full-length TCR chain gene. As the VJ 
region was amplified from cDNA, it was necessary to include —50 bp of the intronic 
sequence immediately downstream of the J region, to allow for correct splicing. 
Restriction sites that were used to create the VJ-intron sequence and to clone the 
sequence into pTPcass are shown, along with the position of the bacterial sequence 
required for the propagation of the construct in bacterial culture. 
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3.2.2.3 Transfer of genes encoding TCR a and 13 chains from the PLP56-7o-specific 
murine T-cell clone D3(3) into the pTcass TCR expression vectors 
3.2.2.3.1 Transfer of the TCRa chain from T-cell clone D3(3) into vector pTacass 
Figure 3.43 shows the strategy used to transfer the rearranged TCRa V-J segment 
(TRAV 7-D4 TRAJ 26-like (95% identity with IMGT database sequence)) from murine 
T-cell clone D3(3) into pTacass. As for the A10(2) constructs, it was necessary to 
combine the rearranged TCRa V-J segment with intronic sequence immediately 
downstream of the J region. Primers were designed to incorporate a KpnI site into the J 
region by changing one base pair from C—~T without changing the underlying amino 
acid sequence. The incorporated site was then used to join the two segments. The first 
PCR product was amplified from the MFG construct, consisting of the rearranged V-J 
segment as far as the introduced KpnI site. The second product was the J region-intron 
segment amplified from murine T-cell genomic DNA, consisting of the J region from 
the introduced KpnI site to a point 50 base pairs into the downstream intron. Products 
were combined in pBluescriptll and transferred into pTacass using XmaI and SacII. 
Figure 3.44 shows gel images of the process, and Figure 3.45 shows the final construct. 
The full sequence of the insert in pTacass is shown in Appendix 25. 
3.2.2.3.2 Transfer of the TCR II chain from T-cell clone D3(3) into vector pTpcass 
The strategy used to transfer the rearranged TCR V-J segment (TRBV 2 TRAJ 2-5) 
from the murine T-cell clone D3(3) into the TCR expression vector pTPcass is shown in 
Figure 3.46. As for the D3(3) TCRa construct, the rearranged TCRP V-J segment was 
combined with intronic sequence immediately downstream of the J region. To achieve 
this, primers were designed to make use of an endogenous BstXI site in the J region to 
join the two sequences. The first PCR product was the rearranged V-J segment as far as 
the BstXI site, amplified from the MFG construct, and the second product was the J 
region-intron segment, comprising the J region from its BstXI site to a point 
approximately 85 base pairs into the downstream intron. These products were joined in 
pUC19 before being transferred into pTPcass using XhoI and SacII. Gel images of the 
process are shown in Figure 3.47, and the final construct is shown in Figure 3.48. The 
full sequence of the insert in pTpcass is shown in Appendix 26. 
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Figure 3.43 Cloning strategy designed to move the TCRa chain (VJ region plus 
intronic sequence) from the mouse Th2 T cell clone D3(3) into the TCR expression 
vector pTacass As pTacass contains as part of its structure a murine TCR Ca region, 
only the VJ region of the D3(3) TCR a chain was moved into the vector along with 
some intronic sequence downstream of the J region to allow correct splicing of the 
sequence to the endogenous C region, as the VJ region was amplified from a fully 
rearranged sequence and not from genomic DNA. The VJ region was amplified from 
MFG(TCRa D3(3)) which contains the full version of the TCR chain gene (a) using 
high-fidelity PCR. The forward primer incorporated an XmaI site at its 3' end to allow 
for cloning of the TCR sequence into pTacass. The reverse primer included a base 
change to incorporate a Kpnl site into the J region, without changing the underlying 
amino acid sequence, to allow the VJ region and the J-intron region to be combined in a 
later cloning step. The PCR product was ligated into pCR2.1 (b). The J region-intron 
was amplified from mouse genomic DNA (c), the forward primer including a base 
change to incorporate the necessary Kpnl site into the J region and the reverse primer 
including a SacII site at its 5' end to allow for cloning of the combined product into 
pTacass. The PCR product was ligated into pCR2.1 (d). Clones containing an insert of 
the correct size upon digestion with EcoRI were sequenced to check that no unintended 
mutations had been introduced. The J region-intron segment was moved into 
pBluescriptll (e) using KpnI and EcoRl. Correct insertion of the sequence was 
determined by restriction digest (f). The VJ region segment was then moved into this 
construct using KpnI and correct insertion and orientation was determined by restriction 
digest (g). A correctly combined sequence was moved into pTacass (supplied 
containing an irrelevant TCRa chain as a circular plasmid) (h) using Xmal and SacII, 
and correct insertion was determined by restriction digest (i). Correct clones were 
sequenced, after which the constructs were ready for use in the Amaxa transfection 
system. All PCR primers, reaction conditions, and sequencing primers are shown in 
Appendix 4. All restriction enzymes used and digest conditions are shown in Appendix 
5. 
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Figure 3.44 Gel images of the stages involved in moving the rearranged VJ 
region from the TCRa chain of murine T cell clone D3(3) combined with intronic 
sequence immediately downstream of the J region terminus into the TCR 
expression vector pTacass The images above show the steps involved in the strategy 
as outlined in Figure 3.43. The PCR product of the J region-intron of the TCRa chain 
obtained from murine NOD.E T cell genomic DNA (c in Figure 3.43) is shown in (a) 
and that of the rearranged VJ region obtained from MFG(D3(3)a) (a in Figure 3.43) is 
shown in (b). PCR products were ligated into pCR2.1 and sequenced to check that no 
unintended mutations had occurred. (c) shows a SacII/XmaI digest of the combined VJ-
intron sequence inserted into pBluescriptll (g in Figure 3.43). The correctly combined 
TCRa VJ-intron segment was moved into pTacass. The final product of the strategy, 
pTacass(TRAV 7D-4 TRAJ ? intron) (i in Figure 3.43) is shown in (d) as a SacII/XmaI 
digest to show correct insertion and in (e) as a BamHI digest, to check that the plasmid 
retained its integrity. Band sizes shown are those expected. Clones with a correctly-
sized insert were sequenced. 
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Figure 3.45 Final construct map showing the insertion of the TCRa chain from 
the Th2 T cell clone D3(3) into the TCR expression vector pTacass Only the 
rearranged VJ region (TRAV 7-D4 TRAJ 26-like) from the sequence was inserted as 
there is an endogenous murine Ca region already in the vector, designed to be spliced to 
the VJ region during mRNA processing to produce a full-length TCR chain gene. As 
the VJ region was amplified from cDNA, it was necessary to include intronic sequence 
(-50 bp) immediately downstream of the J region to allow correct splicing. Restriction 
sites that were used to create the VJ-intron sequence and to clone the sequence into 
pTacass are shown, along with the position of the bacterial sequence needed for 
amplification of the construct in bacterial culture. 
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Figure 3.46 Cloning strategy designed to move the TCR I3 chain (VJ region plus 
intronic sequence) from the mouse Th2 T-cell clone D3(3) into the TCR expression 
vector pTi3cass pTPcass contains as part of its structure a murine TCR CP region, 
hence only the rearranged VJ region of the D3(3) TCRP chain was moved into the 
vector along with —50bp intronic sequence immediately downstream of the J region. 
This allows correct splicing of the sequence to the endogenous C region as the VJ 
region in this case was amplified from a fully rearranged sequence and not from 
genomic DNA. The VJ region was amplified from MFG(TCR(3 D3(3)) which contains 
the full version of the TCR chain gene (a) using high-fidelity PCR. The forward primer 
incorporated an XhoI site at its 3' end to allow for cloning of the TCR sequence into 
pTPcass. The reverse primer incorporated an endogenous BstXI site in the J region to 
allow the VJ region and the J-intron region to be combined in a later step. The PCR 
product was ligated into pCR2.1 (b). The J region-intron was amplified from mouse 
genomic DNA (c), the forward primer incorporating the BstXI site from the J region 
and the reverse primer including a SacII site at its 5' end to allow cloning of the 
combined product into pTi3cass. The PCR product was ligated into pCR2.1 (d). Clones 
containing an insert of the correct size upon EcoRI digestion were sequenced to check 
that no unintended mutations had occurred. As the vector pCR2.1 contains two BstXI 
sites in its MCS, this prevented the use of BstXI as a means of combining the two 
segments from this plasmid, and so it was necessary to move the J-intron region from a 
correct clone into pBluescriptII (f) using EcoRI. Correct insertion and orientation of the 
sequence was determined by restriction digest (h). Simultaneously, the VJ region was 
moved into another cloning vector, pUC19 (e), using EcoRI and correct insertion and 
orientation was determined by restriction digest (g). The J region-intron segment from 
pBluescriptII was then moved into pUC19 (containing the VJ region) using BstXI and 
BamHI, and correct combination was determined by restriction digest (i). A correctly 
combined sequence was moved into pTpcass (supplied as a circular plasmid containing 
an irrelevant TCR chain) (j) using XhoI and Sad!, and correct insertion was 
determined by restriction digest (k). Correct clones were sequenced, after which the 
constructs were ready for use in the Amaxa transfection system. All PCR primers, 
reaction conditions, and sequencing primers are shown in Appendix 4. All restriction 
enzymes used and digest conditions are shown in Appendix 5. 
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Figure 3.47 Gel images of the stages involved in moving the rearranged VJ 
region from the TCRI3 chain of murine T cell clone D3(3) combined with intronic 
sequence immediately downstream of the J region terminus into the TCR 
expression vector pTi3cass The images above show the steps involved in the strategy 
as outlined in Figure 3.46. (a) and (b) show the PCR products corresponding to the J 
region-intron of the TCRI3 chain (a), obtained from murine NOD.E T-cell genomic 
DNA (b in Figure 3.46), and the rearranged V-J region (b), obtained from 
MFG(D3(3)(3) (a in Figure 3.46). The products were ligated into pCR2.1 and sequenced 
to check that no unintended mutations had occurred. (c) shows a SacII/XhoI digest of 
the combined VJ-intron sequence inserted into pUC19 (i in Figure 3.46). The correctly 
combined TCRI3 VJ-intron segment was moved into pT(3cass. The final product of the 
strategy, pT3cass(D3(3 TRBV 2 TRBJ 2-5 intron) (k in Figure 3.46) is shown in (d) as a 
SacII/XhoI digest to show correct insertion of the insert and in (e) as an EcoRI digest, to 
show that the integrity of the plasmid remained intact. Band sizes shown are those 
expected. Clones with a correctly-sized insert were sequenced. 
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Figure 3.48 Final construct map showing the insertion of the TCRI chain from 
the Th2 T-cell clone D3(3) into the TCR expression vector pTi3cass Only the 
rearranged VJ region (TRBV 2 TRBJ 2-5) of the sequence was inserted as the vector 
already contains a murine cp region, designed to be spliced to the VJ region during 
mRNA processing to produce a full-length TCR chain gene. As the VJ region was 
amplified from cDNA, it was necessary to include the beginning of the intronic 
sequence immediately downstream of the J region to allow correct splicing to occur. 
Restriction sites that were used to create the VJ-intron sequence and to clone the 
sequence into pT13cass are shown, along with the position of the bacterial sequence 
required for the propagation of the construct in bacterial culture. 
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3.2.2.4 Transfer of genes encoding dominant TCR a and 13 chains from the human 
peptide 4-specific T-cell line CIR010 into pTcass TCR expression vectors 
3.2.2.4.1 	Transfer of the TCRa chain from T-cell line CIR010 into vector 
pTacass 
The strategy to transfer the dominant rearranged TCRa V-J segment (TRAV 8-4 TRAJ 
32) from the human T-cell line CIR010 into the TCR expression vector pTacass is 
shown in Figure 3.49. As the rearranged TCRa V-J segment was amplified from T-cell 
line cDNA and hence from a rearranged TCRa chain, it was necessary to combine this 
segment with intronic sequence immediately downstream of the J region. To achieve 
this, primers were designed to amplify the rearranged V-J region from the cDNA, and to 
incorporate a HindIII site into the J region by changing one base pair from C—'T 
without changing the underlying amino acid sequence. In addition, a linker 
corresponding to the J region downstream of the incorporated HindIII site (also present 
in the linker) and the first 50 base pairs of the intron immediately following the J region 
was inserted into pBluescriptII. The HindIII site was then used to join the rearranged V-
J segment to the linker, before transfer into pTacass using XmaI and SacII. Figure 3.50 
shows gel images of the process, with the final construct shown in Figure 3.51. The 
sequence of the insert in pTacass is shown in Appendix 27. 
3.2.2.4.2 Transfer of the TCRI3 chain from T-cell line CIR010 into vector pTcass 
Figure 3.52 shows the strategy used to transfer the dominant rearranged TCR V-J 
segment (TRBV 6-1 TRBJ 1-1) from the human T-cell line CIR010 into the TCR 
expression vector pThcass. As for the TCRa construct, the rearranged V-J segment, 
amplified from T-cell line cDNA, was combined with intronic sequence immediately 
downstream of the J region. Primers were designed to amplify the rearranged V-J region 
from the cDNA as far as an endogenous HindIII site in the J region for use in joining 
the V-J region to the J-intron segment. This segment, corresponding to the J region 
downstream of the endogenous HindIII site and the first 50 base pairs of the intron 
immediately following, was inserted as a linker into pBluescriptII. The two segments 
were combined using HindIII, before transfer into pTf3cass using XhoI and SacII. Gel 
images of the process are shown in Figure 3.53, and the final construct is shown in 
Figure 3.54. The full sequence of the insert in pTpcass is shown in Appendix 28. 
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Figure 3.49 Cloning strategy designed to move the dominant TCRa chain (VJ 
region plus intronic sequence) from the human T cell line CIR010 into the TCR 
expression vector pTacass As pTacass contains as part of its structure a murine TCR 
Ca region, only the VJ region of the CIR010 TCRa chain was moved into pTacass, 
along with some intronic sequence immediately downstream of the J region as the VJ 
region was amplified from cDNA and not genomic DNA, to allow correct splicing of 
the sequence to the endogenous C region. A linker was inserted into pBluescriptll (a) 
using HindIII and XhoI. The linker corresponded to the 5'-end of the Ja region and 50 
bp of intronic sequence immediately downstream and also included a base change to 
incorporate a HindIII site in the sequence. This would allow the subsequent 
combination of the J-intron sequence with the VJ sequence (but without changing the 
overall amino acid sequence). A S acII site was added to the end of the intronic sequence 
to allow for cloning into pTacass. The linker also contained a XhoI site to allow 
insertion of the vector into pBluescriptII. Insertion was determined by restriction digest 
(b). The VJ region was amplified from cDNA from the human T cell line CIR010 at its 
3r° restimulation with peptide 4 (c) using high-fidelity PCR. The forward primer 
incorporated an XmaI site to allow for cloning of the TCR sequence into pTacass. The 
reverse primer included a base change to incorporate a HindIII site to allow the VJ 
region and the J-intron region to be combined in a later cloning step. The PCR product 
was ligated into pCR2.1 (d). Clones containing an insert of the correct size upon 
digestion with EcoRI were sequenced to check that no unintended mutations had been 
incorporated during the reaction. The VJ region was moved into pBluescriptII(linker) 
using HindIII and BamHI, and correct insertion was determined by restriction digest (e). 
A correctly combined sequence was moved into pTacass (supplied already containing 
an irrelevant TCR a chain as a circular plasmid) (f) using XmaI and SacII, and correct 
insertion was determined by restriction digest (g). Correct clones were sequenced, after 
which the constructs were ready for use in the Amaxa transfection system. All PCR 
primers, reaction conditions, oligonucleotide linkers and sequencing primers are shown 
in Appendix 4. All restriction enzymes used and digest conditions are shown in 
Appendix 5. 
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Figure 3.50 Gel images of the stages involved in moving the rearranged VJ 
region from the dominant TCRa chain from human T cell line CIR010 combined 
with intronic sequence immediately downstream of the J region terminus into the 
TCR expression vector pTacass The images above show the steps involved in the 
strategy as outlined in Figure 3.49. (a) shows the insertion of an oligonucleotide linker 
comprising the 3'-end of the J region from the dominant TCRa chain in line CIR010 
and the first 50bp of the intronic sequence immediately following it into pBluescriptll 
(b in Figure 3.50). Correct insertion was determined by restriction digest with the 
enzymes (HindIII and XhoI) originally used to insert the linker. A HindIII/XhoI digest 
of pBluescriptll with no linker inserted is shown as a comparison. (b) shows the PCR 
product obtained from cDNA from the human T cell line CIR010 (c in Figure 3.49). 
The product was ligated into pCR2.1 and sequenced to check that no unintended 
mutations had occurred. (c) shows a SacII/XmaI digest of the combined VJ-intron 
sequence inserted into pBluescriptll (e in Figure 3.49). The correctly combined TCRa 
VJ-intron segment was moved into pTacass. The final product of the strategy, 
pTacass(TRAV 8-4 TRAJ 32 intron) (g in Figure 3.49) is shown in (d) as a SacII/XmaI 
digest to show correct insertion of the insert and in (e) as a BamHI digest, to show that 
the integrity of the plasmid remained intact. Band sizes shown are those expected. 
Clones with a correctly-sized insert were sequenced. 
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Figure 3.51 Final construct map showing the insertion of the dominant TCRa 
chain from the human T cell line CIR010 into the TCR expression vector pTacass 
Only the rearranged VJ region (TRAV 8-4 TRAJ 32) from the human sequence was 
inserted as the vector contains a murine Ca region already, which is designed to be 
spliced to the VJ region during mRNA processing to produce a full-length TCR chain 
gene. As the human VJ region was amplified from cDNA, it was necessary to include 
—50bp of the intronic sequence immediately downstream of the J region, to allow 
correct splicing to occur. Restriction sites that were used to create the VJ-intron 
sequence and to clone the sequence into pTacass are shown, along with the position of 
the bacterial sequence required for construct amplification in bacterial culture. 
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Figure 3.52 Cloning strategy designed to move the dominant TCR1 chain (VJ 
region plus intronic sequence) from the human T cell line CIR010 into the TCR 
expression vector pTpcass pT13cass contains as part of its structure a murine TCR C(3 
region, so only the VJ region of the CIR010 TCR(3 chain was moved into the vector 
along with —50bp intronic sequence immediately downstream of the J region to allow 
for correct splicing of the sequence to the endogenous C region, as the VJ region was 
amplified from cDNA and not genomic DNA. A linker was inserted into pBluescriptII 
(a) using HindIII and Sall. The linker corresponded to the 5'-end of the JI3 region and 
50 bp of intronic sequence immediately downstream of it and incorporated an 
endogenous HindIII site in the J region of the sequence, to allow subsequent 
combination of the J-intron sequence with the VJ sequence. A SacII site was added to 
the end of the intronic sequence to allow cloning into pT(3cass. The linker also 
contained a SalI site to allow insertion of the vector into pBluescriptII. Insertion was 
determined by restriction digest (b). The VJ region was amplified from cDNA from the 
human T cell line CIR010 at its 3"1 restimulation with peptide 4 (c) using high-fidelity 
PCR. The forward primer incorporated a XhoI site to allow for cloning of the TCR 
sequence into pTr3cass. The reverse primer incorporated the HindIII site in the J region 
to allow the VJ region and the J-intron region to be combined in a later step. The PCR 
product was ligated into pCR2.1 (d). Clones containing an insert of the correct size 
upon digestion with EcoRi were sequenced to check that no unintended mutations had 
been incorporated during the reaction. The VJ region was moved into 
pBluescriptII(linker) using HindIII and EcoRV, and correct insertion was determined by 
restriction digest (e). A correctly combined sequence was moved into pTI3cass (supplied 
as a circular plasmid containing an irrelevant TCR(3 chain) (f) using XhoI and SacII, 
and correct insertion was determined by restriction digest (g). Correct clones were 
sequenced, after which the constructs were ready for use in the Amaxa transfection 
system. All PCR primers, reaction conditions, oligonucleotide linkers and sequencing 
primers are shown in Appendix 4. All restriction enzymes used and digest conditions 
are shown in Appendix 5. 
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Figure 3.53 Gel images of the stages involved in moving the rearranged VJ 
region from the dominant TCRI3 chain from human T cell line CIR010 combined 
with intronic sequence immediately downstream of the J region terminus into the 
TCR expression vector pTI3cass The images above show the steps involved in the 
strategy as outlined in Figure 3.52. (a) shows insertion of an oligonucleotide linker 
comprising the 3'-end of the J region from the dominant TCRI3 chain in line CIR010 
and the first 60bp of the intronic sequence immediately following it in the genomic 
DNA into pBluescriptII (b in Figure 3.52). Correct insertion was determined by 
restriction digest with the enzymes (HindIll and Sall) originally used for linker 
insertion. (b) shows the PCR product obtained from cDNA from the human T cell line 
CIR010 (c in Figure 3.52). The product was ligated into pCR2.1 and sequenced to 
check that no unintended mutations had occurred. (c) shows a XhoI/SacII digest of the 
combined VJ-intron sequence inserted into pBluescriptII (e in Figure 3.52). The 
correctly combined TCR13 VJ-intron segment was moved into pT(3cass. The final 
product of the strategy, pTf3cass(TRBV 6-1 TR(3J 1-1 intron) (g in Figure 3.52) is 
shown in (d) as a XhoI/SacII digest to show correct insertion of the insert and in (e) as 
an EcoRI digest, to show that the integrity of the plasmid remained intact. Band sizes 
shown are those expected. Clones with a correctly-sized insert were sequenced. 
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Figure 3.54 Final construct map showing the insertion of the dominant TCRi3 
chain from the human T cell line CIR010 into the TCR expression vector pTi3cass 
Only the rearranged VJ region (TRBV 6-1 TRBJ 1-1) from the human sequence was 
inserted as the vector contains a murine cp region already, designed to be spliced to the 
VJ region during mRNA processing to produce a full-length TCR chain gene. As the 
human VJ region was amplified from cDNA, it was necessary to include the beginning 
of the intronic sequence immediately downstream of the J region, to allow correct 
splicing to occur. Restriction sites that were used to create the VJ-intron sequence and 
to clone the sequence into pTI3cass are shown, along with the position of the bacterial 
sequence required for the propagation of the construct in bacterial culture. 
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3.2.3 Summary 
To summarise, seven constructs were produced for use in the retroviral transduction 
system: 
• MFG (TCR A10(2) a 5-D4) 
• MFG (TCR A10(2) a 7-D3) 
• MFG (TCR A10(2) (3) 
• MFG (TCR D3(3) a) 
• MFG (TCR D3(3) (3) 
• MFG (TCR CIR010 a murine Ca) 
• MFG (TCR CIR010 R  murine C(3) 
Seven constructs were produced for use in the Amaxa transduction system: 
• pTacass (TCR A10(2) a 5-D4) 
• pTacass (TCR A10(2) a 7-D3) 
• pT13cass (TCR A10(2) 13) 
• pTacass (TCR D3(3) a) 
• pTi3cass (TCR D3(3) (3) 
• pTacass (TCR CIR010 a) 
• pTkass (TCR CIR010 
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3.3 	Transduction of the TCR-negative murine thymoma line BW7 with TCR 
3.3.1 Retroviral transduction of BW7 with TCR 
3.3.1.1 Overview of the retroviral transduction system 
A retroviral transduction system allows stable expression of a gene of interest in a cell 
type where it is not endogenously found. The system used here (shown as a diagram in 
Figure 3.55) was first described by Pear et al. (613). It employs a packaging cell line 
known as EcoPhoenix. The Phoenix line contains two stably integrated retroviral 
constructs — one that encodes and expresses the gag-pol structural genes but contains a 
mutated env gene that cannot produce envelope protein, and a second construct that 
contains a mutated gag-pol region and thus only expresses the env gene. Both constructs 
are engineered to lack a packaging signal that controls construction of functional viral 
particles from their individual components, thus preventing the production of functional 
retrovirus without the addition of this packaging signal. The signal is supplied via 
transfection with a third plasmid, also containing an extra gene of interest. Upon 
transfection, the cells produce retrovirus containing the gene of interest; subsequent 
infection of a target cell line leads to stable expression of the gene in the target cells as 
the DNA from the construct is integrated into the host cell chromosomes by the action 
of the retrovirus. The constructs that are part of the packaging cell line are not 
transmitted hence the retrovirus produced is replication-deficient. 
The infectivity of the retrovirus produced by a particular packaging line is dependent 
upon the envelope protein that it expresses. The four main types of packaging line —
ecotropic, amphotropic, dualtropic and pantropic - increase in the number of species and 
cell types that they can infect from ecotropic to pantropic. Table 3.8 shows the different 
types of packaging line and the envelope proteins that they express, as well as the 
receptors on their target cells that they interact with. This determines the target species 
they can infect. 
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Figure 3.55 Outline of the basis of the Phoenix retroviral transduction system 
(reference 613) This system allows expression of a gene in a cell type where it would 
not normally be found. The retroviral vector contains both the gene of interest (or target 
gene) and also a packaging signal, T+, that is crucial for the correct packaging of virus 
into infectious particles. This vector is then transfected into a packaging cell line using 
one of a number of methods, such as calcium phosphate transfection, electroporation of 
the use of cationic lipids (` lipofection'). Packaging cell lines have been engineered to 
contain stably transfected genes for the structural gag, pol and env genes of a particular 
retrovirus (the Phoenix system makes use of the Moloney murine leukaemia virus or 
MoMuLV), but they lack the packaging signal V. This signal is provided by 
transcription and translation of the retroviral vector, and is recognized by the viral 
proteins produced in the cell, upon which the proteins are packaged into viral particles 
which include the target gene. These particles bud off from the cell membrane into the 
cell growth media, which can then be harvested and used for the infection of target 
cells. 
245 
      
Envelopes 
   
         
 
Target cells 
  
Ecotropic Amphotropic Dualtropic Pantropic 
(gap70)4270AL10A1)ky8y-G 
 
      
      
 
Rodent (rat, mouse) 
Human 
Other mammalian cell 
types 
Avian 
Fish 
Insect 
       
          
          
Table 3.8 	Packaging cell line types Packaging cell lines are defined by the viral 
envelope protein that they express, as this determines the range of cell types that the 
virus they produce can infect. Ecotropic virus has the most limited range of infectivity, 
as the env protein that it expresses, gap70, is a rodent-specific protein, only capable of 
infecting rat or mouse cells through the rodent receptor protein mCAT-1 found on the 
target cell membrane. Amphotropic and dualtropic viruses have a wider range of 
infectivities, encompassing most mammalian cell types, including rodent cells. They 
express different envelope proteins — the amphotropic env protein, 4070A, binds to the 
mammalian receptor protein RAM1 (Pit2), whilst the dualtropic env protein, 10A1, is 
capable of not only binding to RAM1 but also another mammalian target, GALV (Pit1). 
This increases its range of potential target cell types over the amphotropic virus, as it 
may be able to infect cell types on which RAM1 is expressed at a very low level 
through its second target receptor. Pantropic virus is capable of infecting not only 
mammalian but also some avian, fish and insect cell lines, giving it by far the widest 
range of infectivities. This is achieved through its env protein, VSV-G, which does not 
target a specific protein receptor, but rather lipid components of the plasma membrane 
such as phosphatidylserine or phosphatidylinositol, which are components of cell 
membranes of most cell types. VSV-G is toxic to the packaging line that expresses it, 
and as such it is not stably transfected into the line as in the other packaging lines but is 
instead co-transfected with the retroviral vector encoding the packaging signal and the 
target gene. 
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Examples of previous use of the Phoenix system include investigation of the effects on 
NK-T cell lineage of overexpression of a transcriptional regulator, Id3 (inhibitor of 
DNA binding protein 3), in haematopoietic progenitor cells (614). It has also been used 
to investigate the role of a T cell adaptor protein, SKAP55 (Src kinase associated 
phosphoprotein of 55 kDa) in adhesion and immune complex formation between T cells 
and antigen-presenting cells (615), as well as the effect of transduction of myelin basic 
protein-specific autoreactive T cells with a Thl cytokine antagonist, the p40 subunit of 
IL-12, in the EAE model in mice (616). 
3.3.1.2 Retroviral vectors 
Vectors are available containing the necessary retroviral components and the capacity to 
incorporate a gene of interest. The vector selected for use in this system was MFG 
(Figure 2.1), and the production of constructs containing the TCR genes of interest 
inserted into MFG has been previously described in Section 3.2.1. MFG was chosen for 
use as it lacks a self-inactivating mutation that is often present in other retroviral vectors 
and which allows it to be used in a system requiring the use of packaging lines in series, 
allowing the second packaging line to produce infectious retroviral particles. 
3.3.1.3 Optimisation of the system using eGFP 
The intrinsically fluorescent protein eGFP was used when designing this system as it 
could be easily analysed by flow cytometry. The success of individual steps of the 
protocol could also be monitored on a fluorescent microscope. An initial protocol was 
designed to discover the best conditions for transduction of BW7. A second target line, 
NIH3T3, the 'gold standard' cells for optimising retroviral transduction systems, was 
used as a marker of transduction efficiency. Initial parameters tested included original 
plating density of the EcoPhoenix cells before transfection and the retroviral vector used 
(MFG or pQC). Efficiency of infection was compared between BW7 and NIH3T3 cells 
when infected directly with supernatant harvested from EcoPhoenix cells, or when 
infected with supernatant harvested from the dualtropic line PT67 that had been infected 
with EcoPhoenix supernatant. The initial protocol followed is shown in Table 3.9. 
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until analysis by 
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Table 3.9 	A simple representation of the retroviral system being tested On day 
0, EcoPhoenix cells were plated in 25 cm2 tissue culture flasks at densities of 0.5, 1 and 
1.5 x 106 24 hours prior to transfection on day 1. Cells were incubated with 25 1,1A4 
chloroquine for 30 minutes before transfection if required, and transfection mixes 
containing 10 lug of the relevant retroviral vector were prepared. This mix was added to 
the cells, which were then incubated at 37°C and 5% CO2, and the mix was removed 
after 8 hours (to prevent damage to the cells from the toxic chloroquine). Supernatant 
was harvested from the cells 48 hours after transfection and used to infect one of three 
target lines — NIH3T3, BW7, the ultimate target line, and a second packaging line, 
PT67. NIH3T3 and PT67 cells were plated at a density of 1 x 105 cells 18 hours before 
infection. In each case, infection occurred in the presence of 4µg/ml polybrene — PT67 
cells were infected using undiluted supernatant, whilst NIH3T3 and BW7 cells were 
infected with supernatant diluted to 1 in 10. BW7 cells were infected by spinoculation' ; 
cells were centrifuged in the presence of polybrene and retroviral supernatant for 90 
minutes at 2000 rpm at 32°C. All cells were then incubated at 37°C and 5% CO2. Target 
cells were then grown normally until they were analysed by FACS. Retroviral 
supernatant from the PT67 line was harvested after 72 hours and used to infect NIH3T3 
cells (plated 18 hours previously) and BW7 cells as before. Cells were harvested 48 
hours after the second infections and analysed by FACS. 
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Figure 3.56 shows the results obtained using the protocol outlined in Table 3.9 and the 
retroviral vector pQC(eGFP). Cells were analysed for eGFP expression by flow 
cytometry 48 hours after infection. It was apparent that EcoPhoenix supernatant derived 
using pQC(eGFP) was unable to infect BW7 cells under any of the conditions tested, 
despite infecting the NIH3T3 cells to a maximum of 21.7% when using the highest 
original density of EcoPhoenix cells. This in itself was not optimal as transduction 
levels of over 70% should be achieved in NIH3T3 cells. In addition, as expected when 
using packaging lines in series with this vector, no transduction of the target line is 
seen, hence pQC is not a useful vector for use in this system. As EcoPhoenix 
supernatant appears to be unable to infect BW7 cells directly, a serial system of 
packaging lines would be required, precluding the use of pQC in the system. 
Figure 3.57 shows the results obtained using the protocol in Table 3.9 using only the 
highest original density of EcoPhoenix cells (1.5 x 106) and comparing the efficiency of 
infection using MFG(eGFP) with that of pQC(eGFP). The results here were more 
encouraging; whilst EcoPhoenix supernatant was unable to infect BW7 cells directly 
using MFG as the transfected vector, the serial system involving both EcoPhoenix and 
PT67 led to 23.9% infection of the target line BW7 with eGFP. The corresponding level 
of NIH3T3 cell infection was 57.9%, a level close to what is considered to be optimal. 
It appears that the system involving transfection of EcoPhoenix cells with the retroviral 
vector MFG, using EcoPhoenix supernatant to infect a second packaging line, PT67, 
and using the resulting supernatant from this line to infect BW7, results in successful 
transduction of the target line. Whilst 23.9% is considerably lower than the 'optimal' 
level of transduction of approximately 70%, it is significant and should allow for 
successful transduction of BW7 cells with TCR genes. 
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Figure 3.56 Transduction of the target lines BW7 and NIH3T3 with eGFP using 
pQC(eGFP) and retroviral supernatant harvested from the EcoPhoenix packaging 
cell line or the PT67 packaging cell line Transductions occurred according to the 
protocol outlined in Table 3.9. The PT67 packaging line was transduced with the eGFP 
gene through infection with EcoPhoenix supernatant as this was determined to be the 
best way to achieve transduction in this line. EcoPhoenix supernatant alone could not 
transduce the BW7 line with eGFP, despite successfully transducing the NIH3T3 line 
with eGFP at the highest original plating density. Using the serial transduction system 
with PT67 was unsuccessful in transducing either line with eGFP using this vector. 
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Figure 3.57 Transduction of the target lines BW7 and NIH3T3 with either 
pQC(eGFP) or MFG(eGFP) using retroviral supernatant harvested from the 
EcoPhoenix packaging cell line or the PT67 packaging cell line Transductions 
occurred according to the protocol outlined in Table 3.9. The original density of 
EcoPhoenix cells was 1.5 x 106. The PT67 packaging line was transduced with eGFP 
through infection with EcoPhoenix supernatant as before. EcoPhoenix supernatant alone 
could not transduce the BW7 line with eGFP using either vector, despite both vectors 
successfully transducing the NIH3T3 line with eGFP at the highest original plating 
density. Using the serial transduction system with PT67 was successful in transducing 
both target lines with eGFP only when using the vector MFG. 
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An additional experiment, shown in Figure 3.58, investigated the persistence of the 
target gene expression over the first 96 hours following infection. Retroviral 
transduction can give rise to stable integration of the target gene into the host cell 
chromosomes, but if this does not occur, transduction is transient as the plasmid is 
eventually lost from the cells or not transferred during cell division so that transduced 
cells become an increasingly smaller population within the culture. NIH3T3 cells were 
transduced with eGFP using the conditions previously found to give the highest level of 
transduction of this line, and cells were analysed by flow cytometry at 24 hour intervals 
starting 24 hours after infection until 96 hours after infection. At 24 hours after 
transduction, 79.00% of NIH3T3 cells were expressing the eGFP gene, and this level of 
transduction persisted for the course of the experiment, with approximately 80% of cells 
showing expression of eGFP throughout. This suggests that the transduction of target 
cells using this system is stable, as no decrease in target gene expression was seen in the 
days after the infection. A transiently transduced line would be expected to show a 
gradual decrease in target gene expression during the same time frame. 
A modified protocol was designed for use in transducing BW7 with TCR genes, as 
shown in Table 3.10. This protocol incorporated the conditions that gave the highest 
level of BW7 transduction with eGFP, including using the serial system with both 
EcoPhoenix and PT67 packaging lines, using the highest original plating density of 
EcoPhoenix and using the MFG retroviral vector. 
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Figure 3.58 eGFP expression in NIH3T3 cells transduced according to the 
optimised retroviral transduction system outlined in Table 3.9 The top panels show 
the forward scatter-side scatter properties of NIH3T3 cells, and the gate that 
corresponds to live NIH3T3 cells. The top right-hand panel shows fluorescence in the 
FL1 (green) channel of untransduced NIH3T3 cells, showing that NIH3T3 cells have no 
intrinsic fluorescence in this channel, as demonstrated by the lack of cells in the M2 
region (corresponding to eGFP-transduced cells in the lower panels). The lower panels 
show the level of eGFP expression in transduced NIH3T3 cells. Expression was 
analysed by flow cytometry 24, 48, 72 and 96 hours after the final infection with 
supernatant from PT67 cells. The initial level of eGFP expression in NIH3T3 cells at 24 
hours was 79%, indicating that the system being used was capable of achieving high 
levels of transduction in these cells. Over the four time points, expression of eGFP in 
this line remained steady at approximately 80% (the percentage of cells from gate R1 in 
M2), suggesting that transduction of the cells was stable. 
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EcoPhoenix PT67 	I Target cell — BW7_1 
Day I I I 
0 Plate cells at density of 
1.5 x 106 
1 Transfect cells with 
10[Ag MFG, using 
calcium phosphate, in 
the presence of 25 IAM 
chloroquine for 8 hours 
2 Plate cells at density of 
1 x 105  
3 Collect retroviral 
supernatant and infect 
target cells 
Infection with 
retroviral supernatant —
undiluted — in the 
presence of 4[1g/m1 
polybrene 
4/5  
6 
Collect retroviral 
supernatant and infect 
target cells 
Infection with retroviral 
supernatant —1 in 10 
dilution - in the presence 
of 4µg/m1 polybrene 
7 Analyse cells for gene 
expression by FACS 
8 Analyse cells for gene 
expression by FACS 
9 Analyse cells for gene 
expression by FACS 
10 Analyse cells for gene 
expression by FACS 
Table 3.10 The protocol used to transduce the target line BW7 with the D3(3) 
TCR EcoPhoenix cells were plated on day 0 at a density of 1.5 x 106 24 hours prior to 
transfection on day 1. Cells were incubated with 25 [AM chloroquine for 30 minutes 
before transfection, whilst transfection mixes containing 10 [ig of the relevant retroviral 
vector (MFG with TCR chain gene inserted) were prepared. This mix was added to the 
cells, which were then incubated at 37°C and 5% CO2, and the mix was removed after 8 
hours (to prevent damage to the cells from the toxic chloroquine). Supernatant was 
harvested from the cells 48 hours after transfection and used to infect the second 
packaging line, PT67, which had been plated at a density of 1 x 105 cells 18 hours 
before infection. Infection occurred using undiluted supernatant in the presence of 4 
µg/ml polybrene. Retroviral supernatant from the PT67 line was harvested after 72 
hours and used to infect BW7 cells by spinoculation', in the presence of 4 µg/ml 
polybrene, as described previously. Cells were harvested at 24, 48, 72 and 96 hours 
after the second infection and analysed for TCR gene expression by FACS. 
Transfection with eGFP was carried out as a positive control. 
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3.3.1.4 Retroviral transduction of the line BW7 with genes encoding the TCR from 
the PLP56-7o-specific murine T-cell clone D3(3) 
The protocol outlined in Table 3.10 was used to transduce BW7 cells with the retroviral 
constructs MFG (TCR D3(3)a) and MFG (TCR D3(3)(3) (5 [.tg of each). The cells were 
analysed after infection with PT67 retroviral supernatant by flow cytometry. Figure 
3.59 shows the analysis at 48 hours after infection. The cells were stained with two 
antibodies — the first an antibody specific for the D3(3) TCR chain V region, FITC-
conjugated anti-V(34-antibody (V(34 corresponds to the IMGT TRBV 2). The second 
antibody was a general PE-conjugated anti-TCR CP region antibody, which should be 
capable of recognising any expressed ot(3 TCR. As shown in Figure 3.59, a slight shift in 
fluorescence intensity is seen when staining TCR-transduced BW7 cells with the anti-
V134 antibody as compared with untransduced cells stained with the same antibody. This 
may suggest that a small number of BW7 cells have been successfully transduced with 
the D3(3) TCR. Staining with the anti-TCR C(3 antibody gives a much less clear answer 
— as the lower left-hand panel of Figure 3.59 shows, even in untransduced BW7 cells, 
there is a high level of staining with this antibody. As the cell line does not express TCR 
endogenously, this staining is likely to be non-specific binding to the cells. In the TCR-
transduced lines, the peak of staining with this antibody appears to shift backwards 
when compared to the untransduced cells, which is unexpected, as TCR expression 
would be expected to increase antibody staining. Due to the high level of non-specific 
staining seen with this antibody, however, it is unlikely that any specific staining would 
be obvious, particularly if the level of transduction is low, as suggested by the anti-V(34 
staining. As a difference between the transduced and untransduced cells can be seen 
using the antibody that is specific to the D3(3) TCR, this antibody was used in further 
analysis of D3(3) TCR-transduced lines. 
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Figure 3.59 Expression of TCR D3(3) on transduced BW7 Using an anti-V(3 4 
FITC-conjugated antibody, which is specific for the D3(3) TCR, and a general anti-
TCR Cf3 PE-conjugated antibody, the expression of TCR on BW7 cells transduced with 
MFG plasmid encoding the D3(3) TCR a and f3 chain genes was analysed by flow 
cytometry. The top histogram shows anti-V(3 4 staining on untransduced BW7 (filled 
histogram) overlaid with anti-VP 4 staining on TCR D3(3) transduced BW7 (open 
histogram). A very slight shift in fluorescence can be seen. The bottom panels show 
anti-TCR Cf(3 staining on untransduced BW7 (right-hand panel) and TCR D3(3) 
transduced BW7 (left-hand panel). The high fluorescence intensity of staining shown in 
the untransduced, TCR-negative BW7 cells suggests a high level of non-specific 
staining — a shift in the pattern of staining is seen in the transduced cells, but rather than 
increasing staining intensity, as would be expected if cells were successfully 
transduced, the staining appears to have decreased in intensity. Antibodies used in 
staining are shown in Appendix 7. 
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As the level of transduction suggested by the anti-V(34 staining is very low, the 
transduced line was cloned by limiting dilution, and individual clones were analysed by 
staining with the same anti-V(34 antibody after 14 days of growth. Figure 3.60 shows 
the analysis for two representative clones, A6(4) and A5(4). When analysing the culture 
as a whole (as shown in the FL-1 histograms marked 'No gate'), it appeared that in both 
clones there were two populations of cells, one staining with the antibody and one not 
i.e. there was a transduced population of BW7 cells expressing the D3(3) TCR. 
However, when looking at a forward scatter vs. side-scatter dot plot of BW7 cells (as 
seen in the top right-hand panel), there are two clear populations of cells in the culture, 
labelled R1 and R2. R1 is the region thought to correspond to live cells in the culture, 
whilst R2 is thought to contain predominantly dead or dying cells. When these regions 
were applied as gates to the two clones, shown in the lower panels of Figure 3.60, it was 
seen that the WP4-positive' population was only found in R2, and not the live region 
R1. As such, the increase in fluorescence was more likely to come from the natural 
autofluorescence seen in dead or dying cells. 
It is possible that successful transduction of the cells with a target gene could alter the 
forward scatter-side scatter characteristics of the cells such that they might appear in the 
region associated with dead or dying cells. D3(3) transduced BW7 cells were stained 
with propidium iodide (PI), a stain that is taken up by dead cells, causing them to 
fluoresce in the FL-2 (red) channel. The two populations R1 and R2 were then analysed 
individually, as shown in Figure 3.61a. In both populations, there was a certain 
proportion of PI-positive cells, 46.7% in R1 and 89.7% in R2. The staining seen in 
population R1, the 'live' gate, could be due to a slight overlap between the populations. 
The much higher proportion of PI-positive cells in R2 confirms that this population 
consists primarily of dead and dying cells. However, as not all cells in R2 stained with 
PI (again, this could possibly be due to overlap with R1 or due to the presence of live 
cells in R2), there was a possibility that the non-staining and therefore alive cells could 
be the TCR-transduced cells. Figure 3.61b shows the same culture of cells stained with 
both PI and the FITC-conjugated anti-V(34 antibody, again analysed as separate 
populations. PI staining was only seen in population R2, whilst little anti-VP4 staining 
was seen in either population; however, there appeared to be a slight increase in this 
staining seen in population R2, suggesting that the TCR-transduced cells might be 
found in this region. 
257 
201000 020 
1;P 	,o2 	v03  
F11.11 
R2 
A5(4) 
201000 010 
No gate 
A6(4) 
No gate 
sm 
R1 
201C06.020 
10 
111-11 
Figure 3.60 Analysis of TCR D3(3) expression in clones derived from the D3(3) 
transduced BW7 line Analysis was carried out using a D3(3) TCR specific anti-V(34 
antibody conjugated to FITC (FL-1 channel). The top panel shows a representative 
forward scatter vs side scatter dot plot for these cells (right-hand side) and a diagram 
defining the populations R1 and R2 (left-hand side). Two clones, A6(4) (left-hand 
panels) and A5(4) (right-hand panels), derived from limiting dilution of the original 
transduced line are shown in the lower panels. Data was initially obtained on samples 
with no gate applied i.e. every cell shown in the dot plot in the top panel was counted 
and analysed as shown in the histograms labelled 'no gate'. In each case, there appears 
to be a population of cells staining positively for the antibody. When the cells in each 
region, R1 and R2, are analysed separately however (lower panels), it can be seen that 
the 'positive' population is found in region R2, the region found to contain dead and 
dying cells, and so this staining is likely to be an artefact. Antibodies and chemicals 
used in staining are shown in Appendix 7. 
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Figure 3.61 Characterisation of the disparate BW7 populations defined on the 
basis of their light scattering properties. As can be seen in the left-hand panel of a, 
BW7 cells in a typical forward-scatter vs side-scatter plot divide into two distinct 
populations (labelled R1 and R2). When staining untransduced BW7 cells with the cell 
death marker propidium iodide, which is detected in the red fluorescence channel FL-2, 
and gating on and compensating for each population separately, as shown in the right-
hand panels of a, there is a higher proportion of PI staining in R2 than R1 (89.7% of 
cells are in the upper left quadrant in the R2 plot compared with only 46.7% in the 
corresponding quadrant in the R1 plot).This suggests that the region R2 corresponds to 
dead or dying cells, whose light-scattering properties have changed accordingly. 
Staining both populations in TCR transduced BW7 for specific vp region or PI is 
shown in b. D3(3) transduced BW7 (open histograms, each histogram corresponds to an 
independent transduction) are compared with untransduced BW7 (filled histograms). In 
region R1, containing live cells, there is little PI staining in any line, and there is no 
increase in anti-V13 staining, suggesting transduction has failed. In region R1, 
containing the majority of dead cells, whilst there is, as expected, an extensive amount 
of PI staining, there is also a potential increase in staining with the anti-VP antibody in 
the transfected lines. All antibodies and chemicals used in staining are shown in 
Appendix 7. 
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In order to finally confirm if retrovirally transduced BW7 cells did change their forward 
scatter-side scatter characteristics such that they then appeared in the R2 population of 
dead and dying cells, eGFP transduced cells were stained with PI and analysed as 
described above, and as shown in Figure 3.62. The populations R1 and R2 were 
analysed separately. The lower panels of the figure show FL1 (corresponding to eGFP 
fluorescence) and FL2 (corresponding to PI fluorescence) dot plots of the two 
populations (R1 on the left, R2 on the right). PI-positive cells are those in the upper two 
quadrants of the dot plots, eGFP-positive cells are those in the right-hand quadrants. 
Although the level of eGFP expression in these lines was low (only 3%), this was a high 
enough level to show that eGFP-positive cells were only seen in population R1, in the 
lower right-hand quadrant of the plot. No corresponding eGFP-positive population was 
seen in the lower right-hand quadrant of the dot plot for population R2. This therefore 
suggests that the process of retroviral transduction does not in itself alter the light-
scattering properties of the cells, and transduced cells reside in the region corresponding 
to live cells. The apparent increase in fluorescence intensity seen in R2 in TCR-
transduced lines is therefore likely to be due a non-specific staining artefact, although it 
cannot be ruled out that transduction with a construct leading to the expression of a 
surface TCR might change the properties of the transduced cells in a different way to 
intracellular eGFP expression. 
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Figure 3.62 eGFP expression in disparate populations of transduced BW7 cells 
The top left-hand panel shows the definition of the two populations, RI and R2, 
according to their light-scattering properties; a representative dot plot is shown in the 
top righthand panel. The lower panels show FL1 vs FL2 dot plots obtained from an 
eGFP-transduced BW7 line, gating on and compensating for R1 (green, right) or R2 
(pink, left). The lower right quadrant of each plot shows the live, eGFP-transduced 
cells. In R2, 3.01% of BW7 cells are positive for eGFP; in R3, this figure is 
negligible, suggesting that transduced BW7 are found in the same population as live 
untransduced cells, and their physical properties (size and granularity) are not affected 
by the process of transduction itself. 
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3.3.1.5 Use of a modified retroviral transduction protocol to transduce the line 
BW7 with genes encoding the TCRs from the PLP56-7o-specific murine T-
cell clones A10(2) and D3(3) 
As the previous protocol appeared to be unable to successfully transduce BW7 cells 
with TCR genes, a new protocol was designed with the help of Dr. Hongyan Wang, 
Imperial College, London, based on the protocol she had determined to be optimal for 
the transduction of cell lines using the Phoenix retroviral packaging system, and then 
adapted to accommodate the use of the second packaging line, PT67, after initial 
transfection of the EcoPhoenix line with the MFG retroviral constructs. The protocol is 
shown in Table 3.11, and involves infecting the target line BW7 on four successive days 
with retroviral supernatant from the PT67 line. In order to achieve this, two rounds of 
transfection of EcoPhoenix (newly re-selected cells provided by Professor Julian Dyson 
were used to ensure optimum levels of transfection and retrovirus production) occurred 
two days apart using a total of 20 txg of vector for each transfection. Supernatant was 
collected on two occasions, at 36 and 60 hours after initial transfection, and used to 
infect PT67 cells (also newly re-selected). Supernatant harvested from the first 
transfection of EcoPhoenix cells was used to infect one culture of PT67 cells, and 
supernatant from the second transfection was used to infect a second culture of PT67 
cells. Supernatant was then collected from PT67 cells at 48 and 72 hours after infection 
and used to infect BW7 cells. In contrast to the previous protocol, all infections were 
carried out using undiluted supernatant. In addition, the spinoculation' used for the 
infection of BW7 cells was modified to be less harsh — the previous procedure led to a 
high level of cell death, and a reduced yield of cells for flow cytometric analysis. The 
new procedure involved spinning cells at a lower speed for less time, yielding a higher 
level of cell survival after infection. 
The new protocol was initially tested using eGFP transduction in both BW7 and 
NIH3T3 cells. The results are shown in Figure 3.63 for both cell types (NIH3T3 in the 
upper panels, BW7 in the lower panels). Use of the new system yielded 65.5% 
transduction of NIH3T3 cells at 24 hours after the final infection, compared with 19.5% 
transduction of BW7 cells (subsequent transduction using eGFP showed expression in 
up to 44.5% of BW7 cells). These levels are higher than those seen initially using the 
first optimised protocol, and so this protocol appeared to be more efficient in 
transducing the line BW7. 
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EcoPhoenix 	I PT67 	I Target cell — BW7 	I 
Day 	I I I I 
0 	I Plate cells at density of 1 x 106 
1 Transfect cells with lOgg 
retroviral vector, using calcium 
phosphate, in the presence of 25 
gM chloroquine for 8 hours 
Plate cells at density of 1 x 105  
2 Plate cells at density of 1 x 106 
Collect retroviral supernatant and 
infect target cells 
Infection with retroviral 
supernatant — undiluted — in 
the presence of 4µg/m1 
polybrene 
3 Transfect cells with lOgg 
retroviral vector, using calcium 
phosphate, in the presence of 25 
1JM chloroquine for 8 hours 
Collect retroviral supernatant and 
infect target cells 
Infection as on day 2 
Plate cells at density of 1 x 105 
4 Collect retroviral supernatant and 
infect target cells 
Infection as on day 2 
5 Collect retroviral supernatant and 
infect target cells 
Infection as on day 2 
Collect retroviral supernatant 
and infect target cells 
Infection with 
retroviral supernatant —
undiluted - in the 
presence of 4µg/m1 
polybrene 
6 
Collect retroviral supernatant 
and infect target cells 
Infection as on day 5 
7 Collect retroviral supernatant 
and infect target cells 
Infection as on day 5 
8 Collect retroviral supernatant 
and infect target cells 
Infection as on day 5 
9-12 Analyse cells for gene 
expression by FACS 
Table 3.11 The modified protocol used to transduce the target line BW7 with 
the D3(3) and A10(2) TCRS Newly re-selected EcoPhoenix cells were plated on day 0 
and day 2 (shown in blue) at a density of 1 x 106 cells 24 hours prior to transfection on 
day 1 or day 3. Cells were incubated with 25 [IN4 chloroquine for 45 minutes before 
transfection, whilst transfection mixes containing 20 jAg of the relevant retroviral vector 
were prepared and left to stand at room temperature for at least 30 minutes. This mix 
was added to the cells, which were then incubated at 37°C and 5% CO2, and the mix 
was removed after 8 hours. Supernatant was harvested from the cells 36 hours after 
transfection (on days 2 and 4) and used to infect the second packaging line, PT67, 
which had been plated at a density of 1 x 105 cells 18 hours before infection (on days 1 
and 3). A second collection of EcoPhoenix supernatant occurred 60 hours after 
transfection and used to infect the same culture of PT67 as the first supernatant. 
Undiluted supernatant was used for infection in the presence of 4 pg/ml polybrene. 
Supernatant from the PT67 cultures was harvested 72 and 96 hours after initial infection 
and used to infect BW7 cells — cells were centrifuged at 1800 rpm for 30 minutes at 
room temperature in the presence of 4 µg/ml polybrene. Cells were harvested 24, 48, 72 
and 96 hours after the final infection and analysed for TCR gene expression by FACS. 
Transfection with eGFP was carried out as a positive control. 
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Figure 3.63 eGFP expression in NIH3T3 and BW7 cells transduced according to 
the modified retroviral transduction system outlined in Table 3.11 The top panels 
show the level of eGFP expression (65.5%) in transduced NIH3T3 cells (right-hand 
panel) when infected by supernatant from PT67 cells, 24 hours after the final infection. 
Forward scatter-side scatter properties of NIH3T3 cells, and the gate that corresponds to 
live NIH3T3 cells are shown in the left-hand panels. The lower panels show the level of 
eGFP expression in transduced BW7 cells, as a comparison with the level of 
transduction obtained in the 'gold standard' line NIH3T3. Expression of eGFP 24 hours 
after the final infection with supernatant from PT67 cells was at 19.5% in these cells. 
Whilst being only approximately one-third of the level achieved in NIH3T3 cells, this is 
nonetheless a reasonable level of transduction. 
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This protocol was then used to transduce the BW7 cells with the TCR from the clone 
D3(3) (in this case, 10 lug of a construct and 10 1.tg of (3 construct were used making a 
total of 20 ug retroviral construct per transfection). Flow cytometric analysis of the cells 
24 hours after the final infection is shown in Figure 3.64. TCR transduced cells were 
stained with FITC-conjugated anti-V(34 antibody as before (upper left-hand panel). 
Transduction with eGFP is shown as a comparison (upper right-hand panel). As can be 
seen for the TCR-transduced cells, there is a small shift in the fluorescence intensity of 
the anti-V(34 staining in the transduced cells compared with the untransduced cells. The 
shift is not large, but is greater than that seen when using the original protocol, 
suggesting that this system may have allowed successful transduction of the line BW7 
with the D3(3) TCR. The lower panel in Figure 3.64 shows the same transduced line, 
again stained with anti-V134 antibody, 15 days after the final infection with retroviral 
supernatant. A similar shift in fluorescence intensity is seen, suggesting that 
transduction is stable. 
The same protocol was then used to transduce the BW7 cells with the two possible 
TCRs from the clone A10(2) (either the TCRa 5-D4 or TCRa 7-D3 chain with the 
common TCR(3 chain). Figure 3.65 shows the flow cytometric analysis of the cells 24 
hours after the final infection. TCR transduced cells were stained with FITC-conjugated 
anti-V(313 antibody (V(313 corresponds to the IMGT-defined TRBV 14) as shown in the 
left-hand panels of the figure, with TCRa 5-D4 TCR(3 being shown in the upper panel 
and TCRa 7-D3 TCRP being shown in the lower panel. Transduction with eGFP is 
shown as a comparison (upper right-hand panel). However, in this case, no positive shift 
is seen for either TCR-transduced line; instead, as was seen with the anti-TCR C13 
antibody used previously on the D3(3) TCR-transduced lines, the peak of staining shifts 
backwards, meaning it is impossible to tell from the staining whether transduction has 
been successful. The anti-V(3 13 antibody, like the anti-TCR Cf3 antibody, appears to 
stain BW7 cells non-specifically to a significant degree. 
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Figure 3.64 Expression of the TCR D3(3) in transduced BW7 cells BW7 cells 
were transduced with the a and (3 chains for the D3(3) TCR according to the protocol 
outlined in Table 3.11. Transduction with eGFP was carried out as a positive control. 
The filled histograms represent untransduced BW7 cells, either unstained (left-hand 
panel) or stained with anti-V(3 4-FITC (right-hand panels), the open histograms 
represent the transduced cells. Expression of eGFP is shown in the left-hand plot as an 
FL1 histogram 24 hours after the final infection, showing that 44.5% of BW7 cells were 
expressing eGFP at this time point, and that the system had worked in this instance. The 
right hand panels show TCR D3(3)-transduced BW7 cells stained with anti-V(3 4-FITC 
as an FL1 histogram. The upper panel shows expression levels 24 hours after the final 
infection. The shift seen is not easily quantifiable as a measure of TCR expression, but 
it indicates that the transduced cells may be expressing TCR to some degree. The lower 
right-hand panel shows expression levels 15 days after the final infection, showing that 
a shift in staining is still appreciable in this line, and suggests that the line may be stably 
transduced with TCR. All antibodies used for staining are shown in Appendix 7. 
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Figure 3.65 Expression of the TCRs A10(2) 5-D4 and A10(2) 7-D3 in transduced 
BW7 cells BW7 cells were transduced with the a and 13 chains for the A10(2) TCRs 
according to the protocol outlined in Table 3.11. Transduction with eGFP was carried 
out as a positive control. The filled histograms represent untransduced BW7 cells, either 
unstained (left-hand panel) or stained with anti-V[3 13-FITC (right-hand panels), the 
open histograms represent the transduced cells, stained as described for the 
untransduced cells. Expression of eGFP is shown in the left-hand plot as an FL1 
histogram 24 hours after the final infection, showing that 19.4% of BW7 cells were 
expressing eGFP at this time point, and that the system had worked in this instance. The 
right hand panels show TCR A10(2)-transduced BW7 cells stained with anti-V(3 13-
FITC as an FL1 histogram. The upper panel shows expression levels 24 hours after the 
final infection in the cells transduced with TCR A10(2) 5-D4. The lower right-hand 
panel shows expression levels 24 hours after the final infection in the cells transduced 
with TCR A10(2) 7-D3. It is impossible to tell from these plots whether transduction of 
the cells with TCR has been successful as the fluorescence has shifted downwards. 
Untransduced BW7 cells do not express any TCR, and so the staining seen here is non-
specific in nature — the fact that the staining has changed suggests something has 
happened in the transduced cells but gives no evidence of this being TCR expression. 
All antibodies used for staining are shown in Appendix 7. 
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Figure 3.66 investigates the extent to which the staining seen in the TCR-transduced 
BW7 lines is non-specific. Transduced and untransduced BW7 were stained with both 
the specific anti-V(3 antibody and the corresponding FITC-conjugated isotype control 
(rat IgG2b for the anti-V(34 antibody and mouse IgG1 for the anti-V(313 antibody). 
Specific antibody staining was then overlaid with the isotype control staining and 
compared. In both the D3(3) TCR-transduced line and the A10(2) TCR-transduced 
lines, the staining with isotype overlapped with the specific antibody staining. The only 
difference seen was that whilst with untransduced BW7, the isotype for the anti-V(34 
antibody seemed to stain more strongly than the specific antibody, the staining 
overlapped fully in the D3(3) TCR-transfected cells i.e. there was a shift in anti-V(34
staining between untransduced and TCR-transduced cells, whilst the isotype staining 
remained the same. However, the shift in specific antibody staining did not increase the 
intensity of the fluorescence beyond that seen with the corresponding isotype. It is 
therefore possible that there is no transduction with TCR in this line. 
An alternative approach to detect successful transduction of BW7 cells with the TCRs 
from T-cell clones D3(3) and A10(2) 7-D3 involved carrying out PCRs probing for the 
presence of the TCR genes in both genomic DNA (for detection of insertion into the 
cell genome) and cDNA (for detection of mRNA expression of the TCR genes within 
the cell). The primers used to determine if there had been successful transduction of the 
TCR genes were those that were originally used in the cloning of these sequences into 
the pQC vectors by Dr. Alexander Annenkov, and they amplified from the beginning of 
the V region to just into the C region and are shown, along with PCR conditions, in 
Appendix 3. Genomic DNA and cDNA from untransduced BW7 cells was also assayed 
to serve as a negative control. As shown in Figure 3.67, PCR analysis showed that the 
TCRa chains from both D3(3) and A10(2) 7-D3 were both present in the cDNA 
products (and in the case of A10(2) 7-D3 also integrated into the host cell genomic 
DNA). Analysis of TCRI3 chain expression in these cells was inconclusive. This result 
suggests that B W7 cells may have been in some cases positively transduced with the 
genes encoding at least the TCRa chains. This suggests that the transduction system 
itself is capable of transferring the constructs into the target cells, and the lack of 
apparent expression at the cell surface may either be due to a failure in expression at the 
cell surface or that the high apparent levels of non-specific antibody staining in these 
cells prevents specific detection of the TCRs using flow cytometry. 
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Figure 3.66 Comparison of specific anti-VD antibody staining with isotype 
controls in TCR-transduced and untransduced BW7 To investigate the extent of 
non-specific staining that occurs on BW7 cells, cells were stained either with the 
specific VI3 antibody (FITC-conjugated) or the corresponding FITC-conjugated isotype. 
(a) Staining of untransduced BW7 with the TCR D3(3) specific anti-V(3 4-antibody or 
the rat IgG2b isotype (left-hand panel) shows that a higher level of staining occurs with 
the isotype as shown by the small shift upwards in fluorescence intensity. Staining of 
the transduced line with these antibodies (right-hand panel) shows almost total overlap 
between the antibody and its isotype, suggesting that all staining seen is non-specific 
and not due to TCR expression. (b) Staining of untransduced BW7 with the TCR 
A10(2) specific anti-Vp 13-antibody or the mouse IgG1 isotype (left-hand panel) shows 
a very similar pattern of staining for both, suggesting that any staining is non-specific in 
nature. Staining of the transduced line with these antibodies shows total overlap 
between the antibody and its isotype, suggesting that all staining seen is non-specific 
and not due to TCR expression. All antibodies used for staining are shown in Appendix 
7. 
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Figure 3.67 Agarose gel images of the PCR products obtained when analysing 
D3(3) and A10(2) 7-D3 TCR-transduced BW7 cells for the presence of specific 
TCRa chain PCRs assaying for the specific VJ region using a forward primer specific 
for the V region (the same forward primer was used for both D3(3) and A10(2) 7-D3 as 
they use V regions with sequence that is identical at the 5' end) and a reverse primer 
specific for the murine region TRAC (the same reverse primer was used for both D3(3) 
and A10(2) 7-D3 as there is only one murine C region) were carried out on both 
genomic DNA and cDNA isolated from the transduced BW7 lines. Genomic DNA and 
cDNA from untransduced BW7 cells was used as a negative control. Band sizes for the 
PCR product were expected to be the same in both genomic DNA and cDNA as the 
genes in MFG were fully rearranged. Expected band size for D3(3), shown in (a), was 
505 bp, and for A10(2) 7-D3, shown in (b), was 495 bp. Primers and reaction conditions 
are shown in Appendix 3. (+RT — cDNA produced in the presence of reverse 
transcriptase, -RT — control cDNA reaction lacking reverse transcriptase), gDNA —
genomic DNA) 
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3.3.1.6 Measurement of TCR expression using the IL-2 dependent cell line CTLL-2 
The BW7 lines transduced with TCRs from the murine T-cell clones A10(2) and D3(3) 
were analysed for evidence of TCR expression through use of the IL-2-dependent cell 
line CTLL-2. The lines were stimulated with PLP56.70, presented by NOD.E APCs; any 
cells expressing the peptide-specific TCR will respond to this stimulation by 
proliferating and by producing the cytokine IL-2. As BW7 is a transformed line, and 
unlike a T-cell line can grow indefinitely in the absence of any peptide stimulation, use 
of the CTLL-2 line gives a better estimation of TCR expression than a proliferation 
assay of the BW7 cells themselves. Supernatant from the stimulated lines was harvested 
from the cells 48 hours after peptide stimulation and added to CTLL-2 cultures to 
investigate the ability of the supernatant to promote survival and proliferation in the IL-
2 dependent line. Any line that had responded to peptide would be expected to have 
produced significant quantities of IL-2 and hence would induce a higher level of 
proliferation in the CTLL-2 cells. The results of the assays are shown in Figure 3.68. 
Untransduced BW7 were also assayed as a comparison, and induced higher levels of 
proliferation in the CTLL-2 cells than any of the transduced lines. BW7 cells appear to 
produce a small amount of IL-2 under baseline conditions, as the counts achieved in the 
untransduced line were much lower than would have been expected for a peptide-
specific response. Of the TCR-transduced lines, none induced a higher level of 
proliferation in the CTLL-2 cells when stimulated with peptide than when left 
unstimulated. The results of the assay therefore suggest that none of the TCR-
transduced lines are expressing TCR as shown by their inability to respond to the 
peptide for which the TCR is specific. 
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Figure 3.68 Proliferation of the IL-2 dependent CTLL-2 line in supernatant 
derived from retrovirally-transduced BW7 lines expressing TCRs from the PLP56-
7o-specific murine T-cell clones A10(2) and D3(3) that had been stimulated with 
PLP 56-70 peptide Assays were carried out independently on two separate occasions. In 
A, three transfected lines (the lines shown in Figures 3.64 and 3.65) were assayed for 
TCR expression through their ability to respond to stimulation with specific peptide, 
measured as stimulation-induced production of IL-2 through the IL-2 dependent line 
CTLL-2. Untransduced cells were also assayed. A positive control for T-cell activation, 
stimulation with ConA (5µg/m1), and a positive control for CTLL-2 proliferation, 
stimulation with 20 U/ml IL-2, were included. Responses of the cells were measured at 
baseline or at a peptide concentration of 25 µg/ml. In B, only the D3(3) TCR-
transfected line (the line shown in Figures 3.64) was assayed, as described in A, except 
that a peptide concentration of 50 µg/ml was used. Responses in all three `TCR-
transduced' lines were significantly lower than for the untransfected line at baseline, as 
well as when stimulated with peptide or ConA in all assays. 
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3.3.2 Transduction of BW7 with TCR genes using the Amaxa Nucleofector 
system 
3.3.2.1 Principles of the Amaxa Nucleofector system 
The Amaxa Nucleofector system is an electroporation-based non-viral method of 
transducing cell lines with a target gene. An expression vector containing a gene of 
interest is transfected into a target cell line using one of the many programmes provided 
by the Nucleofector device. The target cells are also resuspended prior to transfection in 
one of a number of Nucleofector solutions provided by Amaxa which to promote 
transfection. The electrical programme used and the solution in which the cells are 
resuspended is dependent upon the cell type being transfected, but the company does 
not release information about the components of the Nucleofector solutions or details 
about the different programmes that can be used. An extensive database 
(www.amaxa.comJcell-database) provided by Amaxa contains information on the 
optimal conditions for transfecting particular cell types. 
Transfection using the Amaxa Nucleofector system is usually transient, as the plasmid 
constructs transfected into the cells do not integrate into the host cell chromosomes as 
happens in retroviral transduction. However, as the target gene can be transduced 
directly into the target cell line of choice, it is possible to achieve a far higher level of 
initial expression with this system than is achieved with retroviral transduction systems. 
Stable transfection can be achieved with this system, if a linearised construct is used, 
but the extent of transfection in this case is significantly lower than when circularised 
constructs are used. 
Here, I describe my attempts to transduce the BW7 line using the Amaxa system and 
the specialised TCR expression vectors, pTacass and pTr3cass, containing TCRs of 
interest, the production of which were outlined in Section 3.2.2. 
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3.3.2.2 Use of the Amaxa system to transfect BW7 with GFP 
A control vector containing the GFP gene is supplied with all Amaxa Nucleofector kits, 
pmaxGFP (shown in Appendix 29). Transfection of BW7 cells was attempted using this 
vector, which has been specifically designed for use with the Amaxa system. As 
suggested by the Amaxa cell line database for the line BW7, transfection was attempted 
using Nucleofector Solution V, and the programmes T-001 and T-016. Results obtained 
for these conditions are shown in Figure 3.69. Transfected cells were analysed for GFP 
expression by flow cytometry at 24 hour intervals for 3 days after transfection, and then 
at 3 day intervals until 6 days post-transfection (for the programme T-001) or 9 days 
post-transfection (for the programme T-016). Untransfected cells were also analysed as 
a comparison. Both programmes induced GFP gene expression in BW7 cells, 
programme T-001 to a maximum level of 36.07%, whilst programme T-016 induced 
GFP expression to a maximum level of 88.12%. However, this programme induced a 
much higher level of cell death than T-001, so that cells undergoing protocol T-001 
looked healthier than those transfected using T-016. Expression of GFP fell off steadily 
in cells transfected by both protocols, so that by day 6, levels of GFP expression in the 
cells transfected using T-001 had fallen to less than 1%. High levels of GFP expression 
(nearly 30%) were seen in the line transfected by T-016 at this time point, but by 9 days 
after transfection, GFP expression in this line had also fallen to less than 1%. 
Transfection of BW7 cells using this system appears to be transient in nature, but using 
programme T-016, significant target gene expression is seen up to 6 days after 
transfection. 
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Figure 3.69 GFP expression in BW7 cells transduced with the vector pmaxGFP 
using the Amaxa Nucleofector system Amaxa programmes T-001 and T-016 were 
used to transduce BW7 cells according to the manufacturers protocol with 1 I.,tg 
pmaxGFP control vector, and analysed by flow cytometry every 24 hours for the first 
three days, and then every three days until GFP expression was comparable to 
untransduced BW7 cells. The highest level of expression occurred in cells transduced 
using programme T-016, with over 88% of cells expressing GFP (measured as an 
increase in fluorescence in the FL-1 (green) channel compared with untransduced cells), 
compared with maximal expression of over 35% in the cells transduced using 
programme T-001. GFP expression decreased with time, with no expression detectable 
in the cells transduced using programme T-001 by 6 days after initial transfection, and 
no expression in the cells transduced using programme T-016 by 9 days after initial 
transfection, indicating that transduction using the Amaxa system is transient in nature, 
and expression of the transduced gene is rapidly lost from the cells. 
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3.3.2.3 Use of the Amaxa system to transfect BW7 with the TCR from the PLP56-7o-
specific murine T-cell clone D3(3) 
Programmes T-001 and T-016 were used to transfect BW7 cells with the D3(3) TCR 
using the pTacass (TCR D3(3) a) and pT(3cass (TCR D3(3) (3) constructs. Cells were 
analysed by flow cytometry for TCR expression by staining with the D3(3)-specific 
FITC-conjugated anti-V134 antibody at 24 and 72 hours after transfection, as shown in 
Figure 3.70. At 24 hours after transfection, there was no TCR expression apparent from 
the analysis, as anti-V(34 staining was the same in both transfected and sham-transfected 
(i.e. subjected to the same Nucleofector protocol but without the addition of plasmid 
DNA) BW7. Staining at 72 hours after transfection showed the same lack of TCR 
expression, suggesting that the system had failed under these conditions to transfect the 
BW7 cells with genes encoding the D3(3) TCR. 
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Figure 3.70 Specific anti-V13 4-FITC staining to assess TCR D3(3) expression in 
BW7 transduced using the Amaxa Nucleofector BW7 cells were transduced using 
one of the two programmes recommended by the manufacturer for use in transduction 
of this cell line, T-001 or T-016. TCR expression induced through using the programme 
T-001 is shown in a. TCR expression induced through using the programme T-016 is 
shown in b. Expression was assessed at 24 and 72 hours after transduction. 
Untransduced BW7 cells were stained as a negative comparison. At both 24 and 72 
hours, staining of both TCR-transduced and untransduced BW7 cells from both 
programmes was the same, suggesting that transduction had been unsuccessful. All 
antibodies used for staining are shown in Appendix 7. 
277 
3.3.3 Summary 
Two different systems of transduction were used to try to transduce the TCR-negative 
murine thymoma line BW7 with TCRs from the PLP56-7o-specific murine T-cell clones 
A10(2) and D3(3). For retroviral transduction of the lines, a system was used that 
allowed good transduction of the target line BW7 with the gene eGFP. This involved 
the transfection of a series of packaging lines, EcoPhoenix and PT67, with the retroviral 
vector MFG containing the target gene. BW7 cells were transduced with the genes 
encoding the TCRs from clones A10(2) and D3(3), after which TCR expression was 
assessed by flow cytometry, staining for the specific Vr3 region of each TCR. The flow 
cytometry results for the D3(3) TCR, suggested that successful transduction had 
occurred at a low level. However, when the TCR-transduced lines were further assayed 
for their ability to induce proliferation in the IL-2-dependent cell line CTLL-2 upon 
stimulation with the peptide PLP56-7o,  none of the transduced lines were able to induce 
proliferation in the CTLL-2 cells when stimulated with peptide. I was not successful in 
the transduction of TCR using the retroviral system. 
The Amaxa Nucleofector system was then used to transduce the BW7 line with the 
TCRs from the clone D3(3). The system was initially tested for its ability to transduce 
BW7 using the control vector pmaxGFP, and it showed the capacity to transduce BW7 
to a high extent. Constructs encoding the D3(3) TCRa and TCRI3 chains (pTacass 
(TCR D3(3) a) and pT(3cass (TCR D3(3) (3)) were transfected into BW7 cells using this 
system and TCR expression was assessed by flow cytometry, staining for the specific 
vp region of the TCR. No difference in staining was seen between TCR-transduced and 
sham-transduced BW7. I was once again unable to successfully transduce the BW7 line 
with TCR using the Amaxa Nucleofector system. 
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3.4 	Discussion 
TCR CDR3 analysis of HLA-DR1-restricted T-cell lines grown in response to an 
important epitope (peptide 4) of Fel d 1 identified the presence of expanded populations 
of T-cells bearing a particular TCR. The greater the number of times a line had been 
stimulated with peptide, the more restricted the repertoire of expressed TCRs became, 
and the more dominant the expanded TCR was within the population. Expanded TCRs 
sometimes had elongated CDR3 a or 13 loops, in support of the hypothesis being tested, 
that in the human Th2-mediated disease allergic asthma, TCRs carrying elongated 
CDR3 loops expand in response to allergen challenge. During a T-cell-mediated 
immune response, it has been observed that there is a rapid expansion of pathogen-
specific T-cells expressing a particular receptor (593, 594) which is somehow selected 
for as being particularly well-suited to driving the response in an appropriate direction. 
Clonal expansions of cells bearing particular receptors has been observed in a range of 
immune responses mediated by both CD4+ T-helper type cells, and CD8+ cytotoxic T-
cells. For example, expansions of cytotoxic T-cells bearing the same (or highly similar) 
TCRs have been documented in responses to infection with human immunodeficiency 
virus (HIV) (617), acute infectious mononucleosis caused by Epstein-Barr virus (EBV) 
infection (618) and influenza virus infection (619). Analysis of TCR usage in CD4+ T-
cells in a number of these systems, namely HIV (620) and EBV (618), suggested that 
whilst expansions in CD4+ T-cells could be identified (in the case of HIV infection), 
expansions were smaller and more polyclonal than those seen in CD8+ T-cells. 
However, a different study instead found a greater degree of clonality in CD4+ T-cells 
than CD8÷ T-cells in HIV-infected patients (621). EBV infection did not appear to be 
associated with the development of any CD4+ T-cell clonal expansion (618), although it 
was suggested that the system used for analysis may have been unable to detect any 
such expansions. 
In diseases more strongly associated with aberrant T-helper cell immune responses such 
as autoimmune diseases, a similar pattern of clonal expansion is seen as that in virally-
induced responses, with expansions of antigen-specific CD8+ T-cells tending to be more 
oligoclonal or monoclonal than expansions of antigen-specific CD4+ T-cells, which in 
general are more variable and polyclonal in nature. For example, in aplastic anaemia 
(622), an association between disease severity and prevalence of a particular CD8+ T-
cell clonotype expressing a specific TCR was demonstrated (623). Whilst this study 
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observed only small, polyclonal expansions in CD4+ T-cells, another study described 
marked clonal expansions in CD4+ T-cells in aplastic anaemia (624). These cells had a 
Thl phenotype (i.e. produced IFN-y) and were strongly implicated in causing disease. A 
similar pattern of expansion has been seen in T-cells isolated from lesions in the brain 
tissue of multiple sclerosis patients, with both CD4+ and CD8+ T-cells showing clonal 
expansion, but which was more marked and limited in CDC T-cells (625). However, 
analysis of TCR usage in the mouse model of multiple sclerosis, EAE, showed a clear 
clonotypic expansion of CD4+ T-cells specific for the antigen used to induce disease, 
MBP (594). A highly clonotypic response to a particular epitope of glutamic acid 
decarboxylase (GAD65), GAD6553o-543, which is implicated in the development of 
spontaneous diabetes in NOD mice was identified (626). The TCRI3 chain involved in 
this response is consistently present in the pancreatic islets of pre-diabetic NOD mice, 
but is not seen in other strains of mice or in other inflamed organs in NOD mice. The V, 
D and J regions of this TCR are identical in each case, with the TCR differing only at 
the CDR3, and here only slightly - all receptors share a specific DWG motif preceded in 
most cases by a polar glutamine or arginine residue. 
Whilst clonal expansions of specific TCRs in both viral infections and autoimmune 
disease have been extensively described, the situation in atopic disease is less well 
characterised. Analysis of T-cell responses in atopic dermatitis caused by house dust 
mite extract demonstrated the presence of clonotypic expansions in both peripheral 
blood lymphocytes cultured in vitro with HDM extract and also in T-cells extracted 
from atopic dermatitis lesions in the skin and analysed immediately ex vivo (627). 
However, only in rare cases was expansion of cells expressing the same TCR seen in 
both peripheral blood and skin lesion T-cells, but where this phenomenon did occur, it 
was associated with increased disease severity. It was also noted that the T-cell response 
in both compartments was of a highly oligoclonal nature. In addition, clonotypic 
expansion of T-cells bearing a TCR containing VI311 (TRBV 25) was observed after 
stimulation of PBMCs in vitro with crude peanut extract in peanut-allergic subjects 
(628). PBMCs from non-allergic siblings did not show this expansion in response to in 
vitro stimulation with peanut extract, suggesting that the expansion was allergen-
specific. A study of TCR usage in house dust mite allergy associated clonal expansions 
of T-cells expressing TCRs composed of V1318.1 (TRBV 18-1) or Va2.3 (TRAV 12-1) 
with disease (629). Allergies to cat and birch pollen have also been linked to particular 
vp subsets (630). Birch pollen allergy was associated with expansions of VI316.1+ 
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(TRBV 14) and V1320.1+ (TRBV 30) T-cells during the pollen season, whilst cat allergy 
was associated with the expansion of V1317.1+ (TRBV 19) T-cells. The findings 
described here, of expansions of Fel d 1-specific T-cells bearing a particular receptor in 
response to in vitro stimulation with peptide 4, are in agreement with previous findings 
of allergen-specific T-cell responses in allergic disease. Repeated stimulation with 
peptide 4 appeared to further focus the response in favour of particular dominant TCR 
chains (either TCRa or TCR(3) with identical CDR3 loops. There are a number of 
reservations concerning the propensity for in vitro culture and re-stimulation to bias a 
T-cell response. Such restimulation polarises the line and encourages the expansion of 
antigen-specific T-cells that are not present in such large numbers in vivo, even in a 
target organ (for example, 1-2% of T-cells isolated from HDM-sensitive atopic 
dermatitis skin lesions were clonotypically expanded in response to antigen (627), and 
this has also been observed in other systems (631, 632)). In the case of HDM-sensitive 
atopic dermatitis, TCRs expanded from a pool of PBMCs through in vitro culture were 
not in many instances found in the skin lesions, and it may therefore be possible to 
expand T-cells that would not reach the target organ in vivo, despite their potential 
antigen responsiveness. As such, analysis of TCR usage in T-cells isolated directly from 
the target organ, in this case the lung, of allergic asthmatic subjects, either from BAL 
fluid, induced sputum or lung biopsy samples would support the data presented here if 
T-cells expressing such TCRs were also found to be present in the lungs of these 
subjects. Such a finding would demonstrate the pathological importance of T-cells 
bearing specific TCRs in allergic asthma pathogenesis. 
Dominant TCRs that are clonally expanded in response to antigen challenge often have 
a number of structural features, especially in the antigen-binding site (made up of CDRs 
1, 2 and 3), that mediate the interaction with cognate peptide-MHC, optimising it to 
give an appropriate response (597). Some of these features are encoded in the germline 
V and J sequences, hence selection for particular V and J regions with these features 
will be promoted, as has been observed both here and elsewhere. Other features may be 
incorporated during N region addition of nucleotides by terminal deoxynucleotidyl 
transferase at the V-J region junction making up the CDR3 (402, 403). Those receptors 
with the requisite amino acid types or numbers incorporated in this region will be 
further promoted by the developing response. This is possibly demonstrated in the 
TCRa chain selection seen in line CIR014, where the main expansion in terms of V and 
J region usage (TRAY 26-2 TRAJ 48) did not show the same clonality in terms of 
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CDR3a selection. Seven different CDR3a loops were identified, which differed mostly 
in terms of the non-germline N region, where insertions and the use of diverse residues 
could be seen. Analysis of this line through a number of restimulations with peptide 4 
would allow tracking of the response to determine whether one of these early selected 
CDR3 loops comes to dominate the response, or whether all seven (or a proportion of 
them) contain a required structural motif that allows the correct response to be elicited. 
In addition, in line Bl, it was observed that two TCRa and two TCR(3 chains were 
expanded to the same extent. There was no obvious correlation between the chains in 
terms of germline segment usage or CDR3 length/composition, and it was not possible 
to tell which TCRa and which TCR13 chains paired with each other from this analysis. 
Further analysis of the line through cloning by limiting dilution would allow the TCR 
pairs to be identified. It is possible that the two TCRs formed in this response either 
contain different motifs that mediate the same level of response or, at the three-
dimensional level, the structure at the antigen-binding site may be similar, despite the 
different components used to construct it, but modelling studies and/or structural studies 
would be required to confirm this. Alternatively, the two expanded TCRs could mediate 
different responses through their interaction with the same peptide-MHC, though this 
may be less likely due to their existence in the same cytokine conditions. The ability to 
study the responses induced by each TCR separately and to compare them, perhaps 
through their expression in a system such as the BW7 expression system that was 
attempted here, could clarify the roles of these TCRs. 
An interesting aspect of the TCR CDR3 analysis described here was that, despite the 
analysis of T-cell lines derived from cat allergic asthmatic subjects who were HLA-
DR1+ and therefore likely to be able to respond to the same peptide epitope of Fel d 1, 
peptide 4, the expanded TCR (or TCRs) identified in each case were different. TCRs 
that are expanded by only one or a few individuals in response to the same stimulus is 
known as private TCRs, whilst a TCR or TCR chain that is widely expressed amongst 
all or most individuals in a population (e.g. all people with a certain HLA haplotype) in 
response to a particular antigen is known as a public TCR. Public TCR responses have 
been described in genetically identical strains of mice, for example, in influenza 
infection in response to an epitope of viral nucleoprotein (633), in the response to 
GAD65 in the development of autoimmune diabetes in NOD mice (626) and in the 
development of EAE in response to MBP in B10.PL mice (634), amongst others. 
Private TCR responses were also elicited in response to antigen challenge in each of the 
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examples described above (633, 626, 634), but always to a lesser extent than the public 
response, suggesting that a public response may be the most appropriate or 'best fit' 
response to the antigen in question (alternatively, the genetically identical background 
of the mice in each case may enhance the frequency of appearance of the public TCR, 
but this does not necessarily preclude the public response from being the 'best fit' 
response). Other studies have suggested an alternative explanation, that public 
responses may be induced by peptide antigens of a particular shape — for example, those 
peptides that form relatively flat surfaces when bound to MHC molecule may provide 
few features for recognition by TCR, resulting in only a small number of TCRs being 
capable of mounting a response to the antigen (635, 636). Other studies have suggested 
that a peptide that protrudes from the MHC binding cleft, and forms a bulged 
conformation may also constrain the repertoire of TCRs that are able to form the correct 
interface with the peptide-MHC, and again lead to the formation of a public response 
(637). Those antigens presumed to induce private responses in this hypothesis are 
therefore thought to have a shape intermediate between the two extremes and are hence 
capable of being recognised by a number of TCRs with different V(D)J and CDR3 
compositions. Another theory suggests that the conformational change induced upon 
binding of TCR to its cognate peptide-MHC antigen can drive development of a public 
T-cell response through limiting antigen specificity to those TCRs with a structure 
capable of inducing the required change in conformation (585). In addition, it has been 
suggested that public responses may arise as a result of their being more likely to occur 
due to the increased number of ways in which the same amino acid sequence can be 
generated from different underlying nucleotide sequences due to the degeneracy of the 
genetic code (638, 639). Not only can multiple recombination events produce the same 
nucleotide sequence, but also differing nucleotide sequences can produce the same 
amino acid sequence; the greater the number of ways of generating the same amino acid 
sequence at the CDR3 loop, the higher the probability of its forming a public response 
to an antigen for which it is specific. The lack of any overlap in TCR usage between 
lines in the expansions seen in the peptide 4-specific HLA-DR1-restricted T-cell lines 
indicates that this particular response may be primarily governed by private TCR 
responses. However, the finding in another study of TCR usage in cat-sensitive allergic 
asthma that a particular TCR V13 chain was associated with allergic responses to cat 
allergen (630) may suggest that public responses to allergen may be possible, depending 
on the epitope and MHC class II haplotype involved in the response. Further extensive 
study of TCR usage in allergic asthma, with particular reference to HLA haplotypes, 
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would be required to determine if there are public responses involved in allergic asthma 
pathogenesis, or if the disease is mediated wholly by private, individual responses. Such 
a finding would have implications for the development of therapies to treat allergic 
asthma — if a public response could be demonstrated, it might be possible to develop an 
antibody treatment targeted against the public TCR which would have broad 
applicability. A similar approach could be possible even with private TCRs, but each 
patient would require treatment with a different anti-TCR antibody therapeutic. 
The interaction between TCR and peptide-MHC complex may govern the strength and 
efficiency of TCR triggering and signalling, and in such a way determine the phenotype 
of the response i.e. development of a naive CD4+ T-cell into a Thl or Th2 effector cell 
upon activation, so that it is appropriate to the nature of the pathogen or the 
environment of the cell. It has therefore been suggested that the prevailing conditions 
surrounding the activation of a T-cell may determine the structure of the TCR that is 
preferentially expanded, by selecting those receptors for which the kinetics of binding 
peptide-MHC are optimal for developing the appropriate response. For example, TCRs 
expanded in Th2-promoting conditions may be preferentially selected for the presence 
of elongated CDR3a loops with a high proportion of bulky side chains within their 
structure compared with the lengths of CDR3a loops expanded in the corresponding 
Thl -promoting conditions (601). The three-dimensional structure of such an elongated 
loop has been predicted by computer modelling to impede the interaction between TCR 
and peptide-MHC, resulting in an interaction that is lower in affinity and with a reduced 
half-life. The development of Th2 cells from naive precursors has been linked to 
predicted weaker signalling through the TCR, and a lower affinity interaction with 
peptide-MHC. The expansion of TCRs with structural features in the antigen-binding 
site that lead to this outcome, such as elongated CDR3 loops, could therefore be 
favoured under Th2-promoting conditions. The identification of some TCRs with 
elongated CDR3 loops (compared to the mean length of CDR3 regions in human T-
cells as defined by Moss and Bell (586) which under IMGT definitions are 
approximately 12 amino acids for both TCRa and TCRf3 chains) in the TCR CDR3 
analysis described here supports this hypothesis. 
In addition, the lack of any common TCR gene usage between the three lines analysed 
demonstrates how diverse the T-cell response to a single antigen can be; the lines were 
derived from three cat-sensitive allergic asthmatic patients who were all HLA-DR1+, 
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and yet the TCR (or TCRs) expanded in response to peptide 4 stimulation in each case 
was different, but presumably capable of eliciting the same response (i.e. allergic 
disease). This suggests that if the structure of the TCR is selected for on the basis of its 
ability to elicit the most appropriate response, there is not necessarily only one defined 
structure that is capable of effecting this response, and the dominant structure(s) 
selected for in each individual will also be determined by the available repertoire 
established in the thymus during T-cell development and thymic selection events. 
This chapter also outlined attempts to develop a system in which the impact of TCR 
structure on T-cell function and differentiation could be studied. As discussed 
previously, it may be that the structure of expanded TCRs in a T-cell response may play 
a role in promoting the development of a particular response i.e. Thl or Th2. At the 
point of identification, however, the T-cells bearing the receptors of interest are already 
committed to a mature phenotype, and thus the impact of the TCR structure on its 
differentiation is difficult to assess. The use of expression systems that allow the 
transduction of such TCRs should allow analysis of the extent to which TCR structure 
itself can influence downstream events in T-cell activation. The ability to compare the 
responses induced by stimulation of the I-Ag7/PLP56_70-specific `Thl' and `Th2' TCRs 
(601) with cognate peptide-MHC in a system where the only difference between the 
transduced lines is the TCR they express may identify the capacity of a particular TCR 
to influence cell function. For example, cytokine production, proliferation and 
signalling events downstream of the TCR-CD3 complex could be compared, as well as 
the measurement of kinetic parameters such as affinity for peptide-MHC complex and 
the interaction half-life using tetramer analysis (640) or surface plasmon resonance 
(641). Any differences between the two lines could only be due to the structure of the 
TCR itself, and in this way the effect of structure on function could be determined. In 
addition, T-cell signalling induced by the expanded TCR from the HLA-DR1/peptide 4-
specific line could be analysed. These responses could be compared against the PLP-
specific responses in the first instance to give a general idea of how TCR signalling 
compares in the two systems. In addition, it might also be informative to compare the 
responses induced by the asthma-related TCRs with responses induced by a TCR 
carrying the same peptide-MHC specificity but isolated from either a non-allergic 
subject or from a line that has been polarised towards a Thl-phenotype by the addition 
of exogenous cytokines. 
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The attempts by me to create such a system that are shown in this chapter proved 
unsuccessful. A number of factors may have contributed to the failure to achieve 
successful transduction of BW7 with TCRs of interest. For example, the original 
packaging line, EcoPhoenix, is an ecotropic cell line, which means that its range of 
infectivity is limited to rodent cell lines (603, 613). BW7 is a line of murine origin and 
thus would be expected to be susceptible to infection with virus produced from this line. 
However, attempts at directly infecting BW7 with retrovirus derived from EcoPhoenix 
were unsuccessful. It is therefore possible that BW7 cells lack significant expression of 
the ecotropic receptor (mCAT-1) (642) at the cell surface. This difficulty was 
apparently overcome by the use of a serial system using a second packaging line, the 
dualtropic line PT67 (attempts to transfect PT67 directly with retroviral vector were 
also unsuccessful). Dualtropic lines have a greater range of infectivity, and are 
potentially able to infect all mammalian cell types (643), and this was shown by the 
ability of virus derived from PT67 cells to infect BW7 with eGFP. However, the use of 
a serial system decreased the overall efficiency of the system (as seen when comparing 
the level of infection of NIH3T3 cells with EcoPhoenix-derived virus directly and with 
virus from PT67 which had been infected itself with EcoPhoenix-derived virus. Use of a 
serial system decreased efficiency of infection by at least one-fifth). In addition, 
optimisation with eGFP involved transduction with one vector. Transduction with TCR 
genes involved the use of two vectors, and for a cell to be successfully transduced, it 
had to be infected with copies of both vector. In the BW7 line, approximately 20% of 
cells were successfully transduced with eGFP; if approximately the same rate of 
transduction was achieved for both TCRa and TCR13 vectors (i.e. 1 in 5 cells would be 
transduced with the TCRa vector, and 1 in 5 cells would be transduced with the TCRI3 
vector), this could mean that less than 5% (1/5 x 1/5 = 1/25, or 4%) of BW7 cells would 
be transduced with both simultaneously. Transduction using a non-retroviral system, the 
Amaxa Nucleofector, was also attempted, and also ultimately proved unsuccessful, 
despite the ability to transduce BW7 cells with eGFP. Possible reasons for this could be 
that the TCR expression vectors used, the pTcass vectors, are over 20 kb in size (346). 
The control GFP vector used for optimising the system is 6 kb, and so for the same 
concentration of DNA (for which there is a maximum that can be used per transfection), 
the number of copies of pTcass available would be more than three times lower than the 
same concentration of control vector. This would presumably impact on the efficiency 
of transfection and may explain why this system was also unsuccessful. 
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An alternative explanation for the failure to express TCR in the BW7 line may not be 
due to problems with the transduction systems used, but instead it may be due to 
problems with expression of the genes from the constructs. As the methods used to 
assess correct transduction (flow cytometry and IL-2 production through use of the 
CTLL-2 line) require the expression of TCR at the cell surface, they do not assess the 
possibility that the cells may be transduced with the constructs, but the genes may not 
be expressing correctly. The presence of the MFG constructs within the BW7 cells was 
assayed on one occasion, where it was shown that the TCRa genes for both clones 
D3(3) and A10(2) were present, suggesting that transduction of the line retrovirally was 
possible to some degree. However, as no corresponding TCRI3 chain gene could be 
identified, the expression of the genes could not be assessed, as expression of TCR at 
the cell surface requires both chains to be present. The MFG constructs containing the 
TCR genes were modified from the MFG(eGFP) construct through the addition of a 
short oligonucleotide linker to allow destruction of the unwanted NcoI site — it is 
possible that the extra base pairs incorporated through this linker have altered the 
relationship between the gene sequence and promoter and/or enhancer regions within 
the construct, and therefore expression of the gene could have been diminished 
compared to eGFP which was situated at exactly the correct position in the construct 
(604) for expression. In the case of the Amaxa system, the pTcass constructs have been 
previously used in an electroporation system (but not the Amaxa system) to transduce 
the BW7 line (606). However, in this study, the TCR chain genes were amplified from 
genomic DNA, whereas here, the genes were amplified from cDNA. Although the 
addition of intronic sequence from downstream of the J region should have allowed 
correct expression of these genes, it is possible that there was a problem in expression in 
these constructs. 
There are a number of ways in which the systems used here could be modified to 
achieve successful transduction. Although the PT67 packaging line could not be used as 
the sole packaging cell line due to its resistance to transfection with retroviral vector 
using calcium phosphate, virus produced from this line was able to successfully infect 
BW7, at least with eGFP. One possibility therefore would be to use a different 
packaging cell line, either a dualtropic line like PT67 or possibly an amphotropic line, 
such as AmphoPhoenix (between ecotropic and dualtropic lines in its range of 
infectivity of mammalian cell types) as the packaging line. The susceptibility of these 
cells to calcium phosphate transfection and the best conditions for transfection and 
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infection would have to be determined through optimisation experiments. Alternatively, 
a different means of transfecting PT67 could be attempted, such as lipofection (use of 
lipofectamine instead of calcium phosphate as a means of facilitating DNA entry into 
cells), or electroporation with the Amaxa Nucleofector. Another approach could be to 
use different expression vectors - either the use of vectors with a selectable antibiotic 
resistance marker, or the use of a vector which is able to incorporate both genes on the 
same plasmid, so that successful transduction with one plasmid leads to transduction of 
both genes simultaneously. The advantage of using selectable markers is that 
transduction with each chain could be carried out separately, and selection of those cells 
containing the first plasmid before transduction with the second could greatly enhance 
the efficiency of TCR transduction. In addition, use of a different vector would 
potentially also solve the problem if the lack of apparent transduction was due to a 
failure of expression from the constructs used here. None of the above modifications are 
trivial; for example, use of a different packaging line would require optimisation of the 
system to determine the conditions giving the highest level of transduction. The same 
would be true of using a different method of transfection, not least as the use of the 
Nucleofector system to transfect an adherent cell line such as PT67 is more technically 
difficult than transfection of a non-adherent line such as BW7. Also, the use of different 
vectors would involve cloning of the TCR genes into new vectors, and optimisation of 
the systems using them. A retroviral vector containing more than one gene of interest 
requires an IRES, or internal ribosomal entry site, between the two to ensure the 
transcription and translation of both genes. Use of such vectors can be problematic, and 
whilst potentially the most useful of vectors for the transduction of cells with TCR, are 
also more difficult to use successfully. However, the potential value of such a system if 
it can be developed is such that trying one or more of these modifications, though time-
consuming, would be worthwhile. Because I was not able to transduce the BW7 cell 
line with TCR using these systems, I was unfortunately not able to take this line of work 
forward and was not able to study the impact of TCR structure on function in vitro. 
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	4. 	Induction of allergic disease and analysis of T-cell costimulatory 
molecule expression in P4 TCR/DR1/ABO transgenic mouse 
lines 4 and 16 
4.1 	Characterisation of P4 TCR/DR1/ABO transgenic mice 
4.1.1 Overview 
P4 TCR transgenic mice were generated previously in our laboratory. Dr. Carol 
Pridgeon (National Heart and Lung Institute, Imperial College, London) generated and 
characterised the HLA-DR1-restricted human T-cell lines against peptide 4, derived 
from cat allergic individuals with allergic asthma. Dr. Daniel Douek (National Institutes 
of HealthNRC, United States of America) carried out a detailed clonotypic analysis of 
the human T-cell lines and identified the dominant TCRs expressed. Dr. Alexander 
Annenkov (Lung Immunology Group, Imperial College, London) cloned the rearranged 
V-J regions from a dominant TCR (a and (3 chains) (shown in Appendix 30) into the 
pTacass and pTI3cass vectors (346, supplied by Diane Mathis and Christophe Benoist). 
Dr. Catherine Reynolds (Lung Immunology Group, Imperial College, London) prepared 
the constructs for injection. Ms. Zoe Webster (Research Technician, Central Biomedical 
Services, Hammersmith Hospital, Imperial College, London) injected the constructs 
into C57BL/6 x CBA oocytes. Dr. Catherine Reynolds screened the founders by TCR-
specific PCR and identified two P4 TCR transgenic founder mice. Dr. Catherine 
Reynolds and Dr. Xiaoming Cheng carried out the initial characterisation of the P4 TCR 
transgenic mouse lines and crossed them with a DR1/ABO transgenic mouse line, to 
produce P4 TCR/DR1/ABO transgenic mouse lines 4 and 16. Dr. Catherine Reynolds 
and Dr. Xiaoming Cheng developed the protocols to induce allergic inflammation in the 
lung in this transgenic model. All the experiments described using this model were 
carried out with Dr. Catherine Reynolds and Dr. Xiaoming Cheng. 
4.1.2 PCR genotyping identifies P4 TCR/DR1/ABO transgenic mice 
Five PCRs are used to genotype the P4 TCR/DR1/ABO transgenic mice, the products of 
which are shown in Figure 4.1 for both a P4 TCR positive (P4 TCR/DR1/ABO) and a 
P4 TCR negative (DR1/ABO) mouse from each line. All PCR primers and reaction 
conditions are shown in Appendix 6. Primers for the PCR to identify the P4 TCR (a and 
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13 chains) were designed by Dr. Catherine Reynolds, primers identifying the HLA-DR1 
a and 13 chains and the murine MHC class II H2-A knockout status were designed by 
Danny Altmann. PCRs amplifying the transgenic TCRa and TCRE3 chains, if present, 
are shown in a and b of Figure 4.1. PCRs amplifying the a and 13 chains of the human 
MHC class II molecule HLA-DR1 are shown in c and d of Figure 4.1. As the DR1/ABO 
transgenic line is bred to express transgenic human HLA-DR1 homozygously, all mice 
are expected to give a positive result for these genes. The PCR assaying for murine 
MHC class II H2-A knockout status amplifies a product of the neomycin resistance 
cassette insert that was used to disrupt their expression, shown in e of Figure 4.1. The 
DR1/ABO transgenic line is also bred for homozygosity of the knockout insertion and 
as such, all mice are expected to give a positive result. This PCR is unable to 
differentiate between mice which are heterozygous or homozygous for the knockout 
insertion, as both will give a positive result with this PCR, hence mice were also 
phenotyped for expression of murine MHC class II H2-A by flow cytometry, as 
described in section 4.1.3. A P4 TCR/DR1/ABO transgenic mouse was therefore 
defined as a mouse with positive products for all five of the PCRs. Mice negative for 
the TCR transgenes but positive for the HLA-DR1 and murine MHC class II knockout 
PCRs were defined as DR1/ABO transgenic mice. 
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Figure 4.1 Genotyping PCRs to identify P4 TCR/DR1/ABO mice in lines 4 and 
16 (a) — (e) show representative gels of the five PCRs required to identify a P4 TCR 
positive mouse. Each gel shows a TCR positive transgenic (P4 TCR/DR1/ABO above) 
mouse and a TCR negative transgenic (DR1/ABO above) mouse from each line for 
comparison. (a) shows the typical product of 250 bp for the P4 TCRa gene; a band is 
only seen in the mice which are TCR positive. (b) shows the typical product of 400 bp 
for the P4 TCRI3 gene; a band is only seen in the mice which are TCR positive. The 
positive control for both P4 a and p PCRs above was human genomic DNA from which 
the P4 TCR was originally identified. (c) shows the typical product of 150 bp for the 
human MHC class II HLA-DR1 a gene and (d) shows the typical product of 200 bp for 
the human MHC class II HLA-DR1 p gene; a band is seen for all mice. (e) shows the 
typical product of 500 bp seen in murine class MHC II H2-A knockout mice — a band is 
seen for all mice. The positive control for the HLA-DR1 a and p and the class H 
knockout PCRs was murine genomic DNA from the HLA-DR1/mouse class II 
knockout line. 
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4.1.3 FACS phenotyping of P4 TCR/DR1/ABO transgenic mouse lines confirms 
murine MHC class II knockout status 
The status of the transgenic lines in terms of murine MHC class II molecule expression 
was determined by flow cytometry, as shown in Figure 4.2. A generic anti-mouse MHC 
class II antibody (anti I-A/I-E) was used in conjunction with an anti-CD45R antibody to 
stain B-cells, which under normal conditions express MHC class II, to identify whether 
a mouse was homozygous or heterozygous for the knockout insertion, as the genotyping 
PCR used to probe for presence of the knockout insertion cannot differentiate between 
them. All antibodies and their working concentrations are shown in Appendix 6. B-cells 
from a mouse homozygous for the knockout insertion do not stain with the anti-I-A/I-E 
antibody. B-cells from a heterozygous mouse do stain with the anti-I-A/I-E antibody, 
but the levels of MHC class II expression would be lower than for a wild-type mouse, 
which would manifest as decreased brightness of staining. Typical FL1 vs FL2 plots for 
a homozygous knockout mouse from line 4 (A) or 16 (B), and typical plots for 
homozygous knockout, heterozygous knockout and wild-type mice from the DR1/ABO 
line (C) are shown for comparison in Figure 4.2. The TCR transgenic founder/HLA-
DR1 murine MHC class II knockout cross generated offspring that were heterozygous 
(this would be expected as the TCR transgenic founders expressed murine MHC class II 
molecules normally whereas the DR1/ABO line has been bred for homozygosity of the 
knockout insertion). All subsequent breeding was carried out so as to create offspring 
homozygous for the knockout insertion at the earliest possible opportunity. In mice that 
are homozygous for the knockout insertion, the only MHC class II molecule available 
for presenting peptides and binding to T-cells is the human molecule HLA-DR1. As this 
is the molecule to which the transgenic TCR is restricted, knocking out expression of 
endogenous MHC class II molecules prevents other MHC class II-TCR interactions 
from occurring. However, these mice still retain the capacity to rearrange and express 
endogenous TCRa chains on T-cells, and all such TCRs will be restricted to HLA-DR1. 
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C. DR1/ABO transgenic mouse line 
Mouse MHC class 
II wild-type (+/+) 
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Anti-CD45R-FITC (B220) 
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Figure 4.2 Phenotyping FACS to show mouse MHC class II H2-A knockout 
status of P4 TCR/DR1/ABO transgenic mice in lines 4 and 16 To ascertain the 
mouse MHC class II knockout status of the P4 TCR/DR1/ABO transgenic mice, freshly 
isolated PBMCs from tailbleed samples were stained with anti-CD45R-FITC (a B-cell 
marker) and anti-I-A/I-E-PE (a general mouse MHC class II-reactive antibody). 
Representative FACS plot for a line 4 (A) and a line 16 (B) transgenic mouse are shown 
in the upper panels indicating that B cells from these mice show no staining with the 
anti-I-A/I-E-antibody. The plots in the lower panel (C) show the expected plots from a 
wild type MHC class II mouse, an heterozygous MHC class II knockout mouse, and a 
homozygous MHC class II knockout mouse. The mean fluorescence intensity of the 
CD45R4- cells is shown: it is highest in the wild type mice, which have the highest 
expression of murine MHC class II, intermediate in the heterozygous MHC class II 
knockout mice, which have intermediate levels of expression, and lowest in the 
homozygous knockout mice which do not express murine MHC class II. 
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4.1.4 Southern analysis confirms the presence of TCR transgenes in the genomic 
DNA of P4 TCR/DR1/ABO transgenic mice 
Southern analysis of the lines was carried out, probing for the transgenic TCRa and 
TCR(3 chains in genomic DNA from transgenic mice, shown for line 4 in Figure 4.3. A 
similar result was also seen for line 16 (data not shown). Southern analysis is a more 
robust genotyping method than PCR, as the probe used in detecting the DNA sequence 
is several hundred base pairs long in comparison to the 20-25 base pairs that is the usual 
length of a PCR primer. Southern hybridisation is therefore less prone to errors through 
binding of the probe to non-specific sequences than PCR, making it a more accurate 
method of ascertaining whether a particular gene sequence is present or absent in a 
DNA sample. In addition, the pattern and/or intensity of the bands obtained in a 
Southern hybridisation can give information on the copy number of an inserted 
transgene. The more intense a band is, the higher the number of copies that have been 
inserted into the genomic DNA of the recipient animal. 
From the known sequence data for the pTacass and pTi3cass vectors and the TCRa and 
TCR(3 chains, it was predicted that digesting genomic DNA with EcoRV and probing 
for the TCRa chain would yield a band of 3.2 kb in TCR transgene-positive animals. 
Digesting with the enzyme HindIII and probing for the TCRa chain would yield a 
positive band of 4.5 kb. It was also predicted that digesting genomic DNA with BamHI 
and probing for the TCR(3 chain would yield a band of 5.6 kb in TCR transgene-positive 
animals. Probes were derived from PCR products of about 600 bp amplifying a portion 
of the TCR chain gene sequences (restriction enzymes, primers and PCR conditions are 
shown in Appendix 6) which were then DIG-labelled before hybridisation. This strategy 
was designed with the help of Dr. Catherine Reynolds. 
For the P4 TCR Southern hybridisations, bands were seen using the probes for the 
TCRa and TCR(3 chains when genomic DNA from TCR-positive P4 TCR/DR1/ABO 
transgenic mice (as determined by PCR genotyping) was digested with the appropriate 
restriction enzyme, as shown in Figure 4.3. Bands were not seen in equivalently-
digested genomic DNA from TCR-negative (by PCR) DR1/ABO transgenic mice. 
However, staining the gel with ethidium bromide caused a very high background upon 
development of the blot and made it impossible to interpret them, hence the gels for 
these hybridisations were not stained — unfortunately, this prevented the use of a DNA 
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Figure 4.3 	Southern analysis of the P4 TCR/DR1/ABO transgenic line 4 (a) 
shows a representative Southern blot, probing for the P4 TCRa chain in a line 4 P4 
TCR/DR1/ABO transgenic mouse (by PCR analysis) (P4 TCR/DR1/ABO Tg above) 
and a TCR-negative (by PCR) DR1/ABO transgenic mouse (DR1/ABO Tg above) from 
the same line. (b) shows a representative Southern blot, probing for the P4 TCRf3 chain 
in a P4 TCR/DR1/ABO line 4 transgenic mouse (by PCR analysis) and a TCR-negative 
(by PCR) DR1/ABO transgenic mouse from the same line. As no band of the same size 
as that seen in the TCR transgenic mice is seen in the littermate mice, these bands 
appear to be transgene-specific and thus confirm the transgenic status of the mice. 
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ladder with bands of known size as a marker for determination of band sizes. As such, 
the presence of bands in the DNA of TCR-positive (by PCR) mice and the absence of 
any bands in the DNA of TCR-negative (by PCR) mice suggests that these bands 
correspond to the probe binding to transgenic TCR-specific DNA, and confirm the 
findings from the genotyping PCRs. 
4.1.5 mRNA products of the TCR transgenes in P4 TCR/DR1/ABO transgenic 
mice are correctly spliced 
To investigate if the transgene was being processed correctly at the transcriptional level, 
a PCR strategy was designed by Dr. Catherine Reynolds and Dr. Xiaoming Cheng 
making use of an intron contained within TCRa and TCRP chains between the leader 
peptide of the TCR chain and the rearranged V-J regions. The sequence inserted into the 
pTacass and pTPcass vectors was derived from T-cell genomic DNA, hence this intron 
is present within the TCR chain transgenes and thus the primary mRNA transcript. For 
the transcripts to be correctly translated, this intronic sequence must be spliced out of 
the mRNA during processing of the primary transcript. As the intron is of a sufficient 
size in both chains (132 bp in the TCRa chain, 153 bp in the TCRP chain), it is possible 
to visualise whether the intron has been removed by PCR. PCRs were carried out using 
primers positioned on either side of the intronic sequence on genomic DNA and also 
cDNA isolated from splenocytes (as the promoter in the pTcass constructs is T-cell 
lineage-specific, only cDNA products from cells of this lineage will transcribe the 
transgenes). All PCR primers and reaction conditions are shown in Appendix 6. In 
genomic DNA, where the intron is not removed from the sequence, a product size 
corresponding to the unspliced message should be seen (478 bp for the TCRa chain, 
425 bp for the TCRP chain). In T-cell cDNA, if correct processing has occurred, the 
product size should correspond to the unspliced product size minus the intron (346 bp 
for the TCRa chain, 272 bp for the TCRP chain). Figure 4.4 shows PCR products from 
genomic DNA and T-cell cDNA from P4 TCR/DR1/ABO transgenic mice from lines 4 
and 16 and also from a DR1/ABO transgenic mouse. The TCRa chain PCR is shown in 
a, and the TCRP chain PCR in b. For P4 TCR/DR1/ABO transgenic mice from both 
lines 4 and 16, a larger band corresponding to the unspliced sequence was amplified 
from the genomic DNA in both PCRs. A smaller band, corresponding to the correctly-
spliced mRNA, was amplified from the spleen cDNA for both PCRs, indicating that 
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Figure 4.4 PCRs to identify correct splicing of the TCR mRNA gene products 
to remove intronic sequence in P4 TCRJDR1/ABO transgenic mice in lines 4 and 
16 (a) and (b) show representative gels of the PCRs that identify correct splicing of the 
P4 TCR a (a) and 13 (b) mRNA products in P4 TCR/DR1/ABO transgenic mice. A 
difference in size between the bands obtained from the genomic DNA and the cDNA 
from TCR-positive mice indicates correct splicing of the transgenes to remove the 
intron is occurring. No band is seen for the PCRs carried out in the TCR-negative 
DR1/ABO transgenic mouse as it does not carry the TCR transgenes. Each gel shows 
the PCR products obtained from genomic DNA (gDNA) and cDNA in a line 4 P4 
TCR/DR1/ABO transgenic mouse, a line 16 P4 TCR/DR1/ABO transgenic mouse and a 
DR1/ABO transgenic mouse. 
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correct processing of the primary mRNA transcript occurs in both lines. A less intense 
band was seen corresponding to the unspliced product in the cDNA lanes — this band 
represented transcripts that had not yet been processed. No bands were seen in any PCR 
using the DNA or cDNA from DR1/ABO transgenic mice, as they lack the TCR 
transgenes. 
298 
4.2 Induction of allergic inflammation in the lung of P4 TCR/DR1/ABO 
transgenic mice using Fel d 1 
4.2.1 Overview 
A murine model of allergic inflammation in the lung using Fel d 1 in transgenic 
DR1/ABO mice on a mouse MHC class II knockout background was previously 
developed by our laboratory in collaboration with Altmann, Larche and Lloyd 
(submitted for publication in the Journal of Experimental Medicine). As the TCR for 
which P4 TCR mice are transgenic recognises peptide 4 of Fel d 1 bound to HLA-DR1, 
the TCR transgenic mice were crossed with the DR1/ABO mice on a mouse MHC class 
II knockout background. This model was developed to test the hypothesis that a 
humanised TCR/MHC class II transgenic model of allergic asthma would be an 
improved model of disease. The protocols for inducing allergic inflammation in this 
model were developed by Dr. Catherine Reynolds and Dr. Xiaoming Cheng in our 
laboratory. 
This protocol, outlined in Figure 4.5, involves two sensitisations 11 days apart 
comprising an intraperitoneal injection of recombinant Fel d 1 protein in alum, followed 
by intranasal challenges with whole cat dander extract on three consecutive days 
starting ten days after the second sensitisation. The Penh response to increasing doses of 
methacholine was measured by whole-body plethysmography 24 hours after the last 
challenge. Resistance and compliance measurements, also in response to increasing 
doses of methacholine, were made 24 hours later before tissues were harvested for 
further analysis. 
Other mouse models of asthma, such as the ovalbumin model, have shown induction of 
allergic disease characterised by increased bronchial hyperreactivity, increased 
production of IgE, airway eosinophilia and lung inflammation (287). In addition to 
measuring lung function, blood was taken from the mice for measurement of total IgE 
in the serum, BAL fluid was collected for differential cell counting and for cytokine 
measurement, one lobe of the lung was inflated and frozen for histological analysis and 
lung tissue was collected and either disaggregated for differential cell counting or 
homogenised for the cytokine measurement. All work described here about the TCR 
transgenic model of allergic inflammation was carried out with Dr. Catherine Reynolds. 
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Day 11 — 0.01 mg 
Fel d 1 in 200 iLd 
alum (or 10 Ill PBS 
in 190 !Al alum) i.p. 
Days 21/22/23 — 25 pi 
10 (line 4) or 20 (line 
16) mg/ml cat dander 
(or 25111 PBS) i.n. 
Day 0 — 0.01 mg 
Fel d 1 in 200111 
alum (or 10111 PBS 
in 190 iitl alum) i.p 
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measurement in 
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0/3/10/30/1001A,g/ml 
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measurement in 
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0/3/10/30/100 µg/m1 
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Figure 4.5 	The disease induction protocol used to induce allergic lung 
inflammation in the P4 TCR/DR1/ABO transgenic lines 4 and 16 Mice were 
sensitised twice intraperitoneally with recombinant Fel d 1 in alum, or, in the case of 
control mice, with an equivalent volume of PBS in alum. Mice were then challenged 
with intranasally administered cat dander extract, at a concentration of either 10 (250 [tg 
per challenge) or 20 mg/ml (500 [A,g per challenge). Penh in response to methacholine 
provocation was measured by whole body plethysmography 24 hours after the last 
intranasal challenge. Resistance/compliance measurements were recorded in response to 
methacholine provocation 24 hours after Penh measurement, after which BAL fluid, 
blood and lung tissue was harvested, for analysis of cytokine production, serum IgE and 
for differential cell counting. One lobe of the lung was inflated and frozen for 
histological analysis. 
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Both lines were analysed for disease induction following this protocol. Two doses of 
whole cat dander extract were used for intranasal challenge (as shown in Figure 4.5). 
The sensitisation dose of Fel d 1 was constant for all experiments. Numbers of mice per 
group for the two experiments carried out are shown in Table 4.1. In line 4, a lower 
dose of whole cat dander extract (25 µ,1 at 10 mg/ml) was used for challenge; in line 16, 
a higher dose (25 µI at 20 mg/ml) was used for challenge. Four groups were used in the 
experiments — a P4 TCR/DR1/ABO transgenic Fel d 1-sensitised group, a DR1/ABO 
transgenic Fel d 1-sensitised group, and P4 TCR/DR1/ABO transgenic and DR1/ABO 
transgenic PBS-treated control groups. In the line 4 experiment, it was notable that of 
the P4 TCR/DR1/ABO transgenic mice sensitised with Fel d 1, approximately half of 
the mice died before the end of the experiment (3 out of 7). This did not happen in the 
experiment using line 16 mice. It is possible that more severe disease had been induced 
in the mice that died in the line 4 experiments; unfortunately, it was not possible to 
examine any of the mice that died to see if this was the case. 
4.2.2 Disease induction with Fel d 1 induces increased airway hyperreactivity and 
bronchoconstriction in response to methacholine challenge 
Lung function was assayed by three parameters: measurement of Penh by unrestrained 
whole-body plethysmography, and measurement of pulmonary resistance and dynamic 
compliance in anaesthetised tracheotomised mice by whole-body plethysmography. 
Penh measurement was carried out with the help of Dr. Catherine Reynolds; 
measurement of resistance and compliance was performed by Dr. Kate Choy and Dr. 
Catherine Reynolds. 
4.2.2.1 Lung function data from the line 4 experiment 
Lung function measurements for the line 4 experiment are shown for both P4 
TCR/DR1/ABO transgenic and DR1/ABO transgenic mice in Figure 4.6. Perth 
measurements for the P4 TCR/DR1/ABO transgenic mice showed that in general, Fel d 
1-sensitised mice responded to a greater degree to methacholine provocation than PBS-
treated controls, although this did not reach statistical significance at any dose assayed 
(Student's unpaired t test, two-tailed). This suggests that there may have been a greater 
degree of airway hyperreactivity in the Fel d 1-sensitised P4 TCR/DR1/ABO transgenic 
mice than in the PBS-treated controls. This was in contrast to the DR1/ABO transgenic 
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Group numbers 
line i.n. challenge TCR/DR1 Tg TCR/DR1 DR1 only DR1 only, 
dose Fel d 1 T. PBS 
2 
T. Fel d 1 T. PBS 
2 4 250 [kg 4/7* 2 
16 500 [kg 7 2 5 
Table 4.1 	Group numbers used in the Fel d 1 disease induction experiments 
Two disease induction experiments were carried out. In the experiments in line 4, for 
the P4 TCR/DR1/ABO transgenic mice sensitised with Fel d 1 (denoted by *), the first 
number indicates the number of mice surviving until day 25 for lung function 
measurements and harvest, whilst the second number shows the number of mice 
originally entered into the experiment. All mice survived the protocol in the line 16 
experiment. (TCR/DR1 Tg = P4 TCR/DR1/ABO transgenic mice, DR1 only Tg = 
DR1/ABO transgenic mice) 
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Figure 4.6 	Lung function parameter measurements in response to methacholine 
provocation in the line 4 Fel d 1 disease induction experiment P4 TCR/DR1/ABO 
transgenic mice and DR1/ABO transgenic mice are shown separately — P4 
TCR/DR1/ABO transgenic mice are shown on the left-hand side, DR1/ABO transgenic 
mice on the right. (a) shows Penh data, with Fel d 1- and PBS-treated groups compared 
for P4 TCR/DR1/ABO transgenic mice and DR1/ABO transgenic mice. (b) shows 
resistance data and (c) shows compliance data. Group size for P4 TCR/DR1/ABO 
transgenic mice sensitised with Fel d 1 was n = 4. Group size for DR1/ABO transgenic 
mice treated with Fel d 1 was n = 2. Group size for both TCR transgenic and littermate 
PBS-treated mice was n = 2. Data are shown as mean ± SEM. Where significance 
values are shown, the statistical test used was Student's t test (two-tailed). 
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C. 
mice which, although responding to methacholine to a similar extent overall as the P4 
TCR/DR1/ABO transgenic mice, did not noticeably differ between Fel d 1-sensitised 
and PBS-treated groups. Resistance and compliance measurements for the P4 
TCR/DR1/ABO transgenic mice were uninterpretable due to technical difficulties. 
Measurement of resistance in the DR1/ABO transgenic mice followed the expected 
pattern, with Fel d 1-sensitised mice responding to a greater extent in response to 
methacholine than the PBS-treated mice, and this was significant at the 30 mg/ml 
methacholine dose (p = 0.0337, Student's unpaired t test, two-tailed). The compliance 
measurements for DR1/ABO transgenic mice showed that the Fel d 1-sensitised mice 
responded to methacholine to a greater extent than the PBS-treated controls, but this 
was not significant at any dose. These results follow the expected pattern as dynamic 
compliance would be expected to decrease as airway resistance increased. 
4.2.2.2 Lung function data from the line 16 experiment 
Lung function measurements for the line 16 experiment are shown for P4 
TCR/DR1/ABO transgenic mice in Figure 4.7. Penh measurements for the P4 
TCR/DR1/ABO transgenic mice showed that Fel d 1-sensitised mice appeared to 
respond to a greater extent to methacholine provocation than PBS-treated controls, 
which could be seen particularly at the 30 mg/ml dose although this was not statistically 
significant (using Student's unpaired two-tailed t test). For the P4 TCR/DR1/ABO 
transgenic mice, there was a greater increase in resistance in response to methacholine 
in the Fel d 1-sensitised mice than in the PBS-treated mice; this was in correlation with 
the Penh data. The difference between the groups at the 30 mg/ml methacholine dose 
was the most marked, but was not statistically significant (Student's unpaired two-tailed 
t test). Dynamic compliance in these mice decreased to a greater extent in response to 
methacholine provocation in the Fel d 1-sensitised mice, but to a lesser extent than that 
seen in the Penh and resistance measurements; this correlated with the Penh and 
resistance data overall. 
The data obtained for the P4 TCR/DR1/ABO transgenic mice is consistent with the 
induction of airway hyperreactivity in the Fel d 1-sensitised mice, as an increase in 
AHR in response to methacholine provocation was consistently seen for all three 
parameters. 
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Figure 4.7 Lung function parameter measurements in response to methacholine 
provocation in the line 16 Fel d 1 disease induction experiment Data for P4 
TCR/DR1/ABO transgenic mice are shown. (a) shows Penh data, with Fel d 1- and 
PBS-treated groups compared for P4 TCR/DR1/ABO transgenic mice. (b) shows 
resistance data and (c) shows compliance data. Group size for P4 TCR/DR1/ABO 
transgenic mice sensitised with Fel d 1 was n = 7. Group size for P4 TCR/DR1/ABO 
transgenic mice treated with PBS was n = 2. Data are shown as mean ± SEM. 
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4.2.3 Differential cell counts in BAL fluid and disaggregated lung tissue of Fel d 
1-treated mice showed substantial eosinophilic influx into the lungs 
Cytospins were prepared from cells isolated from BAL fluid and disaggregated lung 
tissue and stained with Wright-Giemsa stain. Cells were counted (300 per slide) on the 
basis of differential cell morphology and staining pattern (as shown in Appendix 8). 
Neutrophils, eosinophils, macrophages and lymphocytes were counted, and total 
numbers of each cell type in the original samples was calculated based on total cell 
counts, as shown in Figure 4.8. 
4.2.3.1 Differential cell counts in BAL fluid from line 4 and line 16 experiments 
Fel d 1-sensitised groups in both P4 TCR/DR1/ABO transgenic mice and DR1/ABO 
transgenic mice showed a large increase in cells recovered from BAL fluid compared 
with PBS-treated control groups (in each group, the mean cell count increased from less 
than 50,000 to at least 100,000. This result reached significance for the line 16 P4 
TCR/DR1/ABO transgenic group (p = 0.0150, Student's unpaired t test with Welch's 
correction, two-tailed)). Total number of cells recovered from BAL fluid in the line 16 
experiment (which used the higher dose challenge) was higher than in the line 4 
experiment for the Fel d 1-sensitised P4 TCR/DR1/ABO transgenic groups (645,427 ± 
181018 compared with 132,000 ± 104467). Total cells recovered from BAL fluid in the 
Fel d 1-sensitised DR1/ABO transgenic groups were comparable to the P4 
TCR/DR1/ABO transgenic Fel d 1-sensitised groups in each experiment (78,000 ± 
22800 for line 4 and 652,400 ± 220278 for line 16). This increase in total cells between 
the Fel d 1- and PBS-treated groups was predominantly caused by an increase in 
eosinophils in BAL fluid in both experiments which would be expected as an allergic 
phenotype had been induced by Fel d 1 sensitisation and cat dander challenge. The 
increase in eosinophils reached significance for the DR1/ABO transgenic group in the 
line 4 experiment (p = 0.0108, Student's unpaired two-tailed t test), and for the P4 
TCR/DR1/ABO transgenic (p = 0.0158, Student's unpaired two-tailed t test with 
Welch's correction) mice in the line 16 experiment. 
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Figure 4.8 	Differential cell counts in BAL fluid and lung tissue in the Fel d 1 
disease induction experiments in TCR P4/DR1/ABO lines 4 and 16 Cells were 
harvested from BAL fluid (left-hand side) and from disaggregated lung tissue (right-
hand side) and total cells were counted. Cytospin slides for each sample were prepared 
and cells were differentially counted (300 cells per slide) on the basis of cell 
morphology. Total cells are shown for each group alongside the numbers of cells 
comprising each subset. Slides were counted by three independent, blinded investigators 
and counts for each slide were averaged. Data is shown as mean values ± SEM. (a) 
shows cell counts obtained from the line 4 experiment. (b) shows cell counts obtained 
from the line 16 experiment. Group size for line 4 P4 TCR/DR1/ABO transgenic mice 
sensitised with Fel d 1 was n = 4. Group size for DR1/ABO transgenic mice treated 
with Fel d 1 in the line 4 experiment was n = 2. Group size for both P4 TCR/DR1/ABO 
transgenic and DR1/ABO transgenic PBS-treated mice in the line 4 experiment was n = 
2. Group size for line 16 P4 TCR/DR1/ABO transgenic mice sensitised with Fel d 1 was 
n = 7. Group size for DR1/ABO transgenic mice treated with Fel d 1 in the line 16 
experiment was n = 5. Group size for both P4 TCR/DR1/ABO transgenic and 
DR1/ABO transgenic PBS-treated mice in the line 16 experiment was n = 2. (TCR/DR1 
= P4 TCR/DR1/ABO transgenic mice, DR1 only = DR1/ABO transgenic mice, Fdl = 
Fel d 1 sensitised, PBS = PBS control.) * = p < 0.05 (Student's unpaired two-tailed t 
test) 
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4.2.3.2 Differential cell counts in disaggregated lung tissue from line 4 and line 16 
experiments 
Total cell numbers recovered from disaggregated lung tissue was similar for both Fel d 
1-sensitised and PBS-treated groups in the line 4 experiment for the P4 TCR/DR1/ABO 
transgenic mice and also the DR1/ABO transgenic mice. 
Despite there being no overall increase in total cell count from the disaggregated lung 
tissue between Fel d 1- and PBS-treated mice in either experiment, the proportions of 
cell types making up the total number differed between the two treatment groups in all 
cases. The main difference between Fel d 1-sensitised and PBS-treated mice was an 
increase in lung eosinophils in the Fel d 1-sensitised mice. This increase was seen in 
both line 4 and line 16, in both P4 TCR/DR1/ABO transgenic and DR1/ABO transgenic 
mice, but did not reach statistical significance in any case (Student's unpaired two-
tailed t test). 
4.2.4 Fel d 1 treatment induced an increase in serum total IgE 
Serum was isolated from blood obtained by cardiac puncture and assayed for IgE 
content by ELISA. The capture and detection antibodies and standard used are shown in 
Appendix 9. In both lines 4 and 16, IgE production was only seen at high levels in the 
Fel d 1-sensitised/cat dander challenged groups, as shown in Figure 4.9. The difference 
in IgE production reached significance in the line 16 experiment when comparing the 
Fel d 1- and PBS-treated P4 TCR/DR1/ABO transgenic groups (p = 0.0304, Student's 
unpaired two-tailed t test with Welch's correction). The lack of IgE production in the 
PBS-treated mice compared against the production of high levels of IgE in the Fel d 1-
sensitised mice is relevant in a biological context, indicating that there is induction of 
IgE production in response to sensitisation and challenge with cat allergen in these mice 
which is a characteristic feature of allergic disease induction. Where P4 TCR/DR1/ABO 
transgenic mice were compared with DR1/ABO transgenic mice, there was a tendency 
for IgE production to be higher in the P4 TCR/DR1/ABO transgenic mice. 
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Figure 4.9 	Total serum IgE production in the Fel d 1 disease induction 
experiments in TCR P4/DR1/ABO lines 4 and 16 Total [IgE] was measured in the 
serum of mice undergoing the Fel d 1 disease induction protocol by ELISA, against a 
general IgE standard. Data is shown as mean values for each group ± SEM. (a) shows 
total serum [IgE] obtained from the line 4 experiment. (b) shows shows total serum 
[IgE] obtained from the line 16 experiment. Group size for line 4 P4 TCRJDR1/ABO 
transgenic mice sensitised with Fel d 1 was n = 4. Group size for DR1/ABO transgenic 
mice treated with Fel d 1 in the line 4 experiment was n = 2. Group size for both P4 
TCR/DR1/ABO transgenic and DR1/ABO transgenic PBS-treated mice in the line 4 
experiment was n = 2. Group size for line 16 P4 TCR/DR1/ABO transgenic mice 
sensitised with Fel d 1 was n = 7. Group size for DR1/ABO transgenic mice treated 
with Fel d 1 in the line 4 experiment was n = 5. Group size for both P4 TCR/DR1/ABO 
transgenic and DR1/ABO transgenic PBS-treated mice in the line 16 experiment was n 
= 2. (TCR/DR1 = P4 TCR/DR1/ABO transgenic mice, DR1 only = DR1/ABO 
transgenic mice, Fdl = Fel d 1 sensitised, PBS = PBS controls.) * = p < 0.05 (Student's 
unpaired two-tailed t test) 
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4.2.5 Levels of the Th2-type cytokines IL-4, IL-5 and IL-13 were increased in 
BAL fluid in response to treatment with Fel d 1 when using the lower dose 
challenge protocol 
Cytokines were analysed by ELISA of BAL fluid against recombinant standards of 
known concentration. All capture and detection antibodies and recombinant standards 
used are shown in Appendix 9. 
In the line 4 experiment, higher levels of the Th2-associated cytokines IL-4, IL-5 and 
IL-13 were seen in the BAL fluid of the Fel d 1-sensitised groups than the PBS-treated 
groups for the P4 TCR/DR1/ABO transgenic mice only, as shown in Figure 4.10. This 
did not reach significance for any of the cytokines assayed, probably due to small group 
sizes (using the Student's unpaired two-tailed t test). No difference was seen between 
Fel d 1- and PBS-treated groups in the DR1/ABO transgenic mice. There was very little 
IFN-y in the BAL fluid in any group. 
In the line 16 experiment, there was no statistically significant difference (Student's 
unpaired two-tailed t test) in the amount of IL-4, IL-5 and IL-13 seen in BAL fluid in 
PBS-treated groups compared with Fel d 1-sensitised groups in both P4 TCR/DR1/ABO 
transgenic mice and DR1/ABO transgenic mice, as shown in Figure 4.11. No IFN-y was 
detected under any of the experimental conditions. 
4.2.6 The amount of IL-4, IL-5 and IL-13 in lung tissue homogenate supernatant 
following disease induction 
Cytokines were analysed by ELISA in the supernatant of homogenised lung tissue 
against recombinant standards of known concentration. All capture and detection 
antibodies and recombinant standards used are shown in Appendix 9. 
Levels of IL-4, IL-5, IL-13 and IFN-y detected in the supernatant of lung homogenate 
from the two disease induction experiments are shown in Figure 4.12. There was an 
increase in IL-4, IL-5 and IL-13 production in the Fel d 1-sensitised line 16 P4 
TCR/DR1/ABO transgenic mice. This approached significance for IL-13 (p = 0.0565, 
Student's unpaired two-tailed t test). 
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Figure 4.10 Th2-associated cytokines in the BAL fluid of line 4 P4 
TCR/DR1/ABO transgenic mice and DR1/ABO transgenic mice after Fel d 1 
sensitisation/cat dander challenge Cytokines were measured in BAL fluid samples 
from each mouse by ELISA, against recombinant standards. Data is shown as mean 
values ± SEM. (a) shows the concentration of IL-4 measured in the BAL fluid. (b) 
shows the concentration of IL-5 measured in the BAL fluid. (c) shows the concentration 
of IL-13 measured in the BAL fluid. Group size for P4 TCR/DR1/ABO transgenic mice 
sensitised with Fel d 1 was n = 4. Group size for DR1/ABO transgenic mice treated 
with Fel d 1 was n = 2. Group size for both P4 TCR/DR1/ABO transgenic and 
DR1/ABO transgenic PBS-treated mice was n = 2. (TCR/DR1 = P4 TCR/DR1/ABO 
transgenic mice, DR1 only = DR1/ABO transgenic mice, Fdl = Fel d 1 sensitised, PBS 
= PBS controls) 
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Figure 4.11 Production of Th2-associated cytokines in the BAL fluid of line 16 
P4 TCR/DR1/ABO transgenic mice and DR1/ABO transgenic mice after Fel d 1 
sensitisation/cat dander challenge Cytokines were measured in the supernatant of 
BAL fluid samples from each mouse by ELISA, against recombinant standards. Data is 
shown as mean ± SEM. (a) shows the concentration of IL-4 measured in the BAL fluid. 
(b) shows the concentration of IL-5 measured in the BAL fluid. (c) shows the 
concentration of IL-13 measured in the BAL fluid. Group size for P4 TCR/DR1/ABO 
transgenic mice sensitised with Fel d 1 was n = 7. Group size for DR1/ABO transgenic 
mice treated with Fel d 1 was n = 5. Group size for both P4 TCR/DR1/ABO transgenic 
and DR1/ABO transgenic PBS-treated mice was n = 2. (TCR/DR1 = P4 TCR 
transgenic mice, DR1 only = DR1/ABO transgenic mice, Fdl = Fel d 1 sensitised, PBS 
= PBS controls). 
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Figure 4.12 Thi- and Th2-associated cytokines in the lung tissue of line 4 and 
line 16 P4 TCR/DRI/ABO transgenic and DR1/ABO transgenic mice after Fel d 1 
sensitisation/cat dander challenge Cytokines were measured in the supernatant of lung 
homogenate samples resuspended at 100 mg/ml tissue by ELISA against recombinant 
standards. Data are shown as mean ± SEM. Results from line 4 mice are shown on the 
left, results from line 16 are shown on the right. The concentrations of (a) IFN-y, (b) IL-
4, (c) IL-5 and (d) IL-13 are shown. Group size for line 4 P4 TCR/DR1/ABO transgenic 
mice sensitised with Fel d 1 was n = 4. Group size for DR1/ABO transgenic mice 
treated with Fel d 1 in the line 4 experiment was n = 2. Group size for both P4 
TCR/DR1/ABO transgenic and DR1/ABO transgenic PBS-treated mice in the line 4 
experiment was n = 2. Group size for line 16 P4 TCR/DR1/ABO transgenic mice 
sensitised with Fel d 1 was n = 7. Group size for DR1/ABO transgenic mice treated 
with Fel d 1 in the line 16 experiment was n = 5. Group size for both P4 
TCR/DR1/ABO transgenic and DR1/ABO transgenic PBS-treated mice in the line 16 
experiment was n = 2. (TCR/DR1 = P4 TCR/DR1/ABO transgenic mice, DR1 only = 
DR1/ABO transgenic mice, Fdl = Fel d 1 sensitised, PBS = PBS controls). 
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4.2.7 Histological analysis of frozen lung sections shows inflammation in the 
lungs of Fel d 1-treated mice 
Frozen lung inflations were sectioned by Dr. Catherine Reynolds and stained with 
haematoxylin and eosin for analysis of inflammation. Scoring of the sections was 
carried out as described in Chapter 2, and as defined in ref. 607 by two independent, 
blinded investigators, and both absolute (modal value) and average (mean value) scores 
for both bronchioles and blood vessels were calculated for each group. Figure 4.13 
shows the absolute and average scores obtained for the two experiments for bronchioles 
and blood vessels. Figure 4.14 shows stained sections for control and Fel d 1-sensitised 
mice in the line 16 experiment as a general illustration of the inflammation induced by 
Fel d 1 sensitisation and cat dander challenge. For both line 4 and line 16, both absolute 
and average scores suggest that there is more inflammation in Fel d 1-sensitised mice 
than in PBS-treated controls. When using the average score, some inflammation was 
seen in the control groups as well as the sensitised groups. The scoring system assesses 
each individual bronchiole and blood vessel separately, so each contributes to the 
average score. It is possible for occasional mild inflammation to occur in an otherwise 
healthy animal which could therefore potentially skew the average score towards 
indicating the presence of lung inflammation where there is actually none. As such, use 
of the absolute scores (i.e. the most frequent score) to represent the overall level of 
inflammation in the lung may give a more accurate picture of what is happening by 
excluding these values. This is borne out by the results obtained here; when using the 
absolute score, inflammation is only seen in the Fel d 1-sensitised mice and not in the 
PBS-treated controls. The absolute score is more differentiating between the Fel d l-
and PBS-treated groups than the average score and is a better measure of inflammation 
in this model. 
314 
airway score 
=vessel score 
0.00 	r i 
TCR/DR1 Fd1 TCR/DR1 PBS DR1 only Fd1 DR1  only PBS 
airway score 
=vessel score 
I r f 
Min  
TCRIDRI PBS DR1 on y Fd1 DR1 only PBS 
A
bs
o
lu
te
  i
nf
la
m
m
at
io
n  
sc
or
e  1.00 
0.75-
0.50-
0.25- 
0.00 	r 
TCR/DR1 Fd1 
c 0.75- o — 
ti 
E 
E 0.50- 
2 0 0 . 
1.00- 
m 1.00 
`o 
a 
o c 0.75- 7, 
2 
0.50- 
4": 
C 
2 0.25- c 
Ti N 
< 0.00 
airway score 
= vessel score 
... 
TCR/DR1 PBS DR1 on
f 
y Fd1 DR1 only PBS 
M airway score 
=vessel score 
I  
TCR/DR1 Fd1 TCRIDRI PBS DR1 only Fdl DM only PBS TCR1DR
r 
1 Fdl 
1.00- 
0.75 
0.50- 
0.25- 
A
ve
ra
ge
  in
fla
m
m
at
io
n  
sc
or
e  
0.00 
Absolute score 	 Average score 
a. Line 4 
b. Line 16 
Figure 4.13 Inflammation scores obtained from H&E-stained sections of inflated 
lung from line 4 and line 16 P4 TCR/DR1/ABO transgenic and DR1/ABO 
transgenic mice (a) shows the scores obtained from the line 4 experiment. (b) shows 
the scores obtained from the line 16 experiment. The absolute score is shown on the 
left, whilst the average score is shown on the right. All sections were scored by at least 
two independent blinded investigators. Representative scores from one of the 
investigators are shown above for each experiment — scores obtained from the other 
investigator scoring each experiment were in agreement with the scores shown above. 
Data are shown as mean ± SEM. Group size for line 4 P4 TCR/DR1/ABO transgenic 
mice sensitised with Fel d 1 was n = 4. Group size for DR1/ABO transgenic mice 
treated with Fel d 1 in the line 4 experiment was n = 2. Group size for both P4 
TCR/DR1/ABO transgenic and DR1/ABO transgenic PBS-treated mice in the line 4 
experiment was n = 2. Group size for line 16 P4 TCR/DR1/ABO transgenic mice 
sensitised with Fel d 1 was n = 7. Group size for DR1/ABO transgenic mice treated 
with Fel d 1 in the line 16 experiment was n = 5. Group size for both P4 
TCR/DR1/ABO transgenic and DR1/ABO transgenic PBS-treated mice in the line 16 
experiment was n = 2. (TCR/DR1 = P4 TCR/DR1/ABO transgenic mice, DR1 only = 
DR1/ABO transgenic mice, Fdl = Fel d 1 sensitised, PBS = PBS controls) 
315 
we • 
a.  Fel d 1-sensitised PBS-treated control 
blocd, vesiel 
1)-00pghic0 
b.  Fel d 1-sensitised PBS-treated control 
x10 
11,  
Figure 4.14 Haematoxylin and eosin stained sections used for scoring lung 
inflammation in line 16 P4 TCR/DR1/ABO mice The scores shown in Figure 4.13 
were derived from scoring of slides such as these. (a) shows stained lung sections from 
P4 TCR/DR1/ABO transgenic mice in the line 16 experiment; a section from a PBS-
treated control is shown on the left, and a section from a Fel d 1-sensitised mouse on the 
right. Each section is shown at x10 magnification, with additional images of bronchioles 
and blood vessels shown at x40 magnification. (b) shows stained lung sections from 
DR1/ABO transgenic mice in the line 16 experiment, set out as described for (a). 
Typical structures of alveoli, bronchioles and blood vessels are marked. 
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4.2.8 Histological analysis of frozen lung sections shows goblet cell hyperplasia and 
mucus production in the lungs of Fel d 1-treated mice 
Frozen lung inflations were sectioned by Dr. Catherine Reynolds and stained using 
Periodic acid-Schiff s (PAS) reagent for analysis of mucus production and goblet cell 
hyperplasia. Scoring of the sections was carried out as described in Chapter 2 and as 
defined in ref. 608; both absolute (modal value) and average (mean value) scores for all 
bronchioles were calculated for each group. The scores were too low to merit reporting 
here but did show positive results in the Fel d 1-sensitised groups compared with PBS 
controls in both experiments. Figure 4.15 shows stained sections for control and Fel d 1-
sensitised mice in the line 16 experiment as a general illustration of mucus production 
and goblet cell hyperplasia induced by Fel d 1 sensitisation and cat dander challenge. 
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Figure 4.15 PAS stained (and haematoxylin counter-stained) sections used for 
scoring goblet cell hyperplasia and mucus production in line 16 P4 TCR/DR1/ABO 
mice (a) shows stained lung sections from P4 TCR/DR1/ABO transgenic mice in the 
line 16 experiment; a section from a PBS-treated control is shown on the left, and a 
section from a Fel d 1-sensitised mouse on the right. Each section is shown at x10 
magnification, with additional images of bronchioles shown at x 40 magnification. (b) 
shows stained lung sections from DR1/ABO transgenic mice in the line 16 experiment, 
set out as described for (a). PAS has a characteristic pink colour, and stains mucus and 
mucus-producing cells; examples of positive staining are indicated by the arrows. 
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4.2.9 Summary of findings 
Allergic lung inflammation occurred in the Fel d 1-sensitised groups in both line 4 and 
line 16 P4 TCR/DR1/ABO transgenic and DR1/ABO transgenic mice. 
Disease was assessed through a number of factors — lung function parameters, cell 
numbers and types in BAL fluid and lung tissue, total IgE levels in serum, Th2-
associated cytokine levels in BAL fluid and homogenised lung tissue and histological 
assessment of frozen lung sections for the presence of inflammatory infiltrates and 
goblet cell hypertrophy. 
Lung function results in general suggested that sensitisation with Fel d 1 led to an 
increase in AHR in response to methacholine provocation, as measured by changes in 
Penh, airway resistance and dynamic compliance. Fel d 1 sensitisation was associated 
with eosinophilic influx into the BAL fluid and lung tissue, causing an overall increase 
in cell number in the BAL fluid and the lung tissue. Fel d 1 sensitisation was also 
associated with high levels of IgE in the serum. IL-4, IL-5 and IL-13 were increased in 
the BAL fluid by Fel d 1 sensitisation in the line 4 P4 TCR/DR1/ABO transgenic mice. 
Analysis of lung inflammation by histological examination indicated that there was an 
inflammatory infiltrate in response to Fel d 1 sensitisation in both lines 4 and 16 in the 
P4 TCR/DR1/ABO transgenic and DR1/ABO transgenic mice. Mucus production and 
goblet cell hypertrophy occurred in Fel d 1-sensitised groups. 
These findings suggest that this sensitisation and challenge protocol using cat allergen is 
biologically successful in inducing allergic lung disease in the P4 TCR/DR1/ABO 
transgenic mice and DR1/ABO transgenic mice. However, the small group sizes 
prevented many of the findings from reaching statistical significance. These early 
preliminary findings indicate that the P4 TCR/DR1/ABO transgenic mice may be a 
more refined model than the DR1/ABO transgenic mice. Further experiments with 
modified protocols and increased group numbers (> 10 per group) will need to be 
undertaken to clarify this point. 
319 
4.3 	Analysis of T-cell costimulatory molecule expression in P4 TCR/DR1/ABO 
transgenic mouse lines 4 and 16 
4.3.1 Overview 
T-cell development in the thymus of an ap TCR transgenic mouse is abnormal due to 
the expression at an early stage (the DN stage) of a rearranged ap TCR (425). This is 
most often seen as an increased number of DN cells in the thymus due to the inability of 
the aP TCR to efficiently signal for the cell to pass the (3-selection checkpoint (424), for 
which the pre-TCR (comprising the pre-TCRa chain and a rearranged TCR(3 chain) is 
required (423). In addition, the expression of a transgenic aP TCR leads to restriction of 
the T-cell TCR repertoire - the presence of an already rearranged TCRP chain prevents 
the rearrangement and production of endogenous TCRP chains and to a lesser extent, 
the same is true of an already rearranged TCRa chain with regard to the rearrangement 
and production of endogenous TCRa chains (644). This can potentially act to restrict 
the responses of T-cells in the periphery (645) although this has not always been shown 
to be the case (646). It is therefore possible that these abnormalities may lead to 
differences in expression of costimulatory molecules associated with the TCR signalling 
events that occur in T-cells, both in the thymus and the periphery, hence the expression 
of some of these molecules was analysed in the thymus and spleen of P4 
TCR/DR1/ABO transgenic mice and compared with their expression in DR1/ABO 
transgenic control mice. 
The expression and function of a number of costimulatory molecules has been analysed 
in the thymus of non-transgenic mice and they have been found to play important roles 
in T-cell development. For example, CD44 is implicated in the correct homing of T-cell 
precursors to the thymus and its expression is seen at high levels at the DN stage of 
thymocyte development where, along with CD25, its expression or lack of defines a 
further four populations within the DN subset (416). As the expression of a rearranged 
aP TCR at this stage of development causes a block in development here, it might be 
expected that expression levels or patterns of CD44 expression may differ between TCR 
transgenic and non-TCR transgenic mice. CD3 is required in both the thymus and the 
periphery for correct assembly of the TCR complex and in the thymus is also required 
for the expression at the cell surface of the pre-TCR (384); its level of expression 
changes throughout T-cell development. The expression of a transgenic TCR in T-cells 
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undergoing thymic development might therefore be expected to affect the levels of CD3 
expression; CD3 expression would be required whenever TCR expression was 
occurring and its expression would in some way be related to the levels of expression of 
the transgenic TCR on the thymocyte surface. It might therefore be expected that 
expression of a transgenic TCR would increase CD3 expression throughout thymocyte 
development. Other molecules such as CD69 and CD62L are more strongly associated 
with later stages of thymocyte development (although CD62L is also thought to be 
expressed on those common lymphoid progenitors (CLPs) that will ultimately develop 
into T-cells (647) and thus CD62L expression may also be associated with very early 
thymocyte development); they are expressed at different stages of the maturation 
process in SP thymocytes. CD69 is thought to be associated with ongoing positive 
selection (648) and so is expressed in DP and immature SP thymocytes — its expression 
diminishes as a SP thymocyte matures and this decrease correlates with an increase in 
CD62L expression, an indication that the thymocyte is reaching maturity and will soon 
emigrate from the thymus (649). The impact of transgenic TCR expression on the later 
stages of thymocyte development is less well characterised but if there is an effect on 
either selection or maturation and egress from the thymus, it might be expected that 
there would be an effect discernible on the levels of expression of these molecules. The 
adhesion molecule CD54, through its interaction with its ligand, the integrin LFA-1, has 
been suggested to play an important role in T-cell development in the thymus as 
blocking of this interaction prevents the development of DP cells (650). Levels of CD54 
expression on thymocytes change as they develop, being highly expressed on the DN 
subset and at a low level on DP cells; in SP cells differential expression is seen with 
CD54 being expressed to a much higher level on CD8 SP than CD4 SP, a phenomenon 
also seen in the periphery (650). In addition, expression of secondary costimulatory 
molecules such as ICOS and OX40, which are associated in peripheral T-cells with T-
cell activation and the promotion of survival and development of memory T-cells 
respectively (651, 652), have been seen in the thymus (653, 649). Both molecules are 
expressed in the thymic medulla, which is predominantly populated by cells of the SP 
subsets and cells undergoing thymic selection, and to a lesser extent in the cortex. 
Although the function of these molecules in the thymus is unknown, it is likely that it 
will relate to their function in the periphery and it is therefore possible that expression 
of a transgenic TCR may affect their expression levels. 
321 
In order to investigate the hypothesis that expression of a transgenic TCR alters the 
expression of other T-cell signalling-associated molecules on cells of the T-cell lineage 
in both the thymus and the periphery, expression of such molecules was analysed on 
unstimulated, freshly isolated thymocytes and splenocytes. The expression of CD3, 
CD25, CD44, CD54, CD62L, CD69, OX40 (and its ligand OX4OL) and ICOS was 
analysed immediately ex vivo in the thymus and the periphery in P4 TCR/DR1/ABO 
transgenic lines 4 and 16 and in DR1/ABO transgenic controls by flow cytometry and 
analysed against the expression of the T-cell co-receptors CD4 and CD8. All antibodies 
used are shown in Appendix 10. 
4.3.2 A block in thymocyte development is seen at the double negative (DN) stage 
in P4 TCR/DRVABO transgenic mice 
Development of T-cell precursors in the thymus can be tracked by expression of the T-
cell coreceptors CD4 and CD8. During the earliest phase of development neither 
coreceptor is expressed and cells are characterised as belonging to the double negative 
(DN) subset. As the cells develop further they express both coreceptors concurrently 
and are characterised as belonging to the double positive (DP) subset. The last stage of 
development before thymic emigration is characterised by the loss of expression of one 
of the coreceptors and these cells belong to the CD4 (CD4 SP) or CD8 (CD8 SP) single 
positive subsets, depending upon which coreceptor they continue to express. When 
isolated thymocytes falling within a live lymphocyte gate, as shown in a in Figure 4.16, 
are analysed in terms of CD4 and CD8 expression a characteristic dot plot is obtained, 
shown in b in Figure 4.16. Four clear populations are seen, corresponding to the DN, 
DP, CD4 SP and CD8 SP subsets. The proportions of each subset in P4 TCR/DR1/ABO 
transgenic mice from lines 4 and 16 as well as in DR1/ABO transgenic controls were 
calculated and are shown for line 4 in Figure 4.16c and in Figure 4.16d for line 16. The 
proportions of cells that were present in the DP, CD4 SP and CD8 SP subsets are shown 
in tables on the left-hand side along with the numbers of mice in each group. In each 
case, the proportions were similar in both P4 TCR/DR1/ABO transgenic mice and 
DR1/ABO transgenic control mice for each of these subsets and comparable to the 
proportions seen in wild-type mice of the same strains i.e. C57BL/6 and CBA (416), 
with possibly a slightly lower proportion of CD8 SP seen in both P4 TCR/DR1/ABO 
transgenic mice and DR1/ABO transgenic control mice; the published proportion is 4-
4.5% whilst the mean proportion seen in the mice in these experiments was less than 
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Figure 4.16 Analysis of CD4 vs. CD8 staining on thymocytes from P4 TCR/ 
DR1/ABO transgenic mice Thymocytes were analysed on the basis of their staining 
for CD4 and CD8 expression. The gate used to identify live thymocytes, R10, is shown 
in (a) on a forward scatter-side scatter plot. The division of thymocytes into four subsets 
according to their staining for CD4 and CD8 is shown in (b). Thymocytes were defined 
as double negative (DN) CD4-CD8", double positive (DP) CD4+CD8+ or single positive 
for either CD8 (CD8 SP), CD4-CD8+ or CD4 expression (CD4 SP), CD4+CD8". The 
extent of each population as a proportion of total thymocytes is shown in (c) for line 4 
and in (d) for line 16. In each case, P4 TCR/DR1/ABO transgenic mice were compared 
against DR1/ABO transgenic control mice. Where no difference was seen between P4 
TCR/DR1/ABO transgenic mice and DR1/ABO transgenic control mice, data is 
displayed in a table as mean ± s.d. For DN cells, data is displayed as a scatter graph 
with the mean and error bars representing the standard deviation shown. # = p < 0.05 
(Mann-Whitney U test, two-tailed), * = p < 0.05 (unpaired Student's t test, two-tailed) 
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3%. A significant difference was seen between the proportion of DN cells in the P4 
TCR/DR1/ABO transgenic mice and the DR1/ABO transgenic control mice for both 
lines 4 (p = 0.0167, Mann-Whitney U test, two-tailed) and 16 (p = 0.025, Student's 
unpaired two-tailed t test) (shown in the graphs on the right-hand side in Figures 4.16c 
and d), with the proportion being higher by 2.38% (difference between the means) for 
line 4 P4 TCR/DR1/ABO transgenic mice and by 2.53% (difference between the 
means) for line 16 P4 TCR/DR1/ABO transgenic mice. An increase in DN cells in the 
P4 TCR/DR1/ABO transgenic mice is indicative of a block in development at this stage 
due to the expression of a pre-rearranged functional TCR interfering with normal TCRI3 
chain rearrangement, and has been shown previously (425). It is an indication that the 
TCR transgenes in the P4 TCR/DR1/ABO mice are being expressed in the transgene-
positive mice. 
4.3.3 Expression of CD44 on DN thymocytes is decreased in P4 TCRJDR1/ABO 
transgenic mice 
CD44 is expressed in the thymus, particularly in the DN and CD4 and CD8 SP subsets; 
very low expression is generally seen in the DP subset (414). Thymocytes, defined as 
outlined in Figure 4.16 in terms of CD4/CD8 subsets, were analysed for CD44 
expression within these subsets. Figure 4.17a shows the gates used to analyse the cells 
in terms of CD44 expression. Three gates were used to allow differentiation - M1 and 
M2 differentiated between CD44" and all CD44+ cells (regardless of whether expression 
was low or high) whilst M3 indicated cells where expression of CD44 was especially 
high (CD44high), as there was a separate peak corresponding to these cells. The 
proportion of CD44high i.e. gate M3 DN cells in both line 4 (p = 0.0003, Student's 
unpaired two-tailed t test) and line 16 (p = 0.0061, Mann-Whitney U test, two-tailed) P4 
TCR/DR1/ABO transgenic mice was significantly lower than for the DR1/ABO 
transgenic control mice, as shown in Figure 4.17b. The proportion of CD44high in 
DR1/ABO transgenic control mice was 4.79% higher (difference between the means) 
than line 4 P4 TCR/DR1/ABO transgenic mice and 6.90% higher (difference between 
the means) than line 16 P4 TCR/DR1/ABO transgenic mice. The table in Figure 4.17b 
shows the number of mice in the experiment and the proportion of CD441ligh cells in the 
remaining subsets where no difference was seen between P4 TCR/DR1/ABO transgenic 
mice and DR1/ABO transgenic control mice. A decrease in the mean fluorescence 
intensity (MFI) of the CD44high and CD444- (i.e. M2) populations in the DN subset in P4 
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Figure 4.17 CD44 expression on thymocyte subsets in P4 TCR/DR1/ABO 
transgenic mice Thymocyte subsets were defined as in Figure 4.16 on the basis of CD4 
and CD8 expression. Subsets were also analysed for CD44 expression (FL-1 channel). 
(a) shows an anti-CD44 single-stained sample indicating the gates used to distinguish 
populations on the basis of CD44 expression. M1 defines the CD44- population, M2 
defines the total CD44+ population and M3 defines the CD441"g" population. P4 
TCR/DR1/ABO transgenic mice were compared against DR1/ABO transgenic control 
mice. In (b), where no differences were seen between groups in CD44 expression, data 
is displayed in a table as mean ± s.d. For DN cells, data is displayed as a scatter graph 
with the mean and error bars representing the standard deviation shown. In (c) and (d), a 
comparison of mean fluorescence intensity (MFI) in the M2 (c) and M3 (d) gates for 
DN cells is shown with data displayed as in b. # = p < 0.05 (Mann-Whitney U test, two-
tailed), * = p < 0.05 (unpaired two-tailed Student's t test). 
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TCR/DR1/ABO transgenic mice was also seen as shown in Figures 4.17c and d. For the 
CD44high population (shown in d), the downward shift in MFI was only significant in 
the line 4 P4 TCR/DR1/ABO transgenic mice (mean 999.7 compared with mean 
1072.0, p = 0.0335, Student's unpaired two-tailed t test with Welch's correction) - there 
was no difference between the MFI obtained for the line 16 P4 TCR/DR1/ABO 
transgenic mice (mean 1077.0) and the DR1/ABO transgenic control mice. However, in 
the case of all CD44+ cells whether high- or low- expressing, shown in Figure 4.17c, the 
downward shift in MFI in P4 TCR/DR1/ABO transgenic mice from both lines was 
significant when compared to DR1/ABO transgenic control mice. The difference 
between the mean MFI values in line 4 P4 TCR/DR1/ABO transgenic mice was -89.9 
(p = 0.0001, Student's unpaired two-tailed t test) and in line 16 P4 TCR/DR1/ABO 
transgenic mice was -117.0 (p = 0.0061, Mann-Whitney U test, two-tailed) compared 
with DR1/ABO transgenic control mice. In summary, the numbers of DN cells 
expressing CD44 to a high extent was lower in P4 TCR/DR1/ABO transgenic mice in 
both lines 4 and 16 in comparison to the DR1/ABO transgenic control mice. 
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4.3.4 Expression of CD62L on thymocyte subsets is generally increased in P4 
TCR/DR1/ABO transgenic mice from line 16 
CLPs, the precursor cells of early T- and B-lineage progenitors, can be differentiated on 
the basis of CD62L expression, with CD62L+ cells developing along the T lineage 
pathway and migrating to the thymus and CD62L' cells developing along the B lineage 
pathway and migrating to the bone marrow (647). As such, recent migrant cells into the 
thymus (in the DN subset) express CD62L which is gradually down-regulated as the 
cells develop in the thymus. Expression is then up-regulated at the SP stage of 
development as cells mature to become ready to emigrate from the thymus (654). 
Thymocytes, as defined in Figure 4.16 in terms of CD4 and CD8 expression, were 
analysed for CD62L expression within each subset. The gates used for analysis are 
shown in Figure 4.18a. Four gates were used - M1, M2 and M3 differentiated between 
dead/CD62L" cells (M1), CD62L" (M2) and CD62Lhigh (M3) cells whilst M4 
represented all CD62L+ cells. The proportion of CD62Llugh (M3) DN cells was 
significantly higher by 17.56% (difference between the means) in P4 TCR/DR1/ABO 
transgenic mice from line 16 (p = 0.0061, Mann-Whitney U test, two-tailed) than the 
DR1/ABO transgenic control mice, as shown in Figure 4.18b. This increase in 
expression was not seen in DN cells from the P4 TCR/DR1/ABO transgenic mice from 
line 4, which had a level of CD62Lhigh expression (26.34% ± 2.23) that was similar to 
the DR1/ABO transgenic control mice (26.53% ± 5.52) and was significantly lower 
than that seen in line 16 P4 TCR/DR1/ABO transgenic mice (p = 0.0159, Mann-
Whitney U test, two-tailed, difference between means of 17.75%). The same 
phenomenon of an increase in CD62Lhigh cells in the line 16 P4 TCR/DR1/ABO 
transgenic mice but not in the line 4 P4 TCR/DR1/ABO transgenic mice as compared to 
DR1/ABO transgenic control mice was seen in the DP subset and the CD8 SP subset. 
For the DP cells, as shown in Figure 4.18c, the proportion of CD62Lhigh cells was 
4.88% higher (difference between the means) in the line 16 P4 TCR/DR1/ABO 
transgenic mice than in DR1/ABO transgenic control mice (p = 0.0061, Mann-Whitney 
U test, two-tailed) and 4.61% higher (difference between the means) than in line 4 P4 
TCR/DR1/ABO transgenic mice (p = 0.0159, Mann-Whitney U test, two-tailed). For 
the CD8 SP subset, as shown in Figure 4.18d, high-level expression of CD62L was 
13.31% higher in the line 16 P4 TCR/DR1/ABO transgenic mice (difference between 
the means) than in the DR1/ABO transgenic control mice (p < 0.0061, Mann-Whitney 
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Figure 4.18 CD62L expression on thymocyte subsets in P4 TCR/DR1/ABO 
transgenic mice Thymocyte subsets were defined as shown in Figure 4.16 on the basis 
of CD4 and CD8 expression. Subsets were analysed for CD62L expression (FL-1 
channel). (a) shows an anti-CD62L single-stained sample, indicating the gates used to 
distinguish different populations on the basis of CD62L expression, where M1 defines 
dead or CD62L" cells, M2 defines CD62LI' cells, M3 defines CD62Lhigh cells and M4 
defines all CD62L+ cells. P4 TCR/DR1/ABO transgenic mice were compared against 
DR1/ABO transgenic control mice. In (b)-(d), data is displayed as a scatter graph with 
error bars representing the mean ± s.d. for DN (b), DP (c) and CD8 SP (d) subsets. In 
(e), where no differences were seen between groups, the data is displayed in a table as 
mean ± s.d. MFI of the cells in the CD44+ (M4) gate for DN (f) and CD8 SP (g) subsets 
is shown, with the data displayed as scatter graphs with error bars representing the mean 
s.d. # = p < 0.05 (Mann-Whitney U test, two-tailed) 
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U test, two-tailed) and 15.71% higher than in the line 4 P4 TCR/DR1/ABO transgenic 
mice (difference between the means, p = 0.0159, Mann-Whitney U test, two-tailed). 
Expression of CD62Lhigh in CD4 SP cells did not differ between any of the groups as 
shown in the table in Figure 4.18e. 
The same pattern with respect to the line 16 P4 TCR/DR1/ABO transgenic mice 
compared with the line 4 P4 TCR/DR1/ABO transgenic mice and DR1/ABO transgenic 
control mice was also seen in the MFI of the CD62L+ cells (i.e. those in gate M4) in the 
DN (Figure 4.180 and CD8 SP (Figure 4.18g) subsets. The MFI in gate M4 for the 
thymocytes from line 16 P4 TCR/DR1/ABO transgenic mice was significantly higher 
than for the thymocytes from line 4 P4 TCR/DR1/ABO transgenic mice (p = 0.0159 
(Mann-Whitney U test, two-tailed) for DN, difference between means, 121.2 and p = 
0.0159 (Mann-Whitney U test, two-tailed) for CD8 SP, difference between means, 
37.05) and DR1/ABO transgenic control mice (p = 0.0061 (Mann-Whitney U test, two-
tailed) for DN, difference between means, 131.6 and p = 0.0061 (Mann-Whitney U test, 
two-tailed) for CD8 SP, difference between means, 36.56). These results support the 
findings from analysis of the proportion of CD62Lhigh cells in the thymocyte subsets as 
MFI is higher in the line 16 P4 TCR/DR1/ABO transgenic mice than the line 4 P4 
TCR/DR1/ABO transgenic mice and DR1/ABO transgenic control mice, which 
corresponds to there being a higher proportion of CD62Lhigh cells present in gate M4. 
In summary, CD62L expression is higher in DN, DP and CD8 SP subsets in line 16 P4 
TCR/DR1/ABO transgenic mice in comparison to both DR1/ABO transgenic control 
mice and also P4 TCR/DR1/ABO transgenic mice from line 4. 
4.3.5 There is a small increase in expression of OX40 on cells of the DN 
thymocyte subset in line 4 and line 16 TCR transgenic mice 
OX40 is expressed in the thymus, particularly in the CD4 and CD8 SP subsets (low 
levels of expression are also seen in the DP and DN subsets). It is more highly 
expressed on the CD4 SP than the CD8 SP subset (649). Thymocyte CD4/CD8 subsets 
were defined as outlined in Figure 4.16 and analysed for OX40 expression within these 
subsets. Figure 4.19a shows the gates used to analyse the cells for OX40 expression. 
Two gates, M1 and M2, were used to differentiate between OX40+ (M2) and OX40" 
(M1) cells. OX40 expression on DN thymocytes was slightly but significantly higher on 
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Figure 4.19 0X40 expression on thymocyte subsets in P4 TCRJDR1/ABO 
transgenic mice Thymocyte subsets were defined as shown in Figure 4.16 on the basis 
of CD4 and CD8 expression. Subsets were additionally analysed for 0X40 expression 
(FL-1 channel). (a) shows a single-stained anti-0X40 sample, indicating the gates used 
to distinguish OX40+ (M2) and 0X40" (M1) staining. P4 TCR/DR1/ABO transgenic 
mice were compared against DR1/ABO transgenic control mice. In (b), data is 
displayed as a scatter graph with error bars representing the mean ± s.d. for DN cells. In 
(c), where no differences were seen between groups in terms of 0X40 expression, the 
data is displayed in a table as mean ± s.d. * = p < 0.05 (Student's unpaired two-tailed t 
test), # = p < 0.05 (Mann-Whitney U test, two-tailed). 
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C. 
line 4 (p = 0.0004, Student's unpaired two-tailed t test) and line 16 (p = 0.0061, Mann-
Whitney U test, two-tailed) P4 TCR/DR1/ABO transgenic mice than on DR1/ABO 
transgenic control mice, as shown in Figure 4.19b, with the difference between line 4 
P4 TCR/DR1/ABO transgenic mice and DR1/ABO transgenic control mice being 
4.32% (difference between means) and between line 16 P4 TCR/DRI/ABO transgenic 
mice and DR1/ABO transgenic control mice being 3.47% (difference between means). 
OX40 expression in the DP, CD8 SP and CD4 SP subsets did not differ between P4 
TCR/DR1/ABO transgenic mice and DR1/ABO transgenic control mice in either line 4 
or line 16, as shown in the table in Figure 4.19c. Expression of 0X40 was highest in the 
CD4 SP subset (70-75% of all cells were OX40+), lower but still substantial in the CD8 
SP subset (40-45%) and lowest in the DP subset (approximately 14%). This correlates 
with levels and extent of expression reported in the literature (616). In summary, in the 
DN subset only, there was a small increase in the expression of OX40 in the P4 
TCR/DR1/ABO transgenic mice compared with the DR1/ABO transgenic control mice 
in lines 4 and 16. 
4.3.6 Expression of ICOS in P4 TCR/DR1/ABO transgenic mice is significantly 
decreased on the DN, CD4 SP and CD8 SP thymocyte subsets in 
comparison to DR1/ABO transgenic control mice 
ICOS is a member of the CD28 family, sharing 20% sequence homology with CD28 
and in terms of function it is very similar to CD28 in promoting T-cell proliferation, 
survival and differentiation with a similar degree of potency (618). It is more strongly 
associated with CD4+ than CD8+ T-cells (653). ICOS is also expressed in the thymus 
(620) where it is predominantly associated with the thymic medulla, and thus is likely to 
be expressed primarily within the SP subsets. Some expression is also seen in the 
cortical areas of the thymus, so it is likely that cells in the DN and/or DP subsets may 
also express ICOS to some extent (653). ICOS expression was analysed in thymocyte 
subsets, as defined in Figure 4.16. The gates used for analysis of ICOS expression are 
shown in Figure 4.20a - two gates, M1 and M2, differentiated between ICOS+ (M2) and 
ICOS" (M1) cells. ICOS expression was significantly lower in line 4 (11.62% ± 1.88, p 
= 0.0009, Student's unpaired two-tailed t test) and line 16 (10.71% ± 0.71, p = 0.0061, 
Mann-Whitney U test, two-tailed) P4 TCR/DR1/ABO transgenic mice compared with 
DR1/ABO transgenic control mice (15.91% ± 1.32) in the DN subset, as shown in 
Figure 4.20b. ICOS expression in these mice was notably higher in the medullary SP 
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Figure 4.20 ICOS expression on thymocyte subsets in P4 TCR/DR1/ABO 
transgenic mice Thymocyte subsets were defined as shown in Figure 4.16 on the basis 
of CD4 and CD8 expression. Cells were additionally analysed for ICOS expression 
(FL-2 channel). (a) shows an anti-ICOS single-stained sample, indicating the gates used 
to distinguish ICOS+ (M2) and ICOS- (M1) staining. P4 TCR/DR1/ABO transgenic 
mice were compared against DR1/ABO transgenic control mice. In (b)-(c), the data is 
displayed as a scatter graph with the mean indicated and error bars representing the 
standard deviation shown for DN cells (b) and CD4 SP (c) cells. In (d), as no 
differences were seen between groups, the data is displayed in a table as mean ± s.d. * = 
p < 0.05 (Student's unpaired two-tailed t test), # = p < 0.05 (Mann-Whitney U test, two-
tailed). 
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d. 
SP subsets as expected from previous findings in the literature, shown in Figure 4.20c 
for CD4 SP and Figure 4.20d for CD8 SP. ICOS expression was highest in the CD4 SP 
subset, where more than 80% of CD4 SP cells were ICOS+. In line 16 P4 
TCR/DR1/ABO transgenic mice, ICOS expression was significantly lower in the CD4 
SP subset (84.04% ± 5.88, p = 0.0061, Mann-Whitney U test, two-tailed) than in 
DR1/ABO transgenic control mice (92.67% ± 1.86), a difference of 8.63% (difference 
between means). This was not seen in line 4 P4 TCR/DR1/ABO transgenic mice 
(90.49% ± 3.28). No difference in ICOS expression was seen in either the DP or CD8 
SP subsets of thymocytes between P4 TCR/DR1/ABO transgenic mice from either line 
4 or 16 and DR1/ABO transgenic control mice, as shown in the table in Figure 4.20d. 
ICOS expression in the CD8 SP subset was lower than in the CD4 SP, with 
approximately 30% of cells being ICOS+. ICOS expression was lowest overall in the 
DP subset; only 5-6% of DP cells were ICOS+. In summary, the expression of ICOS in 
the DN and CD4 SP subsets of line 16 P4 TCR/DR1/ABO transgenic mice was lower 
than in DR1/ABO transgenic control mice; a similar phenomenon was not seen in the 
line 4 P4 TCR transgenic mice, where levels of ICOS expression were similar to those 
of the controls. 
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4.3.7 Expression of T-cell costimulatory molecules CD69, CD3, CD54 and CD25 
on thymocytes in P4 TCR/DR1/ABO transgenic mice is similar to the 
expression seen in DR1/ABO transgenic controls 
CD69, CD3, CD54 and CD25 all participate in the events surrounding T-cell activation 
upon signalling through the TCR in the periphery. Each of these molecules is also 
expressed during T-cell development in the thymus and levels of expression differ 
between the subsets depending on the molecule and its purported function. Thymocytes 
from P4 TCR/DR1/ABO transgenic mice from both lines 4 and 16 as well as DR1/ABO 
transgenic control mice were analysed for the expression of CD4, CD8 and the relevant 
signalling molecule. Figure 4.21 shows the definition of the thymocyte subsets used (a 
and b) and the gating of cells into negative and positive populations for the molecules 
CD69 (c), CD3 (d), CD54 (e) and CD25 (f). The extent of each subset that was defined 
as positively expressing the molecule being investigated is shown for both line 4 and 
line 16 P4 TCR/DR1/ABO transgenic mice and compared with the DR1/ABO 
transgenic control mice in Table 4.2 as mean ± s.d. values. No statistically significant 
differences (Student's unpaired two-tailed t test) were seen between the expression of 
any of these molecules on any thymocyte subset in P4 TCR/DR1/ABO transgenic mice 
and DR1/ABO transgenic control mice. 
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Figure 4.21 Gating used for analysis of expression of T-cell co-stimulatory 
molecules on thymocytes from P4 TCRJDR1/ABO transgenic mice by flow 
cytometry (a) shows the gate used to define live thymocytes. The expression of each 
costimulatory molecule (FL-1 channel, x-axis) was analysed for each thymocyte subset, 
defined by their expression of CD4 and CD8, shown in (b) above. Staining was either 
positive or negative, shown by the gates on the histograms above in (c), (d) and (f), 
where M1 indicates negative staining and M2 indicates positive staining. For the 
staining shown in (e), the MI gate defines dead cells, M2 defines negative/low staining, 
and gate M3 defines positive/high staining. FL-1 stains used: (c) CD69, (d) CD3, (e) 
CD54 and (f) CD25. 
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CD4- CD8- CD4+ CD8+ CD4+ CD8- CD4- CD8+ 
double double positive single positive single positive 
negative (%) Ma ________Am coa 
CD69 
TCRJDR1 
Tg line 4 
14.73 ± 3.90 5.43 ± 1.28 54.24 ± 8.61 26.35 ± 5.47 
DR1 only Tg 13.25 ± 0.85 5.48 ± 1.90 58.37 ± 3.10 30.31 ± 9.41 
TCR/DR1 
Tg line 16 
DR1 only Tg 
61.49 ± 7A1 
65.05 ± 0.19 
23.24 ± 2.06 
30.82 ± 4.65 
7.22 ± 5.29 
6.79 ± 2.48 
9.78 ± 1.55 
9.56 ± 0.72 
CD3 
TCR/DR1 
Tg line 4 
30.57 ± 2.99 12.55 ± 1.38 94.57 ± 0.90 56.68 ± 4.01 
DR1 only Tg 22.50 ± 2.30 8.32 ± 0.38 94.83 ± 0.57 54.53 ± 1.05 
TCR/DR1 
Tg line 16 
DR1 only Tg 
9.96 ±1.70 
9.96 ± 8.24 
7.58 ± 1.32 87.27 ± 3.06 55.71 ± 13.29 
5.75 ± 1.58 91.51 ± 1.94 62.89 ± 0.47 
CD54 
TCR/DR1 
Tg line 4 
21.46 ± 8.09 2.83 ± 1.70 5.50 ± 2.78 20.33 ± 12.68 
DR! only Tg 16.12 ± 4.08 1.84 ± 0.40 3.81 ± 0.42 13.93 ± 2.95 
TCR/DR1 
Tg line 16 
16.53 ± 4.60 8.28 ± 2.67 9.66 ± 3.45 14.93 ± 3.47 
DR! only Tg 16.31 ± 12.52 8.32 ± 4.21 10.89 ± 0.57 15.45 ± 0.47 
CD25 
TCRJDR1 
Tg line 4 
32.14 ± 3.41 0.35 ± 0.05 1.94 ± 0.54 1.16 ± 0.74 
DR1 only Tg 	34.33 ± 4.91 0.29 ± 0.03 1.59 ± 0.28 1.23 ± 033 
TCRJDR1 
Tg line 16 
26.10 ± 8.50 0.42 ± 0.21 1.78 -± 0.26 4.45 ± 0.88 
DR! only Tg 28.57 ± 21.39 0.35 ± 0.04 1.15 ± 0.06 3.24 ± 1.27 
Table 4.2 	Expression of T-cell costimulatory molecules on thymocytes from P4 
TCR/DR1/ABO transgenic mice Values shown are the percentages (± standard 
deviation) of each thymocyte subset (as defined in Figure 4.22) that express the 
molecule being analysed (the gates used to define positive and negative expression are 
shown in Figure 4.22). Numbers of mice in each group: P4 TCR/DR1/ABO line 4 
transgenic mice (TCR/DR1 Tg line 4 above) - n = 7, P4 TCR/DR1/ABO line 16 
transgenic mice (TCR/DR1 Tg line 16 above) - n = 4, DR1/ABO transgenic control 
mice (DR1 only Tg above) - line 4 experiment - n = 3, line 16 experiment - n = 2. 
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CD69 is rapidly induced upon T-cell activation in the periphery with expression at the 
surface being detectable 2-3 hours after activation (655). Expression reaches a peak at 
approximately 24 hours after activation and it is down-regulated within 48 hours. It is 
not appreciably expressed on nave or resting cells. It is expressed on approximately 
10% of total thymocytes (648); in these experiments, levels of CD69 expression were 
calculated to be approximately 15%. CD69 expression in the thymus is thought to be 
associated with positive selection events (648) and thus expression is strongest in the 
DP and SP subsets. Exact proportions of subsets expressing CD69 differ in the literature 
between studies - one report (648) showed very low levels of CD69 expression on DP 
and SP subsets of less than 5%, whilst analysis of CD69 expression in an in vitro 
culture of thymocytes suggested approximately 12% of DN thymocytes and 
approximately 78% of CD4 SP thymocytes expressed CD69 (656). The values 
expressed here (shown in Table 4.2) are more in line with the latter levels of expression 
in terms of extent and pattern. The levels of CD69 expression in the SP subsets 
appeared to be lower in the P4 TCR/DR1/ABO transgenic mice in both lines 4 and 16 
when compared to the DR1/ABO transgenic control mice in each case - as CD69 is 
associated with positive selection events, the apparent lower levels of expression in the 
P4 TCR/DR1/ABO mice may indicate a difference in positive selection that is 
associated with the expression of a transgenic TCR. 
CD3 is implicated in events during thymic development; progression from the DN to 
DP stage of development upon correct rearrangement of a TCRI3 chain within the cell 
requires CD3 expression (384). In TCR transgenic mice where a rearranged TCRaf3 
molecule is expressed throughout thymic development, CD3 expression may therefore 
occur differently. CD3 expression is generally extremely low on cells in the DP subset 
(429) but is up-regulated to a high level as the cells mature into the SP subsets. CD3 
expression on the SP subsets ranges from low to high (657); it is expressed at high 
levels on mature thymocytes with a higher degree of expression on CD4 SP cells than 
CD8 SP cells. As such, CD3 expression in the CD4/CD8 subsets of the thymus was 
compared between the P4 TCR/DR1/ABO transgenic mice and the DR1/ABO 
transgenic control mice. The levels of CD3 expression in P4 TCR/DR1/ABO transgenic 
mice and the DR1/ABO transgenic control mice, shown in Table 4.2, correlate well 
with this described pattern. Expression of CD3 is seen in the DN subset, ranging from 
10 to 30%, which is then decreased in the DP subset. A small proportion of DP cells in 
these mice express high levels of CD3, probably corresponding to those cells 
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undergoing maturation into SP cells. In the SP subsets, CD3 expression is much higher 
(more than 90% in CD4 SP cells and over 50% in CD8 SP cells) as would be expected 
from published reports. Whilst the differences when comparing P4 TCR/DR1/ABO 
transgenic mice to DR1/ABO transgenic control mice in lines 4 and 16 did not reach 
statistical significance, there was an apparent difference which could be biologically 
important - in the line 4 experiment, CD3 expression in the DN subset did appear to be 
higher in the P4 TCR/DR1/ABO transgenic mice than the DR1/ABO transgenic control 
mice. This may be related to the expression of the transgenic rearranged TCR molecule 
at the cell surface at this stage. 
CD54 is an intracellular adhesion molecule that binds to integrins such as LFA-1 on the 
surface of endothelial cells, enhancing and facilitating the traffic of T-cells to sites of 
inflammation (658). It is up-regulated on activated T-cells in the periphery and is 
expressed at a low basal level on resting T-cells. CD54 expression has also been seen on 
thymocytes with levels changing throughout development (650). CD54 is expressed 
highly on the DN subset and at a low level on DP cells; in SP cells, differential 
expression is seen with CD54 being expressed to a much higher level on CD8 SP than 
CD4 SP, a phenomenon also seen in the periphery. The values obtained for the mice in 
the experiments described here correlate with these previous findings; the values shown 
in Table 4.2 for CD54 expression show the proportion of the subsets expressing high 
levels of the molecule. CD54 expression was highest in the DN and CD8 SP subsets 
(approximately 15-20% of cells expressed CD54 at a high level), at an intermediate 
level in CD4 SP (approximately 5-10% of cells expressed a high level of CD54), and 
lowest in the DP subset (approximately 2-8% of cells expressed a high level of CD54). 
CD54 expression in the DN and CD8 SP subsets appeared to be higher in the P4 
TCR/DR1/ABO transgenic mice than the corresponding DR1/ABO transgenic controls 
in the line 4 experiment but the large standard deviations from the mean of the results 
from the DR1/ABO transgenic controls prevented this from reaching significance. 
Repeating the experiment with larger group numbers might confirm this finding. 
The expression of CD25, the IL-2Ra chain, is up-regulated early after activation of T-
cells in the periphery (659, 660). It is also used as a marker in conjunction with Foxp3 
for regulatory T-cells, or Tregs (196). Expression of CD25 is well-documented in the 
DN subset of thymocytes where, along with CD44, its expression defines four sub-
stages in the subset development, from migration into the thymus through to the 
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development into DP cells (416). CD25 expression is then up-regulated in a small 
population of CD4 SP cells, thought to be the precursors of Tregs (661). The values 
obtained for the mice in the experiments described here, shown in Table 4.2, correlate 
with previous findings; CD25 expression was highest in the DN subset as expected 
(approximately 30% of cells expressed CD25), whilst in the DP and SP subsets, 
expression of CD25 was at a much lower level (negligible in DP cells, and 
approximately 1-4% in the CD4 and CD8 SP subsets). There was no difference in CD25 
expression in any subset in P4 TCR/DR1/ABO transgenic mice from either line 4 or 
line 16 when compared to the corresponding DR1/ABO transgenic control mice. 
In summary, no statistically significant differences in the levels of expression of CD69, 
CD3, CD54 or CD25 were seen in line 4 or line 16 P4 TCR/DR1/ABO transgenic mice 
compared with DR1/ABO transgenic control mice. However, some differences that may 
have biological importance were seen. CD69 expression appeared to be lower in the SP 
subsets of P4 TCR/DR1/ABO transgenic mice in both lines 4 and 16 than in DR1/ABO 
transgenic control mice. CD3 expression in the DN subset of the line 4 P4 
TCR/DR1/ABO transgenic mice was higher than in the corresponding DR1/ABO 
transgenic control mice, whilst CD54 expression in the DN and CD8 SP subsets 
appeared to be higher; changes in CD3 or CD54 expression were not seen in the line 16 
experiment. No difference in CD25 expression between P4 TCR/DRI/ABO transgenic 
mice and DR1/ABO transgenic control mice was detected. 
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4.3.8 Expression of the T-cell costimulatory molecules CD69, CD3, CD54, CD25, 
CD44 and CD62L on freshly-isolated splenocytes in P4 TCR/DR1/ABO 
transgenic mice is similar to the expression seen in DR1/ABO transgenic 
control mice 
Splenocytes were isolated from the same mice as those used for analysis of 
costimulatory molecule expression in thymocytes and analysed for expression of the 
same molecules in conjunction with either CD4 or CD8, in order to investigate if the 
findings from the analysis of thymocytes were replicated in the spleen and hence the 
periphery. The gates used to define populations of splenocytes are shown in Figure 
4.22. The live splenocyte (or lymphocyte) gate determined on the basis of light-
scattering properties is shown in Figure 4.22a (as R3). Definition of populations on the 
basis of CD4 or CD8 expression and the expression of the costimulatory molecule being 
analysed are shown as FL-1 vs. FL-2 dot plots in Figure 4.22 b-g. Populations that were 
analysed are labelled accordingly. Table 4.3 shows the percentage of total splenocytes 
that were CD4+ or CD8+ only, and those that expressed CD4 or CD8 and were also 
positive for expression of the relevant costimulatory molecule. 
CD69 expression on P4 TCR/DR1/ABO transgenic thymocytes was broadly similar to 
the expression seen in DR1/ABO transgenic control thymocytes. In the spleen, very 
little CD69 expression was seen on either CD4+ or CD8+ T-cells, with CD4+CD69+ and 
CD8+CD69+ populations each accounting for less than 1.5% of total splenocytes. This is 
perhaps not surprising as the cells in this case were freshly isolated from the spleen and 
had not been activated in vitro before analysis and CD69 is a marker of activated T-
cells. In addition, they were isolated from healthy animals kept in clean conditions, so 
that no ongoing immune responses would be expected. There was no discernible 
difference in expression between P4 TCR/DR1/ABO transgenic mice and the 
DR1/ABO transgenic control mice in the line 4 experiment. 
There was no difference in the levels of CD3 expression seen in the thymocyte subsets 
of P4 TCR/DR1/ABO transgenic mice compared to DR1/ABO transgenic control mice, 
except for a possible increase in CD3 expression in the DN subset in the line 4 P4 
TCR/DR1/ABO transgenic mice. In the spleen, no difference in CD3 expression on 
either CD4+ or CD8+ T-cells between P4 TCR/DR1/ABO transgenic mice and 
DR1/ABO transgenic control mice was seen for the line 4 mice, as shown in Table 4.3. 
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Figure 4.22 Gating used for analysis of co-stimulatory molecule expression on splenocytes from P4 TCR/DRVABO transgenic mice by flow 
cytometry Each costimulatory molecule (in the FL-1 channel, x-axis) was analysed against CD4 (left-hand plot in (b)-(g) above) or CD8 expression 
(right-hand plot in (b)-(g) above) in the FL-2 channel (y-axis). Staining was positive or negative as shown by the quadrant gates above. (a) shows a 
forward- vs side-scatter plot identifying the live splenocyte gate. FL-1 stains used: (b) CD69, (c) CD3, (d) CD54, (e) CD25, (f) CD44 and (g) CD62L. 
TCR/DR1 DR1 only Tg TCR/DR1 
T1 - line 4 - line 4 T1 - line 16 
n=7 n n = 
CD69 
CD4+ CD69 1.40 ± 0.44 
CD4+ only 
CD8+ CD69÷ 
15.65 ± 4.32 
0.47 ± 0.12 
CD8+ only 6.71 ± 1.12 
CD3 
CD4+ CD3 12.12 _ 4.38 
CD4 only 1.62 ± 0.46 
CD8 CD3+ 
CD8+ only 
3.23 ± 0.45 
0.92 ± 0.19 
CD54 
13.60 ± 2.01 CD4+ CD54+ 14.97 ± 1.29 12.13 ± 1.95 
CD4 only 5.80 ± 2.64 7.25 ± 1.07 1.91 ± 0.40 
CD8+ CD54 4.52 ± 0.86 4.55 ± 0.77 4.93 ± 1.07 
CD8 only 0.26 ± 0.12 0.43 ± 0.14 0.16 ± 0.06 
CD25 
D4+ 	 P 
D4+ only 
0.99 ± 0.20 
16.94 ± 4.01 
0.90 ± 0.11 0.65 ± 0.06 
10.74 ± 0.90 17.98 ± 2.20 
D8+ CD25 0.45 ± 0.12 0.32 ± 0.13 0.17 ± 0.03 
D8 only 3.81 7.1.-. 0.87 3.75 ± 0.96 4.15 ± 1.31 
D44 
D4 	 P 	g 14.18 _ 2.23 13.72 ± 1.35 8.20 _ 3.06 
D4 	 P 	'  
D8+ CD44g 
9.85 ± 3.49 9.51 ± 1.31 7.33 ± 3.02  
4.76 ± 1.65 5.54 ± 2.45 4.60 ± 0.95 
CD8+ CD44" 2.96 ± 0.93 3.31 ± 0.64 2.48 ± 0.77 
CD62L 
CD4+ CD62L high 7.85 ± 2.85 8.25 ± 1.90 3.16 ± 0.48 
CD4+ CD62L " 15.64 ± 3.74 13.70 ± 0.39 10.04 ± 2.16 
CD8+ CD62L high 2.41 ± 0.62 3.04 ±  1.26 
1.42 ± 0.82 
1.27 ± 0.25 
CD8+ CD621,1" 1.75 ± 0.31 2.43 ± 0.96 
Table 4.3 	Expression of T-cell costimulatory molecules on splenocytes from P4 
TCR/DR1/ABO transgenic mice Values shown are percentages (± standard deviation) 
of total cells analysed in the R3 splenocyte gate as shown in Figure 4.23. Only CD4+ or 
CD8+ cells are shown. No DR1/ABO transgenic control mouse data is available for the 
line 16 experiment. 
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Approximately 12% of total splenocytes were CD4+CD3+ and approximately 4% of 
total splenocytes were CD8+CD3+. Also, in agreement with published reports, the 
majority of CD4+ (approximately 88%) and CD8+ (approximately 80-90%) cells also 
expressed CD3. 
No statistically significant difference in the level of CD54 expression was seen in the 
thymus of P4 TCR/DR1/ABO transgenic mice compared to DR1/ABO transgenic 
control mice; however, in the line 4 experiment, there was an apparent higher level of 
CD54 expression in the DN and CD8 SP subsets in P4 TCR/DR1/ABO transgenic mice. 
There was also no discernible difference in CD54 expression between P4 
TCR/DR1/ABO transgenic mice from line 4 and DR1/ABO transgenic control mice in 
the spleen, as shown in Table 4.3. Approximately 15% of total splenocytes were 
CD4+CD54+ whilst approximately 5% of total splenocytes were CD8+CD54+. The 
majority of CD4+ cells were also CD54÷ (ranging from 70 to 90%) as were the majority 
of CD8+ cells (approximately 90 to 95%). As can be seen in Figure 4.22d, staining with 
anti-CD54 antibody did not give rise to a discrete CD54+ population but rather a range 
of expression from low to high. Those CD4+ or CD8+ cells that did not express CD54 in 
this analysis may express very low levels and therefore appear in the CD54- gate. In 
summary, no difference in CD54 expression was seen on the CD4+ or CD8+ cells in the 
spleen of P4 TCR/DR1/ABO transgenic mice compared with the corresponding 
DR1/ABO transgenic control mice in the line 4 experiment. 
CD25 expression on P4 TCR/DR1/ABO transgenic thymocytes was similar to the level 
of expression seen in DR1/ABO transgenic control thymocytes. In the spleen, very little 
CD25 expression was seen on either CD4+ or CD8+ T-cells, as shown in Table 4.3. 
CD4+CD25+ and CD8+CD25+ populations each accounted for less than 1% of total 
splenocytes. As the cells in this case were freshly isolated from the spleen and therefore 
not activated and had not been activated in vitro before analysis, it was not expected 
that they would express high levels of CD25. There was no discernible difference in 
CD25 expression between P4 TCR/DR1/ABO transgenic mice in line 4 and the 
corresponding DR1/ABO transgenic control mice. 
CD44 is a cell adhesion molecule that is thought to be involved in the migration and 
homing of T-cells. There are a number of CD44 isotypes and it can also be differentially 
glycosylated; it is thought that CD44 may regulate tissue-specific homing of T-cells in 
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addition to its interaction with a number of different ligands, including hyaluronic acid 
and other components of the extracellular matrix such as collagen and fibronectin (662). 
CD44 is expressed at variable levels on peripheral T-cells depending upon the degree of 
differentiation of the cell. Memory T-cells are associated with the expression of high 
levels of CD44 but most peripheral T-cells express CD44 to some degree. CD44 
expression is also up-regulated on T-cells shortly after their activation (663). A decrease 
in CD44 expression on the DN subset of thymocytes was seen when comparing P4 
TCR/DR1/ABO transgenic mice with DR1/ABO transgenic control mice in both lines 4 
and 16, possibly as a consequence of the block in thymocyte development that is often 
seen in TCR transgenic mice in the DN subset. When analysing the extent of CD44 
expression on splenocytes these differences were not seen, as shown in Table 4.3. Using 
the gating shown in Figure 4.22f, approximately 14% of total splenocytes in line 4 P4 
TCR/DR1/ABO transgenic mice and DR1/ABO transgenic control mice were defined 
as CD4+CD44high (59% of total CD4+ cells) and approximately 10% of total splenocytes 
were defined as CD4+CD441' in these same mice. Approximately 5% of total 
splenocytes from these mice were defined as CD8+CD44high (55-65% of total CD8+ 
cells) and approximately 3% of total splenocytes were defined as CD8+CD441'. 
CD62L is a homing receptor for T-cells, facilitating interactions between T-cells and 
high endothelial venules (HEVs) and hence entry into the lymph nodes (664). As such, 
it is more highly expressed on non-activated cells such as naive and some memory T-
cells and is rapidly shed from the surface of the cell through proteolytic cleavage upon 
T-cell activation (665). Expression of CD62L in thymocytes from P4 TCR/DR1/ABO 
transgenic line 16 mice was higher in the DN, DP and CD8 SP subsets when compared 
to DR1/ABO littermates and P4 TCR/DR1/ABO transgenic mice from line 4. No 
difference in expression between DR1/ABO transgenic control mice and P4 
TCR/DR1/ABO transgenic mice from line 4 was seen. In the line 4 experiment, no 
difference in CD62L expression on CD4+ or CD8+ cells between P4 TCR/DR1/ABO 
transgenic mice and DR1/ABO transgenic control mice was seen, as shown in Table 
4.3. CD62L expression on CD4+ and CD8+ cells was defined as being either high or low 
as shown in Figure 4.23g. 30-40% of CD4+ splenocytes were thus defined as also being 
CD62Lhigh in P4 TCR/DR1/ABO transgenic mice from both line 4 and line 16 as well as 
the DR1/ABO transgenic control mice from the line 4 experiment. 
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4.3.9 Expression of the T-cell costimulatory molecules OX40 and its ligand 
OX4OL and ICOS on freshly-isolated splenocytes in P4 TCR/DR1/ABO 
transgenic mice is similar to the expression seen in DR1/ABO transgenic 
control mice 
As described previously, splenocytes were isolated from the same mice as those used 
for analysis of costimulatory molecule expression in thymocytes and analysed for 
expression of those molecules in conjunction with either CD4 or CD8. The gates used 
to define populations of splenocytes are shown in Figure 4.23. The live lymphocyte gate 
was determined on the basis of light-scattering properties (forward and side) and is 
shown in Figure 4.23a (R3). Populations, defined on the basis of CD4 or CD8 
expression and the expression of the costimulatory molecule being analysed, are shown 
as FL-1 vs. FL-2 dot plots in Figure 4.23 b-d. Table 4.4 shows the percentage of total 
splenocytes that were CD4+ or CD8+ only and those that expressed CD4 or CD8 and 
were also positive for expression of the relevant costimulatory molecule. In the case of 
OX4OL, which is not appreciably expressed on T-cells, OX40L+ cells are also shown. 
OX40, through interaction with its ligand OX4OL, is a costimulatory molecule that is 
expressed only after activation of a T-cell and expression peaks 2-3 days after initial 
activation (666). It is associated more strongly with CD4 T-cell responses than CD8 T-
cell responses. OX4OL is only expressed on antigen-presenting cells that have 
previously been activated themselves (652). OX40 promotes survival of T-cells through 
production of anti-apoptotic factors and promotes the development of memory T-cells 
(667). Expression of OX40 in thymocytes from P4 TCR/DR1/ABO transgenic line 4 
and line 16 mice was slightly higher in the DN subsets when compared to DR1/ABO 
transgenic control mice. In the spleen, very little OX40 expression was seen on either 
CD4+ or CD8+ T-cells as shown in Table 4.4, with CD4+0X40+ and CD8+0X40+ 
populations each accounting for less than 1% of total splenocytes. As the cells in this 
case were freshly isolated from the spleen and therefore not activated and had not been 
activated in vitro before analysis, it was not expected that they would express 
appreciable levels of OX40. There was no discernible difference in OX40 expression 
between P4 TCR/DR1/ABO transgenic mice and the DR1/ABO transgenic control mice 
in line 4. OX4OL is not highly expressed upon T-cells under any circumstances and 
hence CD4+ and CD8+ cells from the spleen did not express OX4OL to a detectable 
extent. 
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Figure 4.23 Gating used for analysis of expression of late activation-associated 
T-cell co-stimulatory molecules on splenocytes from P4 TCRIDR1/ABO transgenic 
mice by flow cytometry Each costimulatory molecule (FL-1 channel, x-axis for (b), 
FL-2 channel, y-axis for (c) and (d)) was analysed against CD4 (left-hand plot in (b)-(d) 
above) or CD8 expression (right-hand plot in (b)-(d) above) in the FL-2 channel (y-
axis) for (b), or the FL-1 channel (x-axis) for (c) and (d). Staining was either positive or 
negative, as shown by the quadrant gates above. (a) shows a forward scatter vs side-
scatter plot identifying the live splenocyte gate. FL-1 stains used: (b) 0X40, (c) OX4OL 
and (d) ICOS. 
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TCR/DR1 Tg DR1 only Tg - TCR/DR1 Tg 
- litie zlal limiCa_ - line 16 (%)  
n=7 n=3 n = 4 
OX40 
CD4+ OX40+ 
CD4+ only 
1.16 
16.93 
± 0.41 
± 3.76 
0.97 
18.37 
± 0.28 
± 2.35 
0.13 ± 0.03 
11.76 ± 1.28 
CD8+ OX40+ 0.14 ± 0.07 0.09 ± 0.04 0.05 ± 0.02 
CD8+ only 4.67 ± 1.04 5.51 ± 0.50 4.66 ± 1.79 
OX4OL 
CD4+ OX40L+ 0.12 ± 0.04 0.12 ± 0.03 1.59 ± 0.81 
CD4+ only 6.70 ± 2.72 8.95 ± 2.03 6.54 ± 1.22 
CD4" OX40L+ 
CD8+ OX40L+ 
0.87 
0.01 
± 0.31 0.82 ± 0.12 8.42 ± 1.49 
0.49 ± 0.23 ± 0.01 0.01 ± 0.01 
CD8+ only 1.91 ± 0.68 1.87 ± 0.94 1.68 ± 0.83 
CD8" OX40L+ 0.88 ± 0.58 0.56 ± 0.11 6.36 ± 1.43 
ICOS 
CD4+ ICOS+ 0.19 ± 0.11 0.26 ± 0.08 0.23 ± 0.06 
CD4+ only 6.75 ± 2.43 7.53 ± 2.12 ! 	5.36 ± 0.74 
CD8+ ICOS+ 
CD8+ only 
0.01 
2.46 
± 0.00 0.01 ± 0.01 0.02 ± 0.01 
1.57 ± 0.49 ± 0.49 2.45 ± 0.72 
Table 4.4 	Expression of the late activation-associated T-cell costimulatory 
molecules OX40, ICOS and OX4OL on splenocytes from P4 TCR/DR1/ABO 
transgenic mice Values shown are percentages (± standard deviation) of total cells 
analysed in the R3 splenocyte gate as shown in Figure 4.24. Only CD4+ or CD8+ cells 
are shown, except for the analysis of OX4OL, where CD4" CD8- OX40L+ cells are also 
shown. No data for DR1/ABO transgenic control mice in the line 16 experiment was 
available. 
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ICOS, like OX40, is an inducible costimulatory molecule that is only expressed on T-
cells some time after they have been activated. Expression of ICOS in thymocytes from 
P4 TCR/DR1/ABO transgenic line 4 and line 16 mice was lower in the DN subsets than 
in DR1/ABO transgenic control mice, and in the line 16 P4 TCR/DR1/ABO transgenic 
mice ICOS expression was also lower in the CD4 and CD8 SP subsets than when 
compared to DR1/ABO transgenic control mice. Very little ICOS expression was seen 
in the spleen of line 4 or line 16 P4 TCR/DR1/ABO transgenic mice or the DR1/ABO 
transgenic control mice from the line 4 experiment on either CD4+ or CD8+ T-cells. 
CD4+ICOS+ and CD8+ICOS± populations both accounted for less than 1% of total 
splenocytes. As the cells in this case were freshly isolated from spleen and hence were 
not activated, they were not expected to express appreciable levels of ICOS. There was 
no discernible difference in ICOS expression between P4 TCR/DR1/ABO transgenic 
mice and the DR1/ABO transgenic control mice in line 4. 
4.3.10 Summary of findings 
Expression of the costimulatory molecules CD69, CD3, CD54, CD25, CD44, CD62L, 
OX40, OX4OL and ICOS was analysed on the surface of freshly isolated splenocytes 
and thymocytes of P4 TCR/DR1/ABO transgenic mice from line 4 and line 16 and 
compared with the expression on DR1/ABO transgenic control mice. No differences 
were seen between P4 TCR/DR1/ABO transgenic mice from line 4 and DR1/ABO 
transgenic control mice in the expression of any of the studied molecules on freshly 
isolated splenocytes. In addition, no statistically significant differences were seen in the 
expression of CD69, CD3, CD54 or CD25 on freshly isolated thymocytes between P4 
TCR/DR1/ABO transgenic mice from either line and DR1/ABO transgenic control 
mice. However, some differences were noted between P4 TCR/DR1/ABO transgenic 
mice and DR1/ABO transgenic control mice. A block in thymocyte development at the 
DN stage was apparent in both line 4 and line 16 P4 TCR/DR1/ABO transgenic mice, 
shown as an increase in the proportion of CD4-CD8- cells in the thymus when compared 
with DR1/ABO transgenic control mice. In addition, CD44 expression in P4 
TCR/DR1/ABO transgenic mice from line 4 and line 16 was decreased in the DN subset 
when compared to DR1/ABO transgenic control mice. An increase in high expression 
of CD62L in the DN, DP and CD8 SP subsets was seen in line 16 P4 TCR/DR1/ABO 
transgenic mice when compared to both DR1/ABO transgenic control mice and line 4 
P4 TCR/DR1/ABO transgenic mice. In addition, a small but significant increase in 
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OX40 expression was seen on DN thymocytes from line 4 and line 16 P4 
TCR/DR1/ABO transgenic mice when compared to DR1/ABO transgenic control mice. 
Finally, down-regulation of ICOS expression was seen in DN thymocytes from both 
line 4 and line 16 P4 TCR/DRI/ABO transgenic mice when compared to DR1/ABO 
transgenic control mice. ICOS expression was also down-regulated in CD4 SP 
thymocytes from line 16 P4 TCR/DR1/ABO transgenic mice in comparison to both line 
4 P4 TCR/DRI/ABO transgenic mice and DR1/ABO transgenic control mice. The main 
differences identified through this analysis are shown in Table 4.5. 
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Molecule Difference seen in the thymus 
CD4/CD8 i Increase in the number of DN (i.e. CD4" CD8) thymocytes in P4 
TCR/DR1/ABO transgenic mice compared with DR1/ABO 
transgenic controls 
CD44 
CD62L 
Decreased level of expression on cells of the DN subset in P4 
TCR/DR1/ABO transgenic mice compared with DR1/ABO 
transgenic controls 
Increased levels of expression on cells of the DN, DP and CD8 
SP subsets of P4 TCR/DR1/ABO transgenic mice compared with 
DR1/ABO transgenic controls (line 16 only) 
OX40 	Small increase in expression on DN cells of TCR/DR1/ABO 
transgenic mice compared with DR1/ABO transgenic controls 
ICOS 	Decreased expression on cells of the DN and CD4 SP subsets in 
TCR/DR1/ABO transgenic mice compared with DR1/ABO 
transgenic controls (line 16 only) 
Table 4.5 	The differences identified in levels of expression of costimulatory 
molecules at the cell surface of thymocyte subsets between P4 TCR/DR1/ABO 
transgenic mice from lines 4 and 16 and DR1/ABO transgenic control mice by flow 
cytometry. 
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4.4 	Discussion 
This chapter describes some very preliminary experiments on the characterisation of a 
humanised TCR/MHC class II transgenic mouse, the P4 TCR/DR1/ABO mouse, 
developed for use as a model of allergic asthma in the Boyton laboratory by three post-
doctoral scientists (Dr. Alexander Annenkov, Dr. Catherine Reynolds and Dr. Xiaoming 
Cheng) with funding from Asthma UK. Sensitisation (by intraperitoneal injection of Fel 
d 1) and challenge (by intranasal administration of whole cat dander extract) was used 
to investigate whether an allergic airway disease phenotype was seen in these mice 
(287). Fel d 1-sensitised mice responded to methacholine challenge to a greater extent 
than did unsensitised mice (both Penh and resistance/compliance parameters). The use 
of larger groups (n=10) and repeat experiments to refine the protocols should improve 
the disease phenotype of the model. Cell counts in the BAL fluid and lung tissue of 
mice that had been sensitised with Fel d 1 were increased compared to controls, and in 
line 16 this result was statistically significant. Such an influx of cells into the lung is 
consistent with the development of an immune response in the lungs of these mice. In 
all cases, this influx of cells was predominantly eosinophilic. A similar result was seen 
when analysing cell counts recovered from the lung tissue in terms of eosinophilic 
influx - the proportion of cells recovered that were eosinophils was greatly increased in 
sensitised mice. Allergic asthmatic disease in humans is associated with an influx of 
eosinophils into the lung and is thus a feature of the disease that is replicated faithfully 
in this mouse model. Another common feature of allergic asthma in humans is the 
increase in incidence of IgE in the serum and this was also seen in the Fel d 1-sensitised 
mice. Analysis of Th2-type cytokine production in the experiment using line 4 mice 
(lower dose of cat dander extract for challenge) showed increased IL-4, IL-5 and IL-13 
in the BAL fluid with Fel d 1 sensitisation. IL-4, IL-5 and IL-13 cytokine production in 
the lung tissue increased in line 16 P4 TCR/DR1/ABO transgenic mice between 
sensitised and unsensitised groups. Histological analysis of frozen lung sections 
suggested that there was mild lung inflammation (both peribronchiolar and 
perivascular) and mucus production in Fel d 1-sensitised mice. Both of these are 
features of the human disease and their induction in this system further lends to the 
faithfulness of the TCR/MHC class II transgenic mouse model of allergic asthma to 
human disease. 
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Use of a mouse expressing human genes as the basis for the development of a model of 
allergic asthma may make the model more relevant to the human disease than the other 
models currently in use. This has been shown to be the case in mouse models of 
multiple sclerosis (EAE) where use of humanised TCR transgenic mice produced a 
model that replicated the disease in humans more faithfully than using non-humanised 
mice (283). Most mouse models of allergic asthma in use today make use of ovalbumin 
as an allergen, often in the Balb/c strain of mice (286). Whilst a phenotype correlating 
with allergic asthma (lung function defects, increased levels of IgE, lung inflammation 
and mucus hypersecretion) is seen in these mice, there are disadvantages to this 
approach. Humans do not develop allergic asthma in response to ovalbumin and hence 
this model utilises an irrelevant antigen and the use of mice which do not naturally 
become sensitised to allergen through inhalational exposure and are of a strain that have 
a tendency to mount Th2-biased immune responses means that a highly artificial system 
of sensitisation is employed, involving systemic injection of high doses of allergen. It is 
also difficult to develop a chronic phenotype in such mice as they quickly become 
tolerised to the allergen; however, a chronic phenotype, particularly involving 
remodelling of the lung, is far more relevant to human disease. Other models have 
attempted to address these issues and have had more success — use of a more relevant 
allergen, Der p 1 from house dust mite, has shown more promising results in terms of 
development of a chronic disease phenotype (315); however, systemic sensitisation is 
often (though not always) required in this model. There are TCR transgenic mouse 
models of both OVA- (D011.10, 326, 328) and HDM-induced (330) allergic asthma 
which appear to be somewhat more receptive to induction of disease through inhalation, 
making them more relevant to the human disease. 
Induction of a disease-like phenotype was achieved in the P4 TCR/DR1/ABO mice. It 
will now be possible to develop this model of allergic airway disease to study prolonged 
(chronic) exposure to allergen through inhalation, thus providing a model that is highly 
similar in terms of both disease induction and disease pathogenesis to the human 
disease. In addition, the presence of a human TCR implicated in disease pathogenesis in 
allergic asthma may allow additional study of the precise role of dominant TCR-
expressing T-cells in allergic asthmatic disease. The mechanisms underlying the 
tolerance to allergen that is induced by peptide immunotherapy in humans can also be 
investigated through the development of a model of peptide-induced tolerance in this 
mouse line. The transgenic T-cells are likely to act as pathogenic effector cells in this 
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allergic disease model and the effect of peptide immunisation on the development of 
disease in these mice could give valuable insights into the underlying mechanisms 
involved in tolerance induction in human allergic asthma. In addition, these mice may 
also be useful in the study of other aspects of allergic disease pathogenesis. For 
example, the role of pulmonary infections such as respiratory syncytial virus (RSV) or 
influenza virus, especially the role such infections may have on the T-cells involved in 
causing asthma pathogenesis, could be investigated using this model. In particular, the 
impact of the timing of viral infection on the development and severity of allergic 
asthma pathogenesis has been shown to be important (668, 26). Viral infection prior to 
allergen exposure is thought to exacerbate the allergic syndrome which develops, 
somewhat counter-intuitively, as such infections promote a Thl -type response and the 
production of significant quantities of IFN-y. It was therefore supposed that such 
infections would protect against the development of asthma by antagonising the 
development of Th2-type responses in the lung but findings from other mouse studies 
have contradicted this view (668, 26). The development of a humanised TCR transgenic 
mouse model of allergic asthma may allow a more detailed investigation of the effect of 
such infections on the allergen-specific TCR transgenic T-cells. Another aspect of 
allergic asthma that is difficult to study in humans is lung remodelling, both the 
underlying mechanisms of remodelling and its function. Mouse models have been 
developed that show features of remodelling such as airway smooth muscle hyperplasia, 
basement membrane thickening and epithelial cell changes (293, 315) and have begun 
to identify factors that are important in the development of lung remodelling such as 
TGF-13 (669, 670) and VEGF (671). The development of a humanised TCR transgenic 
mouse model of allergic asthma that shows features of remodelling would also allow, 
among other lines of study, the investigation of the role of allergen-specific T-cells in 
inducing remodelling. 
It has been observed in other TCR transgenic mice that T-cell development is often 
abnormal, particularly in the thymus where expression of a rearranged TCRa chain at 
the DN stage of development impedes normal progression through the 13-selection 
checkpoint (425). This causes a block in development at this point due to the TCRa 
chain having a higher affinity for newly rearranged (or transgenic) TCRJ3 chains than 
the pre-TCRa chain and it is the signals transmitted through the pre-TCRa-TCRP 
complex that allow progression through the checkpoint. This manifests as an increase in 
DN cell number in TCR transgenic mice when compared to non-TCR transgenic mice 
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and this phenomenon was observed in both line 4 and line 16 P4 TCR/DR1/ABO 
transgenic mice, suggesting that transgenic TCR expression is occurring in these mice. 
T-cell numbers and function in the peripheral circulation of TCR transgenic mice is 
comparable to that seen in non-transgenic mice but the repertoire of expressed TCRs is 
usually more restricted and dominated by the transgenic TCR. 
To investigate whether the expression of a transgenic TCR affected the expression of 
membrane-bound costimulatory molecules involved in T-cell signalling and function, 
expression of these molecules was analysed immediately ex vivo by flow cytometry in 
the P4 TCR/DR1/ABO transgenic mice in both the thymus and the spleen (i.e. 
peripheral T-cells) and compared to the expression seen in non-TCR transgenic 
DR1/ABO mice. Differences in the expression of a number of these analysed molecules 
were seen in the thymi of P4 TCR/DR1/ABO transgenic mice when compared to the 
non-TCR transgenic DR1/ABO transgenic control mice. CD44 expression in the DN 
subset of thymocytes was shown to be lower in the P4 TCR/DR1/ABO transgenic mice 
than in the DR1/ABO transgenic control mice in both lines 4 and 16. Together with 
CD25, CD44 expression defines a further four subsets in the DN population, DN1-DN4 
(DN1 - CD44±CD25-, DN2 - CD44+CD25±, DN3 - CD44-CD25+ and DN4 - CD44-
CD25-) (416). A decrease in CD44 expression in DN cells from P4 TCR/DR1/ABO 
transgenic thymi indicates either a decrease in the number of CD44-expressing cells or 
an increase in the number of CD44- cells. As it has been shown that transgenic TCR 
expression in the thymus at the DN stage prevents progression through the f3-selection 
checkpoint (424), this results in a build-up of thymocytes at the DN3 (CD44-CD25+) 
stage as the checkpoint occurs at the DN3 to DN4 transition. This would be shown not 
only as an overall increase in DN cell number (which is also seen in these mice) but 
more particularly an increase in the number of DN3 cells and this would manifest as a 
decrease in the proportion of DN cells expressing CD44 which is also seen in these 
mice. A corresponding increase in the levels of expression of CD25 might also be 
expected in these mice - however, this was not seen in these experiments. 
Analysis of CD62L expression in the thymus showed differences in expression levels 
between TCR transgenic and non-TCR transgenic mice in line 16 mice only, more 
specifically an increase in expression in the DN (by 15%), DP (by 5%) and CD8 SP (by 
15%) subsets. In addition, a concomitant increase in MFI of the CD62L+ cells in these 
mice was seen. None of these differences were seen in the CD4 SP subset. CD62L 
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identifies those cells of the common lymphoid progenitor lineage that are destined to 
migrate to the thymus and develop along the T-cell lineage (647). An increase in 
CD62L expression in the DN subset which has been shown to gradually down-regulate 
as the cell progresses through the thymus, may indicate a higher proportion of the 
earliest T-cell progenitors in the thymus in this line of mice. This might suggest that a 
higher number of common lymphoid progenitors in these mice have been directed to the 
T-cell lineage or that there may be an early block (at the DN1 stage) in thymocyte 
development in these mice. No other data from this experiment suggests this however, 
and the analysis of CD44 expression in the DN subset would appear to contradict it. In 
addition, CD62L expression is up-regulated on mature SP thymocytes prior to their 
emigration from the thymus and it is thus used as a marker for the most mature 
thymocytes in the SP populations (655). Interestingly, in the line 16 P4 TCR/DR1/ABO 
transgenic mice expression of CD62L was higher in the CD8 SP subset than in 
DR1/ABO transgenic control mice and line 4 P4 TCR/DR1/ABO mice - the difference 
in expression seen in these lines may represent a difference in emigration rates of CD8+ 
mature thymocytes with mature CD8 SP thymocytes not emigrating as efficiently as 
CD4 SP in the line 16 mice. This is perhaps not borne out by analysis of T-cell numbers 
in the periphery where numbers of CD4+ and CD8+ T-cells and the ratio of CD4/CD8 T-
cells was similar in both P4 TCR/DR1/ABO transgenic mice and their DR1/ABO 
transgenic control mice, but there are likely to be other mechanisms of controlling T-
cell numbers and maintaining their homeostasis in the periphery. 
In the analysis of differences in costimulatory molecule expression in the thymi of P4 
TCR/DR1/ABO transgenic mice compared with their DR1/ABO transgenic control 
mice, it became apparent that in some cases only line 16 P4 TCR/DR1/ABO transgenic 
mice showed a difference in expression when compared with DR1/ABO transgenic 
control mice, whilst line 4 P4 TCR/DR1/ABO transgenic mice showed similar 
responses to the non-TCR transgenic DR1/ABO controls. As line 4 and line 16 mice 
were generated from different founders and were not interbred, they may differ in terms 
of TCR transgene expression e.g. copy number or position of insertion into the genome. 
Such differences may lead to a difference in expression levels of the transgenes and thus 
differences in the response of the two lines to varying stimuli. Increased copy number 
may translate into increased surface expression whilst different locations of transgene 
insertion may cause differences in expression levels due to differing influences on 
expression from nearby endogenous promoter or repressor regions within the genome. 
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Insertion near a strong global enhancer or promoter region could increase expression 
levels; conversely, insertion near a strong global repressor region could decrease 
expression. It might be possible to develop a Southern hybridisation strategy that could 
determine the number of insertion sites for each line - this was not possible with the 
Southern hybridisation protocol described here as the restriction enzyme used to digest 
the genomic DNA cut on either side of the transgene within the pTcass construct 
sequence - and which might also give some information as to the number of transgene 
copies inserted. 
Other molecules that were assessed including CD3, CD25, CD54 and CD69, showed no 
statistically significant differences in expression in thymocytes between P4 
TCR/DR1/ABO transgenic mice and DR1/ABO transgenic control mice in either line. 
Levels of expression of these molecules correlated in terms of expression patterns and 
approximate extent of expression with levels reported in the literature. It was predicted 
that CD3 expression would be altered in the TCR transgenic mice due to the presence of 
a transgenic TCR which would alter the levels of TCR expression in each subset and 
would be reflected in the alteration of CD3 expression. An increase in CD3 expression 
in the DN subset was seen in the P4 TCR/DR1/ABO mice from line 4 when compared 
with DR1/ABO transgenic control mice which was not statistically significant. 
Nonetheless this difference could be of genuine relevance, caused by the expression of 
the transgenic rearranged TCR molecule at the cell surface at this stage where TCR 
expression is not normally seen. CD69, an early activation marker on peripheral T-cells, 
is associated with positive selection events in the thymus (648) and hence is expressed 
most strongly on DP and SP thymocytes. The effect of a transgenic TCR in the thymus 
at this stage of development has not been well characterised; a change in the levels of 
CD69 might indicate that there is an effect. Although not a statistically significant 
finding, CD69 expression in the SP subsets appeared to be lower in the P4 
TCR/DR1/ABO transgenic mice in both lines 4 and 16 when compared to the 
DR1/ABO transgenic control mice in each case — this might suggest that there is a 
difference in positive selection that is associated with the expression of a transgenic 
TCR. 
Other costimulatory molecules such as ICOS and OX40 are expressed later in 
activation, reaching a peak of expression 2-3 days after activation. The roles of these 
secondary costimulatory molecules in the thymus are not well characterised although 
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expression of both OX40 (649) and ICOS (653) in the thymus has been reported. They 
are predominantly expressed in the thymic medulla which suggests that they are 
associated with SP thymocytes. In the periphery, ICOS is more associated with CD4+ T-
cells than CD8+ T-cells and it is related to CD28, exerting a similar function as CD28 
but later in the activation process (651) where it is thought to promote survival of 
activated cells through inhibition of apoptosis. Although the function of ICOS in the 
thymus is currently unknown, its function might be related to its peripheral function, 
perhaps through promotion of survival of thymocytes undergoing thymic selection or 
which have been positively selected and this function may be affected by the presence 
of a transgenic TCR. Thymocytes in the line 16 P4 TCR/DR1/ABO transgenic mice 
showed down-regulated levels of ICOS in the CD4 single positive subset (a 
phenomenon not observed in the line 4 P4 TCRJDR1/ABO transgenic mice); as yet the 
significance of this is unclear as the role of ICOS in the thymus has not been determined 
in any detail, but this difference between TCR transgenic and non-TCR transgenic mice 
suggests that it warrants further investigation. If, as suggested above, the function of 
ICOS is to prolong survival of thymocytes undergoing selection, giving them more 
opportunity to produce a positively-selectable TCR, the down-regulation of ICOS 
expression in the line 16 P4 TCR/DR1/ABO transgenic mice may reflect this role - as 
TCR transgenic thymocytes already express a rearranged cq3 TCR, there may be less 
opportunity for endogenous TCRa rearrangement to occur and therefore less 
requirement for ICOS expression to prolong the life of these thymocytes, hence its 
lower expression. 
As with ICOS, the role of OX40 (and its ligand OX4OL) in the thymus is not well-
characterised. OX40 is expressed in the CD4 and CD8 SP subsets of the thymus and 
expression is higher on the CD4 SP than the CD8 SP subset, although lower levels of 
expression in the DP and DN subsets have also been reported (649). This is similar to 
the distribution of ICOS in the thymus and as both molecules play a role in the 
periphery in promoting T-cell survival (667) this may also be their thymic function. The 
analysis of OX40 expression in the thymus undertaken here showed a small increase in 
OX40 expression in the DN cells of P4 TCRJDR1/ABO transgenic thymi. However, 
OX40 expression was not related to the expression of other DN cell markers such as 
CD44 or CD25, hence it was not possible to tell whether this increase was common to 
all DN cells or a particular subset or subsets, and thus it is difficult to suggest the role of 
OX40 in the thymus in these mice. Possibly, OX40 is involved in promoting survival of 
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thymocytes at the n-selection checkpoint, perhaps through prolonging the lifespan of 
thymocytes undergoing TC1113 chain rearrangement and giving them more opportunity 
to correctly rearrange the gene; the increase in OX40 expression in TCR transgenic DN 
thymocytes may be due to the failure of thymocytes expressing a transgenic TCR to 
progress through the checkpoint. However, further study of the expression of OX40 in 
conjunction with other molecules such as CD3, CD44 or CD25 would be required to 
confirm this theory. 
The immediately ex vivo analysis of the expression of these molecules in splenocytes 
did not show any differences between the P4 TCR/DR1/ABO transgenic mice and the 
DR1/ABO transgenic control mice and thus the differences seen in the thymus were not 
replicated in the periphery. It is possible that differences would be seen if the 
splenocytes were activated in vitro, either specifically with peptide 4/DR1 or non-
specifically with anti-CD3/anti-CD28, before analysis, particularly in the case of 
molecules such as ICOS which are associated with activated T-cells. The expression of 
these molecules could be assessed at different time points after activation to investigate 
if there are any differences in the splenocyte responses and if analysis of activated 
thymocytes was also carried out, whether the same or other differences are apparent in 
the thymocytes under these circumstances. 
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5. 	Summary 
In this thesis, analysis of TCR CDR3 usage in human T-cell lines derived from HLA-
DR1+, cat-allergic asthmatic subjects and generated against the important T-cell epitope 
of Fel d 1 (the major cat allergen), peptide 4, identified populations of T-cells 
expressing particular TCRs which expanded in response to peptide stimulation. Some 
expanded TCRs carried CDR3a and 13 loops which were elongated when compared to 
the mean length of these loops in unstimulated human T-cells, as defined by Moss and 
Bell (586). Previous work from our laboratory (601) had suggested that the length of 
TCR CDR3 loops may influence T-cell phenotype upon activation through interaction 
with cognate peptide-MHC complex, with elongated CDR3s being favoured by 
developing Th2 cells. Attempts were made to transduce the murine lymphoma TCR-
negative line BW7 with TCRs both from this previous study (601) and those identified 
in the human TCR CDR3 analysis here but these attempts were not successful and I did 
not take this line of investigation forward. 
Early characterisation of a humanised TCR/MHC class II transgenic mouse model of 
allergic asthma, the P4 TCR/DR1/ABO model, originally developed by postdoctoral 
research associates in our laboratory, is described. The P4 TCR expressed by these mice 
was identified through clonotypic analysis of multiple HLA-DR1-restricted peptide 4-
specific T-cell lines derived from FILA-DR1+ cat allergic subjects. It is expressed with 
HLA-DR1 on a murine MHC class II knockout background. Characterisation of this 
TCR transgenic mouse in terms of the expression of costimulatory molecules in the 
spleen and thymus is described. Differences in the expression of some costimulatory 
molecules, namely CD44, CD62L, ICOS and OX40, were seen in the thymus but not 
spleen. 
Many factors have been shown to affect the fate of a naive T-cell upon its activation by 
encounter with antigen, such as the prevailing cytokine environment (i.e. IL-12 favours 
Thl (511) whilst IL-4 favours Th2 (232)) or the type of cell presenting the antigen (e.g. 
DC1 or DC2 (547)). Other factors that influence the development of an activated naive 
T-cell are related to the direct interaction between the TCR and peptide-MHC complex, 
such as the dose of antigen available (very high or very low favours Th2 whilst 
intermediate doses favour Thl (572, 573)) and the affinity/avidity of the TCR itself for 
peptide-MHC, which may influence the strength and duration of binding. The strength 
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of the interaction and the length of time for which it persists directly affect the T-cell's 
fate — it is thought that a shorter, less optimal binding may promote Th2 development 
through its failure to initiate the full TCR signalling complement whilst interactions that 
persist for long enough to initiate full signalling appear to promote Thl differentiation 
(575, 576). The affinity and avidity of the TCR-peptide-MHC interaction is likely to be 
at least in part a function of TCR structure. CDR loops 1, 2 and 3 in the variable 
(V(D)J) regions of the TCRa and 13 chains have been shown by crystallographic studies 
to contact the peptide-MHC and thus constitute the antigen-binding site (379, 380). The 
structure of the TCR at this region is therefore likely to be the most crucial in terms of 
affecting the affinity/avidity of the interaction. Mutagenesis studies suggest that these 
loops are responsible for antigen specificity and that the CDR3 loop (formed during 
gene rearrangement events at the V(D)J junction (404)) in particular confers specificity 
for peptide onto the TCR (589, 592). Clonal expansions of T-cells bearing receptors 
with not only identical V(D)J usage but also identical CDR3 loop amino acid sequence 
(or sequence motifs) suggest the importance of features in the CDR3 loops in conferring 
this specificity (597). In our laboratory, analysis of CDR3 loop structure in TCRs 
isolated from T-cell clones raised against the same antigen but polarised towards Thl or 
Th2 differentiation by the addition of exogenous cytokines suggested that Th2-
polarising conditions favoured the expansion of TCRs containing elongated CDR3 
loops with bulkier amino acid sidechains when compared with those favoured by Thl-
polarising conditions (601). Molecular modelling studies of the CDR3 loops from the 
Thl and Th2 clones suggested that the elongated loop and the bulky sidechains 
protruded into the interface with the cognate antigen peptide-MHC complex and 
prevented tight binding, thus promoting a less optimal interaction that has been linked 
to the development of a Th2 response, suggesting that the structure of the TCR 
expressed by a T-cell may influence the ability of the T-cell to mount a particular 
immune response in response to challenge with antigen. 
The clonal expansion of T-cells bearing a particular TCR in response to an antigenic 
challenge have been well documented in instances of CTL responses to viral infection 
(618, 621) and in T helper cell responses implicated in autoimmune diseases such as 
multiple sclerosis (625, 626) or rheumatoid arthritis (631) but have not been extensively 
investigated in Th2-mediated responses such as those implicated in the development of 
allergic disease. As such, TCR CDR3 sequence analysis was carried out (as shown in 
Chapter 3 of this thesis) on T-cell lines derived from allergic asthmatic subjects who 
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were sensitive to the major allergen of cat dander, Fel d 1, and carried the MHC class II 
molecule HLA-DR1. Such subjects mount T-cell responses to a particular epitope of Fel 
d 1 known as peptide 4 (221) and lines were grown and restimulated in vitro in response 
to this peptide presented by HLA-DR1+ APCs and analysed at different restimulation 
timepoints. TCR sequence analysis of these lines identified the expansion of T-cells 
bearing the same or similar receptors within each line, with the expansions becoming 
more oligoclonal in nature as the number of restimulations the line had been subjected 
to increased. In addition, in two out of three lines one of the expanded CDR3 loops was 
elongated in comparison to the defined mean lengths of CDR3 loops in unstimulated 
human T-cells (586) on either the TCR a or 13 chain. My attempts to express the TCRs 
identified from the human T-cell lines and the Thl and Th2 clone TCRs (601) in the 
immortalised T-cell lineage cell line, BW7, were unsuccessful. The transduction of such 
a line would have allowed the study of the impact of TCR structure on T-cell 
phenotype. 
Allergic asthma is a human disease that is widely accepted to be caused by the actions 
of allergen-specific Th2 cells in the lung (215-218) leading to airway hyperreactivity, 
eosinophilic lung inflammation (238), the production of allergen-specific IgE (60), 
mucus hypersecretion in the airways (241) and chronic remodelling changes in the lung. 
There are difficulties, as with any human disease, in conducting in vivo studies in 
humans due to both practical and ethical constraints and so investigations into disease 
mechanisms in a human system are limited to in vitro cell cultures and histological 
analysis. As such, the development of animal models of the disease in order to study the 
mechanisms involved in allergic airway disease is crucially important. The most 
common model in use is the ovalbumin model in Balb/c mice (286, 287) or its variant in 
the D011.10 OVA-specific TCR transgenic mouse (325, 326) in spite of problems with 
the model, namely that it uses an irrelevant antigen and the method of disease induction 
used, systemic sensitisation followed by challenge in the lung, is the only method that 
has been found that consistently induces allergic lung disease in this model but bears 
little relation to the disease induction pathways in humans. In addition, it is difficult to 
induce a chronic disease phenotype through the airways in this model (292). As such, 
there is little relation between this model and the human disease although there have 
been modifications made to the protocol that are reported to improve the accuracy of 
this model. A significant body of work has also been carried out in a model that makes 
use of house dust mite allergen (312). Use of this allergen has allowed the development 
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of a protocol for the induction of chronic disease which shows some features of 
remodelling (315). There are TCR transgenic models for both OVA and HDM which 
both show some promise in improving the accuracy of the disease model to the human 
condition (325, 330). However, in both cases the transgenic TCR was derived from the 
murine systems that were originally used. There are no published humanised TCR 
transgenic models for allergic asthma despite their superiority as models of other human 
diseases, for example in multiple sclerosis/EAE. The P4 TCR/DR1/ABO transgenic 
mouse lines described in Chapter 4 were developed in the Boyton laboratory by 
postdoctoral research associates funded by Asthma UK. Here, these mice were 
subjected to an allergic disease induction protocol, comprising an intraperitoneal 
sensitisation phase (with Fel d 1) and an intranasal challenge phase (with whole cat 
dander extract) and the induction of disease was measured by various parameters. The 
disease phenotype induced comprised induction of AHR, lung eosinophilia, increased 
total serum IgE, lung inflammation and mucus secretion. This is a potentially excellent 
model of allergic airway disease that has the advantage of being a humanised 
TCR/MHC class II transgenic model of allergic disease against a relevant allergen. 
The presence of a rearranged al3 TCR in the thymus in TCR transgenic mice has been 
shown to cause abnormalities in T-cell development in the thymus as its expression at 
the thymocyte cell surface interferes with the progression of the thymocyte through the 
p-selection checkpoint (424). The effect of transgenic TCR expression on the 
expression of costimulatory molecules involved in T-cell function and signalling 
through the TCR was therefore investigated in the thymus and spleen of the P4 
TCR/DR1/ABO mice, as shown in Chapter 4 of this thesis. Cells were analysed 
immediately ex vivo without any further intervention to give a biologically relevant 
picture of events in the thymus as they were occurring in vivo and then compared 
against splenocytes in the same unactivated state. It might be that further differences 
will be seen if the cells are analysed after in vitro activation (or in vivo activation in the 
mouse itself), particularly in the peripheral T-cells, as no differences were seen in any of 
the molecules analysed between P4 TCR/DR1/ABO transgenic mice and DR1/ABO 
transgenic control mice in the periphery, despite differences being seen in the thymus. 
In thymocytes, a block in development at the DN stage identified as an increase in the 
number of cells expressing neither CD4 nor CD8 was seen. This is a characteristic of 
TCR transgenic mice due to the premature expression of a rearranged TCRa chain at 
this stage of development preventing efficient passage through the I3-selection 
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checkpoint (425). In addition, a decrease in CD44 expression was seen in the TCR 
transgenic mice, also at the DN stage, which may also be linked to the block in 
development seen in TCR transgenic thymocytes at this stage; as the block in 
development occurs at the DN3 stage (CD44- CD25+), one might expect there to be an 
overall apparent decrease in CD44 expression in these mice, as there are increased 
numbers of cells in this subset present in the thymus. Other molecules showing 
differences included CD62L, the expression of which was increased in all subsets 
except the CD4 SP subset but this was seen only in TCR transgenic mice from line 16. 
The increase in CD62L expression in the DN subset (where it is thought to be 
particularly expressed on cells that have recently migrated into the thymus (647)) may 
indicate a block in development at a very early stage and the later increase in the CD8 
SP may indicate a difference in the TCR transgenic mice in the rates of emigration of 
mature thymocytes from the thymus, with CD8 SP emigrating less efficiently than CD4 
SP thymocytes. Both OX40 and ICOS expression showed differences between the TCR 
transgenic mice when compared against the non-TCR transgenic control mice. ICOS 
and OX40 are both expressed late after T-cell activation in the periphery (667, 651) and 
although both are expressed in the thymus (primarily in the medulla) their function there 
is currently unknown (653, 649). OX40 expression was shown to be slightly increased 
in the DN subset in TCR transgenic mice whilst ICOS expression decreased in the DN 
and CD4 SP subsets in TCR transgenic mice from line 16 mice only. In the periphery, 
both OX40 and ICOS promote the survival of activated T-cells through inhibition of 
apoptosis in these cells. OX40 also promotes the development of activated T-cells into 
memory cells (667). If these molecules have a similar anti-apoptotic role in the thymus 
then it would be expected that the presence of a transgenic TCR might have some 
impact on their function. As a difference in OX40 expression was seen in the DN 
subset, OX40 may be involved in promoting the survival of thymocytes at the (3-
selection checkpoint, increasing the time available for correct rearrangement of the 
TCR13 chain, and the increase in expression seen might be caused by the inefficiency 
with which thymocytes expressing a transgenic TCR can pass the checkpoint. Part of 
the function of ICOS in the thymus may be to prolong survival of thymocytes 
undergoing positive and negative selection, thus allowing such thymocytes a greater 
opportunity of correctly rearranging a TCRa chain to produce a fully-rearranged TCR 
that can be positively selected. The observed down-regulation of ICOS expression in the 
line 16 TCR transgenic mice may therefore be caused by the decreased requirement for 
endogenous TCRa rearrangement due to the presence of an already rearranged apTCR 
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and the ensuing decreased requirement for ICOS to prolong the life of these thymocytes 
leads to its lower expression. Further study of the expression of these molecules in 
terms of each other and other processes such as TCR signalling will enable elucidation 
of the meaning of such findings. 
There are a number of different approaches that could be used to further the research 
described in this thesis. For example, the P4 TCR/DR1/ABO transgenic mice can be 
used to develop an improved humanised model of allergic disease by attempting to 
develop a model in which disease can be induced through a more physiologically 
relevant protocol i.e. with both sensitisation and challenge occurring through the 
airways and which induces a chronic condition with features of remodelling. Such a 
model can then be used to investigate aspects of allergic airway disease, such as the 
impact of viral infection on allergic airway disease and the development of a model that 
will allow the investigation of the mechanisms underlying the development of peptide-
induced tolerance as this has particularly important therapeutic applications. In addition, 
these mice could be used in the investigation of the impact of TLR signalling through 
various receptors and ligands on both the development and progression of allergic 
disease. The hygiene hypothesis suggests that as standards of cleanliness and hygiene 
have improved, children are being exposed to lower levels of foreign pathogens which 
results in the incorrect development of their immune system (5). The TLR system works 
as an 'early warning system', alerting the immune system to the presence of foreign 
antigens through recognition of particular pathogen-associated motifs followed by 
signalling to raise the alarm (672). This implicates TLR signalling in the correct 
development of a naive immune system and suggests that signals through different 
TLRs could differentially impact upon allergic airway disease, and this model would 
provide a means of investigating TLR signalling in allergic asthma. As the T-cell (Th2 
cell) is so strongly implicated in the development of allergic asthma, the presence of a 
transgenically expressed allergen-specific TCR in these mice may allow the easier 
investigation of the role of the T-cell and the impact of other phenomena (e.g. viral 
infection, different TLR signals, tolerance induction) on the allergen-specific transgenic 
TCR-expressing T-cell response. The existence of HLA-DR1-peptide 4 tetramers 
allows the cells to be easily isolated for culture in vitro or identified in histological 
analysis to show their distribution in affected lung tissue. In addition, the development 
of a model which is similar to human disease in terms of disease induction, progression 
and pathogenesis will be very useful as a means of testing new asthma therapies, in 
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identifying new possible targets, elucidating the underlying mechanisms of disease 
pathogenesis and using all of the above to develop more effective strategies for disease 
treatment. As the model is humanised, the results of investigations, particularly in terms 
of testing new therapies, will be more relevant to the human disease. 
In addition, the use of a humanised TCR transgenic model should facilitate the 
investigation of the role of pathogenic T-cells in allergic asthma in more general terms. 
The original view of allergic asthma is of a Th2-mediated disease where all aspects of 
disease pathogenesis can be linked back to Th2 T-cells, either as direct mediators of 
inflammation or through their effects on other aspects of the response, such as the cells 
implicated in the early asthmatic response (e.g. mast cells, basophils). It was therefore 
believed that a potential means of therapy would be to skew the responses in an 
asthmatic lung back towards the opposing Thl phenotype, much as the reverse was 
believed to be a means of treating autoimmune disease. However, attempts to skew 
pulmonary immune responses towards a Thl phenotype in allergic asthma often had 
little effect or exacerbated disease (175). The original idea of a Thl /Th2 dichotomy has 
not only been challenged by these findings but also by the emergence of another T 
helper cell subset, the Th17 subset (161, 162) and the likelihood that there are yet more 
subsets (such as the recently described Th9 subset (673)) to be discovered. In the 
specific case of allergic asthma, there is also controversy over the relative importance of 
invariant NKT cells over Th2 cells with some evidence in support of the idea that iNKT 
cells may be a more significant contributor to asthma pathogenesis (138-141). There are 
many cells of the innate immune system, such as mast cells and eosinophils, that are 
also believed to play a role in asthmatic disease and the importance of these cell types in 
development and persistence of disease is also debated, particularly in light of the recent 
finding that mast cells in airway smooth muscle cells may be required for the 
development of AHR, a hallmark of allergic asthma (79, 81). As such, it is crucial to be 
able to study the interplay between these differing cell types in order to eludicate 
mechanisms of disease development and to attempt to quantify the importance of each 
cell type in causing disease to allow identification of new targets for therapy. Peptide 
immunotherapy appears to show much promise in the treatment of allergic asthma (341, 
342), suggesting the importance of controlling T-cell responses to control asthmatic 
disease. As such, a TCR transgenic mouse model of the disease should aid in 
investigating the exact role of pathogenic Th2-type cells and also the role that Tregs 
may play in the induction of tolerance, in order to identify new potential therapies. It is 
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also true that there is another form of asthma that is not believed to be related to atopy 
or allergy. This form of asthma is characterised by lung neutrophilia as opposed to 
eosinophilia and tends to present with a more severe phenotype (30). Neutrophils can be 
directed to areas of inflammation through the action of the cytokine IL-8 (674); IL-8 
production can be induced through the action of Th17 cells in an inflammatory response 
(168, 169). It may be that it is not just Th2 cells that are capable of mediating asthmatic 
disease and production of a mouse model of this form of asthma will also potentially be 
useful for the development of novel therapies. 
The P4 TCR transgenic mice can also be used to investigate aspects of T-cell signalling 
and T-cell activation. The analysis of T-cell costimulatory molecule expression 
described here can be extended further and investigated in situations of in vivo and in 
vitro activation. In addition, any differences in expression of costimulatory molecules 
can be linked to other events occurring in the T-cells and investigation into why there 
are differences in expression will lead to further elucidation of the complex mechanisms 
involved in signalling through the TCR and T-cell activation and differentiation. 
The findings from the analysis of the human T-cell lines are relevant in the study of 
allergic asthma, in particular in the attempts to develop an effective therapy. The 
expansion of peptide-specific TCRs from human asthmatic subjects and the 
identification of the particular epitopes to which they respond may allow for the more 
rational design of peptide immunotherapy vaccines, allowing the use of peptides that 
have been identified as major epitopes of the allergen in question and matched to the 
MHC class II restriction of the patient. The use of a mixture of peptides derived from 
the whole allergen amino acid sequence has previously been shown to have some 
promise in the down-regulation of Th2-cell mediated immune responses caused by cat 
allergen; the ability to identify the immunoreactive epitopes and develop vaccines based 
on them may increase the efficacy of the therapy. The potential for use of peptide 
vaccines in the treatment of autoimmune diseases such as rheumatoid arthritis (675, 
676) and myasthenia gravis (677) has been investigated in experimental models in mice, 
particularly in the use of altered peptide ligands based on the immunoreactive peptide 
epitope sequences. Altered peptide ligands have been shown to be able to skew T-cell-
mediated responses from one phenotype to another and in some instances, such as those 
diseases mentioned previously, show tolerogenic potential and the reversal of symptoms 
in some diseases. The use of peptides in immunotherapy strategies decreases the risk of 
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the induction of systemic anaphylaxis that is a significant problem with the use of whole 
allergen in specific immunotherapy. The use of APLs may further decrease the risk of 
induction of immunoglobulin-mediated responses by changing the inherent structure of 
the epitope that could otherwise potentially still be recognised by specific antibody 
(678). In order to be able to design a vaccine based on the use of altered peptide ligands 
however, it is necessary to identify the sequences of the major epitopes of the allergen 
and the residues that are important in mediating T-cell and MHC class II molecule 
contact, so as to maintain these residues within the APL. Another approach to treating 
T-cell-mediated diseases is the use of specific antibody directed against the dominant 
TCR implicated in causing the pathogenic response. Such an approach has been shown 
in mice to have some efficacy in the treatment of allergic asthma (679); to develop this 
therapy for use in human patients it would be necessary to identify the dominant 
allergen-specific TCRs involved. The TCR CDR3 analysis described here was minimal 
but did not identify any common TCR selection in the lines from three patients; analysis 
of multiple lines from a large panel of patients should be carried out to confirm this. It 
may be that the T-cell response, even to the same peptide presented on the same MHC 
class II molecule, may be significantly heterogeneous. This would decrease the 
likelihood of a universally effective anti-TCR antibody therapy being developed but this 
approach could still have efficacy if the dominant TCR in each patient could be 
identified and antibodies raised against it. Such an approach could also be used with the 
development of peptide vaccines to target the epitopes most relevant to each patient on 
the basis of their T-cell responses. 
To further investigate the role of TCR structure on the response induced upon activation 
of a T-cell and its subsequent differentiation, molecular modelling of the TCRs 
identified in the TCR CDR3 analysis of the human allergic asthmatic T-cell lines might 
identify features of the TCRs that lead to them being particularly well-suited to the 
induction of an allergic asthmatic response. Although there were no obvious differences 
identified from the analysis of the CDR3 amino acid sequences, the three-dimensional 
structure would be informative and it might be possible to identify a shared structural 
feature or features that could be used to predict the fate of a T-cell upon its activation on 
the basis of the receptor it expresses. 
My attempts to express TCRs of interest in the murine thymoma line BW7 were 
unsuccessful but it should be possible to achieve this. Once such lines are in existence, 
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they can be used as a means of investigating the role of the TCR itself in determining 
the signalling pathways that are activated and the phenotype that is induced upon 
antigen-specific activation of the cells. As the only difference between the lines would 
be the TCR that they express, any differences between the lines would be due to the 
TCR itself and would hopefully allow dissection of the different events that occur in the 
development of a Thl and a Th2 response. These cells would also be useful for binding 
studies to measure interaction kinetics between the TCR and peptide-MHC tetramers 
using flow cytometry and surface plasmon resonance to determine if there is a 
noticeable difference in the avidity of the interactions from the `Thl ' and `Th2' TCRs. 
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Appendix 1 - Stock solutions and buffers 
TAE buffer 
• 40 mM Tris-acetate (Tris-base, Sigma, T1503, acetic acid, Sigma 45726) 
• 1 mM EDTA, pH 8.0 (Sigma, E4884) 
6X loading buffer 
• 40% sucrose (Sigma, 57903) 
• 0.25% bromophenol blue (Sigma, B8026) 
Tetracycline (Sigma, T3258) 
• 5 mg/ml stock solution, prepared in 100% ethanol 
• Working concentration — 50 pg/m1 
Chloramphenicol (Sigma, C0378) 
• 34 mg/ml stock solution, prepared in 100% ethanol 
• Working concentration — 25 pg/m1 
Solution A for competent cells 
• 100 j.tM CaC12 (Sigma, C3881) 
• 10 mM MgC12 (Sigma, M8266) 
• 400 uM MES (Sigma, M3671) 
Solution B for competent cells 
• 10 mM CaC12 (Sigma, C3881) 
• 2 mM MgC12 (Sigma, M8266) 
• 800 uM MES (Sigma, M3671) 
• 5% glycerol (Sigma, G5516) 
Ampicillin (Sigma, A9518) 
• 50 mg/ml stock solution, prepared in deionised water 
• Working concentration — 50 µg/ml 
Tail digestion buffer 
• 50 mM Tris-hydrochloride (Sigma, T3253) 
• 100 mM EDTA (ethylene diammine tetrasodium acetate) (Sigma, ED-500) 
• 100 mM sodium chloride (Sigma, S7653) 
• 1% sodium dodecyl sulphate (Sigma, L6026) 
Sodium dodecyl sulphate (Sigma, L3490) 
• 10% stock solution (w/v), prepared in deionised water 
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Complete growth medium — RPMI-1640 
• RPMI-1640 medium (Invitrogen, 31870-074) 
• 10% heat-inactivated foetal calf serum (Globepharm) 
• 2 mM L-glutamine (Invitrogen, 25030-012) 
• 100 U/ml penicillin/100 vg/m1 streptomycin (Invitrogen, 15140-122) 
• 50 [IM (3-mercaptoethanol (2-ME) (Sigma, M7522), prepared in sterile PBS 
FACS buffer 
• lx PBS (Invitrogen, 10010-056) 
• 10% heat-inactivated foetal calf serum (Globepharm) 
Depurination solution for Southern analysis 
• 0.2 M hydrochloric acid (Sigma, H9892), diluted in dH2O 
Denaturation buffer for Southern analysis 
• 1.5 M sodium chloride (Sigma, 57653) 
• 0.5 M sodium hydroxide (Sigma, 58045) 
• diluted in dH2O 
Neutralisation buffer for Southern analysis 
• 1.5 M sodium chloride (Sigma, 57653) 
• 0.5 M Tris-base (Sigma, T1503) 
• pH 7.5, diluted in dH2O 
20x SSC 
• 3 M sodium chloride (Sigma, S7653) 
• 0.3 M sodium citrate (Sigma, C3434) 
• pH 7.0, diluted in dH2O 
DNA dilution buffer 
• 50 µg/ml salmon sperm DNA Roche, 11 585 614 910), prepared in TE buffer 
• pH 8.0 
TE buffer 
• 10 mM Tris-HC1 (Sigma, T3253) 
• 1 mM EDTA (Sigma, ED-500), pH 8.0 
Maleic acid buffer 
• 0.1 M maleic acid (Sigma, M0375) 
• 0.15 M sodium chloride (Sigma, C3434) 
• pH 7.5, diluted in dH2O 
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Maleic acid washing buffer 
• maleic acid buffer 
• 0.3% Tween 20 (Sigma, P1379) 
DIG-detection buffer for Southern analysis 
• 0.1 M Tris-HC1 (Sigma, T3253) 
• 0.1 M sodium chloride (Sigma, C3434) 
• pH 9.5, diluted in dH20 
Complete growth medium — DMEM 
• Dulbecco's Modified Eagle's Medium (Invitrogen, 11960-044) 
• 10% heat-inactivated foetal calf serum (Globepharm) 
• 2 mM L-glutamine (Invitrogen, 25030-012) 
• 100 U/ml penicillin/100 µg/ml streptomycin (Invitrogen, 15140-122) 
DMEM-HAT medium 
• complete growth medium — DMEM 
• 30 IAM hypoxanthine (Sigma, H9377) 
• 11AM aminopterin (Sigma, A3411) 
• 20 uM thymidine (Sigma, T1895) 
Aminopterin (Sigma, A3411) 
• 5 uM stock solution, prepared in lx PBS (Invitrogen, 10010-056), 0.2 IAM 
filtered 
Thymidine (Sigma, T1895) 
• 1 mM stock solution, prepared in lx PBS (Invitrogen, 10010-056), 0.2 um 
filtered, 500x working concentration 
Hypoxanthine (Sigma, H9377) 
• 1.5 mM stock solution, prepared in lx PBS (Invitrogen, 10010-056), 0.2 !AM 
filtered, 500x working concentration 
DMEM-HT medium 
• complete growth medium - DMEM 
• 30 !AM hypoxanthine (Sigma, T1895) 
• 20 ,tM thymidine (Sigma, T1895) 
Chloroquine (Sigma, C6628) 
• 25 mM stock solution, prepared in lx PBS (Invitrogen, 10010-056), 0.2µm 
filtered 
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Calcium chloride (Sigma, C3881) 
• 2 M stock solution, prepared in deionised water, 0.2 pm filtered 
HEPES-buffered saline (2x) 
• 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Gibco, 
15630-056) 
• 10 mM potassium chloride (Sigma, P9333) 
• 12 mM D-(+)-glucose (Sigma, G7528) 
• 280 mM sodium chloride (Sigma, C3434) 
• 1.5 mM sodium phosphate (dibasic sodium orthophosphate, Sigma, S7907) 
Polybrene (hexadimethrine bromide, Sigma, H9268) 
• 4 mg/ml stock solution, prepared in lx PBS (Invitrogen, 10010-056), 0.2 pm 
filtered 
Complete HL-1 medium 
• HL-1 serum-free medium (Lonza, 77201) 
• 2 mM L-glutamine (Invitrogen, 25030-012) 
• 50 U/ml penicillin/50 pg/m1 streptomycin (Invitrogen, 15140-122) 
Collagenase type D (Roche, 11 088 858 001) 
• 30 mg/ml stock solution, prepared in lx PBS (Invitrogen, 10010-056) 
• Working concentration — 0.15 mg/ml 
DNase I (Roche, 11 284 932 001) 
• 5 mg/ml stock solution, prepared in lx PBS (Invitrogen, 10010-056) 
• Working concentration — 25 µg/m1 
Phosphate buffered saline, lx (for ELISAs) 
• 5 tablets of PBS (Sigma, P4417) dissolved in 1 1 deionised water gives: 
• 27 mM potassium chloride 
• 137 mM sodium chloride 
• 10 mM phosphate buffer 
ELISA wash buffer (all ELISAs) 
• 0.05% Tween 20 (Sigma, P1379) in lx PBS 
ELISA blocking buffer and diluent (for IgE ELISA) 
• 10% heat-inactivated foetal calf serum in PBS (Globepharm) 
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ELISA blocking buffer (for all other ELISAs) 
• 1% bovine serum albumin (w/v) (Sigma, A7906) 
• 5% sucrose (w/v) (Sigma, 57903) 
• 0.05% sodium azide (v/v) (Sigma, 58032) 
• lx PBS 
Sodium azide (Sigma, S032) 
• 5% stock solution (w/v), prepared in deionised water 
ELISA diluent (for all other ELISAs) 
• 1% bovine serum albumin (Sigma, A7906) (w/v), in lx PBS 
ELISA stop solution (all ELISAs) 
• 1 M sulphuric acid (Sigma, 435589) 
I% Eosin Y solution 
• 10 g eosin powder (VWR, 341973R) in 1 1 tap water 
1% periodic acid 
• 1 g periodic acid (Sigma, P5463) in 100 ml deionised water 
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Enzyme Buffer Incubation temp. (°C1 1 Restriction site (5'.-0.3') 	Enzyme source 
    
EcoRI 
	
4-CORE H (Promega) 
	
37 
	
AATTC 
	
Promega (R6011) 
Primer name 	 Primer se Primer concentration (nM) 
   
M13 forward 
	
GTAAAACGACGGCCAG 	 I 	 10 
Appendix 2 — PCR conditions and primers and restriction enzymes for TCR CDR3 
analysis in the HLA-DR1-restricted human T-cell lines grown in response to 
peptide 4 of Fel d 1  
PCR conditions and primers 
Primer sequence (5'—b3') Product Annealing LlVigah 
size (bp) temp. (°C) mM 
Human TCRa anchor PCR 
Anchor polyC primer if) CTATCTAGAGAGCTCGCGGCCGCCC 
CCCCCCCCCC 300-700 50/60* 1.5 
3' Ca primer 
( 
r) GATAGATCTTAGAGTCTCTCAGC 
Human TC110 anchor PCR 
Anchor polyC primer (f) CTATCTAGAGAGCTCGCGGCCGCCC 
CCCCCCCCCC 300-700 50/60* 	1.5 
3' C13 primer (r) CGCGAATTCAGATCTCTGCTTCTGATG 
* = reaction conditions for these PCRs are quite atypical. Reactions comprised of an initial 
denaturing step (95°C for 5 minutes), followed by 28 cycles of denaturation - 95°C for 1 
minute, annealing - 50°C for 45 seconds, then 60°C for 15 seconds and elongation - 72°C 
for 10 minutes, and finished with a final elongation step (72°C for 10 minutes). 
Primer sequences and PCR conditions as outlined in reference 609. 
Restriction enzyme used to identify E.coli clones containing TCR chain inserts 
Promega buffer — 4-CORE H composition (1x): 
• 90 mM Tris-HC1 
• 10 mM MgC12 
• 50 mM NaC1 
• pH 7.5 (37°C) 
Sequencing primer 
Primer designed by a postdoctoral researcher in the Boyton laboratory. 
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Appendix 3 — PCR conditions, primers and linkers used in MFG cloning strategies 
PCR conditions and primers 
Primer sequence (5'—o ') Product size Annealing IMgClz1, 
(bp)  temp. (°C) mM 
MFG (TCR CIR010a chain) 
RAV8-4Not1 (f) GCGGCCGCATGCTCCTGCTGCTCGTCCCAGTGC 878 64 1.5 
RAC1noNotI # (r) CTCAGCTGGACCACAGCCGC 
MFG (TCR CIROlOamCa) 
• 3.CIR010aVJNotI (f) GCGGCCGCATGCTCCTGCTGCTCGTCCC 439 65 1.5 
3.CIR010aVJCPstI (r) GCTGGTACACTGCAGGATCAGGGTTC 
• 2.CIR010mCaPstI (0 CAGAACCTGCAGTGTACCAG 422 60 1.5 
• 2.CIR010mCallotI (r) GCGGCCGCCTCAACTGGACCACAGCCTC 	J 
MFG (TCR 0100mC0) 
• 5.CIR0 1 OpVJNotI (f) GCGGCCGCATGAGCATCGGGCTCCTGTGC 414 63.5 1.5 
• 5.CIROIOPVJH indIII (r) GAAAGCTTCAGTGCCCGACGCC 
• 4.CIR010mCPPpuM11(0 AGGACCTGAGAAATGTGACTCC 530 53 1.5 
• 4.CIR010mCPNotI 	j(r) GCGGCCGCTTCATGAATTCTTTCTTTTG 
MFG (TCR A10(2) 0 chain) 
PmutationClal 
PmutationEcoR1 
(f) CCCTCGGATCGATTTTCTGCTG 
700 60 2.0 (r) GAATTCGGCTTACCGGTCAGGAATTTTTTTTC 
TTGACCATGGC 
MFG (TCR D3(3) 0 chain) 
mutationB stXI 
mutationEcoRI 
(f) CCAGTACTTTGGGCCAGGCAC 
577 60 1.5 (r) GAATTCGGCTTACCGGTCAGGAATTTTTTTTC 
TTGACCATGGC 
Linkers 
Cloning step 	 Linker name Linker sequence (5'—.3') 
To insert an additional NotI 
site into pBluescriptll 
NotIPBSlinkertop TCGAGATGCCATTCATTGGACTATAAC 
TGACTGTTACATCGCGGCCGCAT 
NotIPBSlinkerbottom CGATGCGGCCGCGATGTAACAGTCAG 
TTATAGTCCAATGAATGGCATC , 
To insert an additional NotI 
site into MFG 
NcolNotlMFGlinkertop CATGGCGGCCGCACTTTCGGATCTATG 
CTCGTAGCCATTGCGGCCGCGTC 
NcoINotIMFGlinkerbottom CATGGACGCGGCCGCAATGGCTACGA 
GCATAGATCCGAAAGTGCGGCCGC 
To allow linkage of 
CIR01013 VJ region with a 
murine Cp region 
CIR010pHindIIIJCPpuMIlinkertop AGCTTTCTTTGGACAAGGCACCAGACT 
CACAGTTGTAGAGGTCCTC 
CIR010pHindIIIJCPpuMIlinkerbotto TCGAGAGGACCTCTACAACTGTGAGTC 
TGGTGCCTTGTCCAAAGAA 
434 
Primers and conditions used for orienting TCR sequences in MFG 
Primer sequence (5'-1.3') Product size Product size Annealing [MEW, 
mM (bp) — correct (bp) — temp. (°C) 
orientation incorrect 
orientation 
MFG (TCR 010a chain) 
TRAV8-4NotI (f) GCGGCCGCATGCTCCTG 
CTGCTCGTCCCAGTGC 938 0 61 1.5 
MFGreverse (r) CTGGACCACTGATATCC 
TGTC 
TRAV8-4NotI (f) GCGGCCGCATGCTCCTG 
CTGCTCGTCCCAGTGC 0 958 61 1.5 
MFGforward (r) AGTAGACGGCATCGCA 
GCTTG 
MFG (TCR 010amCa) 
CIR010aVJNotI (f) GCGGCCGCATGCTCCT 
GCTGCTCGTCCC 887 0 66 1,5 
MFGreverse (r) CTGGACCACTGATATC 
CTGTC 
CIR010aVJNotI 
--, 
MFGforward 
(f) GCGGCCGCATGCTCCTG 
CTGCTCGTCCC 
(r) AGTAGACGGCATCGCA 
GCTTG 
0 907 67 1.5 
MFG (TCR 01013mC13) 
CIR01013VJNotI (f) GCGGCCGCATGAGCA 
TCGGGCTCCTGTGC 1004 0 66 1.5 
MFGreverse (r) CTGGACCACTGATATC 
CTGTC 
CIR01 OPVJNotI 
0 1.5 
(f) GCGGCCGCATGAGCA 
TCGGGCTCCTGTGC 1024 67 
MFGforward (r) AGTAGACGGCATCGC 
AGCTTG 
MFG (TCR A10(2) a 5-D4 a chain) 
TRAV5-D4 * (f) ATGAAAACATATGCTC 
CTAC 962 0 59 1.5 
MFGreverse (r) CTGGACCACTGATATC 
CTGTC 
1.5 
TRAV5-D4 * (0 ATGAAAACATATGCTC 
CTAC 0 982 60 
MFGforward (r) AGTAGACGGCATCGCA 
GCTTG 
MFG (TCR A10(2) a 7-D3 and D3(3) a chains) 
TRAV7-D3/4 * (0 ATGAAATCCTTGAGTG 
TTTC 957 (7-D3) 
965 (D3) 
0 63 1.5 
MFGreverse (r) CTGGACCACTGATATC 
CTGTC 
TRAV7-D3/4 * (0 ATGAAATCCTTGAGTG 
TTTC 0 977 (7-D3) 
985 (D3) 
65 1.5 
MFGforward (r) AGTAGACGGCATCGC 
AGCTTG 
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TRAV 7D3f* (f) ATGAAATCCTTGAGTGTTTC 
NJ109 * 	(r) CAGGAAACAGCTATGAC 	—500 
	
54 1.5 
 
Primer name 
  
Primer sequence (5'-0.3') 
 
Product 
size b  
Annealing 	1.11gc 
temp. (°C) 	JmMi  
      
        
          
Detection of D3(3) and A10(2) 7-D3 TCRa genes in BW7 
Primer sequence (5'—►3') ' 	Product size Product size Annealing LMIg_gal 
(bp)—correct (bp) — temp. (°C) mM 
orientation incorrect 
orientation 
MFG (TCR A10(2) (3 chain) 
TRBV14F * (0 ATGGGCACCAGGCTTC 
TTGGCTG 1072 0 64 1.5 
MFGreverse 	(r) CTGGACCACTGATATCC 
j TGTC 
1092 66 1.5 
TRBV14F * (f) ATGGGCACCAGGCTTCT 
TGGCTG 0 
MFGforward (r) AGTAGACGGCATCGCA 
GCTTG 
MFG (TCR D3(3) B chain) 
TRBV2F * (0 ATGGGCTCCATTTTCCT 
CAGTTGCCT 1059 0 62 1.5 
MFGreverse (r) CTGGACCACTGATATCC 
TGTC 
TRBV2F * (f) ATGGGCTCCATTTTCCT 
CAGTTGCCT 0 1079 63 1.5 
MFGforward (r) AGTAGACGGCATCGCA 
GCTTG 
Sequencing primers 
Primer name 	 Primer sequence (5' 	3 1 	 Primer concentration (nM) 
All sequences amplified by high-fidelity PCR and cloned into TA cloning vector pCR2.1 
M13 forward * 
M13 reverse' 
(0GTAAAACGACGGCCAG 10 
(r) CAGGAAACAGCTATGAC 10 
All final constructs (i.e. MFG (TCR chain) 
MFGforward (f) AGTAGACGGCATCGCAGCTTG 10 
MFGreverse (r) CTGGACCACTGATATCCTGTC 10 
Primers and conditions used for detecting TCR genes in transduced BW7 lines 
Primers marked with an asterisk (*) were designed by postdoctoral researchers in the 
Boyton laboratory. I designed all other primers and linkers. The primer marked # was 
redesigned as the no PCR product could be obtained using the original primer which 
had an additional restriction site added to it. This site was removed in the resdesigned 
primer. 
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Appendix 4 — PCR conditions, primers and linkers used in pTcass cloning strategies 
PCR conditions and primers 
Primer sequence (5'—'3') Product Annealing LMgclaj, 
size temp. (°C) mM 
010 
pTa (TCR CIR010a VJ-intron) 
CIRO 1 OpTaXmal (f) CC CGGGATGCTCCTGCTGCTCGTCC CAG 375 63 1.5 
CIROlOpTaHindIII (r)GCCAGTTCCAAAGATAAGCTTGTTTGTAGC 
pTB (TCR CIR01013 VJ-intron) 
CIR010pTI3Xhof (f) CTCGAGATGAGCATCGGGCTCCTGTGC 375 64 1.5 
CIRO1OpTilllindIII (r) GAAAGCTTCAGTGCCCGACGCC 
pTa (TCR A10(2) a 5-D4 VJ-intron) 
B2.A105D4aVJXmaI (f) CCCGGGATGAAAACATATGCTCCTAC 512 60 
_.i. 
1.5 
NJ109 *  (r) CGGCACATTGATTTGGGAGTC 
Bl.A105D4ccJiB WC' (1) TTCTGGGACTTACCAGAGGTTTG 109 55 f 	1.5 
B1.A105D4aJiSacII (r) CCGCGGCAAATGCTATATTAGAGAAC 
pTa (TCR A10(2) a 7-D3 VJ-intron) 
367 1.  B4.A107D3aVJXma1 (f) CCCGGGATGAAATCCTTGAGTGTTTC 55 1.5 
B4.A107D3aVJSacI (r) CAAATATCAGAGCTCTGCCTCC 
B3.A107D3aJiSacI (f) GGCAGAGCTCTGATATTTGG 89 57 1.5 
B3.A107D3aJiSacII (r) CCGCGGCGGGCGTCATAATCACCAGC 
pTO (TCR A10(2) 0 VJ-intron) 
B6.A10r3VJXhoI (f) CTCGAGATGGGCACCAGGCTTCTTGGC 397 65 1.5 
B6.A1013VJXmaI (r) CCTGGTCCCGGGACCGAAGTAC 
B5.A1013.1iXmaI 
B5 .A1013JiSacII 
(f) CTTCGGTCCCGGGACCAGGCTC 88 65 	I 1.5 
(r) CCGCGGCCAAACTACTCCAGGGACCCAG 
pTa (TCR D3(3) a VJ-intron) 
C2.D3aVJXmaI (f) CCCGGGATGAAATCCTTGAGTGTTTC 397 57 1.5 
C2.D3aVJKpnI (r) CAGATACTCTGGTACCAAGACCG 
C I .D3 aJiKpnI 
--- _ 
(f)CGGTCTTGGTACCAGAGTATCTG 
T(r) 
87 61 1.5 
CI.D3a.liSacII CCGCGGCCCTCACCCCAGCTCATCCC 
pill (TCR D3(3) B VJ-intron) 
C4.D3I3VDChoI 394 (0 CTCGAGATGGGCTCCATTTTCCTCAG 63 	1.5 
-- 
C4.D313VJBstXI (r) CGAGTGCCGGGCCCAAAGTACTGG 
C3.D313JiBstXIfl (f) CACCCAGTACTTTGGGCCAGG 120 63 1.5 
C3.D313JiSacHrl (r) CCGCGGTGACTCCCAGAGAAACCCGG 
Linkers 
Construct and cloning Linker name Linker sequence (5'—'3') 
	 Ltle 	 
pTa (TCR CIR010a VJ- 
intron) — to insert the J- 
intron region of the TCR a 
sequence into pB luescriptII 
TCRCIRO 1 OaJ-intronpTacasstop 
AGCTTATCTTTGGAACTGGCACTCTG 
CTTGCTGTCCAGCCAAGTACGTAAGT 
AGTGGCATGTGTCAGGTGGATTCTGT 
GTCCATGGCAAGTCCGCGGC 
TCRCIR010aJ- 
intronpTacassbottom 
TCGAGCCGCGGACTTGCCATGGACA 
CAGAATCCACCTGACACATGCCACT 
ACTTACGTACTTGGCTGGACAGCAA 
GCAGAGTGCCAGTTCCAAAGATA 
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AGCTTTCTTTGGACAAGGCACCAGA 
TCRCIR010f3J-intronpTpcasstop CTCACAGTTGTAGGTAAGACATTTTT 
pT$ (TCR CIR010$ VJ- CAGGTTCTTTTGCAGATCCGTCACAG 
intron) — to insert the J- GGAAACCGCGGG 
intron region of the TCR p TCGACCCGCGGTTTCCCTGTGACGGA 
sequence into pBluescriptll TCRCIR0103J- TCTGCAAAAGAACCTGAAAAATGTC 
intronpTi3cassbottom TTACCTACAACTGTGAGTCTGGTGCC 
TTGTCCAAAGAA 
Sequencing primers 
Primer name 	 Primer sequence (5'-03') Primer concentration (nM) 
All sequences amplified by high-fidelity PCR and cloned into TA cloning vector pCR2.1 
M13 forward (f) GTAAAACGACGGCCAG 10 
M 1 3 reverse (r) CAGGAAACAGCTATGAC 10 
Final construct - pTa (TCR CIR010 a VJ-intron) 
CIRO 1 OpTaXmal (f) CCCGGGATGCTCCTGCTGCTCGTCCCAG 10 
CIROlOpTaHindIII (r) GC CAGTTCCAAAGATAAGCTTGTTTGTAGC 10 
Final construct — pT$ (TCR CIR010 $ VJ-intron) 
CIROlOpT$XhoI 
CIRO1OpTI3HindIII 
 (f) CTCGAGATGAGCATCGGGCTCCTGTGC 10 
(r) GAAAGCTTCAGTGCCCGACGCC 10 
Final construct - pTa (TCR A10(2) a 5-D4 VJ-intron) . . 	. _ 
A105D4aVJXmaI (f) CCCGGGATGAAAACATATGCTCCTAC 10 
A105D4aJiSacII (r) CCGCGGCAAATGCTATATTAGAGAAC 10 
Final construct - pTa (TCR A10(2) a 7-D3 VJ-intron) 
A107D3aVJXmal 
A107D3aJiSacII 
(f) CCCGGGATGAAATCCTTGAGTGTTTC 10 
(r) CCGCGGCGGGCGTCATAATCACCAGC 10 
Final construct— pT13 (TCR A10(2) $ VJ-intron) 
A1013VJXhoI (f) CTCGAGATGGGCACCAGGCTTCTTGGC 10 
A 1 OfIRS acII (r) CCGCGGCCAAACTACTCCAGGGACCCAG 10 
Final construct - pTa (TCR D3(3) a VJ-intron)_ 
D3aVJXma1 (f) CCCGGGATGAAATCCTTGAGTGTTTC 10 
D3aJiSacII (r) CCGCGGCCCTCACCCCAGCTCATCCC 10 
Final construct — pTf3 (TCR D3(3) $ VJ-intron) 
D3f3VJXhoI 	i (f) CTCGAGATGGGCTCCATTTTCCTCAG 10 
D3 fiJi S acHrl (r) CCGCGGTGACTCCCAGAGAAACCCGG 10 
Primers marked with an asterisk (*) were designed by postdoctoral researchers in the Boyton laboratory. I 
designed all other primers and linkers. Primer NJ109 was used in place of a primer which I designed but 
which did not produce a PCR product upon use in a reaction. 
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Appendix 5 — restriction enzymes and digests used in MFG and pTcass cloning 
strategies  
Single restriction enzyme digests 
Enzyme Buffer Incubation1 Restriction site Enzyme source 
temp. (°C) (5'.-03') 
BamHI 4-CORE E (Promega) 37 G I GATCC Promega (R6021) 
BstXI SuRE/Cut H (Roche) 45 CCA(N)5 INTGG Roche (111 177 770 01) 
ClaI 4-CORE C (Promega) 37 AT I CGAT Promega (R6551) 
EcoRI 4-CORE H (Promega) 
REact 3 (Invitrogen) 
37 G I, AATTC Promega (R6011) 
Invitrogen (15202-013) 
Hindi!' 4-CORE E (Promega) 37 Al AGCTT Promega (R6041) 
KpnI 4-CORE J (Promega) 37 GGTAC I C Promega (R6341) 
NcoI 4-CORED (Promega) 37 CI CATGG Promega (R6513) 
Not! 4-CORED (Promega) 37 GC I GGCCGC Promega (R6431) 
SacI 4-CORE J (Promega) 37 GAGCT I C Promega (R6061) 
Double restriction enzyme digests 
Enzymes Buffer Incubation Restriction sites Enzyme sources 
temp. (°C) (5'—'3') 
ApaI/ 
PpuMI 
NE Buffer 4 (New 
England Biolabs) 
37 GGGCCI C Promega (R6361) 
RG I GWCCY New England Biolabs (R0506) 
BamHI/ 
BstXI 
BamHI/ 
Hind!!! 
4-CORE E (Promega) 
4-CORE E (Promega) 
37 G I GATCC Promega (R6021) 
CCA(N)5 INTGG  
G I GATCC I 
 Promega (R6471) 
37 Promega (R6021) 
A I AGCTT Promega (R6041) 
BamHI/ 
PstI 
4-CORE H 
(Promega) 
37 GIGATCC Promega (R6021) 
CTGCA,1 G Promega (R6111) 
BstXI/ 
XbaI 
CIaI/ 
XhoI 
4-CORED 
(Promega) 
37 
L_ 
37 
CCA(M5 INTGG 
Ty CTAGA 
Promega (R6471) _ 
Promega (R6181) 
4-CORE C 
(Promega) 
ATI CGAT Promega (R6551) 
CI TCGAG Promega (R6161) 
EcoRI/ 
KpnI 
4-CORE Multicore 
(Promega) 
37 GI AATTC Promega (R6011) 
GGTAC I C Promega (R6341) 
EcoRI/ 
PstI 
4-CORE H 
(Promega) 
37 G I AATTC Promega (R6011) 
CTGCA I G Promega (R6111) 
EcoRV/ 
HindlIl 
4-CORE Multicore 
(Promega) 
37 GATIATC Promega (R6351) 
A I AGCTT Promega (R6041) 
HindIII/ 
Pstl 
HindIII/ 
Sall 
4-CORE H 
(Promega) 
4-CORE C 
(Promega) 
37 A I AGCTT Promega (R6041) 
CTGCA S G Promega (R6111) 
37 	 A I, AGCTT 
G I TCGAC 
Promega (R6041) 
Promega (R6051) 
HindIII/ 
XhoI 
4-CORE B 
(Promega) 
37 A I AGCTT Promega (R6041) 
CI TCGAG Promega (R6161) 
KpnI/ 
XmaI 
4-CORE Multicore 
(Promega) 
4-CORE E (Promega) 
37 GGTAC I C Promega (R6341)  
CI CCGGG Promega (R6491)  
Sad/ 
SpeI 
37 GAGCT IC Promega (R6061) 
AI CTAGT Promega (R6591) 
SacII/ 
XhoI 
4-CORE H 
(Promega) 
37 CCGC I GG Promega (R6221) 
C I TCGAG 
CCGC I GG 
	 Promega (R6161) 
SacII/ 
XmaI 
4-CORE A 
(Promega) 
37 Promega (R6221) 
CI, CCGGG Promega (R6491) 
XbaI/ 
XmaI 
4-CORE B 
(Promega) 
37 T1 CTAGA Promega (R6181) 
CI CCGGG Promega (R6491) 
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Buffer compositions (lx)  
Promega buffers — 4-CORE 
Buffer A:  
• 6 mM Tris-HCI 
• 6 mM MgC12 
• 6 mM NaC1 
• 1 mM DTT 
• pH 7.5 (37°C) 
Buffer B: 
• 6 mM Tris-HC1 
• 6 mM MgC12 
• 50 mM NaC1 
• 1 mM DTT 
• pH 7.5 (37°C) 
Buffer C: 
• 10 mM Tris-HCI 
• 10 mM MgC12 
• 50 mM NaCI 
• 1 mM DTT 
• pH 7.9 (37°C) 
Buffer D: 
• 6 mM Tris-HCI 
• 6 mM MgC12 
• 150 mM NaC1 
• 1 mM DTT 
• pH 7.9 (37°C) 
Buffer E: 
• 6 mM Tris-HC1 
• 6 mM MgC12 
• 100 mM NaC1 
• 1 mM DTT 
• pH 7.5 (37°C) 
Buffer H:  
• 90 mM Tris-HCI 
• 10 mM MgC12 
• 50 mM NaC1 
• pH 7.5 (37°C) 
Buffer J:  
• 10 mM Tris-HCI 
• 10 mM MgC12 
• 50 mM KCI 
• 1 mM DTT 
• pH 7.5 (37°C) 
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Multi-core buffer: 
• 25 mM Tris-acetate 
• 10 mM Mg-acetate 
• 100 mM K-acetate 
• 1 mM DTT 
• pH 7.5 (37°C) 
Roche buffers — SuRE/Cut 
Buffer 1-1: 
• 50 mM Tris-HCI 
• 10 mM MgC12 
• 100 mM NaC1 
• 1 mM DTE 
• pH 7.5 (25°C) 
New England Biolabs buffers 
Buffer 4:  
• 20 mM Tris-acetate 
• 50 mM K-acetate 
• 10 mM Na-acetate 
• 1 mM DTT 
• pH 7.9 (25°C) 
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Appendix 6 — PCR conditions and primers, fluorescently-labelled FACS antibodies 
and restriction enzymes for Southern hybridisations used in genotyping the P4  
TCR/DR1/ABO transgenic mouse lines  
PCR conditions and primers 
Primer sequence (5'—►3') Product size Annealing Diggal, 
thal temp. (°C) mM 
RBP (housekeeping gene) 
RBPWT I  Kf) GTTCTTAACCTGTTGGTCGGAACC 500 55 	1.5 
_ RBPWT2 * kr) GCTTGAGGCTTGATGTTCTGTATTGC 
HLA-DRla 
HumanDR1aF 	l(f) CTCCAAGCCCTCTCCCAGAG 150 55 1.5 
flumanDR1aR (r) ATGTGCCTTACAGAGGCCCC 
HLA-DR113  
HumanDRI(3F # kt) TTCAATGGGACGGAGCGGGTG 
	
200 
	
55 
	
1.5 
HumanDR1f3R 4  1(r) GAAAGCTTCAGTGCCCGACGCC 
Murine class II knockout 
DR1ABOF 	TCCGCAGGGCATTTCGTGTA 
DRI ABO-K03 	l(r) GAGGATCTCGTCGTGACCCA 
500 60 1.5 
TCR P4a chain 
TCRAP4F * (I) TCTCAATTGCAGTTATGAAG 300 60 2.5 
TCRAP4R * (r) ATGAGCTTGTTTGTAGCACC 
TCR PO chain 
TCRP4VI3F * 	CACCTGATCACAGCAACTGG 400 60 1.5 
TCRP4f3SouthR  * (r) GGTCCACCCTCCGACTCC 
TCR P4a chain (splicing PCR), 
NewP4aF1 * (t) ACTAGCTATCTTTTGGCTTC 478 — gDNA, 
346 — cDNA 
56 1.25 
NewP4aR1 * (r) CTGTGATGTTCAGGATGCTG 
TCR P415 chain (splicing PCR) 
TCRP413SouthF * 	GGTCCACCCTCCGACTCC 425 — gDNA, 
272 — cDNA 
55 1.5 
TCRBP4R * 	CGAAGTACTGCTCGTATACC 
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Fluorescently-labelled antibodies used to identify mouse class II knockout status of P4 
TCR/DRVABO transgenic mouse lines  
Clone Source Cat. no. Working Antibody isotype 
concentration 
FITC-conjugated antibodies (FL I channel) 
Monoclonal anti- 
mouse CD3e 
145-2C11 eBioscience 11-0031 0.5 ug/106 cells Armenian hamster 
IgG 
Monoclonal anti- 
mouse CD45R 
RA3-6B2 AbD 
Serotec 
MCA1258F 1 lxg/106 cells Rat IgG2a 
PE-conjugated antibodies (FL2 channel) 
Monoclonal anti- 
mouse CD4 
GK1.5 eBioscience 12-0041 0.125 ug/106 cells Rat IgG2b 
Monoclonal anti- 
mouse I-A/I-E 
(MHC class II) 
M5/114.15.2 BD 
Phanningen 
557000 1 ug/106 cells Rat IgG2b 
Restriction enzymes used for Southern analysis of P4 TCR/DR1/ABO transgenic mouse 
lines 
Enzyme Buffer Incubation 	Restriction site Enzyme source 
temp. (°C) (5'—►3')  
T  
P4 a Southern digest 
HindIll 4-CORE E (Promega) 37 Al AGCTT Promega (R6041) 
EcoRV 4-CORED (Promega) 37 GAT,1,ATC Promega (R6351) 
1 
P4 (3 Southern digest 
BamHI 	 1 4-CORE E (Promega) 	37 G,I,GATCC Promega (R6021) 
PCR conditions and primers to produce probes for the P4 TCR Southern analysis 
Primer sequence (5'—.3') Product size Annealing111Lachh 
mM 
1 
&RI temp. (°C) 
P4 a probe 
TCRP4aprobeF 	1(1) GGATGATGAAGTGTCCACAGG 593 55 1.5 
TCRP4aprobeR _(r) TGGACACAGAATCCACCTGA 
P4 13 probe 
TCRP4I3SouthF 	—1(f) GGTCCACCCTCCGACTCC 646 55 1.5 
TCRP4f3SouthR 4r) GGTCCACCCTCCGACTCC 
All primers marked * above were designed by researchers in the Boyton laboratory. All primers marked # 
were designed by Prof. Danny Altmann. I designed all other primers. 
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Appendix 7 — fluorescently-labelled antibodies used in FACS analysis of 
potentially-transduced BW7 lines  
Clone Source Cat. no. Working Antibody isotyne 
concentration 
FITC-conjugated antibodies (FL1 channel) 
Monoclonal anti- 
mouse CD4 
GK1.5 eBioscience 11-0041 0.25 Rg/106 cells Rat IgG2b 
Monoclonal anti- 
mouse CD3e 
145- 
2C11 
eBioscience 11-0031 0.5 Rg/106 cells Armenian hamster 
IgG 
Monoclonal anti- 
mouse TC11.13 chain 
H57-597 eBioscience 11-5961 0.5 rag/106 cells Armenian hamster 
IgG 
Monoclonal anti- 
mouse TCR VI3 4 
region 
KT4 BD 
Pharmingen 
553365 1µg/106 cells Rat IgG2b 
Monoclonal anti- 
mouse TCR V1313 
region 
MR12-3 BD 
Pharmingen 
553204 4 [tg/106 cells Mouse IgG1 
PE-conjugated antibodies (FL2 channel) 
Monoclonal anti- 
mouse CD4 
GK1.5 eBioscience 12-0041 0.125 Rg/106 cells Rat IgG2b 
Monoclonal anti- 
mouse TCR[3 chain 
H57-597 eBioscience 12-5961 0.5 Rg/106 cells Rat IgG2b 
Propidium iodide staining for cell death (FL2 channel) 
Propidium iodide n/a Beckman 
Coulter 
731727 10 µ1/106 cells n/a 
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Appendix 8 — differential cell phenotyping of Wright-Giemsa stained cytospins 
Key: 
M - macrophage - large cells, dark purple nucleus, with light purple cytoplasm, 
distinctive 'fried-egg' morphology 
N - neutrophil - dark purple, multi-lobed nucleus, cytoplasm does not stain 
E - eosinophil - dark purple, multi-lobed nucleus, cytoplasm stains pink 
L - lymphocyte - small cells, dark purple nucleus, very little visible cytoplasm 
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Appendix 9 — antibodies and standards used in ELISAs 
Antibodies 
Clone Source Cat. no. Working 
concentration 
Capture antibodies 
Monoclonal rat anti-mouse 
interleukin-4 antibody 
30340.11 R&D 
Systems 
MAB404 2 µg/m1 
Monoclonal rat anti-mouse/human 
interleukin-5 antibody 
TRFK5 R&D 
Systems 
MAB405 1 µg/ml 
Monoclonal rat anti-mouse 
interleukin-13 antibody 
38213 R&D 
Systems 
MAB413 4 µg/ml 
Monoclonal rat anti-mouse interferon- 
y antibody 
37801, 
37875 
R&D 
Systems 
MAB785 4 Wml 
Purified rat anti-mouse 
immunoglobulin E antibody 
R35-72 BD 
Pharmingen 
553413 2 µg/ml 
Detection antibodies 
Biotinylated goat anti-mouse 
interleukin-4 antibody 
Lot no. 
WB05 
R&D 
Systems 
BAF404 100 ng/ml 
Biotinylated rat anti-mouse 
interleukin-5 antibody 
TRFK4 R&D 
Systems 
BAM705 50 ng/ml 
Biotinylated goat anti-mouse 
interleukin-13 antibody 
Lot no. 
AJP09 
R&D 
Systems 
BAF413 100 ng/ml 
Biotinylated goat anti mouse 
interferon-y antibody 
Lot no. 
XR10 
R&D 
Systems 
BAF485 400 ng/ml 
Biotin-conjugated rat anti-mouse 
immunoglobulin E antibody 
R35-118 BD 
Pharmingen 
553419 2µg/ml 
Standards 
Source Cat. no. No.of 2-fold Starting Finishing 
dilutions concentration concentration 
Recombinant mouse 
interleukin-4 
R&D 
Systems 
404-ML 8 4000 pg/ml 15.6 ng/ml 
Recombinant mouse 
interleukin-5 
R&D 
Systems 
405-ML 8 4000 pg/ml 15.6 ng/ml 
Recombinant mouse 
interleukin-13 
eBioscience 14-8131 8 4000 pg/ml 15.6 ng/ml 
Recombinant mouse 
interferon-y 
R&D 
Systems 
485-MI 8 4000 pg/mI 15.6 ng/ml 
Purified mouse 
immunoglobulin E, x 
(anti-TNP) 
BD 
Pharmingen 
557079 
(clone 
C38-2) 
7 500 ng/ml 3.9 ng/ml 
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Appendix 10 — fluorescently-labelled antibodies used in FACS analysis of mice 
from P4 TCIEUDRVABO transgenic lines 4 and 16  
Clone Source Cat. no. Working Antibody 
concentration isotype 
FITC-conjugated antibodies (FL1 channel) 
Monoclonal anti- 
mouse CD4 
GK1.5 eBioscience 11-0041 0.25 [tg/106 cells Rat IgG2b 
Monoclonal anti- 
mouse CD3e 
145-2C11 eBioscience 11-0031 0.5 ttg/106 cells Armenian 
hamster IgG 
Monoclonal anti- 
mouse CD69 
H1.2F3 eBioscience 11-0691 0.5 ttg/106 cells Armenian 
hamster IgG 
Monoclonal anti- 
mouse CD25 
PC61.5 eBioscience 11-0251 0.25 ttg/106 cells Rat IgG1 
Monoclonal anti- 
mouse CD44 
IM7 eBioscience 11-0441 0.5 ttg/106 cells Rat IgG2b 
Monoclonal anti- 
mouse CD54 
YN1/1.7.4 eBioscience 11-0541 1 Rg/106 cells Rat IgG2b 
Monoclonal anti- 
mouse CD62L 
MEL-14 eBioscience 11-0621 0.5 vg/106 cells Rat IgG2a 
Monoclonal anti- 
mouse OX40 
OX-86 AbD 
Serotec 
MCA1420F 1 lig/106 cells Rat IgG1 
PE-conjugated antibodies (FL2 channel) 
Monoclonal anti- 
mouse CD8a 
53-6.7 eBioscience 12-0081 0.25n/106 cells Rat IgG2a 
Monoclonal anti- 
mouse CD4 
GK1.5 eBioscience 12-0041 0.125 [tg/106 
cells 
Rat IgG2b 
Monoclonal anti- 
mouse OX4OL 
RM134L eBioscience 12-5905 0.5 [tg/106 cells Rat IgG2b 
Monoclonal anti 
mouse ICOS 
7E.17G9 eBioscience 12-9942 0.25 ti,g/106 cells Rat IgG2b 
PE-Cy5-conjugated antibodies (FL3 channel) 
Monoclonal anti- 
mouse CD8a 
53-6.7 eBioscience 13-0081 0.125 ttg/106 
cells 
Rat IgG2a 
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HindlIl 
promoter 
MCS/______Apal 404 
IacZ' 
pUC ori 
Fl on 
ampicillin 
Appendix 11 - pCR®2.1 — vector map and multiple cloning site 
kanamycin 
Multiple cloning site:  
XhoI 
PaeR7 I 
Hind III 	Sac I 	Spe
I 	 I 	 I 	 I 	 I 
I EcoR I 	EcoR I 	BstX I 	Ava I 	Xba I 
1 I   
I 	I I 	I 	I 	I 	 I 	I 
Kpn I BamH I 	BstX I 	PCR EcoR V 	Not I Nsi I Apa I 
product 
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ampicillin 
,--- Sacl 653 
M C S 
—NKpnl 760 
lac promoter 
Appendix 12 - pBluescriptII vector map and multiple cloning site 
pUC ori 
Multiple cloning site: 
Hinc II 	Apa I 
Acc I 	Eco0101 I 
Eag I 	Sne I 	Sma I 	EcoR I 	Hind III 	 II 
	
Sal I Dra 
I I I 	 I 	 I 	 I  
I 	I 	I 	I 	I 	I 	 I 	I  
BstX 1 Not I Xba I BamH I Pst I EcoR V 	Cla I 	Xho I 	Knit I 
Bsp106 I 
Sac I 	Sac II lI
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Appendix 13 - Amino acid sequence of the TCR a chain (TRAV 5-D4 TRAJ 13 
TRAC) from the murine T cell clone A10(2) (chain 5-D4) cloned into retroviral vector 
MFG 
1 
ATG AAA ACA TAT GCT CCT ACA TTA TTC ATG TTT CTA TGG CTG CAG CTG GAT GGG ATG AGC CAA 
MK T Y A P T L F M F L W L Q L DG MS Q 
64 
GGC GAG CAG GTG GAG CAG CTT CCT TCC ATC CTG AGA GTC CAG GAG GGA TCC AGT GCC AGC 
G E QV E Q L P S I L R V QE G S S A S 
123 
ATC AAC TGC ACT TAT GAG AAC AGT GCC TCC AAC TAC TTC CCT TGG TAT AAG CAA GAA CCT GGA 
I N C T Y E N S A S N Y F P WY K Q E PG 
186 
GAG AAT CCT AAG CTC ATC ATT GAC ATT CGT TCA AAT ATG GAA AGA AAG CAG ACC CAA GGA CTC 
• N P K L I ID I RS N ME R K Q T Q G L 
249 
ATC GTT TTA CTG GAT AAG AAA GCC AAA CGC TTC TCC CTG CAC ATC ACA GAC ACC CAG CCT GGA 
I V L L D K K AK R F S L H I T D T Q p G 
312 
GAC TCA GCC ATG TAC TTC TGT GCT GCA AAA AAT TCT GGG ACT TAC CAG AGG TTT GGA ACT GGG 
D S A M Y F C A A K NS G T Y Q R F G T G 
375 
ACA AAA CTC CAA GTC GTT CCA AAC ATC CAG AAC CCA GAA CCT GCT GTG TAC CAG TTA AAA GAT 
T K L Q V V P N I Q N P E P A V Y Q L K D 
438 
CCG CGG TCT CAG GAC AGC ACC CTC TGC CTG TTC ACC GAC TTT GAC TCC CAA ATC AAT GTG CCG 
P RS Q D S T LC L F T D F D SQ I N VP 
501 
AAA ACC ATG GAA TCT GGA ACG TTC ATC ACT GAC AAA ACT GTG CTG GAC ATG AAA GCT ATG GAT 
K TME SG T F I T D K T V L DM K A MD 
564 
TCC AAG AGC AAT GGG GCC ATT GCC TGG AGC AAC CAG ACA AGC TTC ACC TGC CAA GAT ATC TTC 
SK S N G A I A W SN Q TS F T C Q D IF 
627 
AAA GAG ACC AAC GCC ACC TAC CCC AGT TCA GAC GTT CCC TGT GAT GCC ACG TTG ACT GAG AAA 
K E T N A T Y P S S D V PC D A T L T E K 
690 
AGC TTT GAA ACA GAT ATG AAC CTA AAC TTT CAA AAC CTG TCA GTT ATG GGA CTC CGA ATC CTC 
S F E T DMN L NF Q N L S V MG L R I L 
753 	 810 
CTG CTG AAA GTA GCC GGA TTT AAC CTG CTC ATG ACG CTG AGG CTG TGG TCC AGT TGA 
L L K V AG FN L L M T L R L W S SSTOP 
TRAV 5-D4 is highlighted in green, TRAJ 13 in purple and TRAC 1 in turquoise. The CDR3 is highlighted in 
blue with the coding DNA sequence underlined. 
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Appendix 14 - Amino acid sequence of the TCR a chain (TRAY 7-D3 TRAJ 15 
TRAC) from the murine T cell clone A10(2) (chain 7-D3) cloned into retroviral 
vector MFG 
1 
ATG AAA TCC TTG AGT GTT TCC CTA GTG GTC CTG TGG CTC CAG TTA AAC TGG GTG AAC AGC CAG 
M KSL S VSL V V L W L Q L N WV N S Q 
64 
CAG AAG GTG CAG CAG AGC CCA GAA TCC CTC ATT GTC CCA GAG GGA GCC ATG ACC TCT CTC AAC 
Q K V Q Q S P E S L IV PE GA MTSLN 
127 
TGC ACT TTC AGC GAC AGT GCT TCT CAG TAT TTT GCA TGG TAC AGA CAG CAT TCT GGG AAA GCC 
C T FS DS AS Q Y F AWY R Q H SG K A 
190 
CCC AAG GCA CTG ATG TCC ATC TTC TCC AAT GGT GAA AAA GAA GAA GGC AGA TTC ACA ATT CAC 
P K A LMS IF SNGE K EE G R F T I H 
253 
CTC AAT AAA GCC AGT CTG CAT TTC TCG CTA CAC ATC AGA GAC TCC CAG CCC AGT GAC TCT GCT 
L N K A S L H F SL H I R DSQP S D S A 
316 
CTC TAC CTC TGT GCA GGA GGG CAG GGA GGC AGA GCT CTG ATA TTT GGA ACA GGA ACC ACG GTA 
L Y L C AGGQG G R A L I F G 'I G T TV 
379 
TCA GTC AGC CCC AAC ATC CAG AAC CCA GAA CCT GCT GTG TAC CAG TTA AAA GAT CCG CGG TCT 
S V SPNIQNPE PAVYQL K DP RS 
442 
CAG GAC AGC ACC CTC TGC CTG TTC ACC GAC TTT GAC TCC CAA ATC AAT GTG CCG AAA ACC ATG 
Q D S T L C L F T D F D S Q I N V P K TM 
505 
GAA TCT GGA ACG TTC ATC ACT GAC AAA ACT GTG CTG GAC ATG AAA GCT ATG GAT TCC AAG AGC 
F SG T F I T D K TV L D M K AMDSK S 
568 
AAT GGG GCC ATT GCC TGG AGC AAC CAG ACA AGC TTC ACC TGC CAA GAT ATC TTC AAA GAG ACC 
N G A IAWSNQ T S F TCQDIFK E T 
631 
AAC GCC ACC TAC CCC AGT TCA GAC GTT CCC TGT GAT GCC ACG TTG ACT GAG AAA AGC TTT GAA 
N A T Y P SS DV PCD ATL T E K S FE 
694 
ACA GAT ATG AAC CTA AAC TTT CAA AAC CTG TCA GTT ATG GGA CTC CGA ATC CTC CTG CTG AAA 
T D MNL NE Q N L S V MGL R IL L L K 
757 	 804 
GTA GCC GGA TTT AAC CTG CTC ATG ACG CTG AGG CTG TGG TCC AGT TGA 
✓ A G F N L LM T L R L W S SSTOP 
TRAV 7-D3 is highlighted in green, TRAJ 15 in purple and TRAC 1 in turquoise. The CDR3 is highlighted 
in blue with the coding DNA sequence underlined. 
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Appendix 15 - Amino acid sequence of the TCR a chain (TRAV 7-D4 TRAJ 26-like 
TRAC) from the murine T cell clone D3(3) cloned into retroviral vector MFG 
1 
ATG AAA TCC TTG AGT GTT TCA CTA G GTC CTG TGG CTC CAG GTA AAC TGC GTG AGG AGC CAG 
MK SL S V S L V V L W L Q V NC V R SQ 
64 
CAG AAG GTG CAG CAG AGC CCA GAA TCC CTC AGT GTC CCA GAG GGA GGC ATG GCC TCT TTC AAC 
Q K V Q Q SP ES LS VPE GGMASFN 
127 
TGC ACT TCA AGT GAT CGT AAT TTT CAG TAC TTC TGG TGG TAC AGA CAG CAT TCT GGA GAA GGC 
C T S SD RNF Q Y F W WY R Q HSO E G 
190 
CCC AAG GCA CTG ATG TCA ATC TTC TCT GAT GGT GAC AAG AAA GAA GGC AGA TTT ACA GCT CAC 
P K ALMS IF SD GDKK E G R F T A H 
253 
CTC AAT AAG GCC AGC CTG CAT GTT TCC CTG CAC ATC AGA GAC TCC CAG CCC AGT GAC TCC GCT 
L N K A S L H V S L H 1 RD S Q PS D SA 
316 
CTC TAC TTC TGT GCA GCT AGT GCC GTG GAT AAC TAT GCC CAG GGA TTA ACC TTC GGT CTT GGC 
L Y F C A A S AV D N Y A Q G L T F G L G 
379 
ACC AGA GTA TCT GTG ITT CCC TAC ATC CAA AAC CCA GAA CCT GCT GTG TAC CAG TTA AAA GAT 
T R V S V F P Y I Q N PE PA V Y Q L K D 
442 
CCG CGG TCT CAG GAC AGC ACC CTC TGC CTG TTC ACC GAC TTT GAC TCC CAA ATC AAT GTG CCG 
P R S Q D S'I'LCLF T D F D S Q I N VP 
505 
AAA ACC ATG GAA TCT GGA ACG TTC ATC ACT GAC AAA ACT GTG CTG GAC ATG AAA GCT ATG GAT 
K TMES G T F I T D K TV L D M K AMD 
568 
TCC AAG AGC AAT GGG GCC ATT GCC TGG AGC AAC CAG ACA AGC TTC ACC TGC CAA GAT ATC TTC 
SK S N G A I A W S N Q T SF T C Q D IF 
631 
AAA GAG ACC AAC GCC ACC TAC CCC AGT TCA GAC GTT CCC TGT GAT GCC ACG TTG ACT GAG AAA 
K E TN A T Y PS S DV PCD AT LT E K 
694 
AGC TTT GAA ACA GAT ATG AAC CTA AAC TTT CAA AAC CTG TCA GTT ATG GGA CTC CGA ATC CTC 
S F E T D MNLN F Q N L S V MG L R I L 
757 	 813 
CTG CTG AAA GTA GCC GGA TTT AAC CTG CTC ATG ACG CTG AGG CTG TGG TCC AGT TGA 
L L K VAGF NLLMT L R LWS SSTOP 
TRAY 7-D4 is highlighted in green, TRAJ 26-like (95% identity) in purple and TRAC 1 in turquoise. The 
CDR3 is highlighted in blue with the coding DNA sequence underlined. 
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Appendix 16 - Amino acid sequence of the TCRII chain (TRBV 14 TRBJ 2-7 TRBC 1) 
from the murine T cell clone A10(2) cloned into retroviral vector MFG 
ATG GGC ACC AGG CTT CTT GGC TGG GCA GTG TTC TGT CTC CTT GAC ACA GTA CTG TCT GAA GCT 
MG T R L L G W A V F CL L D T V L SE A 
64 
GGA GTC ACC CAG TCT CCC AGA TAT GCA GTC CTA CAG GAA GGG CAA GCT GTT TCC TTT TGG TGT 
G V T QS PR Y A V L Q E G Q A V SF WC 
127 
GAC CCT ATT TCT GGA CAT GAT ACC CTT TAC TGG TAT CAG CAG CCC AGA GAC CAG GGG CCC CAG 
D P I S G H D T L Y W Y Q Q P R D Q G P Q 
190 
CTT CTA GTT TAC TTT CGG GAT GAG GCT GTT ATA GAT AAT TCA CAG TTG CCC TCG GAT CGA TIT 
L L V Y F RDE A V I DNS Q L PS D R F 
253 
TCT GCT GTG AGG CCT AAA GGA ACT AAC TCC ACT CTC AAG ATC CAG TCT GCA AAG CAG GGC GAC 
S A V RP KG TNS T L K I Q S A K Q G D 
316 
ACA GCC ACC TAT CTC TGT GCC AGC AGC CCC CTC GAC TGG GGG GAT GAA CAG TAC TTC GGT CCC 
T ATY LC AS SP L DWGDEQ Y F GP 
379 
GGC ACC AGG CTC ACG GTT TTA GAG GAT CTG AGA AAT GTG ACT CCA CCC AAG GTC TCC TTG TTT 
• T R L T V L EDL RNV TPP K VSLF 
442 
GAG CCA TCA AAA GCC GAG CTG GCA AAC AAA CAA AAG GCT ACC CTC GTG TGC TTG GCC AGG GGC 
E PSK A E L A N K Q K AT LV CL A R G 
505 
TTC TTC CCT GAC CAC GTG GAG CTG AGC TGG TGG GTG AAT GGC AAG GAG GTC CAC AGT GGG GTC 
F F PD H V E LS WWV N G K 17, V HS G V 
568 
AGC ACG GAC CCT CAG GCC TAC AAG GAG AGC AAT TAT AGC TAC TGC CTG AGC AGC CGC CTG AGG 
S T D P Q AY K E SN Y S Y C L S S R L R 
631 
GTC TCT GCT ACC TTC TGG CAC AAT CCT CGA AAC CAC TTC CGC TGC CAA GTG CAG TTC CAT GGG 
✓ S A TF WHN PR N HE R C Q V Q F HG 
694 
CTT TCA GAG GAG GAC AAG TGG CCA GAG GGC TCA CCC AAA CCT GTC ACA CAG AAC ATC AGT GCA 
L S E E D K W P E G S P K P VT Q N I S A 
757 
GAG GCC TGG GGC CGA GCA GAC TGT GGA ATC ACT TCA GCA TCC TAT CAT CAG GGG GTT CTG TCT 
E A W G R A DCG I T S A S Y HQ G V L S 
820 
GCA ACC ATC CTC TAT GAG ATC CTA CTG GGG AAG GCC ACC CTA TAT GCT GTG CTG GTC AGT GGC 
A TILYE IL L G K A T L Y AVL VS G 
883 	 921 
CTG GTG CTG ATG GCC ATG GTC AAG AAA AAA AAT TCC TGA 
L V L M A M V K KKNSSTOP 
TRBV 14 is highlighted in green, TRBJ 2-7 in purple and TRBC 1 in turquoise. The CDR3 
is highlighted in blue with the coding DNA sequence underlined. The letter underlined in 
red indicates the base pair that was inserted by site-directed mutagenesis in order to 
convert the incorrect sequence to the original DNA sequence, thus allowing for correct 
read-through of the amino acid sequence and correct positioning of the stop codon. 
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Appendix 17 - Amino acid sequence of the TCRI3 chain (TRBV 2 TRBJ 2-5 TRBC 1) 
from the murine T cell clone D3(3) cloned into retroviral vector MFG 
ATG GGC TCC ATT TTC CTC AGT TGC CTG GCC GTT TGT CTC CTG GTG GCA GGT CCA GTC GAC CCG 
M GS IF LS CL A V C L L V A G PV DP 
64 
AAA ATT ATC CAG AAA CCA AAA TAT CTG GTG GCA GTC ACA GGG AGC GAA AAA ATC CTG ATA TGC 
K I I Q K PKY LV AV TG SEK IL IC 
127 
GAA CAG TAT CTA GGC CAC AAT GCT ATG TAT TGG TAT AGA CAA AGT GCT AAG AAG CCT CTA GAG 
E Q Y L G H N A M Y WY R Q S AK K PL E 
190 
TTC ATG TTT TCC TAC AGC TAT CAA AAA CTT ATG GAC AAT CAG ACT GCC TCA AGT CGC TTC CAA 
F M F S Y S Y Q K L MDN QT A S S R F Q 
253 
CCT CAA AGT TCA AAG AAA AAC CAT TTA GAC CTT CAG ATC ACA GCT CTA AAG CCT GAT GAC TCG 
P Q S SK K N H L D L Q I T AL K PDDS 
316 
GCC ACA TAC TTC TGT GCC AGC AGC CAA GCC GGG ACT GGA GAA GAC ACC CAG TAC TTT GGG CCA 
AT Y F C A S S Q AGT GE DT Q Y FG P 
379 
GGC ACT CGG CTC CTC GTG TTA GAG GAT CTG AGA AAT GTG ACT CCA CCC AAG GTC TCC TTG TTT 
G T R LLVL E DL RNV T P P KVS L F 
442 
GAG CCA TCA AAA GCC GAG CTG GCA AAC AAA CAA AAG GCT ACC CTC GTG TGC TTG GCC AGG GGC 
E PSK A E L A N K Q K A TLV CL AR G 
505 
TTC TTC CCT GAC CAC GTG GAG CTG AGC TGG TGG GTG AAT GGC AAG GAG GTC CAC AGT GGG GTC 
F F PDHV EL SWWVNGKE VHS G V 
568 
AGC ACG GAC CCT CAG GCC TAC AAG GAG AGC AAT TAT AGC TAC TGC CTG AGC AGC CGC CTG AGG 
S T D P Q A Y K E SNYSY CL SS R L R 
631 
GTC TCT GCT ACC TTC TGG CAC AAT CCT CGA AAC CAC TTC CGC TGC CAA GTG CAG TTC CAT GGG 
✓ S A TF W H N P RNH F R C Q V Q F HG 
694 
CTT TCA GAG GAG GAC AAG TGG CCA GAG GGC TCA CCC AAA CCT GTC ACA CAG AAC ATC AGT GCA 
L S E E D K W P E G SP K PV T Q N I S A 
757 
GAG GCC TGG GGC CGA GCA GAC TGT GGA ATC ACT TCA GCA TCC TAT CAT CAG GGG GTT CTG TCT 
E A W G R A DCG I TS A S Y H Q G V LS 
820 
GCA ACC ATC CTC TAT GAG ATC CTA CTG GGG AAG GCC ACC CTA TAT GCT GTG CTG GTC AGT GGC 
A T I L Y E IL L G K A T L Y A V LVSG 
883 	 921 
CTG GTG CTG ATG GCC ATG GTC AAG AAA AAA AAT TCC TGA 
L V L M A M V K K K N SSTOP 
TRBV 2 is highlighted in green, TRBJ 2-5 in purple and TRBC 1 in turquoise. The CDR3 
is highlighted in blue with the coding sequence underlined. The letter underlined in red 
indicates the base pair inserted by site-directed mutagenesis to convert the incorrect 
sequence to the original DNA sequence, allowing for correct read-through of the amino 
acid sequence and correct positioning of the stop codon. 
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Appendix 18 - Amino acid sequence of the dominant TCR a chain (TRAY 8-4 
TRAJ 32 TRAC) from the human T cell line 010 cloned into retroviral vector 
MFG 
1 
ATG CTC CTG CTG CTC GTC CCA GTG CTC GAG GTG ATT TTT ACC CTG GGA GGA ACC AGA 
MLLLLVP V L E V IF T L G G T R 
58 
GCC CAG TCG GTG ACC CAG CTT GGC AGC CAC GTC TCT GTC TCT GAG GGA GCC CTG GTT 
A Q S V T Q L G S H V S V S E G A L V 
115 
CTG CTG AGG TUC AAC TAC TCA TCG TCT GTT CCA CCA TAT CTC TTC TGG TAT GTG CAA 
L L R C N Y S S S V PP Y L F W Y V Q 
172 
TAC CCC AAC CAA GGA CTC CAG CTT CTC CTG AAG TAC ACA ACA GGG GCC ACC CTG GTT 
Y P N Q G L Q L L L KY T T GA TL V 
229 
AAA GGC ATC AAC GGT TTT GAG GCT GAA TTT AAG AAG AGT GAA ACC TCC TTC CAC CTG 
K GINGFE A E F K K SE T SFHL 
286 
ACG AAA CCC TCA GCC CAT ATG AGC GAC GCG GCT GAG TAC TTC TGT GCC GTG TGG AGT 
TK PS A HM S D A A E Y F C A V W S 
343 
GGT GCT ACA AAC AAG CTC ATC TTT GGA ACT GGC ACT CTG CTT GCT GTC CAG CCA AAT 
G AT N K L IF G T G TL L A V Q P N 
400 
ATC CAG AAC CCT GAC CCT GCC GTG TAC CAG CTG AGA GAC TCT AAA TCC AGT GAC AAG 
IQNPDPAV Y Q L R D S K S SDK 
457 
TCT GTC TGC CTA TTC ACC GAT TTT GAT TCT CAA ACA AAT GTG TCA CAA AGT AAG GAT 
S V C L F TDFDSQTN V S QS K D 
514 
TCT GAT GTG TAT ATC ACA GAC AAA ACT GTG CTA GAC ATG AGG TCT ATG GAC TTC AAG 
S D V Y I T D K T V L DM R SM D F K 
571 
AGC AAC AGT GCT GTG GCC TGG AGC AAC AAA TCT GAC TTT GCA TGT GCA AAC GCC TTC 
S NS AV A WS N K SDF A C AN A F 
628 
AAC AAC AGC ATT ATT CCA GAA GAC ACC TTC TTC CCC AGC CCA GAA AGT TCC TGT GAT 
N N S I IP ED TFF P S P E S SCD 
685 
GTC AAG CTG GTC GAG AAA AGC TTT GAA ACA GAT ACG AAC CTA AAC TTT CAA AAC CTG 
✓ K L V E K SF E TD T N L N F Q N L 
742 
TCA GTG ATT GGG TTC CGA ATC CTC CTC CTG AAA GTG GCC GGG TTT AAT CTG CTC ATG 
S V I G F R I L L L K V A G F N L LM 
799 	 822 
ACG CTG CGG CTG TGG TCC AGC TGA 
T L R L W S S STOP 
TRAV 8-4 is highlighted in green, TRAJ 32 in purple and TRAC 1 in turquoise. The CDR3 is highlighted 
in blue with the coding DNA sequence underlined. 
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Appendix 19 - Amino acid sequence of the dominant TCR a chain (TRAV 8-4 
TRAJ 32) from the human T cell line CIR010 joined to a murine C region (murine 
TRAC 1) cloned into retroviral vector MFG 
1 
ATG CTC CTG CTG CTC GTC CCA GTG CTC GAG GTG ATT TTT ACC CTG GGA GGA ACC AGA GCC 
M L L L LV PV L E V IFT L G G T R A 
61 
CAG TCG GTG ACC CAG CTT GGC AGC CAC GTC TCT GTC TCT GAG GGA GCC CTG GTT CTG CTG 
Q S V T Q L G S H V S V SE G A L V L L 
121 
AGG TGC AAC TAC TCA TCG TCT GTT CCA CCA TAT CTC TTC TGG TAT GTG CAA TAC CCC AAC 
R C N Y SS S VP P Y L F WY V Q Y P N 
181 
CAA GGA CTC CAG CTT CTC CTG AAG TAC ACA ACA GGG GCC ACC CTG GTT AAA GGC ATC AAC 
Q G L Q L L LKY T T G AT LV KGIN 
241 
GGT TTT GAG GCT GAA TTT AAG AAG AGT GAA ACC TCC TTC CAC CTG ACG AAA CCC TCA GCC 
G FE AEF K K SE T S F H L T K PSA 
301 
CAT ATG AGC GAC GCG GCT GAG TAC TTC TGT GCC GTG TGG AGT GGT GCT ACA AAC AAG CTC 
H M S D A A E Y F C A V W S G A T N K L 
361 	 GCC 
ATC TTT GGA ACT GGC ACT CTG CTT GCT GTC CAG CCA AAT ATC CAG AAC CCT GAA CCT GCA_ 
I F G TG TLLAVQPNIQNPE PA 
421 
GTG TAC CAG TTA AAA GAT CCT CGG TCT CAG GAC AGC ACC CTC TGC CTG TTC ACC GAC TTT 
✓ Y Q L K D P R S Q D S I L C L F T D F 
481 
GAC TCC CAA ATC AAT GTG CCG AAA ACC ATG GAA TCT GGA ACG TTC ATC ACT GAC AAA ACT 
D S QINV P K TMES G T F I T D K T 
541 
GTG CTG GAC ATG AAA GCT ATG GAT TCC AAG AGC AAT GGG GCC ATT GCC TGG AGC AAC CAG 
✓ L D MK A MD SK SN G A IA W SN Q 
601 
ACA AGC TTC ACC TGC CAA GAT ATC TTC AAA GAG ACC AAC GCC ACC TAC CCC AGT TCA GAC 
T SF T C Q D I F K E TN ATYP S SD 
661 
OTT CCC TGT GAT GCC ACG TTG ACC GAG AAA AGC TTT GAA ACA GAT ATG AAC CTA AAC TTT 
V P C D A T L T E K SF E T DMNL NF 
721 
CAA AAC CTG TCA GTT ATG GGA CTC CGA ATC CTC CTG CTG AAA GTA GCG GGA TTT AAC CTG 
Q N L S VMGLR ILL L K V AGFNL 
781 	 810 
CTC ATG ACG CTG AGG CTG TGG TCC AGT TGA 
L M T L R L W S SSTOP 
TRAV 8-4 is highlighted in green, TRAJ 32 in purple and murine TRAC 1 in turquoise. The CDR3 is 
highlighted in blue with the coding DNA sequence underlined. The letters underlined in red indicate the 
base pair change (C—>A) that was required to allow the VJ and C regions to be combined using PstI (site 
in italics). This did not cause a change in the amino acid sequence of the translated protein (codons GCC 
and GCA both code for the amino acid alanine). 
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Appendix 20 - Amino acid sequence of the dominant TCR p chain (TRBV 6-1 
TRBJ 1-1) from the human T cell line CIR010 joined to a murine C region 
(murine TRBC 1) cloned into retroviral vector MFG 
ATG AGC ATC GGG CTC CTG TGC TGT GTG GCC TTT TCT CTC CTG TGG GCA AGT CCA GTG AAT 
MS IGLLCCVAF SL L WASP V N 
61 
GCT GGT GTC ACT CAG ACC CCA AAA TTC CAG GTC CTG AAG ACA GGA CAG AGC ATG ACA CTG 
A G V T Q T P K F QV L K T G Q S MTL 
121 
CAG TGT GCC CAG GAT ATG AAC CAT AAC TCC ATG TAC TGG TAT CGA CAA GAC CCA GGC ATG 
Q C A Q DMNH NS M Y WY R Q D PG M 
181 
GGA CTG AGG CTG ATT TAT TAC TCA GCT TCT GAG GGT ACC ACT GAC AAA GGA GAA GTC CCC 
G L R L I Y Y S A SE G T TDKGE V P 
241 
AAT GGC TAC AAT GTC TCC AGA TTA AAC AAA CGG GAG TTC TCG CTC AGG CTG GAG TCG GCT 
N G Y N V S R L N K REF SL R LE SA 
301 
GCT CCC TCC CAG ACA TCT GTG TAC TTC TGT GCC AGC AGT GAG GCT GGG TGG GGG GCG TCG 
A P S Q T S V Y F C A SSE AGWG AS 
361 	 GAT 
GGC ACT GAA GCT TTC TTT GGA CAA GGC ACC AGA CTC ACA GTT GTA GAG GAC CTG AGA AAT 
G T E A F F G Q G T R L T VVEDL RN 
421 
GTG ACT CCA CCC AAG GTC TCC TTG TTT GAG CCA TCA AAA GCA GAG ATT GCA AAC AAA CAA 
✓ T P P K V SLFE PSK AE I A N K Q 
481 
AAG GCT ACC CTC GTG TGC TTG GCC AGG GGC TTC TTC CCT GAC CAC GTG GAG CTG AGC TGG 
TK A L VCL A R GEE P D H V EL SW 
541 
TGG GTG AAT GGC AAG GAG GTC CAC AGT GGG GTC AGC ACG GAC CCT CAG GCC TAC AAG GAG 
WVNGK E V HS G V S T D P Q A Y K E 
601 
AGC AAT TAT AGC TAC TGC CTG AGC AGC CGC CTG AGG GTC TCT GCT ACC TTC TGG CAC AAT 
SNY S Y CL S SR L R VSA T F W H N 
661 
CCT CGC AAC CAC TTC CGC TGC CAA GTG CAG TTC CAT GGG CTT TCA GAG GAG GAC AAG TGG 
P RNEIF RCQVQFHG LS E E D K W 
721 
CCA GAG GGC TCA CCC AAA CCT GTC ACA CAG AAC ATC AGT GCA GAG GCC TGG GGC CGA GCA 
P E G S P K P V T Q N I S AE A W G R A 
781 
GAC TGT GGG ATT ACC TCA GCA TCC TAT CAA CAA GGG GTC TTG TCT GCC ACC ATC CTC TAT 
D C G I TS A S Y Q Q G V L SA T I L Y 
841 
GAG ATC CTG CTA GGG AAA GCC ACC CTG TAT GCT GTG CTT GTC AGT ACA CTG GTG GTG ATG 
E IL L GK A TL Y A VLV S TLVV M 
901 	 927 
GCT ATG GTC AAA AGA AAG AAT TCA TGA 
AM V K R K N S STOP 
TRBV 6-1 is highlighted in green, TRBJ 1-1 in purple and murine TRBC 1 in turquoise. The CDR3 is 
highlighted in blue with the coding DNA sequence underlined. The letters underlined in red indicate the 
base pair change (C-4T) that was required to allow the VJ and C regions to be combined using PpuMI 
(site in italics). This did not cause a change in the amino acid sequence of the translated protein (codons 
GAC and GAT both code for the amino acid aspartic acid). 
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Appendix 21 - pUC19 — vector diagram and multiple cloning site 
lacZ' 
\EcoRI 396 
) M CS 
Hindll1447 
ampicillin 
on 
Multiple cloning site:  
SacI 	XmaI 	XbaI 	BspMI 	PstI 	Hind!!! 
I I I I I I  
I 	 I 	 I 	 I 	 I 	 I 
EcoRI 	KpnI BamHI 	Sall Sbfl SphI 
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Appendix 22 - Amino acid sequence of one of the two TCR a chains (TRAV 5-D4 
TRAJ 13) from the murine T cell clone A10(2) cloned into the TCR cassette vector 
pTacass 
1 
ATG AAA ACA TAT GCT CCT ACA TTA TTC ATG TTT CTA TGG CTG CAG CTG GAT GGG ATG AGC 
MK T Y A PTL F M F L W L Q L DG MS 
61 
CAA GGC GAG CAG GTG GAG CAG CTT CCT TCC ATC CTG AGA GTC CAG GAG GGA TCC AGT GCC 
Q G E Q V EQLPS I L R V Q E G SSA 
121 
AGC ATC AAC TGC ACT TAT GAG AAC AGT GCC TCC AAC TAC TTC CCT TGG TAT AAG CAA GAA 
S INC TYEN SA SNYF PWY K QE 
181 
CCT GGA GAG AAT CCT AAG CTC ATC ATT GAC ATT CGT TCA AAT ATG GAA AGA AAG CAG ACC 
P GENPKL II DIRSNMER K Q T 
241 
CAA GGA CTC ATC GTT TTA CTG GAT AAG AAA GCC AAA CGC TTC TCC CTG CAC ATC ACA GAC 
Q G L I V L L D K K AKRE S L H I TD 
301 
ACC CAG CCT GGA GAC TCA GCC ATG TAC TTC TGT GCT GCA AAA AAT TCT GGG ACT TAC CAG 
T QPGDS A MY F C A A K NS G T Y Q 
361 
AGG ITT GGA ACT GGG ACA AAA CTC CAA GTC GTT CCA AGT AAG TCC ATG TCT GAA TTG TTC 
R F G TO T K L Q V VP 
421 	 447 
TCA TGT TGT TCT CTA ATA TAG CAT TTG 
TRAV 5-D4 is highlighted in green and TRAJ 13 in purple. The additional intronic sequence required for 
correct processing of the vector is also shown, untranslated, in turquoise. The CDR3 is highlighted in blue 
with the coding DNA sequence underlined. Letters shown in red indicate the restriction site (BstX1) used 
to combine the V-J region with the J-intronic sequence. 
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Appendix 23 - Amino acid sequence of one of the two TCR a chains (TRAY 7-D3 
TRAJ 15) from the murine T cell clone A10(2) cloned into the TCR cassette vector 
pTacass 
1 
ATG AAA TCC TTG AGT GTT TCC CTA GTG GTC CTG TGG CTC CAG TTA AAC TGG GTG AAC AGC 
M K SL S VSL V V L W L Q L N W V N S 
61 
CAG CAG AAG GTG CAG CAG AGC CCA GAA TCC CTC ATT GTC CCA GAG GGA GCC ATG ACC TCT 
Q Q K V Q Q S P E SLIVPEG AM TS 
121 
CTC AAC TGC ACT TTC AGC GAC AGT GCT TCT CAG TAT TTT GCA TGG TAC AGA CAG CAT TCT 
L N C T F S D S A SQY F A WY R Q H S 
181 
GGG AAA GCC CCC AAG GCA CTG ATG TCC ATC TTC TCC AAT GGT GAA AAA GAA GAA GGC AGA 
G K A P K A LMS 1 F S N G E K EEG R 
241 
TTC ACA ATT CAC CTC AAT AAA GCC AGT CTG CAT TTC TCG CTA CAC ATC AGA GAC TCC CAG 
FT I H L N K ASLHF SL HI RDSQ 
301 
CCC AGT GAC TCT GCT CTC TAC CTC TGT GCA GGA GGG CAG GGA GGC AGA GCT CTG ATA TTT 
P S D S ALYLCA G G Q G G R AL 1 F 
361 
GGA ACA GGA ACC ACG GTA TCA GTC AGC CCC AGT AAG TAC CTG ATA GCT GGT GAT TAT GAC 
G TOTT VS V SP 
421 	427 
GCC CGC C 
TRAV 7-D3 is highlighted in green and TRAJ 15 in purple. The additional intronic sequence required for 
correct processing of the vector is also shown, untranslated, in turquoise. The CDR3 is highlighted in blue 
with the coding DNA sequence underlined. Letters shown in red indicate the restriction site (Sacl) used to 
combine the V-J region with the J-intronic sequence. 
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Appendix 24 - Amino acid sequence of the TCR 13 chain (TRBV 14 TRBJ 2-7) from 
the murine T cell clone A10(2) cloned into the TCR cassette vector pT13cass 
1 
ATG GGC ACC AGG CTT CTT GGC TGG GCA GTG TTC TGT CTC CTT GAC ACA GTA CTG TCT GAA GCT 
MG T R L L G WA V F C I, L DT V LS E A 
64 
GGA GTC ACC CAG TCT CCC AGA TAT GCA GTC CTA CAG GAA GGG CAA GCT GTT TCC TTT TGG TGT 
G VT QSPR Y A V L Q E G Q AVSFWC 
127 
GAC CCT ATT TCT GGA CAT GAT ACC MT TAC TGG TAT CAG CAG CCC AGA GAC CAG GGG CCC CAG 
D P IS G H DT LYWYQ Q P R D Q G P Q 
190 
CTT CTA GTT TAC TTT CGG GAT GAG GCT GTT ATA GAT AAT TCA CAG TTG CCC TCG GAT CGA TTT 
L L V Y F RDE A V I D N S Q L PS DR F 
253 
TCT GCT GTG AGG CCT AAA GGA ACT AAC TCC ACT CTC AAG ATC CAG TCT GCA AAG CAG GGC 
S A V R P K G TNS TL K I QS AK Q G 
313 
GAC ACA GCC ACC TAT CTC TGT GCC AGC AGC CCC CTC GAC TGG GGG GAT GAA CAG TAC TTC GGT 
D T ATYLC A S S P L D W G D E Q Y F G 
376 GGC 
CCC GGG ACC AGG CTC ACG GTT TTA GGT AAG ATT CAC ATC TCT CGC TTC CAC CCA AAT TCC TGG 
P G T R L T V L 
439 	 456 
GTC CCT GGA GTA GTT TGG 
TRBV 14 is highlighted in green and TRBJ 2-7 in purple. The additional intronic sequence required for 
correct processing of the vector is also shown, untranslated, in turquoise. The CDR3 is highlighted in blue 
with the coding DNA sequence underlined. Letters shown in red and underlined indicate an intentional base 
pair change to allow combination of the V-J region with the J-intronic sequence using XmaI (site in italics). 
The base pair change did not alter the amino acid sequence of the translated protein. 
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Appendix 25 - Amino acid sequence of the TCR a chain (TRAY 7-D4 TRAJ 26-like) 
from the murine T cell clone D3(3) cloned into the TCR cassette vector pTacass 
1 
ATG AAA TCC TTG AGT GTT TCA CTA GIG GTC CTG TGG CTC CAG GTA AAC TGC GTG AGG AGC CAG 
M K S L S V S L V V L W L Q V N C V R S Q 
64 
CAG AAG GTG CAG CAG AGC CCA GAA TCC CTC AGT GTC CCA GAG GGA GGC ATG GCC TCT TTC AAC 
Q K V Q Q S P E S L S VPE GGMA S F N 
127 
TGC ACT TCA AGT GAT CGT AAT TTT CAG TAC TTC TGG TGG TAC AGA CAG CAT TCT GGA GAA GGC 
C T S SD RNF QYFWWY R Q H SG E G 
190 
CCC AAG GCA CTG ATG TCA ATC TTC TCT GAT GGT GAC AAG AAA GAA GGC AGA TTT ACA GCT CAC 
P KALMSIF SD GDK KEG R F T A H 
253 
CTC AAT AAG GCC AGC CTG CAT GTT TCC CTG CAC ATC AGA GAC TCC CAG CCC AGT GAC TCC GCT 
L N K A S L H V SL H I R DSQ P SD SA 
316 	 GGC 
CTC TAC TTC TGT GCA GCT AGT GCC GTG GAT AAC TAT GCC CAG GGA TTA ACC TTC GGT CTT GGT 
L Y F C A A S A V D N Y A Q GL T F GL G 
379 
ACC AGA GTA TCT GTG TTT CCC TGT AAG TAT ACC TGA GTG AAA GGC TGG TGT GGG GAT GAG CTG 
T RV S V FP 
442 	450 
GGG TGA GGG 
TRAV 7-D4 is highlighted in green and TRAJ 26-like (95% identity) in purple. The additional intronic 
sequence required for correct processing of the vector is also shown, untranslated, in turquoise. The CDR3 is 
highlighted in blue with the coding DNA sequence underlined. Letters shown in red and underlined indicate 
an intentional base pair change to allow combination of the V-J region with the J-intronic sequence using 
KpnI (site in italics). The base pair change did not alter the amino acid sequence of the translated protein. 
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Appendix 26 - Amino acid sequence of the TCR 13 chain (TRBV 2 TRBJ 2-5) from 
the murine T cell clone D3(3) cloned into the TCR cassette vector pTl3cass 
1 
ATG GGC TCC ATT TTC CTC AGT TGC CTG GCC GTT TGT CTC CTG GTG GCA GGT CCA GTC GAC CCG 
M GS I F LS CL AVCL LV A G P V D P 
64 
AAA ATT ATC CAG AAA CCA AAA TAT CTG GTG GCA GTC ACA GGG AGC GAA AAA ATC CTG ATA 
K II Q K PKYLV AV T G SE K IL I 
124 
TGC GAA CAG TAT CTA GGC CAC AAT GCT ATG TAT TGG TAT AGA CAA AGT GCT AAG AAG CCT 
CE Q Y L G H N AM Y WY R Q S A K K P 
184 
CTA GAG TTC ATG TTT TCC TAC AGC TAT CAA AAA CTT ATG GAC AAT CAG ACT GCC TCA AGT CGC 
L E F M F S Y S Y Q K LMD N Q TAS S R 
247 
TTC CAA CCT CAA AGT TCA AAG AAA AAC CAT TTA GAC CTT CAG ATC ACA GCT CTA AAG CCT GAT 
F Q P Q S SK KNHLDLQIT AL K pD 
310 
GAC TCG GCC ACA TAC TTC TGT GCC AGC AGC CAA GCC GGG ACT GGA GAA GAC ACC CAG TAC 
D SA T Y F CAS S Q A G T G E D T Q Y 
370 
TTT GGG CCA GGC ACT CGG CTC CTC GTG TTA GGT GAG CTG GGG CCC CAC GTG CGC GTT CTC AGC 
F G P G T R L L V L 
433 	 485 
GGG ATT GGG CTG CAG TGG GCG CGG GTC CCT TGG CCG GGT TTC TCT GGG AGT CA 
TRBV 2 is highlighted in green and TRBJ 2-5 in purple. The additional intronic sequence required for 
correct processing of the vector is also shown, untranslated, in turquoise. The CDR3 is highlighted in blue 
with the coding DNA sequence underlined. Letters shown in red indicate the restriction site (BstXI) used to 
combine the V-J region with the J-intronic sequence. 
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Appendix 27 - Amino acid sequence of the dominant TCR a chain (TRAV 8-4 
TRAJ 32) from the human T cell line CIR010 cloned into the TCR cassette vector 
pTacass 
1 
ATG CTC CTG CTG CTC GTC CCA GTG CTC GAG GTG ATT TTT ACC CTG GGA GGA ACC AGA GCC 
MLLL L VPV L E V IF T L G G T R A 
61 
CAG TCG GTG ACC CAG CTT GGC AGC CAC GTC TCT GTC TCT GAG GGA GCC CTG GTT CTG CTG 
Q S V T Q L G S H V S VSE G AL V LL 
121 
AGG TGC AAC TAC TCA TCG TCT GTT CCA CCA TAT CTC TTC TGG TAT GTG CAA TAC CCC AAC 
R C N Y S S S V P P Y L F WY V Q Y P N 
181 
CAA GGA CTC CAG CTT CTC CTG AAG TAC ACA ACA GGG GCC ACC CTG GTT AAA GGC ATC AAC 
Q G L Q L L L K Y TT G AT LV KGIN 
241 
GGT TTT GAG GCT GAA TTT AAG AAG AGT GAA ACC TCC TTC CAC CTG ACG AAA CCC TCA GCC 
G FE A E F K K SE T SFHL T K P S A 
301 	 CTC 
CAT ATG AGC GAC GCG GCT GAG TAC TTC TGT GCC GTG TGG AGT GOT GCT ACA AAC AAG CTT 
HMS D A A E Y F C A V W S G A T NK L 
361 
ATC TIT GGA ACT GGC ACT CTG CTT GCT GTC CAG CCA AGT ACG TAA GTA GIG GCA TGT GTC 
IF G T G T L L A V Q P 
421 	 446 
AGG TGG ATT CTG TGT CCA TGG CAA GT 
TRAV 8-4 is highlighted in green and TRAJ 32 in purple. The additional intronic sequence required for 
correct processing of the vector is also shown, untranslated, in turquoise. The CDR3 is highlighted in blue 
with the coding DNA sequence underlined. Letters shown in red and underlined indicate an intentional 
base pair change to allow combination of the V-J region with the J-intronic sequence using HindIII (site 
in italics). The base pair change did not alter the amino acid sequence of the translated protein. 
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Appendix 28 - Amino acid sequence of the dominant TCR 13 chain (TRBV 6-1 
TRBJ 1-1) from the human T cell line CIR010 cloned into the TCR cassette vector 
pTi3cass 
1 
ATG AGC ATC GGG CTC CTG TGC TGT GTG GCC TTT TCT CTC CTG TGG GCA AGT CCA GTG AAT 
M S I G L L CCV AFSLLWA S P V N 
61 
GCT GGT GTC ACT CAG ACC CCA AAA TTC CAG GTC CTG AAG ACA GGA CAG AGC ATG ACA CTG 
AGV T Q T P K F Q V L K T GQSM TL 
121 
CAG TGT GCC CAG GAT ATG AAC CAT AAC TCC ATG TAC TGG TAT CGA CAA GAC CCA GGC ATG 
QC A Q D MNHN S M Y WY R Q DP GM 
181 
GGA CTG AGG CTG ATT TAT TAC TCA GCT TCT GAG GGT ACC ACT GAC AAA GGA GAA GTC CCC 
G L R L I Y Y S ASE G T T D K G E V P 
241 
AAT GGC TAC AAT GTC TCC AGA TTA AAC AAA CGG GAG TTC TCG CTC AGG CTG GAG TCG GCT 
N G Y N V S R L N K REF SL R L ESA 
301 
GCT CCC TCC CAG ACA TCT GTG TAC TTC TGT GCC AGC AGT GAG GCT GGG TGG GGG GCG TCG 
AP SQ T S V Y F C A S SE A G W G A S 
361 
GGC ACT GAA GCT TTC TTT GGA CAA GGC ACC AGA CTC ACA GTT GTA GGT AAG ACA TTT TTC 
G TE A F F G Q G T R L T VV 
421 	 450 
AGG TTC TTT TGC AGA TCC GTC ACA GGG AAA 
TRBV 6-1 is highlighted in green and TRBJ 1-1 in purple. The additional intronic sequence required for 
correct processing of the vector is also shown, untranslated, in turquoise. The CDR3 is highlighted in 
blue with the coding DNA sequence underlined. Letters shown in red indicate the restriction site 
(HindIII) used to combine the V-J region with the J-intronic sequence. 
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kanamycin PCMV 
pUC on 
Esp3I 1909 
Eco31I 1896 
BspTI 1891 
BgIII 1676 
Xhol 1680 
acl 1687 
intron 
ESp3I 7 
Eco311 18 
Nsil 27 
pmaxGFP 
3486 bp 
---\
Kpnl 980 
Nhel 988 
Agel 997 
Esp31 2667 Eco47111 933 
SV40 pA max GFP 
Appendix 29 - pmaxGFP 
The diagram shows the components of the Amaxa system positive control vector pmaxGFP 
and the target gene GFP, including all promoter regions required for expression of the 
target gene. The GFP gene in this vector has a fluorescence intensity similar to or slightly 
higher than that of eGFP. 
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Appendix 30 - DNA coding sequences for the P4 TCR a and p chains 
P4 TCR a chain — TRAV 36-DV7 TRAJ 32 TRAC  
ATG ATG AAG TGT CCA CAG GCT TTA CTA GCT ATC TTT TGG CTT CTA CTG AGC 
MMK C PQ A L L A IFW L LL S 
TGG GTG AGC AGT GAA GAC AAG GTG GTA CAA AGC CCT CTA TGT CTG GTT 
WVS S E D K V V Q S P L SL V 
GTC CAC GAG GGA GAC ACC GTA ACT CTC AAT TGC AGT TAT GAA GTG ACT 
✓ HE G D T V T L NC S Y E V T 
AAC TTT CGA AGC CTA CTA TGG TAC ATG CAG GAA AAG AAA GCT CCC ACA 
N F R S L L W Y M Q E K K AP T 
TTT CTA TTT ATG CTA ACT TCA AGT GGA ATT GAA AAG AAG TCA GGA AGA 
FLFML T S S G I E K KS G R 
CTA AGT AGC ATA TTA GAT AAG AAA GAA CTT TTC AGC ATC CTG AAC ATC 
L S S I L D K K E L S S I L N I 
ACA GCC ACC CAG ACC GGA GAC TCG GCC ATC TAC CTC TGT GCG GTA TGG 
T ATQ T G D S AIY LCA VW 
GCG GGT GCT ACA AAC AAG CTC ATC TTT GGA ACT GGC ACT CTG CTT GCT GTC 
A GATNK L IF G TG TL LAV 
CAG CCA AAT ATC CAG AAC CCT GAC CCT GCC GTG TAC CAG CTG AGA GAC 
Q PNIQNPDP A V Y Q L RD 
TCT AAA TCC AGT GAC AAG TCT GTC TGC CTA TTC ACC GAT TTT GAT TCT CAA 
SK S S D K S VC L F I D F DS Q 
ACA AAT GTG TCA CAA AGT AAG GAT TCT GAT GTG TAT ATC ACA GAC AAA 
TNVS QS K DSDVY I TDK 
ACT GTG CTA GAC ATG AGG TCT ATG GAC TTC AAG AGC AAC AGT GCT GTG 
T V L D MRS  M D F K SN S A V 
GCC TGG AGC AAC AAA TCT GAC TTT GCA TGT GCA AAC GCC TTC AAC AAC 
AW S N K S D F A C A N A F NN 
AGC ATT ATT CCA GAA GAC ACC TTC TTC CCC AGC CCA GAA AGT TCC TGT GAT 
S I I P EDT  F F P S P E SSCD 
GTC AAG CTG GTC GAG AAA AGC TTT GAA ACA GAT ACG AAC CTA AAC ITT 
✓ K LV E K SF E TD TN L N F 
CAA AAC CTG TCA GTG ATT GGG TTC CGA ATC CTC CTC CTG AAA GTG GCC 
Q N L S V I G F R I L L L K VA 
GGG TTT AAT CTG CTC ATG ACG CTG CGG CTG TGG TCC AGC TGA 
G F N L L M T L R LWS S • 
Key: TRAV 36 DV7 
TRAJ 32 
TRAC 
CDR3  
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P4 TCR 13 chain — TRBV 9 TRW 2-7 TRBC 2 
ATG GGC TTC AGG CTC CTC TGC TGT GTG GCC TTT TGT CTC CTG GGA GCA GGC 
MG FR L LCCV A F C L L G A G 
CCA GTG GAT TCT GGA GTC ACA CAA ACC CCA AAG CAC CTG ATC ACA GCA 
P V D S G V T Q T P K HL I TA 
ACT GGA CAG CGA GTG ACG CTG AGA TGC TCC CCT AGG TCT GGA GAC CTC 
T G Q R V T L R C S P R SGDL 
TCT GTG TAC TGG TAC CAA CAG AGC CTG GAC CAG GGC CTC CAG TTC CTC ATT 
S V Y W Y Q Q SL D Q G L Q F L I 
CAG TAT TAT AAT GGA GAA GAG AGA GCA AAA GGA AAC ATT CTT GAA CGA 
Q Y Y N GEE R AK G N I L E R 
TTC TCC GCA CAA CAG TTC CCT GAC TTG CAC TCT GAA CTA AAC CTG AGC TCT 
FS A Q Q F PDLHSELNL S S 
CTG GAG CTG GGG GAC TCA GCT TTG TAT TTC TGC CAG GTG CCG GAC AGG 
L E L GDS ALYFCQV PDR 
GGG GTA TAC GAG CAG TAC TTC GGG CCG GGC ACC AGG CTC ACG GTC ACA 
G V Y E Q Y F G P G T R L T V T 
GAG GAC CTG AAA AAC GTG TTC CCA CCC GAG GTC GCT GTG TTT GAG CCA 
E DLK N V F P P E V AVF EP 
TCA GAA GCA GAG ATC TCC CAC ACC CAA AAG GCC ACA CTG GTG TGC CTG 
SE A E I S H T Q K AT LV CL 
GCC ACA GGC TTC TAC CCC GAC CAC GTG GAG CTG AGC TGG TGG GTG AAT 
A T G F Y PD H V E L S W WVN 
GGG AAG GAG GTG CAC AGT GGG GTC AGC ACA GAC CCG CAG CCC CTC AAG 
G K E V HS G V S T D P Q P L K 
GAG CAG CCC GCC CTC AAT GAC TCC AGA TAC TGC CTG AGC AGC CGC CTG 
E QPALNDSRYCLS S R L 
AGG GTC TCG GCC ACC TTC TGG CAG AAC CCC CGC AAC CAC TTC CGC TGT 
R V S A T F W Q N P RNH F R C 
CAA GTC CAG TTC TAC GGG CTC TCG GAG AAT GAC GAG TGG ACC CAG GAT 
Q V Q F Y GL SENDEW T Q D 
AGG GCC AAA CCT GTC ACC CAG ATC GTC AGC GCC GAG GCC TGG GGT AGA 
R AK PV T Q I VS AE AWGR 
GCA GAC TGT GGC TTC ACC TCC GAG TCT TAC CAG CAA GGG GTC CTG TCT GCC 
A DCGF T SE SY Q Q G V L S A 
ACC ATC CTC TAT GAG ATC TTG CTA GGG AAG GCC ACC TTG TAT GCC GTG CTG 
T I L Y E IL L G K A T L Y A V L 
GTC AGT GCC CTC GTG CTG ATG GCC ATG GTC AAG AGA AAG GAT TTC TGA 
✓ S A L V L M AM V K R K D F • 
Key: TRBV 9 	TRAJ 2-7 	CDR3  
Non-germline sequence 	TRBC 2 
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